Quinazoline derivatives for the treatment of t cell mediated diseases

ABSTRACT

The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3  and Q 2  have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

This invention concerns a new therapeutic use of certain quinazolinederivatives, or pharmaceutically-acceptable salts thereof. The compoundshave been found to possess pharmacological properties of use in thetreatment of autoimmune diseases or medical conditions, for example Tcell mediated disease such as transplant rejection or rheumatoidarthritis.

A critical requirement of the immune system is the ability todifferentiate between “self” and “non-self” (i.e. foreign) antigens.This discrimination is required to enable the immune system to mount aresponse to foreign proteins such as those on the surface of pathogenswhilst maintaining tolerance to endogenous proteins and therebypreventing damage to normal tissues. An autoimmune disease results whenself-tolerance breaks down and the immune system reacts against tissuessuch as the joints in rheumatoid arthritis or nerve fibres in multiplesclerosis. Stimulation of the human immune response is dependent on therecognition of protein antigens by T cells. However T cells do notbecome activated by and respond to antigen alone but are only triggeredinto action when the antigen is complexed with major histocompatibilitycomplex (MHC) molecules on the surface of an antigen-presenting cellsuch as a B cell, macrophage or dendritic cell. Thus T cell activationrequires the docking into the T cell receptor of the peptide/MHC complexexpressed on an antigen-presenting cell. This interaction, which confersthe antigen specificity to the T cell response, is essential for fallactivation of T lymphocytes. Subsequent to this docking, some of theearliest signal transduction events leading to full T cell activationare mediated through the action of multiple tyrosine-specific proteinkinases (E. Hsi et al., J. Biol. Chem. 1989, 264, 10836) includingp56^(lck) and ZAP-70. The tyrosine kinase p56^(lck) is a lymphocytespecific member of the src family of non-receptor protein tyrosinekinases (J. D. Marth et al., Cell 1985, 43, 393). The enzyme isassociated with the inner surface of the plasma membrane where it bindsto the T cell receptor associated glycoproteins CD4 (in helper T cells)and CD8 (in cytotoxic or killer T cells) (C. E. Rudd et al., Proc. Natl.Acad. Sci. USA, 1988, 85, 5190 and M. A. Campbell et al., EMBO J. 1990,9, 2125).

It is believed that p56^(lck) tyrosine kinase plays an essential role inT cell activation as, for example, the loss of p56^(lck) expression in ahuman Jurkat T cell line prevents the normal T cell response tostimulation of the T cell receptor D. B. Straus et al., Cell, 1992, 70,585) and a deficiency in p56^(lck) expression causes severe immunedeficiency in humans (F. D. Goldman et al., J. Clin. Invest., 1998, 102,421).

Certain autoimmune conditions or diseases such as inflammatory diseases(for example rheumatoid arthritis, inflammatory bowel disease,glomerulonephritis and lung fibrosis), multiple sclerosis, psoriasis,hypersensitivity reactions of the skin, atherosclerosis, restenosis,allergic asthma and insulin-dependent diabetes are believed to beassociated with inappropriate T cell activation (see, for example, J. H.Hanke et al., Inflamm. Res., 1995, 44, 357). In addition the acuterejection of transplanted organs can also be interpreted as aconsequence of inappropriate T cell activation. Therefore, compoundswhich modulate T cell activation by way of inhibition of one or more ofthe multiple tyrosine-specific protein kinases which are involved in theearly signal transduction steps which lead to full T cell activation,for example by way of inhibition of p56^(lck) tyrosine kinase, areexpected to provide therapeutic agents for such pathological conditions.

Without wishing to imply that the compounds disclosed in the presentinvention possess pharmacological activity only by virtue of an effecton a single biological process, it is believed that the compoundsmodulate T cell activation by way of inhibition of one or more of themultiple tyrosine-specific protein kinases which are involved in theearly signal transduction steps which lead to full T cell activation,for example by way of inhibition of p56^(lck) tyrosine kinase.

In particular, the quinazoline derivatives disclosed in the presentinvention are expected to be useful as immunoregulation orimmunosuppressive agents for the prevention or treatment of organrejection following transplant surgery.

Agents of this kind would offer therapy for transplant rejection andautoimmune diseases whilst avoiding toxicities associated with thecommonly used, less selective immunosuppressants. The leading agent forthe prevention or treatment of transplant rejection is cyclosporin Awhich, although effective, is often associated with side-effects such asrenal damage and hypertension which results in kidney failure in asubstantial number of patients. It is contemporary practice to treatrheumatoid arthritis initially with symptom relief agents such asNSAIDs, which do not have any beneficial effect on disease progressionand are often associated with unwanted side-effects. A rationally based,disease modifying agent, without such deleterious side-effects, wouldtherefore offer significant benefits in the prevention or treatment oftransplant rejection or autoimmune conditions such as rheumatoidarthritis.

As stated above, the present invention is based, in particular, on thediscovery that the quinazoline derivatives disclosed in the inventionmodulate T cell activation by way of inhibition of one or more of themultiple tyrosine-specific protein kinases which are involved in theearly signal transduction steps which lead to fall T cell activation.Accordingly compounds disclosed in the present invention possess higherinhibitory potency against particular non-receptor tyrosine kinases suchas p56^(lck) tyrosine kinase than against other non-receptor tyrosinekinases or against receptor tyrosine kinases (RTKs) such as epidermalgrowth factor (EGF) RTK and/or VEGF RTK. In general, the quinazolinederivatives disclosed in the invention possess sufficient potency ininhibiting non-receptor tyrosine kinases such as p56^(lck) tyrosinekinase that they may be used in an amount sufficient to inhibit, forexample, p56^(lck) tyrosine kinase whilst demonstrating reduced potency,preferably whilst demonstrating no significant activity, against RTKssuch as EGF RTK or VEGF RTK. Thus the quinazoline derivatives disclosedin the invention can be used in the clinical management of thoseparticular diseases which are sensitive to inhibition of suchnon-receptor tyrosine kinases, for example autoimmune diseases ormedical conditions, for example T cell mediated disease such astransplant rejection or rheumatoid arthritis.

According to one aspect of the invention there is provided the use of aquinazoline derivative of the Formula I

wherein m is 0, 1, 2 or 3;

-   -   each R¹ group, which may be the same or different, is selected        from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy,        mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl,        (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,        (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl        (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,        (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,        (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenylamino,        N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,        N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        Q³-X¹—        wherein X¹ is a direct bond or is selected from O, S, SO, SO₂,        N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂,        OC(R⁴)₂, SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is hydrogen or        (1-6C)alkyl, and Q³ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl, or (R¹)_(m) is (1-3C)alkylenedioxy,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, S, SO, SO₂,        N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH═CH        and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂═CH— or HC≡C— group within a R¹ substituent        optionally bears at the terminal CH₂═ or HC≡ position a        substituent selected from halogeno, carboxy, carbamoyl,        (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl and        di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the        formula:        Q⁴-X²—        wherein X² is a direct bond or is selected from CO and N(R⁶)CO,        wherein R⁶ is hydrogen or (1-6C)alkyl, and Q⁴ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group one or more        halogeno or (1-6C)alkyl substituents or a substituent selected        from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X³-Q⁵        wherein X³ is a direct bond or is selected from O, S, SO, SO₂,        N(R⁷), CO, CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂,        C(R⁷)₂O, C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or        (1-6C)alkyl, and Q⁵ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within a        substituent on R¹ optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy,        carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,        (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁴—R⁸        wherein X⁴ is a direct bond or is selected from O and N(R⁹),        wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁵ is        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (2-6C)alkanoylamino-(1-6C)alkyl or        (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the        formula:        —X⁵-Q⁶        wherein X⁵ is a direct bond or is selected from O, CO and        N(R¹⁰), wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁶ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo or thioxo substituents;    -   R² is hydrogen or (1-6C)alkyl;    -   R³ is hydrogen or (1-6C)alkyl;    -   Z is a direct bond or is selected from O, S, SO, SO₂, N(R¹¹),        CO, CH(OR¹¹), CON(R¹¹), N(R¹¹)CO, SO₂N(R¹¹), N(R¹¹)SO₂,        OC(R¹¹)₂, SC(R¹¹)₂ and N(R¹¹)C(R¹¹)₂, wherein R¹¹ is hydrogen or        (1-6C)alkyl;    -   Q¹ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl, or, when Z is a direct bond or O, Q¹        may be (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (1-6C)alkylthio-(1-6C)alkyl, (1-6C)alkylsulphinyl-(1-6C)alkyl or        (1-6C)alkylsulphonyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, S, SO, SO₂, N(R¹²),        CO, CH(OR¹²), CON(R¹²), N(R¹²)CO, SO₂N(R¹²), N(R¹²)SO₂, CH═CH        and C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂═CH— or HC≡C— group within the Q¹-Z- group        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from halogeno, carboxy, carbamoyl,        (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,        di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl and        di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the        formula:        Q⁷-X⁶—        wherein X⁶ is a direct bond or is selected from CO and N(R¹³)CO,        wherein R¹³ is hydrogen or (1-6C)alkyl, and Q⁷ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group one or more        halogeno or (1-6C)alkyl substituents or a substituent selected        from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, S, SO, SO₂,        N(R¹⁴), CO, CH(OR¹⁴), CON(R¹⁴), N(R¹⁴)CO, SO₂N(R¹⁴), N(R¹⁴)SO₂,        C(R¹⁴)₂O, C(R¹⁴)₂S and N(R¹⁴)C(R¹⁴)₂, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within        the Q¹-Z- group optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy,        carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,        (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁸—R¹⁵        wherein X⁸ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl or        di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O, CO and        N(R¹⁷), wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo or thioxo substituents; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from halogeno, trifluoromethyl, cyano,        nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl,        (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,        (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl,        (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,        (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,        (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,        N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,        N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X¹⁰—R¹⁸        wherein X¹⁰ is a direct bond or is selected from O and N(R¹⁹),        wherein R¹⁹ is hydrogen or (1-6C)alkyl, and R¹⁸ is        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl or        di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the        formula:        —X¹¹-Q¹⁰        wherein X¹¹ is a direct bond or is selected from O, S, SO, SO₂,        N(R²⁰), CO, CH(OR²⁰), CON(R²⁰), N(R²⁰)CO, SO₂N(R²⁰), N(R²⁰)SO₂,        C(R²⁰)₂O, C(R²⁰)₂S and N(R²⁰)C(R²⁰)₂, wherein R²⁰ is hydrogen or        (1-6C)alkyl, and Q¹⁰ is aryl, aryl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl        which optionally bears 1 or 2 substituents, which may be the        same or different, selected from halogeno, (1-6C)alkyl and        (1-6C)alkoxy, and any heterocyclyl group within Q¹⁰ optionally        bears 1 or 2 oxo or thioxo substituents,    -   and each of G², G³, G⁴ and G⁵, which may be the same or        different, is selected from hydrogen, halogeno, trifluoromethyl,        cyano, nitro, hydroxy, amino, (1-6C)alkyl, (2-8C)alkenyl,        (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino and        di-[(1-6C)alkyl]amino,    -   or G¹ and G² together form a group of formula:— —CH═CH—CH—CH—,        —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N—,        —N═CH—N═CH—, —CH═N—CH═N—, —N═CH—CH═N—, —N═N—CH═CH—, —CH═CH—N═N—,        —CH═CH—O—, —O—CH═CH—, —CH═CH—S—, —S—CH═CH—, —CH₂—CH₂—O—,        —O—CH₂—CH₂—, —CH₂—CH₂—S—, —S—CH₂—CH₂—, —O—CH₂—O—, —O—CH₂—CH₂—O—,        —S—CH₂—S—, —S—CH₂—CH₂—S—, —CH═CH—NH—, —NH—CH═CH—, —CH₂—CH₂—NH—,        —NH—CH₂—CH₂—, —N═CH—NH—, —NH—CH═N—, —NH—CH₂—NH—, —O—CH—N—,        —N═CH—O—, —S—CH═N—, —N═CH—S—, —O—CH₂—NH—, —NH—CH₂—O—,        —S—CH₂—NH—, —NH—CH₂—S—, —O—N═CH—, —CH═N—O—, —S—N═CH—, —CH═N—S—,        —O—NH—CH₂—, —CH₂—NH—O—, —S—NH—CH₂—, —CH₂—NH—S—, —NH—N═CH—,        —CH—N—NH—, —NH—NH—CH₂—, —CH₂—NH—NH—, —N═N—NH— or —NH—N═N—,    -   or G¹ has any of the meanings defined hereinbefore and G² and G³        together or G³ and G⁴ together form a group of formula:—        —CH═CH—CH═CH—, —N═CH—CH—CH—, —CH═N—CH═CH—, —CH═CH—N═CH—,        —CH═CH—CH═N—, —N═CH—N═CH—, —CH═N—CH—N—, —N═CH—CH═N—,        —N═N—CH═CH—, —CH═CH—N═N—, —CH═CH—O—, —O—CH═CH—, —CH═CH—S—,        —S—CH═CH—, —CH₂—CH₂—O—, —O—CH₂—CH₂—, —CH₂—CH₂—S—, —S—CH₂—CH₂—,        —O—CH₂—O—, —O—CH₂—CH₂—O—, —S—CH₂—S—, —S—CH₂—CH₂—S—, —CH═CH—NH—,        —NH—CH═CH—, —CH₂—CH₂—NH—, —NH—CH₂—CH₂—, —N═CH—NH—, —NH—CH═N—,        —NH—CH₂—NH—, —O—CH═N—, —N═CH—O—, —S—CH═N—, —N═CH—S—, —O—CH₂—NH—,        —NH—CH₂—O—, —S—CH₂—NH—, —NH—CH₂—S—, —O—N═CH—, —CH═N—O—,        —S—N═CH—, —CH═N—S—, —O—NH—CH₂—, —CH₂—NH—O—, —S—NH—CH₂—,        —CH₂—NH—S—, —NH—N═CH—, —CH═N—NH—, —NH—NH—CH₂—, —CH₂—NH—NH—,        —N═N—NH— or —NH—N═N—,    -   and the 9- or 10-membered bicyclic heteroaryl or heterocyclic        ring formed when G¹ and G² together, G² and G³ together or G³        and G⁴ together are linked optionally bears on the heteroaryl or        heterocyclic portion of the bicyclic ring 1, 2 or 3        substituents, which may be the same or different, selected from        halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino,        (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy,        (1-6C)alkylamino and di-[(1-6C)alkyl]amino, and any bicyclic        heterocyclic ring so formed optionally bears 1 or 2 oxo or        thioxo groups;        or a pharmaceutically-acceptable salt thereof;        in the manufacture of a medicament for use in the prevention or        treatment of T cell mediated diseases or medical conditions in a        warm-blooded animal such as man.

We have found that the compounds disclosed in the present invention areof use in the prevention or treatment of autoimmune diseases or medicalconditions, for example T cell mediated disease such as transplantrejection, rheumatoid arthritis or multiple sclerosis. We have furtherfound that these effects are believed to arise by virtue of inhibitionof one or more of the multiple tyrosine-specific protein kinases whichare involved in the early signal transduction steps which lead to full Tcell activation, for example by way of inhibition of the enzymep56^(lck). Accordingly the compounds disclosed in the present inventionare expected to be useful in the prevention or treatment of T cellmediated diseases or medical conditions. In particular the compoundsdisclosed in the present invention are expected to be useful in theprevention or treatment of those pathological conditions which aresensitive to inhibition of one or more of the multiple tyrosine-specificprotein kinases which are involved in the early signal transductionsteps which lead to T cell activation, for example by way of inhibitionof p56^(lck) tyrosine kinase. Further, the compounds disclosed in thepresent invention are expected to be useful in the prevention ortreatment of those diseases or medical conditions which are mediatedalone or in part by inhibition of the enzyme p56^(lck), i.e. thecompounds may be used to produce a p56^(lck) enzyme inhibitory effect ina warm-blooded animal in need of such treatment. Specifically, thecompounds disclosed in the present invention are expected to be usefulin the prevention or treatment of autoimmune conditions or diseases suchas inflammatory diseases (for example rheumatoid arthritis, inflammatorybowel disease, glomerulonephritis and lung fibrosis), multiplesclerosis, psoriasis, hypersensitivity reactions of the skin,atherosclerosis, restenosis, allergic asthma and insulin-dependentdiabetes. In particular the compounds disclosed in the present inventionare expected to be useful in the prevention or treatment of the acuterejection of transplanted tissue or organs.

According to a further feature of this aspect of the invention there isprovided a method for the prevention or treatment of T cell mediateddiseases or medical conditions in a warm-blooded animal, such as man, inneed of such treatment which comprises administering to said animal aneffective amount of a quinazoline derivative of the Formula I, or apharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further feature of the invention there is provided theuse of a quinazoline derivative of the Formula I, or apharmaceutically-acceptable salt thereof, as defined immediatelyhereinbefore in the manufacture of a medicament for use in theprevention or treatment of those pathological conditions which aresensitive to inhibition of one or more of the multiple tyrosine-specificprotein kinases which are involved in the early signal transductionsteps which lead to T cell activation.

According to a further feature of the invention there is provided amethod for the prevention or treatment of those pathological conditionswhich are sensitive to inhibition of one or more of the multipletyrosine-specific protein kinases which are involved in the early signaltransduction steps which lead to T cell activation which comprisesadministering to said animal an effective amount of a quinazolinederivative of the Formula I, or a pharmaceutically-acceptable saltthereof, as defined immediately hereinbefore.

According to a further aspect of the invention there is provided the useas defined hereinbefore of a quinazoline derivative of the Formula Iwherein each of m, R¹, R², R³ and Q² has any of the meanings definedhereinbefore and

-   -   Z is a direct bond or is selected from O, S, SO, SO₂, N(R¹¹),        CO, CH(OR¹¹), CON(R¹¹), N(R¹¹)CO, SO₂N(R¹¹), N(R¹¹)SO₂,        OC(R¹¹)₂, SC(R¹¹)₂ and N(R¹¹)C(R¹¹)₂, wherein R¹¹ is hydrogen or        (1-6C)alkyl; and    -   Q¹ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, S, SO, SO₂, N(R¹²),        CO, CH(OR¹²), CON(R¹²), N(R¹²)CO, SO₂N(R¹²), N(R²)SO₂, CH═CH and        C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group one or more        halogeno or (1-6C)alkyl substituents or a substituent selected        from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, S, SO, SO₂,        N(R¹⁴), CO, CH(OR¹⁴), CON(R¹⁴), N(R¹⁴)CO, SO₂N(R¹⁴), N(R¹⁴)SO₂,        C(R¹⁴)₂O, C(R¹⁴)₂S and N(R¹⁴)C(R¹⁴)₂, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within        the Q¹-Z- group optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy,        carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,        (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁸—R¹⁵        wherein X⁸ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl or        di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O, CO and        N(R¹⁷), wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo or thioxo substituents.

According to a further aspect of the invention there is provided the useas defined hereinbefore of a quinazoline derivative of the Formula Iwherein each of m, R¹, R², R³ and Q² has any of the meanings definedhereinbefore and

-   -   Z is selected from O, S, SO, SO₂, N(R¹¹), CO, CH(OR¹¹),        CON(R¹¹), N(R¹¹)CO, SO₂N(R¹¹), N(R¹¹)SO₂, OC(R¹¹)₂, SC(R¹¹)₂ and        N(R¹¹)C(R¹¹)₂, wherein R¹¹ is hydrogen or (1-6C)alkyl; and    -   Q¹ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl,        (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl        or heterocyclyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, S, SO, SO₂, N(R¹²),        CO, CH(OR¹²), CON(R¹²), N(R¹²)CO, SO₂N(R¹²), N(R¹²)SO₂, CH═CH        and C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group one or more        halogeno or (1-6C)alkyl substituents or a substituent selected        from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,        (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,        (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,        N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,        (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, S, SO, SO₂,        N(R¹⁴), CO, CH(OR¹⁴), CON(R¹⁴), N(R¹⁴)CO, SO₂N(R¹⁴), N(R¹⁴)SO₂,        C(R¹⁴)₂O, C(R¹⁴)₂S and N(R¹⁴)C(R¹⁴)₂, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,        (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1, 2 or 3 substituents, which may be the same        or different, selected from halogeno, trifluoromethyl, cyano,        nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl,        (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,        (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl,        (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,        (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,        (2-6C)alkanoyloxy, (2-6C)alkanoylamino,        N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,        N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and        N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the        formula:        —X⁸—R¹⁵        wherein X⁸ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl or        di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O, CO and        N(R¹⁷), wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is aryl,        aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo or thioxo substituents.

In this specification the generic term “alkyl” includes bothstraight-chain and branched-chain alkyl groups such as propyl, isopropyland tert-butyl, and (3-7C)cycloalkyl groups such as cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. However referencesto individual alkyl groups such as “propyl” are specific for thestraight-chain version only, references to individual branched-chainalkyl groups such as “isopropyl” are specific for the branched-chainversion only and references to individual cycloalkyl groups such as“cyclopentyl” are specific for that 5-membered ring only. An analogousconvention applies to other generic terms, for example (1-6C)alkoxyincludes methoxy, ethoxy, cyclopropyloxy and cyclopentyloxy,(1-6C)alkylamino includes methylamino, ethylamino, cyclobutylamino andcyclohexylamino, and di-[(1-6Calkyl]amino includes dimethylamino,diethylamino, N-cyclobutyl-N-methylamino and N-cyclohexyl-N-ethylamino.

It is to be understood that, insofar as certain of the compounds ofFormula I defined above may exist in optically active or racemic formsby virtue of one or more asymmetric carbon atoms, the invention includesin its compound definition any such optically active or racemic formwhich possesses the above-mentioned activity. The synthesis of opticallyactive forms may be carried out by standard techniques of organicchemistry well known in the art, for example by synthesis from opticallyactive starting materials or by resolution of a racemic form. Similarly,the above-mentioned activity may be evaluated using the standardlaboratory techniques referred to hereinafter.

Suitable values for the generic radicals referred to above include thoseset out below.

A suitable value for any one of the ‘Q’ groups (Q¹, Q³ to Q¹⁰) when itis aryl or for the aryl group within a ‘Q’ group is, for example, phenylor naphthyl, preferably phenyl.

A suitable value for any one of the ‘Q’ groups (Q¹, Q³ to Q⁸) when it is(3-7C)cycloalkyl or for the (3-7C)cycloalkyl group within a ‘Q’ groupis, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for any one ofthe ‘Q’ groups (Q¹, Q³ to Q⁸) when it is (3-7C)cycloalkenyl or for the(3-7C)cycloalkenyl group within a ‘Q’ group is, for example,cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

A suitable value for any one of the ‘Q’ groups (Q¹, Q³ to Q¹⁰) when itis heteroaryl or for the heteroaryl group within a ‘Q’ group is, forexample, an aromatic 5- or 6-membered monocyclic ring or a 9- or10-membered bicyclic ring with up to five ring heteroatoms selected fromoxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl,oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl,oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl,pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl,benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl,benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl,cinnolinyl or naphthyridinyl.

A suitable value for any one of the ‘Q’ groups (Q¹, Q³ to Q¹⁰) when itis heterocyclyl or for the heterocyclyl group within a ‘Q’ group is, forexample, a non-aromatic saturated or partially saturated 3 to 10membered monocyclic or bicyclic ring with up to five heteroatomsselected from oxygen, nitrogen and sulphur, for example oxiranyl,oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, pyrrolinyl,pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl,1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl,piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl,dihydropyrimidinyl or tetrahydropyrimidinyl, preferablytetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl,1,1-dioxotetrahydro-4H-1,4-thiazinyl, piperidinyl or piperazinyl, morepreferably tetrahydrofuran-3-yl, tetrahydropyran-4-yl, pyrrolidin-3-yl,morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino,piperidin-4-yl or piperazin-1-yl. A suitable value for such a groupwhich bears 1 or 2 oxo or thioxo substituents is, for example,2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl,2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl,2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for a ‘Q’ group when it is heteroaryl-(1-6C)alkyl is,for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl.The invention comprises corresponding suitable values for ‘Q’ groupswhen, for example, rather than a heteroaryl-(1-6C)alkyl group, anaryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl,(3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group ispresent.

Suitable values for any of the ‘R’ groups (R¹ to R²⁰), or for variousgroups within an R¹ substituent, or for G¹ or for various groups withinG¹, or for any of the ‘G’ groups (G² to G⁵) within Q², or for variousgroups within Q², or for Q¹ or for various groups within Q¹, or forvarious groups within the Q¹-Z- group include:—

-   for halogeno fluoro, chloro, bromo and iodo;-   for (1-6C)alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl;-   for (2-8C)alkenyl: vinyl, isopropenyl, allyl and but-2-enyl;-   for (2-8C)alkynyl: ethynyl, 2-propynyl and but-2-ynyl;-   for (1-6C)alkoxy: methoxy, ethoxy, propoxy, isopropoxy and butoxy,-   for (2-6C)alkenyloxy: vinyloxy and allyloxy;-   for (2-6C)alkynyloxy: ethynyloxy and 2-propynyloxy;-   for (1-6C)alkylthio: methylthio, ethylthio and propylthio;-   for (1-6C)alkylsulphinyl: methylsulphinyl and ethylsulphinyl;-   for (1-6C)alkylsulphonyl: methylsulphonyl and ethylsulphonyl;-   for (1-6C)alkylamino: methylamino, ethylamino, propylamino,    isopropylamino and butylamino;-   for di-[(1-6C)alkyl]amino: dimethylamino, diethylamino,    N-ethyl-N-methylamino and diisopropylamino;-   for (1-6C)alkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl,    propoxycarbonyl and tert-butoxycarbonyl;-   for N-(1-6C)alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and    N-propylcarbamoyl;-   for N,N-di-[(1-6C)alkyl]carbamoyl: N,N-dimethylcarbamoyl,    N-ethyl-N-methylcarbamoyl and N,N-diethylcarbamoyl;-   for (2-6C)alkanoyl: acetyl and propionyl; for (2-6C)alkanoyloxy:    acetoxy and propionyloxy;-   for (2-6C)alkanoylamino: acetamido and propionamido;-   for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylacetamido and    N,N-methylpropionamido;-   for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and    N-ethylsulphamoyl;-   for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;-   for (1-6C)alkanesulphonylamino: methanesulphonylamino and    ethanesulphonylamino;-   for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino:    N-methylmethanesulphonylamino and N-methylethanesulphonylamino;-   for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;-   for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and    N-methylcrotonamido;-   for (3-6C)alkynoylamino: propiolamido;-   for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;-   for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and    3-aminopropyl;-   for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl,    ethylaminomethyl, 1-methylaminoethyl, 2-methylaminoethyl,    2-ethylaminoethyl and 3-methylaminopropyl;-   for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl,    diethylaminomethyl, 1-dimethylaminoethyl, 2-dimethylaminoethyl and    3-dimethylaminopropyl;-   for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl    and 3-chloropropyl;-   for hydroxy-(1-6C)alkyl: hydroxymethyl, 2-hydroxyethyl,    1-hydroxyethyl and 3-hydroxypropyl;-   for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl,    1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl and 3-methoxypropyl;-   for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and    3-cyanopropyl;-   for (1-6C)alkylthio-(1-6C)alkyl: methylthiomethyl, ethylthiomethyl,    2-methylthioethyl, 1-methylthioethyl and 3-methylthiopropyl;-   for (1-6C)alkylsulphinyl-(1-6C)alkyl: methylsulphinylmethyl,    ethylsulphinylmethyl, 2-methylsulphinylethyl, 1-methylsulphinylethyl    and 3-methylsulphinylpropyl;-   for (1-6C)alkylsulphonyl-(1-6C)alkyl: methylsulphonylmethyl,    ethylsulphonylmethyl, 2-methylsulphonylethyl, 1-methylsulphonylethyl    and 3-methylsulphonylpropyl;-   for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl,    propionamidomethyl and 2-acetamidoethyl; and-   for (1-6C)alkoxycarbonylamino-(1-6C)alkyl:    methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl,    tert-butoxycarbonylaminomethyl and 2-methoxycarbonylaminoethyl.

A suitable value for (R¹)_(m) when it is a (1-3C)alkylenedioxy group is,for example, methylenedioxy or ethylenedioxy and the oxygen atomsthereof occupy adjacent ring positions.

When, as defined hereinbefore, an R¹ group forms a group of the formulaQ³-X¹— and, for example, X¹ is a OC(R⁴)₂ linking group, it is the carbonatom, not the oxygen atom, of the OC(R⁴)₂ linking group which isattached to the quinazoline ring and the oxygen atom is attached to theQ³ group. Similarly, when, for example a CH₃ group within a R¹substituent bears a group of the formula —X³-Q⁵ and, for example, X³ isa C(R⁷)₂O linking group, it is the carbon atom, not the oxygen atom, ofthe C(R⁷)₂O linking group which is attached to the CH₃ group and theoxygen atom is linked to the Q⁵ group. A similar convention applies tothe attachment of the groups of the formulae Q⁴-X²— and —X⁷-Q⁷.

As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylenechain within a R¹ substituent may be optionally separated by theinsertion into the chain of a group such as O, CON(R⁵) or C≡C. Forexample, insertion of a C≡C group into the ethylene chain within a2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy groupand, for example, insertion of a CONH group into the ethylene chainwithin a 3-methoxypropoxy group gives rise to, for example, a2-(2-methoxyacetamido)ethoxy group.

When, as defined hereinbefore, any CH₂═CH— or HC≡C— group within a R¹substituent optionally bears at the terminal CH₂═ or HC≡ position asubstituent such as a group of the formula Q⁴-X²— wherein X² is, forexample, NHCO and Q⁴ is a heterocyclyl-(1-6C)alkyl group, suitable R¹substituents so formed include, for example,N-[heterocyclyl-(1-6C)alkyl]carbamoylvinyl groups such asN-(2-pyrrolidin-1-ylethyl)carbamoylvinyl orN-[heterocyclyl-(1-6C)alkyl]carbamoylethynyl groups such asN-(2-pyrrolidin-1-ylethyl)carbamoylethynyl.

When, as defined hereinbefore, any CH₂ or CH₃ group within a R¹substituent optionally bears on each said CH₂ or CH₃ group one or morehalogeno or (1-6C)alkyl substituents, there are suitably 1 or 2 halogenoor (1-6C)alkyl substituents present on each said CH₂ group and there aresuitably 1, 2 or 3 such substituents present on each said CH₃ group.

When, as defined hereinbefore, any CH₂ or CH₃ group within a R¹substituent optionally bears on each said CH₂ or CH₃ group a substituentas defined hereinbefore, suitable R¹ substituents so formed include, forexample, hydroxy-substituted heterocyclyl-(1-6C)alkoxy groups such as2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy,hydroxy-substituted amino-(2-6C)alkoxy groups such as3-amino-2-hydroxypropoxy, hydroxy-substituted(1-6C)alkylamino-(2-6C)alkoxy groups such as2-hydroxy-3-methylaminopropoxy, hydroxy-substituteddi-[(1-6C)alkyl]amino-(2-6C)alkoxy groups such as3-dimethylamino-2-hydroxypropoxy, hydroxy-substitutedheterocyclyl-(1-6C)alkylamino groups such as2-hydroxy-3-piperidinopropylamino and 2-hydroxy-3-morpholinopropylamino,hydroxy-substituted amino-(2-6C)alkylamino groups such as3-amino-2-hydroxypropylamino, hydroxy-substituted(1-6C)alkylamino-(2-6C)alkylamino groups such as2-hydroxy-3-methylaminopropylamino, hydroxy-substituteddi-[(1-6C)alkyl]amino-(2-6C)alkylamino groups such as3-dimethylamino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkoxygroups such as 2-hydroxyethoxy, (1-6C)alkoxy-substituted (1-6C)alkoxygroups such as 2-methoxyethoxy and 3-ethoxypropoxy,(1-6C)alkylsulphonyl-substituted (1-6C)alkoxy groups such as2-methylsulphonylethoxy and heterocyclyl-substituted(1-6C)alkylamino-(1-6C)alkyl groups such as2-morpholinoethylaminomethyl, 2-piperazin-1-ylethylaminomethyl and3-morpholinopropylaminomethyl.

Similar considerations apply to the attachments and substitutions withinthe -Z-Q¹ group.

When, as defined hereinbefore, G¹ and G² together form, for example, agroup of formula —O—CH═CH—, it is the oxygen atom, not the carbon atom,which is attached to the ortho-position of the phenyl ring of formula Iaand the carbon atom is attached to the adjacent meta-position of thephenyl ring of formula Ia. Similarly, when, for example, G² and G³together form, for example, a group of formula —CH═CH—CH═N—, it is thecarbon atom, not the nitrogen atom, which is attached to the G²meta-position of the phenyl ring of formula Ia and the nitrogen atom isattached to the adjacent G³ para-position of the phenyl ring of formulaIa. A similar convention applies to the attachment of the groups when,for example, G³ and G⁴ are joined.

A suitable pharmaceutically-acceptable salt of a compound of the FormulaI is, for example, an acid-addition salt of a compound of the Formula I,for example an acid-addition salt with an inorganic or organic acid suchas hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric ormaleic acid; or, for example, a salt of a compound of the Formula Iwhich is sufficiently acidic, for example an alkali or alkaline earthmetal salt such as a calcium or magnesium salt, or an ammonium salt, ora salt with an organic base such as methylamine, dimethylamine,trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl) amine.

Particular compounds defined in the invention include, for example,quinazoline derivatives of the Formula I, or pharmaceutically-acceptablesalts thereof, wherein, unless otherwise stated, each of m, R¹, R², R³,Z, Q¹ and Q² has any of the meanings defined hereinbefore or inparagraphs (a) to (cc) hereinafter:—

(a) m is 1 or 2, and each R¹ group, which may be the same or different,is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl,(1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy,(1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl,N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino,N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino andN-(1-6C)alkyl-(3-6C)alkynoylamino, or from a group of the formula:Q³-X¹—wherein X¹ is a direct bond or is selected from O, N(R⁴), CON(R⁴),N(R⁴)CO and OC(R⁴)₂ wherein R⁴ is hydrogen or (1-6C)alkyl, and Q³ isaryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl,heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

-   -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, N(R⁵),        CON(R⁵), N(R⁵)CO, CH═CH and C≡C wherein R⁵ is hydrogen or        (1-6C)alkyl,    -   and wherein any CH₂═CH— or HC≡C— group within a R¹ substituent        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from carbamoyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl and        di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the        formula:        Q⁴-X²—        wherein X² is a direct bond or is CO or N(R⁶)CO, wherein R⁶ is        hydrogen or (1-6C)alkyl, and Q⁴ is heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, (1-6C)alkoxy,        (1-6C)alkylsulphonyl, (1-6C)alkylamino and        di-[(1-6C)alkyl]amino, or from a group of the formula:        —X³-Q⁵        wherein X³ is a direct bond or is selected from O, N(R⁷),        CON(R⁷), N(R⁷)CO and C(R⁷)₂O, wherein R⁷ is hydrogen or        (1-6C)alkyl, and Q⁵ is heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within a        substituent on R¹ optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl,        (1-6C)alkoxy, N-(1-6C)alkylcarbamoyl and        N,N-di-[(1-6C)alkyl]carbamoyl, or optionally bears 1 substituent        selected from a group of the formula:        —X⁴—R⁸        wherein X⁴ is a direct bond or is selected from O and N(R⁹),        wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is        hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,        amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,        di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (2-6C)alkanoylamino-(1-6C)alkyl or        (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the        formula:        —X⁵-Q⁶        wherein X⁵ is a direct bond or is selected from O, CO and        N(R¹⁰), wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁶ is        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;        (b) m is 1 or 2, and each R group, which may be the same or        different, is selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, carbamoyl, methyl, ethyl, propyl, vinyl,        ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,        propylamino, dimethylamino, diethylamino, dipropylamino,        N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido,        propionamido, acrylamido and propiolamido, or from a group of        the formula:        Q³-X¹—        wherein X¹ is a direct bond or is selected from O, NH, CONH,        NHCO and OCH₂ and Q³ is phenyl, benzyl, cyclopropylmethyl,        2-thienyl, 1-imidazolyl, 1,2,3-triazol-1-yl, 2-, 3- or        4-pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl,        2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-, 3- or        4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or        4-pyridyl)propyl, 1-, 2- or 3-pyrrolidinyl, morpholino,        1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino,        piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl,        piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or        3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or        4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl,        2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl,        pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl,        3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperidin-3-ylethyl,        2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl,        3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,        3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or        3-homopiperazin-1-ylpropyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CONH,        NHCO, CH═CH and C≡C,    -   and wherein any CH₂═CH— or HC≡C— group within a R¹ substituent        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from carbamoyl, N-methylcarbamoyl,        N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl,        aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl,        methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl,        4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl,        3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group        of the formula:        Q⁴-X²—        wherein X² is a direct bond or is CO, NHCO or N(Me)CO and Q⁴ is        pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl,        pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,        piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl,        2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl,        4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl,        4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl,        3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl,        2-piperidin-3-ylethyl, piperidin-4-ylmethyl,        2-piperidin-4-ylethyl, piperazin-1-ylmethyl,        2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or        4-piperazin-1-ylbutyl,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino, or from a group of the formula:        —X³-Q⁵        wherein X³ is a direct bond or is selected from O, NH, CONH,        NHCO and CH₂O and Q⁵ is pyridyl, pyridylmethyl, pyrrolidin-1-yl,        pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,        piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl,        3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl,        piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,        2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within a        substituent on R¹ optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and        methoxy, or optionally bears 1 substituent selected from a group        of the formula:        —X⁴—R⁸        wherein X⁴ is a direct bond or is selected from O and NH and R¹        is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl,        3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl,        methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl,        2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,        2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,        methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or        tert-butoxycarbonylaminomethyl, and from a group of the formula:        —X⁵-Q⁶        wherein X⁵ is a direct bond or is selected from O and NH and Q⁶        is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl,        3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl,        3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl        or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2        substituents, which may be the same or different, selected from        fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;        (c) m is 1 or 2 and the R¹ groups, which may be the same or        different, are located at the 6- and/or 7-positions and are        selected from hydroxy, amino, methyl, ethyl, propyl, vinyl,        ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,        dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,        cyclopropylmethoxy, 2-imidazol-1-ylethoxy,        3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy,        3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy,        pyrid-3-ylmethoxy, pyrid-4-ylmethoxy, 2-pyrid-2-ylethoxy,        2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy,        3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, pyrrolidin-1-yl,        morpholino, piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy,        3-homopiperazin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino,        3-pyrrolidin-1-ylpropylamino, pyrrolidin-3-ylamino,        pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino,        3-pyrrolidin-2-ylpropylamino, 2-morpholinoethylamino,        3-morpholinopropylamino,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino,        2-piperidinoethylamino, 3-piperidinopropylamino,        piperidin-3-ylamino, piperidin-4-ylamino,        piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino,        piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino,        2-homopiperidin-1-ylethylamino, 3-homopiperidin-1-ylpropylamino,        2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino,        2-homopiperazin-1-ylethylamino or        3-homopiperazin-1-ylpropylamino,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CH═CH        and C≡C,    -   and when R¹ is a vinyl or ethynyl group, the R¹ substituent        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from N-(2-dimethylaminoethyl)carbamoyl,        N-(3 dimethylaminopropyl)carbamoyl, methylaminomethyl,        2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl,        dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl        and 4-dimethylaminobutyl, or from a group of the formula:        Q⁴-X²—        wherein X² is a direct bond or is NHCO or N(Me)CO and Q⁴ is        imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl,        pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl        pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl,        pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl,        3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl,        3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl,        2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl,        piperidin-3-ylmethyl, 2-piperidin-3-ylethyl,        piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,        piperazin-1-ylmethyl, 2-piperazin-1-ylethyl,        3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl, pyridyl or heterocyclyl group within a        substituent on R¹ optionally bears 1 or 2 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and        methoxy, and a piperidin-3-ylmethyl or piperidin-4-ylmethyl        group within a R¹ substituent is optionally N-substituted with        2-methoxyethyl, 3-methoxypropyl, 2-aminoethyl, 3-aminopropyl,        2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl,        3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or        3-piperazin-1-ylpropyl, the last 8 of which substituents each        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;        (d) m is 1 and the R¹ group is located at the 6- or 7-position        and is selected from hydroxy, amino, methyl, ethyl, propyl,        methoxy, ethoxy, propoxy, methylamino, ethylamino,        dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidinyloxy, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy,        piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy,        2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within a        substituent on R¹ optionally bears 1 or 2 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;        (e) m is 0;        (f) R² is hydrogen;        (g) R³ is hydrogen;        (h) Z is a direct bond or is selected from O, S, SO, SO₂, N(R¹¹)        and CO;        (i) Z is selected from CON(R¹¹), N(R¹¹)CO, SO₂N(R¹¹), N(R¹¹)SO₂,        OC(R¹¹)₂, SC(R¹¹)₂ and N(R¹¹)C(R¹¹)₂, wherein R¹¹ is hydrogen or        (1-6C)alkyl;        (j) the Q¹-Z- group is selected from (1-6C)alkyl, (2-8C)alkenyl,        (2-8C)alkynyl, (1-6C)alkoxy, (2-8C)alkenyloxy, (2-8C)alkynyloxy,        halogeno-(1-6C)allyl, hydroxy-(1-6C)alkyl,        (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl,        halogeno-(1-6C)alkoxy, hydroxy-(1-6C)alkoxy,        (1-6C)alkoxy-(1-6C)alkoxy, cyano-(1-6C)alkoxy,        amino-(1-6C)alkoxy, (1-6C)alkylamino-(1-6C)alkoxy and        di-[(1-6C)alkyl]amino-(1-6C)alkoxy,    -   or Z is a direct bond or is selected from O, S, SO, SO₂, N(R¹¹)        and CO wherein R¹¹ is hydrogen or (1-6C)alkyl, and Q¹ is aryl,        aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, N(R¹²), CON(R¹²),        N(R²)CO, CH═CH and C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂═CH— or HC≡C— group within the Q¹-Z- group        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from carbamoyl N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl and        di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the        formula:        Q⁷-X⁶—        wherein X⁶ is a direct bond or is CO or N(R¹³)CO, wherein R¹³ is        hydrogen or (1-6C)alkyl, and Q⁷ is heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, (1-6C)alkoxy,        (1-6C)alkylsulphonyl, (1-6C)alkylamino and        di-[(1-6C)alkyl]amino, or from a group of the formula:        —X⁷Q⁸        wherein X⁷ is a direct bond or is selected from O, N(R¹⁴),        CON(R¹⁴), N(R¹⁴)CO and C(R¹⁴)₂O, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within        the Q¹-Z- group optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl,        (1-6C)alkoxy, N-(1-6C)alkylcarbamoyl and        N,N-di-[(1-6C)alkyl]carbamoyl, or optionally bears 1 substituent        selected from a group of the formula:        —X⁸—R¹⁵        wherein X⁴ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,        amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,        di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (2-6C)alkanoylamino-(1-6C)alkyl or        (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O, CO and        N(R¹⁷), wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is        heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears        1 or 2 substituents, which may be the same or different,        selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,        and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (k) the Q¹-Z- group is selected from methoxy, ethoxy, propoxy,        isopropoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, 2-aminoethoxy, 3-aminopropoxy,        2-methylaminoethoxy, 3-methylaminopropoxy, 2-ethylaminoethoxy,        3-ethylaminopropoxy, 2-dimethylaminoethoxy,        3-dimethylaminopropoxy, cyclopropyloxy, cyclobutyloxy,        cyclopentyloxy, cyclohexyloxy, cycloheptyloxy,        cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy,        cyclohexylmethoxy and cycloheptylmethoxy,    -   or Z is a direct bond or is selected from O, S, SO, SO₂ and NH        and Q¹ is phenyl, benzyl, 2-thienyl, 1-imidazolyl,        1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl,        2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl,        2-(1,2,3-triazol-1-yl)ethyl, 2-(1,2,4-triazol-1-yl)ethyl,        3-(1,2,3-triazol-1-yl)propyl, 3-(1,2,4-triazol-1-yl)propyl, 2-,        3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3-        or 4-pyridyl)propyl, oxetan-3-yl, tetrahydrofuran-3-yl, 3- or        4-tetrahydropyranyl, 3- or 4-oxepanyl, 1-, 2- or 3-pyrrolidinyl,        morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino,        piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl,        piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or        3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or        4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl,        2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperidin-3-ylethyl,        2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl,        3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,        3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or        3-homopiperazin-1-ylpropyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CONH, NHCO, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino, or from a group of the formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, NH, CONH,        NHCO and CH₂O and Q⁸ is pyridyl, pyridylmethyl, pyrrolidin-1-yl,        pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,        piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl,        3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl,        piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,        2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within        the Q¹-Z- group optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and        methoxy, or optionally bears 1 substituent selected from a group        of the formula:        —X⁸R¹⁵        wherein X⁸ is a direct bond or is selected from O and NH and R¹⁵        is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl,        3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl,        methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl,        2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,        2dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,        methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or        tert-butoxycarbonylaminomethyl, and from a group of the formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O and NH and Q⁹        is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl,        3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl,        3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl        or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2        substituents, which may be the same or different, selected from        fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (l) the Q¹-Z- group is selected from methoxy, ethoxy, propoxy,        isopropoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,        cycloheptyloxy, phenoxy, phenylthio, anilino, benzyloxy,        cyclopropylmethoxy, tetrahydrofuran-3-yloxy, 3- or        4-tetrahydropyranyloxy, 2-imidazol-1-ylethoxy,        3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy,        3-(1,2,4-triazol-1-yl)propoxy, pyrrolidin-1-yl, morpholino,        piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin        4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy,        2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino,        pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino,        2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino,        2-morpholinoethylamino, 3-morpholinopropylamino,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino,        2-piperidinoethylamino, 3-piperidinopropylamino,        piperidin-3-ylamino, piperidin-4-ylamino,        piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino,        piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino,        homopiperidin-3-ylamino, homopiperidin-4-ylamino,        homopiperidin-3-ylmethylamino, 2-homopiperidin-1-ylethylamino,        3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino,        3-piperazin-1-ylpropylamino, 2-homopiperazin-1-ylethylamino or        3-homopiperazin-1-ylpropylamino,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CH═CH and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and        methoxy, and a piperidin-3-ylmethyl or piperidin-4-ylmethyl        group within the Q¹-Z group is optionally N-substituted with        2-methoxyethyl, 3-methoxypropyl, 2-aminoethyl, 3-aminopropyl,        2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl,        3dimethylaminopropyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl 2-morpholinoethyl, 3-morpholinopropyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or        3-piperazin-1-ylpropyl, the last 8 of which substituents each        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z group        optionally bears 1 or 2 oxo substituents;        (m) the Q¹-Z- group is selected from propoxy, isopropoxy,        2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, cyclopentyloxy, cyclohexyloxy, phenoxy,        benzyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z-        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (n) Z is a direct bond or is selected from O, S, SO, SO₂, N(R¹¹)        and CO wherein R¹¹ is hydrogen or (1-6C)alkyl, and Q¹ is aryl,        aryl-(1-6C)alkyl, (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, N(R¹²), CON(R¹²),        N(R²)CO, CH═CH and C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂C— or HC≡C— group within the Q¹-Z- group        optionally bears at the terminal CH₂═or HC≡ position a        substituent selected from carbamoyl, N-(1-6C)alkylcarbamoyl,        N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,        (1-6C)alkylamino-(1-6C)alkyl and        di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the        formula:        Q⁷-X⁶—        wherein X⁶ is a direct bond or is CO or N(R¹³)CO, wherein R¹³ is        hydrogen or (1-6C)alkyl, and Q⁷ is heteroaryl,        heteroaryl-(1-6C)alkyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, (1-6C)alkoxy,        (1-6C)alkylsulphonyl, (1-6C)alkylamino and        di-[(1-6C)alkyl]amino, or from a group of the formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, N(R¹⁴),        CON(R¹⁴), N(R¹⁴)CO and C(R¹⁴)₂O, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any aryl, heteroaryl or heterocyclyl group within        the Q¹-Z- group optionally bears 1, 2 or 3 substituents, which        may be the same or different, selected from halogeno,        trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl,        (1-6C)alkoxy, N-(1-6C)alkylcarbamoyl and        N,N-di-[(1-6C)alkyl]carbamoyl, or optionally bears 1 substituent        selected from a group of the formula:        —X⁸—R¹⁵        wherein X⁴ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,        amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,        di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (2-6C)alkanoylamino-(1-6C)alkyl or        (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O and N(R¹⁷),        wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is heterocyclyl        or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2        substituents, which may be the same or different, selected from        halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (o) Z is a direct bond or is selected from O, S, SO, SO₂ and NH        and Q¹ is phenyl, benzyl 2-thienyl, 1-imidazolyl,        1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl,        2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl,        2-(1,2,3-triazol-1-yl)ethyl, 2-(1,2,4-triazol-1-yl)ethyl,        3-(1,2,3-triazol-1-yl)propyl, 3-(1,2,4-triazol-1-yl)propyl, 2-,        3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3-        or 4-pyridyl)propyl, oxetan-3-yl, tetrahydrofuran-3-yl, 3- or        4-tetrahydropyranyl, 3- or 4-oxepanyl, 1-, 2- or 3-pyrrolidinyl,        morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazinyl, piperidino,        piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl,        piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or        3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or        4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl,        2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperidin-3-ylethyl,        2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl,        3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,        3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or        3-homopiperazin-1-ylpropyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CONH, NHCO, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino, or from a group of the formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, NH, CONH,        NHCO and CH₂O and Q⁸ is pyridyl, pyridylmethyl, pyrrolidin-1-yl,        pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,        piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl,        3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl,        piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,        2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, and wherein any        aryl, heteroaryl or heterocyclyl group within the Q¹-Z- group        optionally bears 1, 2 or 3 substituents, which may be the same        or different, selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, carbamoyl, methyl, ethyl and methoxy, or        optionally bears 1 substituent selected from a group of the        formula:        —X⁸—R¹⁵        wherein X⁸ is a direct bond or is selected from O and NH and R¹⁵        is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl,        3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl,        methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl,        2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,        2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,        methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or        tert-butoxycarbonylaminomethyl, and from a group of the formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O and NH and Q⁹        is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl,        3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl,        3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl        or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2        substituents, which may be the same or different, selected from        fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (p) the Q¹-Z- group is selected from phenoxy, phenylthio,        anilino, benzyloxy, cyclopropylmethoxy, tetrahydrofuran-3-yloxy,        3- or 4-tetrahydropyranyloxy, 2-imidazol-1-ylethoxy,        3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy,        3-(1,2,4-triazol-1-yl)propoxy, pyrrolidin-1-yl, morpholino,        piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy,        2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino,        pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino,        2-pyrrolin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino,        2-morpholinoethylamino, 3-morpholinopropylamino,        2-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)ethylamino,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino,        2-piperidinoethylamino, 3-piperidinopropylamino,        piperidin-3-ylamino, piperidin-4-ylamino,        piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino,        piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino,        homopiperidin-3-ylamino, homopiperidin-4-ylamino,        homopiperidin-3-ylmethylamino, 2-homopiperidin-1-ylethylamino,        3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino,        3-piperazin-1-ylpropylamino, 2-homopiperazin-1-ylethylamino or        3-homopiperazin-1-ylpropylamino,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CH═CH and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and        methoxy, and a piperidin-3-ylmethyl or piperidin-4-ylmethyl        group within the Q¹-Z group is optionally N-substituted with        2-methoxyethyl, 3-methoxypropyl, 2-aminoethyl, 3-aminopropyl,        2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl,        3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or        3-piperazin-1-ylpropyl, the last 8 of which substituents each        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z group        optionally bears 1 or 2 oxo substituents;        (q) the Q¹-Z- group is selected from phenoxy, benzyloxy,        tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, ethylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z-        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (r) Z is selected from O, S, SO, SO₂, N(R¹¹) and CO wherein R¹¹        is hydrogen or (1-6C)alkyl, and Q¹ is (3-7C)cycloalkyl,        (3-7C)cycloalkyl-(1-6C)allyl, heterocyclyl or        heterocyclyl-(1-6C)alkyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, N(R¹²), CON(R¹²),        N(R¹²)CO, CH═CH and C≡C wherein R¹² is hydrogen or (1-6C)alkyl,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, (1-6C)alkoxy,        (1-6C)alkylsulphonyl, (1-6C)alkylamino and        di-[(1-6C)alkyl]amino, or from a group of the formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, N(R¹⁴),        CON(R¹⁴), N(R¹⁴)CO and C(R¹⁴)₂O, wherein R¹⁴ is hydrogen or        (1-6C)alkyl, and Q⁸ is heteroaryl, heteroaryl-(1-6C)alkyl,        heterocyclyl or heterocyclyl-(1-6C)alkyl,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1, 2 or 3 substituents, which may be the same        or different, selected from halogeno, trifluoromethyl, hydroxy,        amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy,        N-(1-6C)alkylcarbamoyl and N,N-di-[(1-6C)alkyl]carbamoyl or        optionally bears 1 substituent selected from a group of the        formula:        —X⁸—R¹⁵        wherein X⁴ is a direct bond or is selected from O and N(R¹⁶),        wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is        hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,        amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,        di-[(1-6C)alkyl]amino-(1-6C)alkyl,        (2-6C)alkanoylamino-(1-6C)alkyl or        (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and a group of the        formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O and N(R¹⁷),        wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is heterocyclyl        or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2        substituents, which may be the same or different, selected from        halogeno, (1-6C)alkyl and (1-6C)alkoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (s) Z is selected from O, S, SO, SO₂ and NH and Q¹ is        oxetan-3-yl, tetrahydrofuran-3-yl, 3- or 4-tetrahydropyranyl, 3-        or 4-oxepanyl, 1-, 2- or 3-pyrrolidinyl, morpholino,        1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino,        piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl,        piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or        3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or        4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl,        2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl, 3-morpholinopropyl,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl,        2-piperidinoethyl, 3-piperidinopropyl, 2-piperidin-3-ylethyl,        2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl,        3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,        3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or        3-homopiperazin-1-ylpropyl,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CONH, NHCO, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino, or from a group of the formula:        —X⁷-Q⁸        wherein X⁷ is a direct bond or is selected from O, NH, CONH,        NHCO and CH₂O and Q⁸ is pyridyl pyridylmethyl, pyrrolidin-1-yl,        pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,        piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl,        2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,        2-morpholinoethyl 3-morpholinopropyl, 2-piperidinoethyl,        3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl,        piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,        2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1, 2 or 3 substituents, which may be the same        or different, selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, carbamoyl, methyl, ethyl and methoxy, or        optionally bears 1 substituent selected from a group of the        formula:        X⁸—R¹⁵        wherein X⁸ is a direct bond or is selected from O and NH and R¹⁵        is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl,        3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl,        methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl,        2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,        2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,        methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or        tert-butoxycarbonylaminomethyl, and from a group of the formula:        —X⁹-Q⁹        wherein X⁹ is a direct bond or is selected from O and NH and Q⁹        is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl,        3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl,        3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl        or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2        substituents, which may be the same or different, selected from        fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (t) the Q¹-Z- group is selected from cyclopropylmethoxy,        tetrahydrofuran-3-yloxy, 3- or 4-tetrahydropyranyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy,        2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino,        pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino,        2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino,        2-morpholinoethylamino, 3-morpholinopropylamino,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino,        2-piperidinoethylamino, 3-piperidinopropylamino,        piperidin-3-ylamino, piperidin-4-ylamino,        piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino,        piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino,        homopiperidin-3-ylamino, homopiperidin-4-ylamino,        homopiperidin-3-ylmethylamino, 2-homopiperidin-1-ylethylamino,        3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino,        3-piperazin-1-ylpropylamino, 2-homopiperazin-1-ylethylamino or        3-homopiperazin-1-ylpropylamino,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within the Q¹-Z- group are optionally separated by the insertion        into the chain of a group selected from O, NH, CH═CH and C≡C,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any heterocyclyl group within the Q¹-Z group        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, carbamoyl, methyl, ethyl and methoxy, and a        piperidin-3-ylmethyl or piperidin-4-ylmethyl group within the        Q¹-Z group is optionally N-substituted with 2-methoxyethyl,        3-methoxypropyl, 2-aminoethyl, 3-aminopropyl,        2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl,        3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl,        3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl 3-morpholinopropyl        2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or        3-piperazin-1-ylpropyl the last 8 of which substituents each        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, methyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z group        optionally bears 1 or 2 oxo substituents;        (u) the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1        μl-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;        (v) Q² is an aryl group of formula Ia        wherein G¹ is selected from halogeno, trifluoromethyl, cyano,        hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and        (1-6C)alkoxy,    -   and each of G², G³, G⁴ and G⁵, which may be the same or        different, is selected from hydrogen, halogeno, trifluoromethyl,        cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and        (1-6C)alkoxy,        (w) Q² is an aryl group of formula Ia wherein G¹ and G² together        form a group of formula:— —CH═CH—CH═CH—, —N═CH—CH═CH—,        —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N—, —CH═CH—O—, —O—CH═CH—,        —CH═CH—S—, —S—CH═CH—, —O—CH₂—O— or —O—CH₂—CH₂—O—,    -   and the 9- or 10-membered bicyclic heteroaryl or heterocyclic        ring formed when G¹ and G² together are linked optionally bears        on the heteroaryl or heterocyclic portion of the bicyclic ring        1, 2 or 3 substituents, which may be the same or different,        selected from halogeno, trifluoromethyl, cyano, hydroxy,        (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy, and        any bicyclic heterocyclic ring so formed optionally bears 1 or 2        oxo or thioxo groups,    -   and each of G³, G⁴ and G⁵, which may be the same or different,        is selected from hydrogen, halogeno, trifluoromethyl, cyano,        hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and        (1-6C)alkoxy;        (x) Q² is an aryl group of formula Ia wherein G¹ is selected        from halogeno, trifluoromethyl, cyano, hydroxy, (1-6C)alkyl,        (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,    -   and G² and G³ together or G³ and G⁴ together form a group of        formula:——CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—,        —CH═CH—N═CH—, —CH═CH—CH═N—, —CH═CH—O—, —O—CH═CH—, —CH═CH—S—,        —S—CH═CH—, —O—CH₂—O— or —O—CH₂—CH₂—O—,    -   and the 9- or 10-membered bicyclic heteroaryl or heterocyclic        ring formed when G² and G³ together or G³ and G⁴ together are        linked optionally bears on the heteroaryl or heterocyclic        portion of the bicyclic ring 1, 2 or 3 substituents, which may        be the same or different, selected from halogeno,        trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl,        (2-8C)alkynyl and (1-6C)alkoxy, and any bicyclic heterocyclic        ring so formed optionally bears 1 or 2 oxo or thioxo groups,    -   and each of G⁴ and G⁵ or G² and G⁵ as appropriate, which may be        the same or different, is selected from hydrogen, halogeno,        trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl,        (2-8C)alkynyl and (1-6C)alkoxy;        (y) Q² is an aryl group of formula Ia wherein G¹ is selected        from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        1-propynyl, 2-propynyl, methoxy and ethoxy,    -   and each of G², G³, G⁴ and G⁵, which may be the same or        different, is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, 1-propynyl, 2-propynyl, methoxy and        ethoxy;        (z) Q² is an aryl group of formula Ia wherein G¹ is selected        from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano,        methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl, methoxy and        ethoxy,    -   and each of G², G³, G⁴ and G⁵, which may be the same or        different, is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy,        (aa) Q² is an aryl group of formula Ia wherein G¹ and G²        together form a group of formula:— —CH═CH—CH═CH—, —O—CH═CH— or        —O—CH₂O—,    -   and the 9- or 10-membered bicyclic heteroaryl or heterocyclic        ring so formed optionally bears on the heteroaryl or        heterocyclic portion of the bicyclic ring 1 or 2 substituents,        which may be the same or different, selected from fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl,        methoxy and ethoxy, and any bicyclic heterocyclic ring so formed        optionally bears 1 or 2 oxo or thioxo groups,    -   and each of G³, G⁴ and G⁵, which may be the same or different,        is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, methoxy and        ethoxy;        (bb) Q² is an aryl group of formula Ia wherein G¹ is selected        from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano, methyl        ethyl, methoxy and ethoxy,    -   and G² and G³ together or G³ and G⁴ together form a group of        formula —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—,    -   and the 9- or 10-membered bicyclic heteroaryl or heterocyclic        ring so formed optionally bears on the heteroaryl or        heterocyclic portion of the bicyclic ring 1 or 2 substituents,        which may be the same or different, selected from fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl,        methoxy and ethoxy, and any bicyclic heterocyclic ring so formed        optionally bears 1 or 2 oxo or thioxo groups,    -   and each of G⁴ and G⁵ or G² and G⁵ as appropriate, which may be        the same or different, is selected from hydrogen, fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl,        methoxy and ethoxy, and        (cc) Q² is an aryl group of formula Ia wherein G¹ and G²        together form a group of formula:— —O—CH₂—O—,    -   and the 9-membered bicyclic heterocyclic ring so formed        optionally bears on the heterocyclic portion of the bicyclic        ring 1 or 2 substituents, which may be the same or different,        selected from fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, methoxy and ethoxy, and the bicyclic        heterocyclic ring so formed optionally bears 1 oxo or thioxo        groups,    -   each of G³ and G⁴, which may be the same or different, is        selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl,        cyano, hydroxy, methyl, ethyl, methoxy and ethoxy,    -   and G⁵ is selected from hydrogen, fluoro, chloro or bromo.

As stated hereinbefore, certain compounds disclosed in the presentinvention, possess higher inhibitory potency against particularnon-receptor tyrosine kinases such as p56^(lck) tyrosine kinase thanagainst other non-receptor tyrosine kinases or RTKs such as EGF RTK orVEGF RTK. Particular groups of compounds disclosed in the invention thatpossess such selectivity include, for example, quinazoline derivativesof the Formula I, or pharmaceutically-acceptable salts thereof, whereineach of m, R¹, R², R³, Z and Q¹ has any of the meanings definedhereinbefore and:—

-   (a) Q² is an aryl group of formula Ia    wherein G¹ is halogeno or trifluoromethyl,    -   each of G² and G⁵ is hydrogen,    -   G³ is selected from hydrogen, halogeno, trifluoromethyl, cyano,        hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and        (1-6C)alkoxy,    -   and G⁴ is halogeno or (1-6C)alkoxy;-   (b) Q² is an aryl group of formula Ia wherein G¹ is fluoro, chloro,    bromo, iodo or trifluoromethyl,    -   each of G² and G⁵ is hydrogen,    -   G³ is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and G⁴ is fluoro,        chloro, bromo, methoxy or ethoxy;-   (c) Q² is an aryl group of formula Ia wherein G¹ and G² together    form a group of formula:— —O—CH₂—O—,    -   each of G³ and G⁴, which may be the same or different, is        selected from hydrogen, halogeno, trifluoromethyl, cyano,        hydroxy, (1-6C)alkyl and (1-6C)alkoxy, and G⁵ is halogeno; or-   (d) Q² is an aryl group of formula Ia wherein G¹ and G² together    form a group of formula:— —O—CH₂—O—,    -   each of G³ and G⁴, which may be the same or different, is        selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl,        cyano, hydroxy, methyl, ethyl, methoxy and ethoxy,    -   and G⁵ is selected from fluoro, chloro or bromo.

A preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 0 or m is 1 and the R¹ group is located at the 6- or        7-position and is selected from hydroxy, amino, methyl, ethyl,        propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,        dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy and        3-homopiperazin-1-ylpropoxy,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within a        substituent on R¹ optionally bears 1 or 2 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;    -   the Q¹-Z- group is selected from propoxy, isopropoxy,        2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, cyclopentyloxy, cyclohexyloxy, phenoxy,        benzyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z-        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G², G³, G⁴        and G⁵, which may be the same or different, is selected from        hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        methoxy and ethoxy,        or G¹ and G² together form a group of formula:— —CH═CH—CH—CH—,        —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered bicyclic        heteroaryl or heterocyclic ring so formed optionally bears on        the heteroaryl or heterocyclic portion of the bicyclic ring 1 or        2 substituents, which may be the same or different, selected        from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,        methyl, ethyl, methoxy and ethoxy, and any bicyclic heterocyclic        ring so formed optionally bears 1 or 2 oxo or thioxo groups, and        each of G³, G⁴ and G⁵, which may be the same or different, is        selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl,        cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, ethoxy, propoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy, 2-hydroxyethoxy,        3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy,        2-methylsulphonylethoxy, 3-methylsulphonylpropoxy and        2-(2-methoxyethoxy)ethoxy;    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from propoxy, isopropoxy,        2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, cyclopentyloxy, cyclohexyloxy,        tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazinyl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        N-methylpiperidin-3-yloxy, piperidin-4-yloxy,        N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,        N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy        and 3-(4-methylpiperazin-1-yl)propoxy,    -   and wherein any CH₂ group within the Q¹-Z- group that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl and        ethynyl, each of G³ and G⁴, which may be the same or different,        is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G² and G⁵        is hydrogen, or G¹ and G² together form a group of formula:—        —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered        bicyclic heteroaryl or heterocyclic ring so formed optionally        bears on the heteroaryl or heterocyclic portion of the bicyclic        ring 1 or 2 substituents, which may be the same or different,        selected from fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl and methoxy, and each of G³, G⁴ and G⁵, which        may be the same or different, is selected from hydrogen, fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl and        methoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, benzyloxy, 3-morpholinopropoxy,        2-hydroxy-3-morpholinopropoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and        2-(2-methoxyethoxy)ethoxy,    -   the Q¹-Z- group is selected from isopropoxy, 2-methoxyethoxy,        cyclohexyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        3-pyrrolidin-1-ylpropoxy, N-methylpyrrolidin-3-yloxy,        3-morpholinopropoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, N-methylpiperidin-4-yloxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy and        3-(4-methylpiperazin-1-yl)propoxy,    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo and iodo, each        of G³ and G⁴, which may be the same or different, is selected        from hydrogen, chloro and methoxy, and each of G² and G⁵ is        hydrogen,        or G¹ and G² together form a group of formula:—        —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or —O—CH₂—O—, and each of G³, G⁴        and G⁵ is hydrogen;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 0 or m is 1 and the R¹ group is located at the 6- or        7-position and is selected from hydroxy, amino, methyl, ethyl,        propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,        dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy and        3-homopiperazin-1-ylpropoxy,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within a        substituent on R¹ optionally bears 1 or 2 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;    -   the Q¹-Z- group is selected from phenoxy, benzyloxy,        tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,        3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,        3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within the Q¹-Z-        group optionally bears 1 or 2 substituents, which may be the        same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G², G³, G⁴        and G⁵, which may be the same or different, is selected from        hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        methoxy and ethoxy,        or G¹ and G² together form a group of formula:— —CH═CH—CH═CH—,        —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered bicyclic        heteroaryl or heterocyclic ring so formed optionally bears on        the heteroaryl or heterocyclic portion of the bicyclic ring 1 or        2 substituents, which may be the same or different, selected        from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,        methyl, ethyl, methoxy and ethoxy, and any bicyclic heterocyclic        ring so formed optionally bears 1 or 2 oxo or thioxo groups, and        each of G³, G⁴ and G⁵, which may be the same or different, is        selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl,        cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, ethoxy, propoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy, 2-hydroxyethoxy,        3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy,        2-methylsulphonylethoxy, 3-methylsulphonylpropoxy and        2-(2-methoxyethoxy)ethoxy;    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        N-methylpiperidin-3-yloxy, piperidin-4-yloxy,        N-methylpiperidin-4yloxy, piperidin-3-ylmethoxy,        N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy        and 3-(4-methylpiperazin-1-yl)propoxy,    -   and wherein any CH₂ group within the Q¹-Z- group that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R¹ and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl and        ethynyl, each of G³ and G⁴, which may be the same or different,        is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G² and G⁵        is hydrogen, or G¹ and G² together form a group of formula:—        —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered        bicyclic heteroaryl or heterocyclic ring so formed optionally        bears on the heteroaryl or heterocyclic portion of the bicyclic        ring 1 or 2 substituents, which may be the same or different,        selected from fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl and methoxy, and each of G³, G⁴ and G⁵, which        may be the same or different, is selected from hydrogen, fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl and        methoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, benzyloxy, 3-morpholinopropoxy,        2-hydroxy-3-morpholinopropoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and        2-(2-methoxyethoxy)ethoxy;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,        2-(1,2,4-triazol-1-yl)ethoxy, 3-pyrrolidin-1-ylpropoxy,        N-methylpyrrolidin-3-yloxy, 3-morpholinopropoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, N-methylpiperidin-4-yloxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy and        3-(4methylpiperazin-1-yl)propoxy,    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo and iodo, each        of G³ and G⁴, which may be the same or different, is selected        from hydrogen, chloro and methoxy, and each of G² and G⁵ is        hydrogen,        or G¹ and G² together form a group of formula:—        —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or —O—CH₂—O—, and each of G³, G⁴        and G⁵ is hydrogen;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 0 or m is 1 and the R¹ group is located at the 6- or        7-position and is selected from hydroxy, amino, methyl, ethyl,        propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,        dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,        2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy and        3-homopiperazin-1-ylpropoxy,    -   and wherein adjacent carbon atoms in any (2-6C)alkylene chain        within a R¹ substituent are optionally separated by the        insertion into the chain of a group selected from O, NH, CH═CH        and C≡C,    -   and wherein any CH₂ or CH₃ group within a R¹ substituent        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any phenyl or heterocyclyl group within a        substituent on R¹ optionally bears 1 or 2 substituents, which        may be the same or different, selected from fluoro, chloro,        trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within a substituent on R¹        optionally bears 1 or 2 oxo substituents;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        piperidin-4-yloxy, piperidin-3-ylmethoxy,        2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,        2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,        homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,    -   and wherein any CH₂ or CH₃ group within the Q¹-Z- group        optionally bears on each said CH₂ or CH₃ group a substituent        selected from hydroxy, amino, methoxy, methylsulphonyl,        methylamino and dimethylamino,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 substituents, which may be the same or        different, selected from fluoro, chloro, trifluoromethyl,        hydroxy, amino, methyl, ethyl and methoxy,    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G², G³, G⁴        and G⁵, which may be the same or different, is selected from        hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        methoxy and ethoxy,        or G¹ and G² together form a group of formula:— —CH═CH—CH═CH—,        —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered bicyclic        heteroaryl or heterocyclic ring so formed optionally bears on        the heteroaryl or heterocyclic portion of the bicyclic ring 1 or        2 substituents, which may be the same or different, selected        from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,        methyl, ethyl, methoxy and ethoxy, and any bicyclic heterocyclic        ring so formed optionally bears 1 or 2 oxo or thioxo groups, and        each of G³, G⁴ and G⁵, which may be the same or different, is        selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl,        cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, ethoxy, propoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy, 2-hydroxyethoxy,        3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy,        2-methylsulphonylethoxy, 3-methylsulphonylpropoxy and        2-(2-methoxyethoxy)ethoxy;    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy,        N-methylpiperidin-3-yloxy, piperidin-4-yloxy,        N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,        N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy        and 3-(4-methylpiperazin-1-yl)propoxy,    -   and wherein any CH₂ group within the Q¹-Z- group that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl and        ethynyl, each of G³ and G⁴, which may be the same or different,        is selected from hydrogen, fluoro, chloro, bromo,        trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,        isopropenyl, ethynyl, methoxy and ethoxy, and each of G² and G⁵        is hydrogen, or G¹ and G² together form a group of formula:—        —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered        bicyclic heteroaryl or heterocyclic ring so formed optionally        bears on the heteroaryl or heterocyclic portion of the bicyclic        ring 1 or 2 substituents, which may be the same or different,        selected from fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl and methoxy, and each of G³, G⁴ and G⁵, which        may be the same or different, is selected from hydrogen, fluoro,        chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl and        methoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, ethoxy, propoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy,        3-methoxypropoxy, 2-methylsulphonylethoxy,        3-methylsulphonylpropoxy, 2-(2-methoxyethoxy)ethoxy,        2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy, 3-pyridylmethoxy and        4-pyridylmethoxy;    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazinyl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, 3-piperidinyloxy,        N-methylpiperidin-3-yloxy, 4-piperidinyloxy,        N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,        N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy, cyclobutyloxy, cyclopentyloxy        and cyclohexyloxy,    -   and wherein any CH₂ group within the Q¹-Z- group that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl,        ethynyl, methoxy and pyrrolidin-lyl, G² is hydrogen, each of G³        and G⁴, which may be the same or different, is selected from        hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        methoxy and ethoxy, and G⁵ is hydrogen or methoxy,        or G¹ and G² together form a group of formula:— —CH═CH—CH═CH—,        —O—CH═CH— or —O—CH₂—O—, and the 9- or 10membered bicyclic        heteroaryl or heterocyclic ring so formed optionally bears on        the heteroaryl or heterocyclic portion of the bicyclic ring 1 or        2 substituents, which may be the same or different, selected        from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,        methyl and methoxy, and each of G³, G⁴ and G⁵, which may be the        same or different, is selected from hydrogen, fluoro, chloro,        bromo, trifluoromethyl, cyano, hydroxy, methyl and methoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, ethoxy, propoxy, isopropoxy,        isobutoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidin-4-ylethoxy,        2-(N-methylpiperidin-4-yl)ethoxy, 2-homopiperidin-1-ylethoxy,        3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        3-(4-cyanomethylpiperazin-1-yl)propoxy,        2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-tetrahydropyran-4-ylethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy,        2-methoxyethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy,        3-methylsulphonylpropoxy, 2-(2-methoxyethoxy)ethoxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,        2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy, 3-pyridylmethoxy,        4-pyridylmethoxy and 3-cyanopyrid-4-ylmethoxy,    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,        N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,        2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy,        2-morpholinoethoxy, 3-morpholinopropoxy,        2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,        3-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)propoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, 3-piperidinyloxy,        N-methylpiperidin-3-yloxy, 4-piperidinyloxy,        N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,        N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy, cyclobutyloxy, cyclopentyloxy        and cyclohexyloxy,    -   and wherein any CH₂ group within the Q¹-Z- group that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   and wherein any heterocyclyl group within the Q¹-Z- group        optionally bears 1 or 2 oxo substituents;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo, iodo,        trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl,        ethynyl, methoxy and pyrrolidin-lyl, G² is hydrogen, each of G³        and G⁴, which may be the same or different, is selected from        hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano,        hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,        methoxy and ethoxy, and G⁵ is hydrogen or methoxy,        or G¹ and G² together form a group of formula:— —CH═CH—CH═CH—,        —O—CH═CH— or —O—CH₂—O—, and the 9- or 10-membered bicyclic        heteroaryl or heterocyclic ring so formed optionally bears on        the heteroaryl or heterocyclic portion of the bicyclic ring 1 or        2 substituents, which may be the same or different, selected        from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,        methyl and methoxy, and each of G³, G⁴ and G⁵, which may be the        same or different, is selected from hydrogen, fluoro, chloro,        bromo, trifluoromethyl, cyano, hydroxy, methyl and methoxy;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from hydroxy, methoxy, benzyloxy, 3-morpholinopropoxy,        2-hydroxy-3-morpholinopropoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and        2-(2-methoxyethoxy)ethoxy;    -   the Q¹-Z- group is selected from tetrahydrofuran-3-yloxy,        tetrahydropyran-4yloxy, 3-pyrrolidin-1-ylpropoxy,        N-methylpyrrolidin-3-yloxy, 3-morpholinopropoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, N-methylpiperidin-4-yloxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy and        3-(4-methylpiperazin-1-yl)propoxy,    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from fluoro, chloro, bromo and iodo, each        of G³ and G⁴, which may be the same or different, is selected        from hydrogen, chloro and methoxy, and each of (G² and G⁵ is        hydrogen,        or G¹ and G² together form a group of formula:—        —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or —O—CH₂—O—, and each of G³, G⁴        and G⁵ is hydrogen;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy,        3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy,        2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy;    -   the Q¹-Z- group is selected from tetrahydropyran-4-yloxy,        3-pyrrolidin-1-ylpropoxy, N-methylpyrrolidin-3-yloxy,        3-morpholinopropoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy,        piperidinylmethoxy, N-methylpiperidin-4-ylmethoxy,        3-(4-methylpiperazin-1-yl)propoxy, cyclopentyloxy and        cyclohexyloxy;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from chloro, bromo, trifluoromethyl,        methyl, methoxy and pyrrolidin-1-yl, G² is hydrogen, G³ is        selected from hydrogen and chloro, G⁴ is methoxy, and G⁵ is        hydrogen,        or G¹ and G² together form a group of formula:—        —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or —O—CH₂—O—, each of G³ and G⁴        is hydrogen, and G⁵ is hydrogen or chloro;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from methoxy, ethoxy, propoxy, isopropoxy, isobutoxy,        2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidin-4-ylethoxy,        2-(N-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy,        3-morpholinopropoxy, 2-(1,        1-dioxotetrahydro-4-1,4-thiazin-4-yl)ethoxy, 3-(1,        1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,        2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        3-(4-cyanomethylpiperazin-1-yl)propoxy,        2-[(2S2-carbamoylpyrrolidin-1-yl]ethoxy,        2-[(2S)-2-t-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        3-methylsulphonylpropoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy,        2-pyridylmethoxy, 3-pyridylmethoxy, 4-pyridylmethoxy and        2-cyanopyrid-4-ylmethoxy,    -   and wherein any CH₂ group within a R¹ substituent that is        attached to two carbon atoms optionally bears a hydroxy group on        said CH₂ group;    -   the Q¹-Z- group is selected from tetrahydropyran-4-yloxy,        3-pyrrolidin-1-ylpropoxy, N-methylpyrrolidin-3-yloxy,        3-morpholinopropoxy,        3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,        2-piperidinoethoxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,        3-(4-methylpiperazin-1-yl)propoxy, cyclopentyloxy and        cyclohexyloxy;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ is selected from chloro, bromo, trifluoromethyl,        methyl, methoxy and pyrrolidin-1-yl, G² is hydrogen, G³ is        selected from hydrogen and chloro, G⁴ is methoxy, and G⁵ is        hydrogen,        or G¹ and G² together form a group of formula:— —O—CH═CH—,        —O—CH═C(Cl)— or —O—CH₂—O—, each of G³ and G⁴ is hydrogen, and G⁵        is hydrogen or chloro;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,        3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy,        3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,        2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy,        2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy,    -   the Q¹-Z- group is selected from tetrahydropyran-4-yloxy,        4piperidinyloxy, N-methylpiperidin-4-yloxy, cyclopentyloxy and        cyclohexyloxy;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ and G² together form a group of formula:— —O—CH₂—O—,        each of G³ and G⁴ is hydrogen, and G⁵ is chloro;        or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound disclosed in the invention is a quinazolinederivative of the Formula I wherein:

-   -   m is 1 and the R¹ group is located at the 7-position and is        selected from methoxy, ethoxy, propoxy, isopropoxy, isobutoxy,        2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy,        2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,        2-piperidinoethoxy, 3-piperidinopropoxy,        3-(4-hydroxypiperidin-1-yl)propoxy, 2-piperidin-4-ylethoxy,        2-(N-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy,        3-morpholinopropoxy, 2-piperazin-1-ylethoxy,        3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,        3-(4-methylpiperazin-1-yl)propoxy,        3-(4-cyanomethylpiperazin-1-yl)propoxy,        2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,        2-[(2S)-2-(N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,        3-methylsulphonylpropoxy, piperidin-4-ylmethoxy,        N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy,        2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy;    -   the Q¹-Z- group is selected from tetrahydropyran-4-yloxy,        4-piperidinyloxy, N-methylpiperidin-4-yloxy,        piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,        cyclopentyloxy and cyclohexyloxy;    -   each of R² and R³ is hydrogen; and    -   Q² is an aryl group of formula Ia        wherein G¹ and G² together form a group of formula:— —O—CH₂—O—,        each of G³ and G⁴ is hydrogen, and G⁵ is chloro;        or a pharmaceutically-acceptable acid-addition salt thereof.

A particular preferred compound disclosed in the present invention is,for example, a quinazoline derivative of the Formula I selected from:—

-   4-(2-chloro-5-methoxyanilino)-5,7-di-(3-morpholinopropoxy)quinazoline,-   4-(2-bromo-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(2-chloro-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-chloro-5-methoxyanilino)-7-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-chloro-5-methoxyanilino)-7-(2-hydroxy-3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydrofuran-3-yloxyquinazoline,-   4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydrofuran-3-yloxyquinazoline,-   4-(5-chloronaphth-1-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(3-chlorobenzofuran-7-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   7-benzyloxy-4-(2-bromo-5-methoxyanilino)-5-piperidin-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-(3-methylsulphonylpropoxy)-5-piperidin-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,-   4-(2,4-dichloro-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(2,5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(2,4-dichloro-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-(4-pyridyloxyethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,-   4-(2-bromo-5-methoxyanilino)-7-(4-pyridylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(5-methoxy-2-pyrrolidin-1-ylanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,    and-   4-(2-bromo-5-methoxyanilino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline;    or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred compound disclosed in the presentinvention is, for example, a quinazoline derivative of the Formula Iselected from:—

-   4-(2-chloro-5-methoxyanilino)-5-isopropoxy-7-(3-morpholinopropoxy)quinazoline    and-   4-(2-chloro-5-methoxyanilino)-5-isopropoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,    or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred compound disclosed in the presentinvention is, for example, a quinazoline derivative of the Formula Iselected from:—

-   4-(6-chloro-2,3-methylenedioxyamino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-5-piperidinyloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyamino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-pyridyloxy)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,-   4-(6-chloro-2,3-methylenedioxyanilino)-7-piperidin-4-ylmethoxy-5-tetrahydropyran-4-yloxyquinazoline    and-   4-(6-chloro-2,3-methylenedioxyanilino)-7-(N-methylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline;    or a pharmaceutically-acceptable acid-addition salt thereof.

A quinazoline derivative of the Formula I, or apharmaceutically-acceptable salt thereof, may be prepared by any processknown to be applicable to the preparation of chemically-relatedcompounds. Such processes, when used to prepare a quinazoline derivativeof the Formula I are illustrated by the following representative processvariants in which, unless otherwise stated, Q¹, Z, m, R¹, R², R³ and Q²have any of the meanings defined hereinbefore. Necessary startingmaterials may be obtained by standard procedures of organic chemistry.The preparation of such stating materials is described in conjunctionwith the following representative process variants and within theaccompanying Examples. Alternatively necessary starting materials areobtainable by analogous procedures to those illustrated which are withinthe ordinary skill of anorganic chemist.(a) The reaction, conveniently in the presence of a suitable base, of aquinazoline of the Formula II

wherein L is a displaceable group and Q¹, Z, m, R¹ and R² have any ofthe meanings defined hereinbefore except that any functional group isprotected if necessary, with an aniline of the FormulaQ²NHR³wherein Q² and R³ have any of the meanings defined hereinbefore exceptthat any functional group is protected if necessary, whereafter anyprotecting group that is present is removed by conventional means.

A suitable base is, for example, an organic amine base such as, forexample, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine,triethylamine, morpholine, N-methylmorpholine ordiazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkalineearth metal carbonate or hydroxide, for example sodium carbonate,potassium carbonate, calcium carbonate, sodium hydroxide or potassiumhydroxide, or, for example, an alkali metal hydride, for example sodiumhydride.

A suitable displaceable group L is, for example, a halogeno, alkoxy,aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy,phenoxy, pentafluorophenoxy, methanesulphonyloxy ortoluene-4-sulphonyloxy group. The reaction is conveniently carried outin the presence of a suitable inert solvent or diluent, for example analcohol or ester such as methanol, ethanol, isopropanol or ethylacetate, a halogenated solvent such as methylene chloride, chloroform orcarbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, anaromatic solvent such as toluene, or a dipolar aprotic solvent such asN,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-oneor dimethylsulphoxide. The reaction is conveniently carried out at atemperature in the range, for example, 10 to 250° C., preferably in therange 40 to 80° C.

Typically, the quinazoline of the Formula II may be reacted with ananiline of the formula Q²NHR³ in the presence of a protic solvent suchas isopropanol, conveniently in the presence of an acid, for examplehydrogen chloride gas in diethyl ether, or hydrochloric acid, and at atemperature in the range, for example, 0 to 150° C., preferably at ornear the reflux temperature of the reaction solvent.

The quinazoline derivative of the Formula I may be obtained from thisprocess in the form of the free base or alternatively it may be obtainedin the form of a salt with the acid of the formula H-L wherein L has themeaning defined hereinbefore. When it is desired to obtain the free basefrom the salt, the salt may be treated with a suitable base, forexample, an organic amine base such as, for example, pyridine,2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine,morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or,for example, an alkali or alkaline earth metal carbonate or hydroxide,for example sodium carbonate, potassium carbonate, calcium carbonate,sodium hydroxide or potassium hydroxide.

Protecting groups may in general be chosen from any of the groupsdescribed in the literature or known to the skilled chemist asappropriate for the protection of the group in is question and may beintroduced by conventional methods. Protecting groups may be removed byany convenient method as described in the literature or known to theskilled chemist as appropriate for the removal of the protecting groupin question, such methods being chosen so as to effect removal of theprotecting group with minimum disturbance of groups elsewhere in themolecule.

Specific examples of protecting groups are given below for the sake ofconvenience, in which “lower”, as in, for example, lower alkyl,signifies that the group to which it is applied preferably has 1-4carbon atoms. It will be understood that these examples are notexhaustive. Where specific examples of methods for the removal ofprotecting groups are given below these are similarly not exhaustive.The use of protecting groups and methods of deprotection notspecifically mentioned are, of course, within the scope of theinvention.

A carboxy protecting group may be the residue of an ester-formingaliphatic or arylaliphatic alcohol or of an ester-forming silanol (thesaid alcohol or silanol preferably containing 1-20 carbon atoms).Examples of carboxy protecting groups include straight or branched chain(1-12C)alkyl groups (for example isopropyl, and tert-butyl); loweralkoxy-lower alkyl groups (for example methoxymethyl, ethoxymethyl andisobutoxymethyl); lower acyloxy-lower alkyl groups, (for exampleacetoxymethyl, propionyloxymethyl, butyryloxymethyl andpivaloyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (forexample 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl);aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl,2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(loweralkyl)silyl groups (for example trimethylsilyl andtert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups (forexample trimethylsilylethyl); and (2-6C)alkenyl groups (for exampleallyl). Methods particularly appropriate for the removal of carboxylprotecting groups include for example acid-, base-, metal- orenzymically-catalysed cleavage.

Examples of hydroxy protecting groups include lower alkyl groups (forexample tert-butyl), lower alkenyl groups (for example allyl); loweralkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (forexample tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (forexample allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for examplebenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyland 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for exampletrimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (forexample benzyl) groups.

Examples of amino protecting groups include formyl, aryl-lower alkylgroups (for example benzyl and substituted benzyl, 4-methoxybenzyl,2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl);di-4-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (forexample tert-butoxycarbonyl); lower alkenyloxycarbonyl (for exampleallyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for examplebenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyland 4-nitrobenzyloxycarbonyl); trialkylsilyl (for example trimethylsilyland tert-butyldimethylsilyl); alkylidene (for example methylidene) andbenzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groupsinclude, for example, acid-, base-, metal- or enzymically-catalysedhydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenationfor groups such as benzyl and photolytically for groups such as2-nitrobenzyloxycarbonyl.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J.March, published by John Wiley & Sons 1992, for general guidance onreaction conditions and reagents and to Protective Groups in OrganicSynthesis, 2^(nd) Edition, by T. Green et al., also published by JohnWiley & Son, for general guidance on protecting groups.

Quinazoline starting materials of the Formula II may be obtained byconventional procedures. For example, a 3,4-dihydroquinazolin-4-one ofFormula III

wherein m, R¹, Q¹, Z and R² have any of the meanings definedhereinbefore except that any functional group is protected if necessary,may be reacted with a halogenating agent such as thionyl chloride,phosphoryl chloride or a mixture of carbon tetrachloride andtriphenylphosphine whereafter any protecting group that is present isremoved by conventional means.

The 4-chloroquinazoline so obtained may be converted, if required, intoa 4-pentafluorophenoxyquinazoline by reaction with pentafluorophenol inthe presence of a suitable base such as potassium carbonate and in thepresence of a suitable solvent such as N,N-dimethylformamide.

(b) For the production of those compounds of the Formula I wherein Z isan oxygen atom, the coupling, conveniently in the presence of a suitabledehydrating agent, of an alcohol of the FormulaQ¹-OHwherein Q¹ has any of the meanings defined hereinbefore except that anyfunctional group is protected if necessary with a quinazoline of theFormula IV

wherein m, R¹, R², R³ and Q² have any of the meanings definedhereinbefore except that any functional group is protected if necessary,whereafter any protecting group that is present is removed byconventional means.

A suitable dehydrating agent is, for example, a carbodiimide reagentsuch as dicyclohexylcarbodiimide or1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or a mixture of an azocompound such as diethyl or di-tert-butyl azodicarboxylate and aphosphine such as triphenylphosphine. The reaction is convenientlycarried out in the presence of a suitable inert solvent or diluent, forexample a halogenated solvent such as methylene chloride, chloroform orcarbon tetrachloride and at a temperature in the range, for example, 10to 150° C., preferably at or near ambient temperature.

The quinazoline of the Formula IV may be obtained by conventionalprocedures. For example, a quinazoline of the Formula V

wherein L is a displaceable group as defined hereinbefore and m, R¹ andR² have any of the meanings defined hereinbefore except that anyfunctional group is protected if necessary, may be reacted with ananiline of the FormulaQ²NHR³wherein Q² and R³ have any of the meanings defined hereinbefore exceptthat any functional group is protected if necessary, whereafter anyprotecting group that is present is removed by conventional means.(c) For the production of those compounds of the Formula I wherein m is1 and R¹ is a group of the formulaQ³-X¹—wherein Q³ is an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl,(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl orheterocyclyl-(1-6C)alkyl group and X¹ is an oxygen atom, the coupling,conveniently in the presence of a suitable dehydrating agent as definedhereinbefore, of a quinazoline of the Formula VI

wherein Q¹, Z, R², R³ and Q² have any of the meanings definedhereinbefore except that any functional group is protected if necessary,with an appropriate alcohol wherein any functional group is protected ifnecessary, whereafter any protecting group that is present is removed byconventional means.

The reaction is conveniently carried out in the presence of a suitableinert solvent or diluent, for example a halogenated solvent such asmethylene chloride, chloroform or carbon tetrachloride and at atemperature in the range, for example, 10 to 150° C., preferably at ornear ambient temperature.

(d) For the production of those compounds of the Formula I wherein R¹ isa hydroxy group, the cleavage of a quinazoline derivative of the FormulaI wherein R¹ is a (1-6C)alkoxy or arylmethoxy group.

The cleavage reaction may conveniently be carried out by any of the manyprocedures known for such a transformation. The cleavage reaction of acompound of the Formula I wherein R¹ is a (1-6C)alkoxy group may becarried out, for example, by treatment of the quinazoline derivativewith an alkali metal (1-6C)alkylsulphide such as sodium ethanethiolateor, for example, by treatment with an alkali metal diarylphosphide suchas lithium diphenylphosphide. Alternatively the cleavage reaction mayconveniently be carried out, for example, by treatment of thequinazoline derivative with a boron or aluminium trihalide such as borontribromide. The cleavage reaction of a compound of the Formula I whereinR¹ is a arylmethoxy group may be carried out, for example, byhydrogenation of the quinazoline derivative in the presence of asuitable metallic catalyst such as palladium or by reaction with anorganic or inorganic acid, for example trifluoroacetic acid. Suchreactions are preferably carried out in the presence of a suitable inertsolvent or diluent as defined hereinbefore and at a temperature in therange, for example, 10 to 150° C., preferably at or near ambienttemperature.

(e) For the production of those compounds of the Formula I wherein Q¹,R¹ or Q² contains a primary or secondary amino group, the cleavage ofthe corresponding compound of Formula I wherein Q¹, R¹ or Q² contains aprotected primary or secondary amino group.

Suitable protecting groups for an amino group are, for example, any ofthe protecting groups disclosed hereinbefore for an amino group.Suitable methods for the cleavage of such amino protecting groups arealso disclosed hereinbefore. In particular, a suitable protecting groupis a lower alkoxycarbonyl group such as a tert-butoxycarbonyl groupwhich may be cleaved under conventional reaction conditions such asunder acid-catalysed hydrolysis, for example in the presence oftrifluoroacetic acid.

(f) For the production of those compounds of the Formula I wherein Q¹,R¹ or Q² contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a(1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation,conveniently in the presence of a suitable base as defined hereinbefore,of a quinazoline derivative of the formula I wherein Q¹, R¹ or Q²contains a hydroxy group or a primary or secondary amino group asappropriate.

A suitable alkylating agent is, for example, any agent known in the artfor the alkylation of hydroxy to alkoxy or substituted alkoxy, or forthe alkylation of amino to alkylamino or substituted alkylamino, forexample an alkyl or substituted alkyl halide, for example a (1-6C)alkylchloride, bromide or iodide or a substituted (1-6C)alkyl chloride,bromide or iodide, conveniently in the presence of a suitable base asdefined hereinbefore, in a suitable inert solvent or diluent as definedhereinbefore and at a temperature in the range, for example, 10 to 140°C., conveniently at or near ambient temperature.

Conveniently for the production of those compounds of the Formula Iwherein Q¹, R¹ or Q² contains a (1-6C)alkylamino or substituted(1-6C)alkylamino group, a reductive amination reaction may be employed.For example, for the production of those compounds of the Formula Iwherein Q¹, R¹ or Q² contains a N-methyl group, the correspondingcompound containing a N—H group may be reacted with formaldehyde in thepresence of a suitable reducing agent. A suitable reducing agent is, forexample, a hydride reducting agent, for example an alkali metalaluminium hydride such as lithium aluminium hydride or, preferably, analkali metal borohydride such as sodium borohydride, sodiumcyanoborohydride, sodium triethylborohydride, sodiumtrimethoxyborohydride and sodium triacetoxyborohydride. The reaction isconveniently performed in a suitable inert solvent or diluent, forexample tetrahydrofuran and diethyl ether for the more powerful reducingagents such as lithium aluminium hydride, and, for example, methylenechloride or a protic solvent such as methanol and ethanol for the lesspowerful reducing agents such as sodium triacetoxyborohydride and sodiumcyanoborohydride. The reaction is performed at a temperature in therange, for example, 10 to 80° C., conveniently at or near ambienttemperature.

(g) For the production of those compounds of the Formula I wherein Q¹,R¹ or Q² contains an amino-hydroxy-disubstituted (1-6C)alkoxy group(such as 2-hydroxy-3-piperidinopropoxy, 2-hydroxy-3-methylaminopropoxy,3-dimethylamino-2-hydroxypropoxy or3-[N-(3-dimethylaminopropyl)-N-methylamino]-2-hydroxypropoxy), thereaction of a compound of the Formula I wherein Q¹, R¹ or Q² contains anepoxy-substituted (1-6C)alkoxy group with a heterocyclyl compound or anappropriate amine.

The reaction is conveniently carried out in the presence of a suitableinert diluent or carrier as defined hereinbefore and at a temperature inthe range 10 to 150° C., preferably at or near ambient temperature.(h) The reaction, conveniently in the presence of a suitable base asdefined hereinbefore, of a quinazoline of the Formula VII

wherein L is a displaceable group as defined hereinbefore and m, R¹, R²,R³ and Q² have any of the meanings defined hereinbefore except that anyfunctional group is protected if necessary, with a compound of theFormulaQ¹ZHwherein Q¹ and Z have any of the meanings defined hereinbefore exceptthat any functional group is protected if necessary, whereafter anyprotecting group that is present is removed by conventional means.

The reaction is conveniently carried out in the presence of a suitableinert diluent or carrier as defined hereinbefore and at a temperature inthe range 10 to 150° C., preferably at or near 50° C.

(i) For the production of those compounds of the Formula I wherein Q¹,R¹ or Q² contains an amino-substituted (1-6C)alkoxy group (such as3-piperidinopropoxy, 3-methylaminopropoxy or 3-dimethylaminopropoxy),the reaction of a compound of the Formula I wherein Q¹, R¹ or Q²contains a halogeno-substituted (1-6C)alkoxy group with a heterocyclylcompound or an appropriate amine.

The reaction is conveniently carried out in the presence of a suitableinert diluent or carrier as defined hereinbefore and at a temperature inthe range 10 to 150° C., preferably at or near ambient temperature.

When a pharmaceutically-acceptable salt of a quinazoline derivative ofthe Formula I is required, for example an acid-addition salt, it may beobtained by, for example, reaction of said quinazoline derivative with asuitable acid using a conventional procedure.

Biological Assays

The following assays can be used to measure the effects of the compoundsof the Formula I as p56^(lck) inhibitors, as inhibitors of T cellactivation, as inhibitors of cytokine production in mice and asinhibitors of transplant rejection.

(a) In Vitro Enzyme Assay

The ability of test compounds to inhibit phosphorylation by the enzymep56^(lck) of a tyrosine-containing polypeptide substrate was assessedusing a conventional Elisa assay.

The following conventional procedure was used to obtain p56^(lck)enzyme. An EcOR1/Not1 fragment containing the entire coding sequence ofp56^(lck) was generated by the technique of polymerase chain reaction(PCR) from Incyte clone No. 2829606. A 6-His tag was added to thesequence at the N-terminus during the PCR stage. Conventional sequenceanalysis identified a number of changes compared to the publishedsequence and these were found also to have been present in the originalIncyte template. To achieve expression of the enzyme, the PCR fragmentwas inserted downstream of the polyhedrin promotor of pFASTBAC1 (LifeTechnologies Limited, Paisley, UK, Catalogue No. 10360-014). Arecombinant Baculovirus was constructed using the Bac-to-Bac system(Life Technologies Limited). High Five insect cells (Invitrogen BV, POBox 2312, 9704 CH Groningen, The Netherlands, Catalogue No. B855-02)were infected with the recombinant Baculovirus at a multiplicity ofinfection of 1 and incubated for 48 hours. The cells were harvested.Groups of 1.6×10⁹ cells were lysed by incubation in 20 mM Hepes pH7.5buffer containing 10% glycerol, 1% Triton-X-100, magnesium chloride (1.5mM), ethylene glycol bis(2-aminoethyl ether N,N,N′,N′-tetraacetic acid)(EGTA, 1 nM), sodium vanadate (1 mM), sodium fluoride (10 mM), imidazole(5 mM), sodium chloride (150 mM), phenylmethanesulphonyl fluoride (0.1mM), pepstatin (1 mg/ml) and leupeptin (1 mg/ml). A soluble fraction wasobtained by centrifugation and 6-His-p56^(lck) was purified by columnchromatography on a 1 ml Ni-NTA agarose column (Qiagen Limited, Crawley,West Sussex, UK). The protein was eluted using the above-mentionedbuffer except that imidazole (100 mM) was also present. The p56^(lck)enzyme so obtained was stored at −80° C.

Substrate solution [100 μl of a 2 μg/ml solution of the polyamino acidPoly(Glu, Ala, Tyr) 6:3:1 (Sigma Catalogue No. P3899) in phosphatebuffered saline (PBS)] was added to each well of a Nunc 96-wellimmunoplate (Catalogue No. 439454) and the plate was sealed and storedat 4° C. for 16 hours. The excess of substrate solution was discarded,the substrate-coated wells were washed with Hepes pH7.4 buffer (50 mM,300 μl) and blotted dry. Each test compound was dissolved in DMSO anddiluted to give a series of dilutions (from 100 μM to 0.001 μM) of thecompound in a 10:1 mixture of water and DMSO. Portions (25 μl) of eachdilution of test compound were transferred to the 96-well assay plate.Aliquots (25 μl) of a 10:1 mixture of water and DMSO were added followedby aliquots (25 μl) of a mixture of adenosine triphosphate (ATP; 24 μlof a 1 mM aqueous solution) and manganese chloride (3 ml of a 40 mMaqueous solution).

p56^(lck) enzyme (0.3 μl of a 0.5 mg/ml stock solution) was diluted in amixture of Hepes pH 7.4 buffer (200 mM, 3 ml), sodium orthovanadate (2mM, 0.6 ml), 1% Triton X-100 (0.6 ml), dithiothreitol (25 mM, 48 μl) anddistilled water (1.8 ml). Aliquots (50 μl) of the resultant solutionwere transferred to each well in the assay plate and the plate wasincubated at ambient temperature for 8 minutes. The wells were washedsequentially with two aliquots (300 μl) of phosphate-buffered saline(PBS) containing 0.1% Tween 20 (hereinafter PBS/T).

Aliquots (100 μl) were added to each well of a mixture ofantiphosphotyrosine-4G10 monoclonal IgG2bk antibody (UBI Catalogue No.05-321; 30 μl of a 50 μg/ml solution of the antibody in PBS/T), PBS/T(11 ml) and bovine serum albumin (BSA; Sigma Catalogue No. A6793; 55 mg)and the plate was incubated at ambient temperature for 1 hour. The wellswere washed sequentially with two aliquots (300 μl) of PBS/T and blotteddry. Aliquots (100 μl) were added to each well of a mixture of sheepanti-mouse IgG-peroxidase antibody

The extent of inhibition of the phosphorylation reaction at a range ofconcentrations of each test compound was determined and an IC₅₀ valuewas calculated.

(b) In Vitro T Cell Proliferation Assays

The ability of test compounds to inhibit T cell proliferation wasassessed by using human peripheral blood mononuclear cells andstimulation of the T cells by way of the T cell receptor or other thanby way of the T cell receptor.

Peripheral blood mononuclear cells (PBMC) were isolated from heparinised(10 units/ml heparin) human blood by density centrifugation(Lymphoprep™; Nycomed) spinning initially at 2000 rpm at ambienttemperature for 20 minutes. Cells at the interphase were transferred toclean tubes, diluted 1:1 with RPMI 1640 medium (Gibco) and spun at 2000rpm at ambient temperature for 10 minutes. The cell pellet wasresuspended in RPMI 1640 medium and spun at 1400 rpm at ambienttemperature for 10 minutes. The cell pellet was resuspended in RPMI 1640medium and spun at 900 rpm at ambient temperature for 10 minutes toremove platelets. The prepared mononuclear cells were resuspended in anassay medium comprising RPMI 1640 culture medium supplemented with 50units/ml penicillin, 50 μg/ml streptomycin, 1 mM glutamine and 10%heat-inactivated human AB serum.

Test compounds were solubilised in DMSO at a concentration of 10 mM anddiluted 1:83.3 in assay medium. Aliquots (75 μl) were added to each wellof a 96 well flat-bottomed tissue culture plate and subsequently serial1 to 3 dilutions were made into assay medium giving final testconcentrations in the range 0.1 to 30 μM. Control wells contained assaymedium (50 μl) containing 1.2% DMSO. PBMCs (100 μl of a suspension of2×10⁶ cells/ml in assay medium) were added to each well and incubatedfor 1 hour at 37° C. in a humidified (5% CO₂/95% air) incubator.

The extent of inhibition of T cell proliferation at a range ofconcentrations of each test compound was determined and an IC₅₀ valuewas calculated.

(b)(i) T Cell Receptor Stimulation

Aliquots (50 μl) of the T cell receptor stimulatory anti-CD3 antibody(Pharmingen Catalogue No. 30100D; 40 ng/ml in assay medium) were addedto each well and the cells were incubated for 24 hours at 37° C. in ahumidified (5% CO₂/95% air) incubator. Tritiated thymidine (1 μCi perwell) was added and the cells were incubated for up to a further 24hours at 37° C. The cells were harvested onto a filter mat andradioactivity was counted using a Wallac 1450 Microbeta Plus liquidscintillation counter.

(b)(ii) Non T Cell Receptor Stimulation

Aliquots (50 μl) of a mixture of the cell stimulants PMA(phorbol-12-myristate-13-acetate, Sigma Catalogue No. P8139; 40 ng/ml)and Ionomycin (Sigma Catalogue No. 10684; 1.2 μM) were added to eachwell and the cells were incubated and analysed as described in paragraph(b)(i).

(c) In Vivo Skin Graft Rejection Test

The ability of test compounds to inhibit rodent skin allograft rejectionwas assessed using analogous procedures to those disclosed by J. Magaeet al., Cellular Immunology, 1996, 173, 276-281 and R. Tsuji et al., J.Antibiot., 1992, 45, 1295 to assess the effect of cyclosporin A on Tcell properties in vivo.

(d) Test as Anti-Arthritic Agent

Activity of a test compound as an anti-arthritic agent was assessed asfollows. Acid soluble native type II collagen has been shown to bearthritogenic in rats causing polyarthritis when administered in Freundsincomplete adjuvant by (D. E. Trentham et al. J. Exp. Med., 1977, 146,857). This is now known as collagen-induced arthritis (CIA) and similarconditions can be induced in mice and primates. CIA in DBA/1 mice asdescribed by R. O. Williams et al., Proc Natl. Acad. Sci., 1992, 89,9784 and Immunology, 1995, 84, 433 is a tertiary model which can be usedto demonstrate the anti-arthritic activity of a test compound.

Although the pharmacological properties of the compounds of the FormulaI vary with structural change as expected, in general activity possessedby compounds of the Formula I may be demonstrated at the followingconcentrations or doses in one or more of the above tests (a), (b), (c)and (d):—

-   -   Test (a):—IC₅₀ in the range, for example, 0.001-5 μM;    -   Test (b)(i):—IC₅₀ in the range, for example, 0.01-10 μM;    -   Test (b)(ii):—IC₅₀ in the range, for example, 0.5->30 μM;    -   Test (c):—activity in the range, for example, 1-100 mg/kg;    -   Test (d):—activity in the range, for example, 1-100 mg/kg;

No physiologically-unacceptable toxicity was observed at the effectivedose for those compounds of Formula I that were tested. Accordingly nountoward toxicological effects are expected when a compound of FormulaI, or a pharmaceutically-acceptable salt thereof, as definedhereinbefore is administered at the dosage ranges defined hereinafter.

A pharmaceutical composition for the compounds of the Formula Icomprises a quinazoline derivative of the Formula I, or apharmaceutically-acceptable salt thereof, as defined hereinbefore inassociation with a pharmaceutically-acceptable diluent or carrier.

The compositions may be in a form suitable for oral use (for example astablets, lozenges, hard or soft capsules, aqueous or oily suspensions,emulsions, dispersible powders or granules, syrups or elixirs), fortopical use (for example as creams, ointments, gels, or aqueous or oilysolutions or suspensions), for administration by inhalation (for exampleas a finely divided powder or a liquid aerosol), for administration byinsufflation (for example as a finely divided powder) or for parenteraladministration (for example as a sterile aqueous or oily solution forintravenous, subcutaneous, intramuscular or intramuscular dosing or as asuppository for rectal dosing).

The compositions may be obtained by conventional procedures usingconventional pharmaceutical excipients, well known in the art. Thus,compositions intended for oral use may contain, for example, one or morecolouring, sweetening, flavouring and/or preservative agents.

The amount of active ingredient that is combined with one or moreexcipients to produce a single dosage form will necessarily varydepending upon the host treated and the particular route ofadministration. For example, a formulation intended for oraladministration to humans will generally contain, for example, from 0.5mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, forexample from 1 to 30 mg) compounded with an appropriate and convenientamount of excipients which may vary from about 5 to about 98 percent byweight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of acompound of the Formula I will naturally vary according to the natureand severity of the conditions, the age and sex of the animal or patientand the route of administration, according to well known principles ofmedicine.

In using a compound of the Formula I for therapeutic or prophylacticpurposes it will generally be administered so that a daily dose isreceived in the range, for example, 0.1 mg/kg to 75 mg/kg body weight,conveniently 0.1 mg/kg to 30 mg/kg body weight, given if required individed doses. In general lower doses will be administered when aparenteral route is employed. Thus, for example, for intravenousadministration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kgbody weight will generally be used. Similarly, for administration byinhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kgbody weight will be used. Oral administration is however preferred,particularly in tablet form. Typically, unit dosage forms will containabout 0.5 mg to 0.5 g of a compound of this invention.

According to a further aspect of the invention there is provided aquinazoline derivative of the Formula I as defined hereinbefore for usein the prevention or treatment of T cell mediated diseases or medicalconditions in a warm-blooded animal such as man. According to a furtheraspect of the invention there is provided a quinazoline derivative ofthe Formula I as defined hereinbefore for use in the prevention ortreatment of those pathological conditions which are sensitive toinhibition of one or more of the multiple tyrosine-specific proteinkinases which are involved in the early signal transduction steps whichlead to T cell activation.

The compounds disclosed in the present invention may be used incombination with other drugs and therapies used in the treatment of Tcell mediated disease. For example, the compounds of the Formula I couldbe used in combination with drugs and therapies used in the treatment ofautoimmune conditions or diseases such as inflammatory diseases (forexample rheumatoid arthritis, inflammatory bowel disease,glomerulonephritis and lung fibrosis), multiple sclerosis, psoriasis,hypersensitivity reactions of the skin, atherosclerosis, restenosis,allergic asthma and insulin-dependent diabetes. In particular thecompounds of the Formula I could be used in combination with drugs andtherapies such as cyclosporin A used in the prevention or treatment ofthe acute rejection of transplanted organs.

For example, the compounds of the Formula I are of value in thetreatment of certain inflammatory and non-inflammatory diseases whichare currently treated with a cyclooxygenase-inhibitory non-steroidalanti-inflammatory drug (NSAID) such as indomethacin, ketorolac,acetylsalicyclic acid, ibuprofen, sulindac, tolmetin and piroxicam.Co-administration of a compound of the Formula I with a NSAID can resultin a reduction of the quantity of the latter agent needed to produce atherapeutic effect. Thereby the likelihood of adverse side-effects fromthe NSAID such as gastrointestinal effects are reduced. Thus accordingto a further feature of the invention there is provided a pharmaceuticalcomposition which comprises a compound of the Formula I, or apharmaceutically-acceptable salt thereof, in conjunction or admixturewith a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent,and a pharmaceutically-acceptable diluent or carrier.

The compounds of the Formula I may also be used with anti-inflammatoryagents such as an inhibitor of the enzyme 5-lipoxygenase. The compoundsof the Formula I may also be used with anti-inflammatory agents such asan inhibitor of the enzyme COX-2 such as celecoxib or rofecoxib.

The compounds of the Formula I may also be used in the treatment ofconditions such as rheumatoid arthritis in combination withantiarthritic agents such as gold, methotrexate, steroids andpenicillinamine, and in conditions such as osteoarthritis in combinationwith steroids.

The compounds disclosed in the present invention may also beadministered in degradative diseases, for example osteoarthritis, withchondroprotective, anti-degradative and/or reparative agents such asDiacerhein, hyaluronic acid formulations such as Hyalan, Rumalon,Arteparon and glucosamine salts such as Antril.

The compounds of the Formula I may be be used in the treatment of asthmain combination with antiasthmatic agents such as bronchodilators andleukotriene antagonists.

If formulated as a fixed dose such combination products employ thecompounds of this invention within the dosage range described herein andthe other pharmaceutically-active agent within its approved dosagerange. Sequential use is contemplated when a combination formulation isinappropriate.

Although the compounds of the Formula I are primarily of value astherapeutic agents for use in warm-blooded animals (including man), theyare also useful whenever it is required to inhibit the effects of T cellactivation. Thus, they are useful as pharmacological standards for usein the development of new biological tests and in the search for newpharmacological agents.

The compounds defined in the invention will now be illustrated in thefollowing non-limiting Examples in which, unless otherwise stated

-   -   (i) operations were carried out at ambient temperature, i.e. in        the range 17 to 25° C. and under an atmosphere of an inert gas        such as argon unless otherwise stated;    -   (ii) evaporations were carried out by rotary evaporation in        vacuo and work-up procedures were carried out after removal of        residual solids by filtration;    -   (iii) column chromatography (by the flash procedure) and medium        pressure liquid chromatography (MPLC) were performed on Merck        Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18        (Art. 9303) reversed-phase silica obtained from E. Merck,        Darmstadt, Germany or high pressure liquid chromatography (HPLC)        was performed on C18 reverse phase silica, for example on a        Dynamax C-18 60 Å preparative reversed-phase column;    -   (iv) yields, where present, are given for illustration only and        are not necessarily the maximum attainable;    -   (v) in general, the end-products of the Formula I have        satisfactory microanalyses and their structures were confirmed        by nuclear magnetic resonance (NMR) and/or mass spectral        techniques; fast-atom bombardment (FAB) mass spectral data were        obtained using a Platform spectrometer and, where appropriate,        either positive ion data or negative ion data were collected;        NMR chemical shift values were measured on the delta scale        [proton magnetic resonance spectra were determined using a Jeol        JNM EX 400 spectrometer operating at a field strength of 400        MHz, a Varian Gemini 2000 spectrometer operating at a field        strength of 300 MHz or a Bruker AM300 spectrometer operating at        a field strength of 300 MHz]; the following abbreviations have        been used: s, singlet; d, doublet; t, triplet; q, quartet; m,        multiplet; br, broad;    -   (vi) intermediates were not generally fully characterised and        purity was assessed by thin layer chromatographic, HPLC,        infra-red (IR) and/or NMR analysis;    -   (vii) melting points are uncorrected and were determined using a        Mettler SP62 automatic melting point apparatus or an oil-bath        apparatus; melting points for the end-products of the Formula I        were determined after crystallisation from a conventional        organic solvent such as ethanol, methanol, acetone, ether or        hexane, alone or in admixture; and

(viii) the following abbreviations have been used:— DMFN,N-dimethylformamide DMSO dimethylsulphoxide THF tetrahydrofuran NMPN-methylpyrrolidin-2-one

EXAMPLE 1

4-(2-chloro-5-ethoxyanilino)-5-(3-morpholinopropoxy)quinazoline

Di-tert-butyl azodicarboxylate (0.208 g) was added dropwise to a stirredmixture of 4-(2-chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline(0.2 g), 4-(3-hydroxypropyl)morpholine (Bull. Soc. Chim. Fr., 1962,1117; 0.131 g), triphenylphosphine (0.237 g) and methylene chloride (3ml). The reaction mixture was stirred at ambient temperature for 1 hour.The mixture was evaporated and the residue was purified by columnchromatography on silica using a 99:1 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. The material soobtained was triturated under diethyl ether. The resultant solid wasisolated, washed with diethyl ether and dried under vacuum to give thetitle compound (0.12 g); NMR Spectrum: (DMSOd₆ and CF₃COOD) 2.35 (m,2H), 3.1 (t, 2H), 3.3 (t, 2H), 3.5 (d, 2H), 3.68 (t, 2), 3.8 (s, 3H),4.0 (d, 2H), 4.02 (s, 3H), 4.6 (t, 2H), 6.93 (s, 1H), 7.05-7.15 (m, 2H),7.5 (s, 1H), 7.57 (d, 1H), 8.87 (s, 1); Mass Spectrum: M+H⁺ 459 and 461;Elemental Analysis: Found C, 60.0; H, 6.0; N, 12.1; C₂₃H₂₇ClN₄O₄requires C, 60.19; H, 5.93; N, 12.2%.

The 4-(2-chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline used asa starting material was prepared as follows:—

A mixture of 3,5-dimethoxyaniline hydrochloride (54.7 g), oxalylchloride (54 ml) and methanol (500 ml) was stirred and heated to refluxfor 1.5 hours. The mixture was cooled to ambient temperature. Theprecipitate was isolated, washed in turn with methanol and diethyl etherand dried under vacuum to give 4,6-dimethoxy-2,3-dioxoindoline (55 g);NMR Spectrum: (DMSOd₆) 3.85 (s, 3H), 3.9 (s, 3H), 6.0 (s, 1H), 6.2 (s,1H), 10.9 (s, 1H); Mass Spectrum: M+Na⁺ 230.

Hydrogen peroxide (30% solution in water, 30 ml) was added dropwise to astirred solution of 4,6-dimethoxy-2,3-dioxoindoline (27 g) in aconcentrated aqueous sodium hydroxide solution (33%, 220 ml). Theresultant mixture was stirred at ambient temperature for 10 minutes. Icewas added and the basicity of the mixture was reduced to pH9 by theaddition of concentrated aqueous hydrochloric acid and the mixture wasthen acidified to pH3.5 by the addition of glacial acetic acid. Theresultant precipitate was isolated, washed with water and driedovernight under vacuum to give 2-amino-4,6-dimethoxybenzoic acid (15.9g); NMR Spectrum: (DMSOd₆) 3.7 (s, 3H), 3.78 (s, 3H), 5.79 (s, 1H), 5.92(s, 1H).

Using an analogous procedure to that described by Lombardi et al.,Chemistry & Industry, 1990, 708, diazomethane was generated from amixture of N-methyl-N-nitroso-4-toluenesulphonamide (31 g), ethanol (200ml) and a saturated aqueous sodium hydroxide solution (35 ml) andbubbled though a solution of 2-amino-4,6-dimethoxybenzoic acid (15.9 g)in methylene chloride (280 ml) which had been cooled to 0° C. Theresultant reaction mixture was evaporated and the residue was purifiedby column chromatography on silica using methylene chloride as eluent.There was thus obtained methyl 2-amino-4,6-dimethoxybenzoate (16.2 g);NMR Spectrum: (DMSOd₆) 3.65 (s, 3H), 3.7 (s, 6H), 5.75 (s, 1H), 5.9 (s,1H), 6.2 (br s, 2H).

A mixture of methyl 2-amino-4,6-dimethoxybenzoate (16 g), formamidineacetate (24 g) and 2-methoxyethanol (330 ml) was stirred and heated toreflux until all of the starting material had reacted. The mixture wasevaporated and the residue was triturated under water (100 ml). Theresultant solid was isolated, washed with water and dried under vacuumto give 5,7-dimethoxy-3,4-dihydroquinazolin one (14.5 g); NMR Spectrum:(DMSOd₆) 3.82 (s, 3H), 3.86 (s, 3H), 6.5 (s, 1H), 6.7 (s, 1H), 7.9 (s,1H), 11.7 (br s, 1H).

A mixture of a portion (0.35 g) of the material so obtained, phosphorylchloride (0.95 ml) and acetonitrile (8 ml) was stirred and heated toreflux for 2 hours. The mixture was cooled to 0° C. and isopropanol (8ml) and 2-chloro-5-methoxyaniline (0.321 g) were added in turn. Theresultant mixture was heated to reflux for 1.5 hours. The mixture wascooled to ambient temperature and the resultant precipitate wasfiltered, washed with isopropanol and with diethyl ether and dried undervacuum. There was thus obtained4-(2-chloro-5-methoxyanilino)-5,7-dimethoxyquinazoline hydrochloride(0.365 g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 4.0 (s, 3H), 4.2 (s, 3H),7.0 (m, 3H), 7.6 (d, 1H), 7.62 (s, 1H), 8.8 (s, 1H), 10.9 (s, 1H); MassSpectrum: M+H⁺ 346 and 348.

A mixture of 4-(2-chloro-5-methoxyanilino)-5,7-dimethoxyquinazolinehydrochloride (2.5 g), pyridine hydrochloride (0.76 g) and pyridine (50ml) was stirred and heated to reflux for 9 hours. The mixture was cooledto ambient temperature and evaporated. The residue was suspended inwater and the mixture was basified to pH10 by the addition of aqueoussodium bicarbonate solution. The resultant solid precipitate wasisolated, washed in turn with water, with methylene chloride and withdiethyl ether and dried overnight under vacuum at 50° C. There was thusobtained 4-(2chloro-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline(2.1 g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 3.85 (s, 3H), 6.3-6.5 (m,2H), 6.8 (d, 1H), 7.4 (d, 1H), 8.1 (br s, 1H), 8.42 (br s, 1H).

EXAMPLE 2

Using an analogous procedure to that described in Example 1, theappropriate 5-hydroxyquinazoline was reacted with the appropriatealcohol to give the compounds described in Table I. TABLE I

No. & Note (R¹)_(m) Q¹ (R²)_(n) [1] 7-methoxy 3-(4-methylpiperazin-2-chloro-5- 1-yl)propyl methoxy [2] 7-methoxy 2-piperidinoethyl2-chloro-5- methoxy [3] 7-methoxy 3-pyrrolidin-1-ylpropyl 2-chloro-5-methoxy [4] 7-methoxy 2-(1,2,4-triazol-1-yl) 2-chloro-5- ethyl methoxy[5] 7-benzyloxy 3-morpholinopropyl 2-chloro-5- methoxy [6] 7-benzyloxy3-pyrrolidin-1-ylpropyl 2-chloro-5- methoxy [7] hydrogen3-morpholinopropyl 2-bromo-5- methoxy [8] hydrogen 3-(1,1- 2-bromo-5-dioxotetrahydro-4H-1, methoxy 4-thiazin-4-yl)propyl [9] hydrogen2-(4-methylpiperazin- 2-bromo-5- 1-yl)ethyl methoxy [10] hydrogen3-(4-methylpiperazin- 2-chloro-5- 1-yl)propyl methoxy [11] hydrogen2-imidazol-1-ylethyl 2-chloro-5- methoxy [12] 7-methoxyN-methylpiperidin-4-yl 2-chloro-5- methoxy [13] hydrogenN-methylpiperidin-4-yl 2-chloro-5- methoxy [14] hydrogenN-methylpiperidin-4-yl 2-bromo-5- methoxy [15] hydrogenN-methylpiperidin-4-yl 2,5-dichloro [16] hydrogen N-(tert- 2-chloro-5-butoxycarbonyl)- methoxy piperidin-4-ylmethyl [17] hydrogen N-(tert-2-bromo-5- butoxycarbonyl)- methoxy piperidin-4-ylmethyl [18] 7-methoxy2-methoxyethyl 2-chloro-5- methoxy [19] 7-methoxy N-methylpyrrolidin-2-bromo-5- 3-yl methoxy [20] 7-benzyloxy 4-tetrahydropyranyl 2-chloro-5-methoxy [21] hydrogen 4-tetrahydropyranyl 2-chloro-5- methoxy [22]7-benzyloxy 3-tetrahydrofuranyl 2-chloro-5- methoxy [23] 7-(3-3-tetrahydrofuranyl 2-chloro-5- morpholinopropoxy) methoxy [24] 7-[3-(4-3-tetrahydrofuranyl 2-chloro-5- methylpiperazin- methoxy 1-yl)propoxy][25] 7-benzyloxy isopropyl 2-chloro-5- methoxy [26] 7-methoxy4-tetrahydropyranyl 2-bromo-5- methoxy [27] 7-methoxy3-pyrrolidin-1-ylpropyl 6-chloro-2, 3-methylenedioxy [28] 7-methoxy3-(4-methylpiperazin- 6-chloro-2, 1-ylpropyl) 3-methylenedioxyNotes[1] The reaction product was triturated under a mixture of isopropanoland diethyl ether and a 6M solution of hydrogen chloride in isopropanolwas added. The resultant precipitate was isolated, washed with diethylether and dried under vacuum to give the product as the dihydrochloridesalt; NMR Spectrum: (DMSOd₆) 2.2-2.4 (m, 2H), 2.8 (br s, 3H), 3.2-3.7(m, 10H), 3.8 (s, 3H), 4.0 (s, 3H), 4.6 (m, 2H), 6.95-7.0 (m, 2H), 7.08(s, 1H), 7.55 (d, 1H), 7.6 (s, 1H), 8.8 (s, 1H), 10.6 (s, 1H); MassSpectrum: M+H⁺ 472 and 474.

The 1-(3-hydroxypropyl)-4-methylpiperazine used as a starting materialwas prepared as follows:

A mixture of 3-bromopropanol (20 ml), N-methylpiperazine (29 ml),potassium carbonate (83 g) and ethanol (200 ml) was stirred and heatedto reflux for 20 hours. The mixture was cooled to ambient temperatureand filtered. The filtrate was evaporated and the residue was trituratedunder diethyl ether. The resultant mixture was filtered and the filtratewas evaporated. The residue was purified by distillation to give therequired starting material as an oil; NMR Spectrum: (CDCl₃) 1.72 (m,2H), 2.3 (s, 3H), 2.2-2.8 (m, 8H), 2.6 (t, 2H), 3.8 (t, 2H), 5.3 (br s,1H).

[2] The reaction product was dissolved in a mixture of isopropanol anddiethyl ether and a 6M solution of hydrogen chloride in isopropanol wasadded. The resultant precipitate was isolated, washed with diethyl etherand dried under vacuum to give the product as the dihydrochloride salt;NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.3-1.5 (m, 2H), 1.65-1.9 (m, 4H),3.02 (t, 2H), 3.6 (d, 2H), 3.7 (br s, 2H), 3.8 (s, 3H), 4.02 (s, 3H),4.9 (br s, 2H), 7.0 (s, 1H), 7.05 (m, 1H), 7.1 (s, 1H), 7.3 (s, 1H),7.58 (d, 1H), 8.8 (s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

[3] The reaction product was dissolved in a mixture of isopropanol anddiethyl ether and a 6M solution of hydrogen chloride in isopropanol wasadded. The resultant precipitate was isolated, washed with diethyl etherand dried under vacuum to give the product as the dihydrochloride salt;NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.35 (m,2H), 3.02 (m, 2H), 3.35 (t, 2H), 3.6 (m, 2H), 3.8 (s, 3H), 4.02 (s, 3H),4.6 (t, 2H), 6.95 (d, 1H), 7.05 (m, 1H), 7.1 (s, 1H), 7.5 (d, 1H), 7.6(d, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

The N-(3-hydroxypropyl)pyrrolidine used as a starting material wasprepared as follows:

A mixture of 3-chloropropanol (66 g), pyrrolidine (50 g), potassiumcarbonate (145 g) and acetonitrile (1 L) was stirred and heated toreflux for 20 hours. The mixture was cooled to ambient temperature andfiltered. The filtrate was evaporated and the residue was purified bydistillation to give the required starting material as an oil (62 g);NMR Spectrum: (CDCl₃) 1.6-1.8 (m, 6H), 2.55 (br s, 4H), 2.75 (t, 2H),3.85 (t, 2H), 5.5 (br s, 1H).

[4] The product was precipitated from the reaction mixture by theaddition of further methylene chloride. The product was isolated, washedwith diethyl ether and dried under vacuum. The product so obtained gavethe following data: NMR Spectrum: (DMSOd₆ and CF₃COOD) 3.82 (s, 3H), 4.0(s, 3H), 4.8 (m, 2H), 4.85 (m, 2H), 6.9 (s, 1H), 7.05 (s, 1H), 7.1 (m,1H), 7.3 (d, 1H), 7.58 (d, 1H), 7.65 (s, 1H), 8.67 (s, 1H), 8.79 (s,1H); Mass Spectrum: M+H⁺ 427 and 429.

The N¹-(2-hydroxyethyl)-1,2,4-triazole used as a starting material wasprepared according to the procedure disclosed in Ann. Pharm. Fr. 1977,35, 503.

[5] The product gave the following data: NMR Spectrum: (DMSOd₆) 2.1 (m,2H), 2.32 (br s, 4H), 2.45 (t, 2H), 3.52 (m, 4H), 3.8 (s, 3H), 4.5 (t,2H), 5.3 (s, 2H), 6.8 (m, 1H), 6.95 (s, 1H), 6.92 (s, 1H), 7.3-7.6 (m,6H), 8.35 (s, 1H), 8.55 (s, 1H), 10.12 (s, 1H); Mass Spectrum: M+H⁺ 535and 537.

The 7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-hydroxyquinazoline usedas a starting material was prepared as follows:

A mixture of 3,5-dibenzyloxyaniline hydrochloride (J. Org. Chem., 1975,40, 1556; 10 g) and oxalyl chloride (15 ml) was heated to 170° C. for 3hours. The mixture was cooled to ambient temperature, methanol (45 ml)was added and the mixture was heated to reflux for 1 hour. The mixturewas cooled to ambient temperature and the precipitate was isolated,washed with methanol and dried under vacuum to give4,6-dibenzyloxy-2,3-dioxoindoline (8.8 g); NMR Spectrum: (DMSOd₆) 5.22(s, 2H), 5.28 (s, 2H), 6.12 (s, 1H), 6.42 (s, 1H), 7.3-7.55 (m, 10H),10.97 (s, 1H).

Hydrogen peroxide (30% solution in water, 13 ml) was added dropwise to astirred solution of 4,6-dibenzyloxy-2,3-dioxoindoline (14.3 g) in aconcentrated aqueous sodium hydroxide solution (22.3 g in 90 ml ofwater) which had been heated to 70° C. The resultant mixture was stirredat 70° C. for 30 minutes and then cooled to ambient temperature. Ice wasadded and the basicity of the mixture was reduced to pH9 by the additionof 2N aqueous hydrochloric acid and the mixture was then acidified topH3.7 by the addition of glacial acetic acid. The resultant precipitatewas purified by column chromatography on silica using a 99:1 mixture ofmethylene chloride and methanol as eluent. There was thus obtained2-amino-4,6-dibenzyloxybenzoic acid (8 g); NMR Spectrum: (DMSOd₆) 5.05(s, 2H), 5.15 (s, 2H), 6.01 (s, 1H), 6.05 (s, 1H), 7.3-7.6 (m, 10H).

Using an analogous procedure to that described by Lombardi et al.,Chemisty & Industry 1990, 708, diazomethane was generated from a mixtureof N-methyl-N-nitroso-4-toluenesulphonamide (11.5 g), ethanol (60 ml)and a saturated aqueous sodium hydroxide solution (30 ml) and bubbledthough a solution of 2-amino-4,6-dibenzyloxybenzoic acid (8 g) inmethylene chloride (170 ml) which had been cooled to 0° C. The resultantreaction mixture was evaporated and the residue was triturated underdiethyl ether. There was thus obtained methyl2-amino-4,6-dibenzyloxybenzoate (7.7 g); NMR Spectrum: (DMSOd₆) 3.74 (s,3H), 5.07 (s, 2H), 5.11 (s, 2H), 6.0 (s, 1H), 6.04 (s, 1H), 6.25 (br s,2H), 7.28-7.5 (m, 10H).

A mixture of methyl 2-amino-4,6-dibenzyloxybenzoate (7.7 g), formamidineacetate (7.2 g) and 2-methoxyethanol (100 ml) was stirred and heated toreflux until all of the starting material had reacted. The mixture wasevaporated and the residue was triturated under water (60 ml). Theresultant solid was isolated, washed with water and dried under vacuumto give 5,7-dibenzyloxy-3,4-dihydroquinazolin-4-one (6.8 g); NMRSpectrum: (DMSOd₆) 5.24 (s, 4H), 6.75 (s, 1H), 6.8 (s, 1H), 7.3-7.7 (m,10H), 7.95 (s, 1H), 11.75 (br s, 1H).

A mixture of a portion (6 g) of the material so obtained, phosphorylchloride (1.72 ml), diisopropylethylamine (7.3 ml) and1,2-dichloroethane (60 ml) was stirred and heated to reflux for 2 hours.The mixture was evaporated and a mixture of the residue and isopropanol(80 ml) was cooled to 10° C. and 2-chloro-5-methoxyaniline (3.4 g) anddiisopropylethylamine (1.45 ml) were added in turn. The resultantmixture was heated to reflux for 1.5 hours. The mixture was cooled toambient temperature and the resultant precipitate was isolated, washedwith isopropanol and with diethyl ether and dried under vacuum. Therewas thus obtained4-(2-chloro-5-methoxyanilino)-5,7-dibenzyloxyquinazoline hydrochloride(6.35 g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 5.31 (s, 2H), 5.65 (s,2H), 6.95 (m, 1H), 7.02 (s, 1H), 7.15 (s, 1H), 7.3-7.5 (m, 9H), 7.6 (d,2H), 7.7 (s, 1H), 8.8 (s, 1H); Mass Spectrum: M+H⁺ 498 and 500.

A mixture of 4-(2-chloro-5-methoxyanilino)-5,7-dibenzyloxyquinazolinehydrochloride (4.3 g), pyridine hydrochloride (0.94 g) and pyridine (90ml) was stirred and heated to reflux for 9 hours. The mixture was cooledto ambient temperature and evaporated. The residue was triturated underwater. The resultant solid precipitate was isolated, washed with waterand dried overnight under vacuum. The material was then triturated undermethanol. The resultant solid was isolated and dried under vacuum. Therewas thus obtained7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-hydroxyquinazoline (3.1 g);NMR Spectrum: (DMSOd₆ and CF₃COOD) 3.85 (s, 3H), 5.3 (s, 2H), 6.85 (s,2H), 7.0 (m, 1H), 7.3-7.6 (m, 6H), 7.8 (d, 1H), 8.85 (s, 1H).

[6] The product gave the following data: NMR Spectrum: (CDCl₃) 1.75 (brs, 4H), 2.2 (m, 2H), 2.5 (br s, 4H), 2.65 (t, 2H), 3.85 (s, 3H), 4.4 (t,2H), 5.2 (s, 2H), 6.62 (d, 1H), 6.7 (s, 1H), 6.95 (s, 1H), 7.2-7.5 (m,6H), 8.4 (s, 1H), 8.6 (s, 1H), 10.1 (s, 1H); Mass Spectrum: M+H⁺ 519.

[7] The reaction product was triturated under diethyl ether, a 6.3Msolution of hydrogen chloride in isopropanol was added and the mixturewas stirred at ambient temperature for 1 hour. The resultant precipitatewas isolated, washed with diethyl ether and dried under vacuum to givethe product as a dihydrochloride salt which gave the following data: NMRSpectrum: (DMSOd₆ and CF₃COOD) 2.3-2.45 (m, 2H), 3.1 (t, 2H), 3.3 (t,2H), 3.45 (d, 2H), 3.75 (t, 2H), 3.81 (s, 3H), 4.0 (d, 2H), 4.68 (t,2H), 7.08 (m, 1H), 7.5-7.7 (m, 4H), 8.1 (m, 1H), 8.95 (s, 1H); MassSpectrum: M+H⁺ 473 and 475.

The 4-(2-bromo-5-methoxyanilino)-5-hydroxyquinazoline used as a startingmaterial was prepared as follows:

A mixture of 5-methoxy-3,4-dihydroquinazolin-4-one (International PatentApplication WO 96/09294, pages 28 and 29; 2.1 g), phosphoryl chloride(1.23 ml), diisopropylethylamine (5.2 ml) and 1,2-dichloroethane (20 ml)was stirred and heated to 80° C. for 3 hours. The mixture wasevaporated. The residue was dissolved in isopropanol (20 ml) and2-bromo-5-methoxyaniline (J. Amer. Chem. Soc.. 1994, 116, 11797; 2.45 g)and a 6M solution of hydrogen chloride in isopropanol (0.33 ml) wereadded in turn. The resultant mixture was heated to 80° C. for 1.5 hours.The mixture was cooled to ambient temperature and the resultantprecipitate was isolated, washed with isopropanol and with diethyl etherand dried under vacuum. There was thus obtained4-(2-bromo-5-methoxyanilino)-5-methoxyquinazoline hydrochloride (3.8 g);NMR Spectrum: (DMSOd₆ and CF₃COOD) 3.82 (s, 3H), 4.2 (s, 3H), 7.0 (m,1H), 7.48 (d, 1H), 7.5 (d, 1H), 7.55 (d, 1H), 7.75 (d, 1H), 8.1 (m, 1H),7.92 (s, 1H); Mass Spectrum: M+H⁺ 360 and 362.

A mixture of 4-(2-bromo-5-methoxyanilino)-5-methoxyquinazolinehydrochloride (3.5 g), pyridine hydrochloride (2 g) and pyridine (30 ml)was stirred and heated to reflux for 18 hours. The mixture was cooled toambient temperature and evaporated. The residue was suspended in water.the mixture was basified to pH11 by the addition of a concentratedammonium hydroxide solution and stirred for 1 hour. The resultantprecipitate was isolated, washed with water and with diethyl ether anddried under vacuum. There was thus obtained4-(2-bromo-5-methoxyanilino)-5-hydroxyquinazoline (2.15 g); NMRSpectrum: (DMSOd₆ and CF₃COOD) 3.8 (s, 3H), 6.95 (m, 1H), 7.25 (d, 1H),7.3 (d, 1H), 7.7 (s, 1H), 7.75 (d, 1H), 7.9 (m, 1H), 8.9 (s, 1H); MassSpectrum: M+H⁺ 346 and 348.

[8] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) 2.4-2.5 (m, 2H), 3.5 (m, 2H),3.7 (br s, 4H), 3.72-3.9 (br s, 4H), 3.8 (s, 3H), 4.7 (t, 2H), 7.0 (m,1H), 7.4-7.6 (m, 3H), 7.75 (d, 1H), 8.1 (m, 1H), 9.02 (s, 1H); MassSpectrum: M+H⁺ 521 and 523.

The 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol used as astarting material was prepared as follows:

A mixture of 3-aminopropan-1-ol (0.650 ml) and divinyl sulphone (1 g)was heated to 110° C. for 45 minutes. The mixture was allowed to cool toambient temperature and was purified by column chromatography on silicausing a 19:1 mixture of methylene chloride and methanol as eluent. Therewas thus obtained 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol(0.8 g); NMR Spectrum: (CDCl₃) 1.7-1.8 (m, 2H), 2.73 (t, 2H), 3.06 (brs, 8H), 3.25 (s, 1H), 3.78 (t, 2H); Mass Spectrum: M+H⁺ 194.

[9] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: Mass Spectrum: M+H⁺ 472 and 474.

The 1-(2-hydroxyethyl)-4-methylpiperazine used as a starting materialwas prepared as follows:—

A mixture of 2-bromoethanol (2.36 g), N-methylpiperazine (1.26 g),potassium carbonate (5.0 g) and ethanol (150 ml) was stirred and heatedto reflux for 18 hours. The mixture was cooled to ambient temperatureand filtered. The filtrate was evaporated and the residue was trituratedunder a mixture of methylene chloride and acetone. The resultant mixturewas filtered and the filtrate was evaporated to give the requiredstarting material as an oil (0.87 g); NMR Spectrum: (CDCl₃) 2.18 (s,3H), 2.3-2.7 (br m, 8H), 2.56 (t, 2H), 3.61 (t, 2H).

[10] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) 2.35-2.45 (m, 2H), 2.9 (s, 3H),3.2-3.9 (m, 10H), 3.85 (s, 3H), 4.7 (t, 2H), 7.05 (m, 1H), 7.45-7.6 (m,4H), 8.1 (m, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 442 and 444.

[11] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) 3.82 (s, 3H), 4.85 (t, 2H),5.05 (t, 2H), 7.05 (m, 1H), 7.35 (d, 1H), 7.5-7.65 (m, 3H), 7.7 (s, 1H),7.8 (s, 1H), 8.1 (m, 1H), 8.95 (s, 1H), 9.15 (s, 1H); Mass Spectrum:M+H⁺ 396 and 398.

The N-(2-hydroxyethyl)imidazole used as a starting material was preparedaccording to the procedure disclosed in J. Med. Chem., 1993, 2, 4052.

[12] The 4-hydroxy-1-methylpiperidine was added after the other reactioncomponents had been stirred together at 0° C. for 1 hour. The resultantreaction mixture was stirred at ambient temperature for 3 hours. Thereaction mixture was filtered and the filtrate was washed with a 1Naqueous sodium hydroxide solution. The organic solution was evaporatedand the residue was purified by column chromatography on silica using a98:2 mixture of methylene chloride and methanol as eluent. The materialso obtained was triturated under a 6M solution of hydrogenchloride indiethyl ether. The resultant solid was isolated, washed with diethylether and dried under vacuum to give the product as a dihydrochloridesalt which gave the following data: NMR Spectrum: (DMSOd₆ and CF₃COOD)2.0-2.15 (m, 2H), 2.15-2.3 (m, 4H), 2.35 (s, 3H), 2.8-2.9 (m, 2H), 3.85(s, 3H), 3.95 (s, 3H), 4.55 (m, 1H), 6.55 (s, 1H), 6.65 (m, 1m), 6.85(s, 1H), 7.3 (d, 1H), 8.15 (d, 1H), 8.55 (s, 1H), 9.85 (br s, 1H); MassSpectrum: M+H⁺ 429 and 431.

[13] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) (two conformational isomerswere noted in a ratio of about 3:2) 2.2-2.4 (m, 2H), 2.5 (d, 2H), 2.85(s, 3H), 3.1-3.3 (m, 2H), 3.4-3.5 (m, 0.5H minor conformer), 3.55-3.7(d, 1H major conformer and 0.5H minor conformer), 2.8 (s, 3H), 5.1-5.2(m, 1H major conformer), 5.2-5.3 (m, 1H minor conformer), 7.05 (m, 1Hmajor conformer), 7.1 (m, 1H minor conformer), 7.4-7.8 (m, 4H),8.05-8.15 (m, 11), 8.95 (s, 1H minor conformer), 9.0 (s, 1H majorconformer); Mass Spectrum: M+H⁺ 399 and 401.

[14] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) (two conformational isomerswere noted in a ratio of about 3:2) 2.2-2.4 (m, 2H), 2.4-2.65 (m, 2H),2.8 (s, 3H major conformer), 2.82 (s, 3H minor conformer), 3.1-3.3 (m,2H), 3.45 (m, 0.5H minor conformer), 3.5-3.7 (m, 0.5H minor conformer),3.8 (s, 3H), 5.1-5.2 (m, 1H major conformer), 5.25 (br s, 1H minorconformer), 7.0 (m, 1H major conformer), 7.05 (m, 1H minor conformer),7.4-7.8 (m, 4H), 8.12 (m, 1H), 8.9 (s, 1H minor conformer), 9.0 (s, 1H);Mass Spectrum: M+H⁺ 443 and 445.

[15] Using a similar work-up to that described in Note [7] above, theproduct was obtained as a dihydrochloride salt which gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃COOD) (two conformational isomerswere noted in a ratio of about 3:2) 2.15-2.3 (m, 2H), 2.4-2.52 (m, 2H),2.85 (s, 3H), 3.1-3.3 (m, 2H), 3.4-3.5 (m, 0.5H minor conformer),3.6-3.7 (m, 1H minor conformer, 0.5H minor conformer), 5.1-5.2 (m, 1H),5.2-5.3 (m, 1H minor conformer), 7.5-7.6 (m, 21), 7.6-7.8 (m, 2H),8.0-8.25 (m, 2H), 9.0 (s, 1H minor conformer), 9.1 (s, 1H majorconformer); Mass Spectrum: M+H⁺ 402 and 404.

The 4-(2,5-dichloroanilino)-5-hydroxyquinazoline used as a startingmaterial was prepared as follows:—

A mixture of 5-methoxy-3,4-dihydroquinazolin-4-one (1.8 g), phosphorylchloride (1.03 ml), diisopropylethylamine (4.4 ml) and1,2-dichloroethane (20 ml) was stirred and heated to 80° C. for 3 hours.The mixture was evaporated. The residue was dissolved in isopropanol (20ml) and 2,5-dichloroaniline (1.95 g) and a 6M solution of hydrogenchloride in isopropanol (0.33 ml) were added in turn. The resultantmixture was heated to 80° C. for 1.5 hours. The mixture was cooled toambient temperature and the resultant precipitate was isolated, washedwith isopropanol and with diethyl ether and dried under vacuum. Therewas thus obtained 4-(2,5-dichloroanilino)-5-methoxyquinazolinehydrochloride (3.2 g); NMR Spectrum: (DMSOd₆) 4.19 (s, 3H), 7.45 (d,1H), 7.5-7.6 (m, 2H), 7.75 (d, 1H), 8.05-8.15 (m, 2H), 8.95 (s, 1H).

A mixture of 4-(2,5-dichloroanilino)-5-methoxyquinazoline hydrochloride(3.2 g), pyridine hydrochloride (2.1 g) and pyridine (30 ml) was stirredand heated to reflux for 18 hours. The mixture was cooled to ambienttemperature and evaporated. The residue was suspended in water, themixture was basified to pH11 by the addition of a concentrated ammoniumhydroxide solution and stirred for 1 hour. The resultant precipitate wasisolated, washed with water and with diethyl ether and dried undervacuum. There was thus obtained4-(2,5-dichloroanilino)-5-hydroxyquinazoline (1.3 g); NMR Spectrum:(DMSOd₆ and CF₃COOD) 7.25 (d, 1H), 7.3 (d, 1H), 7.5 (m, 1H), 7.7 (d,1H), 7.95 (m, 1H), 8.3 (s, 1H), 9.0 (s, 1H); Mass Spectrum: M+H⁺ 306 and308.

[16] The product gave the following data: NMR Spectrum: (CDCl₃) 1.2-1.4(m, 2H), 1.5 (s, 9H), 1.9 (d, 2H), 2.3 (m, 1H), 2.8 (t, 2H), 3.9 (s,3H), 4.1-4.2 (m, 2H), 4.2 (d, 2H), 6.66 (m, 1H), 6.93 (d, 1H), 7.7 (m,1H), 8.45 (d, 1H), 8.7 (s, 1H); Mass Spectrum: M+H⁺ 499 and 501.

The 4-(2-chloro-5-methoxyanilino)-5-hydroxyquinazoline used as astarting material was prepared as follows:—

A mixture of 5-methoxy-3,4-dihydroquinazolin-4-one (2.1 g), phosphorylchloride (1.23 ml), diisopropylethylamine (5.2 ml) and1,2-dichloroethane (20 ml) was stirred and heated to 80° C. for 3 hours.The mixture was evaporated. The residue was dissolved in isopropanol (20ml) and 2-chloro-5-methoxyaniline (1.9 g) and a 6M solution of hydrogenchloride in isopropanol (0.33 ml) were added in turn. The resultantmixture was heated to 80° C. for 1.5 hours. The mixture was cooled toambient temperature and the resultant precipitate was isolated, washedwith isopropanol and with diethyl ether and dried under vacuum. Therewas thus obtained 4-(2-chloro-5-methoxyanilino)-5-methoxyquinazolinehydrochloride (3.4 g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 4.17 (s, 3H),7.02 (m, 1H), 7.43 (d, 1H), 7.6 (m, 3H), 8.07 (m, 1H), 8.9 (s, 1H).

A mixture of the material so obtained, pyridine hydrochloride (1.1 g)and pyridine (30 ml) was stirred and heated to reflux for 18 hours. Themixture was cooled to ambient temperature and evaporated. The residuewas suspended in water, the mixture was basified to pH11 by the additionof a concentrated ammonium hydroxide solution and stirred for 1 hour.The resultant precipitate was isolated, washed with water and withdiethyl ether and dried under vacuum. There was thus obtained4-(2-chloro-5-methoxyanilino)-5-hydroxyquinazoline (1.4 g); NMRSpectrum: (DMSOd₆ and CF₃COOD) 3.83 (s, 3H), 7.01 (m, 1H), 7.25 (d, 1H),7.3 (d, 1H), 7.6 (d, 1H), 7.82 (d, 1H), 7.92 (m, 11), 8.95 (s, 1H); MassSpectrum: M+H⁺ 302 and 304.

The N-(tert-butoxycarbonyl)piperidin-4-ylmethanol used as a startingmaterial was prepared as follows

A solution of di-tert-butyl dicarbonate (41.7 g) in ethyl acetate (75ml) was added dropwise to a stirred solution of ethylpiperidine-4-carboxylate (30 g) in ethyl acetate (150 ml) which had beencooled to 0 to 5° C. in an ice-bath. The resultant mixture was stirredat ambient temperature for 48 hours. The mixture was poured into water(300 ml). The organic layer was separated, washed in turn with water(200 ml), 0.1N aqueous hydrochloric acid solution (200 ml), a saturatedaqueous sodium bicarbonate solution (200 ml) and brine (200 ml), driedover magnesium sulphate and evaporated. There was thus obtained ethylN-(tert-butoxycarbonyl)piperidine-4-carboxylate (48 g); NMR Spectrum:(CDCl₃) 1.25 (t, 3H), 1.45 (s, 9H), 1.55-1.7 (m, 2H), 1.8-2.0 (d, 2H),2.35-2.5 (m, 1H), 2.7-2.95 (t, 2H), 3.9-4.1 (br s, 2H), 4.15 (q, 2H).

A solution of the material so obtained in THF (180 ml) was cooled at 0°C. and lithium aluminium hydride (1M solution in THF; 133 ml) was addeddropwise. The mixture was stirred at 0° C. for 2 hours. Water (30 ml)and 2N aqueous sodium hydroxide solution (10 ml) were added in turn andthe mixture was stirred for 15 minutes. The resultant mixture wasfiltered through diatomaceous earth and the solids were washed withethyl acetate. The filtrate was washed in turn with water and withbrine, dried over magnesium sulphate and evaporated. There was thusobtained N-(tert-butoxycarbonyl)piperidin-4-ylmethanol (36.3 g); NMRSpectrum: (CDCl₃) 1.05-1.2 (m, 2H), 1.35-1.55 (m, 10H), 1.6-1.8 (m, 2H),2.6-2.8 (t, 2H), 3.4-3.6 (t, 21), 4.0-4.2 (br s, 2H).

[17] The product gave the following data: NMR Spectrum: (CDCl₃) 1.2-1.35(m, 2H), 1.5 (s, 9H), 1.9 (d, 2H), 2.35 (m, 1H), 2.75 (t, 2H), 3.85 (s,3H), 4.05-4.2 (m, 2H), 4.2 (d, 2H), 6.62 (m, 1H), 6.95 (d, 1H), 7.7 (m,1H), 8.25 (d, 1H), 8.7 (s, 1H); Mass Spectrum: M+H⁺ 543 and 545.

The 4-(2-bromo-5-methoxyanilino)-5-hydroxyquinazoline used as a startingmaterial was prepared from 5-methoxy-3,4-dihydroquinazolin-4-one usinganalogous procedures to those described in the portion of Note [16]immediately above except that 2-bromo-5-methoxyaniline was used in placeof 2-chloro-5-methoxyaniline.

[18] The product gave the following data: NMR Spectrum: (DMSOd₆) 3.25(s, 3H), 3.79 (s, 3H), 3.83 (m, 2H), 3.98 (s, 3H), 4.58 (m, 2H), 6.95(s, 1H), 7.0 (m, 1H), 7.07 (s, 1H), 7.55 (m, 2H), 8.8 (s, 1H), 10.64 (s,1H); Mass Spectrum: M+H⁺ 390 and 392.

[19] The reaction product was triturated under a mixture of isopropanoland diethyl ether and a 6M solution of hydrogen chloride in isopropanolwas added. The resultant precipitate was isolated, washed with diethylether and dried under vacuum to give the product as the dihydrochloridesalt; NMR Spectrum: (CDCl₃) 2.2-2.3 (m, 1H), 2.4 (s, 3H), 2.4-2.5 (m,1H), 2.5-2.6 (m, 1H), 2.8-2.9 (m, 1H), 2.95-3.1 (m, 2H), 3.85 (s, 3H),3.95 (s, 3H), 5.05 (m, 1H), 6.42 (s, 1H), 6.65 (m, 1), 6.88 (s, 1H), 7.5(d, 1H), 7.9 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H); Mass Spectrum: M+H⁺ 459and 461.

The 4-(2-bromo-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline used asa starting material was prepared as follows:—

Using analogous procedures to those described in the second lastparagraph of the portion of Example 1 that is concerned with thepreparation of starting materials,5,7-dimethoxy-3,4-dihydroquinazolin-4-one (3 g) was reacted withphosphoryl chloride (1.5 ml) and the resultant product was reacted with2-bromo-5-methoxyaniline (3.53 g). There was thus obtained4-(2-bromo-5-methoxyanilino)-5,7-dimethoxyquinazoline hydrochloride (5g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 4.0 (s, 3H), 4.18 (s, 3H), 6.95(m, 3H), 7.6 (br s, 1H), 7.7 (d, 1H), 7.8 (s, 1H), 10.85 (s, 1H); MassSpectrum: M+H⁺ 391 and 393.

A mixture of the material so obtained, pyridine hydrochloride (1.4 g)and pyridine (100 ml) was stirred and heated to reflux for 6 hours. Asecond portion (2.8 g) of pyridine hydrochloride was added portionwiseand the mixture was heated to reflux for a further 18 hours. The mixturewas cooled to ambient temperature and evaporated. The material soobtained was triturated under water. The precipitate was isolated andwashed with methylene chloride (100 ml) for 1 hour. The solid wasisolated and dried under vacuum. There was thus obtained4-(2-bromo-5-methoxyanilino)-5-hydroxy-7-methoxyquinazoline (39 g); NMRSpectrum: (DMSOd₆ and CF₃COOD) 3.75 (s, 3H), 3.9 (s, 3H), 6.75 (s, 2D,6.92 (m, 1H), 7.58-7.7 (m, 2H), 8.8 (s, 1H).

[20] 4-Hydroxytetrahydropyran was used as the appropriate alcohol. Theproduct gave the following data: NMR Spectrum: (DMSOd₆) 1.75-1.9 (m,2H), 2.15 (d, 2H), 3.5 (t, 21), 3.8 (s, 3H), 3.9 (m, 2H), 5.05 (m, 1H),5.3 (s, 2H), 5.8 (m, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 7.3-7.6 (m, 6H),8.1 (d, 1H), 8.5 (s, 1H), 9.85 (s, 1H); Mass Spectrum: M+H⁺ 492 and 494.

[21] The reaction product was dissolved in diethyl ether and a 6Msolution of hydrogen chloride in diethyl ether (0.1 ml) was added. Theresultant precipitate was isolated, washed with diethyl ether and driedunder vacuum to give the product as a hydrochloride salt which gave thefollowing data: NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.9-2.05 (m, 2H),2.18 (d, 2H), 3.55 (t, 2H), 3.82 (s, 3H), 3.95 (m, 2H), 5.15 (m, 1H),7.05 (m, 1H), 7.5 (d, 1H), 7.58 (d, 2H), 7.65 (d, 1H), 8.05 (m, 1H),8.95 (s, 1H); Mass Spectrum: M+H⁺ 1386 and 388.

[22] The product gave the following data: NMR Spectrum: (DMSOd₆ andCF₃CO₂D) 2.2-2.3 (m, 1H), 2.35-2.5 (m, 1H), 3.8 (s, 3H), 3.8-3.9 (m,1H), 3.9-4.0 (m, 2H), 4.2 (d, 1H), 5.4 (s, 2H), 5.6 (br s, 1H), 7.01 (d,1H), 7.05 (s, 1H), 7.18 (s, 1H), 7.42 (d, 1H), 7.45 (m, 21), 7.52 (s,1H), 7.55 (d, 2H), 7.6 (d, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 477 and479.

[23] The product gave the following data: NMR Spectrum: (DMSOd₆) 1.9-2.0(m, 2H), 2.15-2.25 (m, 1H), 2.3-2.5 (m, 5H), 2.5 (t, 2H), 3.6 (t, 4H),3.8 (s, 3H), 3.9-4.0 (m, 3H), 4.1 (d, 1H), 4.2 (t, 2H), 5.45 (t, 1H),6.75-6.8 (m, 2H), 6.85 (s, 1H), 7.45 (d, 1H), 8.1 (s, 1H), 8.5 (s, 1H),9.72 (s, 11); Mass Spectrum: M+H⁺ 515 and 517.

[24] The product gave the following data: NMR Spectrum: (DMSOd₆) 1.9-2.0(m, 2H), 2.14 (s, 3H), 2.15-2.35 (m, 2H), 2.2-2.6 (m, 10H), 3.8 (s, 3H),3.85-4.0 (m, 3H), 4.12 (d, 1H), 4.2 (t, 2H), 5.45 (t, 1H), 7.75-7.8 (m,2H), 7.85 (s, 1H), 7.45 (d, 1H), 8.1 (s, 1H), 8.5 (s, 1H), 9.72 (s, 1H);Mass Spectrum: M+H⁺ 528 and 530.

[25] The product gave the following data: NMR Spectrum: (DMSOd₆ andCF₃CO₂D) 1.5 (d, 6H), 3.82 (s, 3H), 5.2 (m, 1H), 5.4 (s, 2H), 6.98 (s,1H), 7.0 (m, 1H), 7.18 (s, 1H), 7.4 (d, 1H), 7.45 (m, 2H), 7.5-7.6 (m,2H), 7.65 (d, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 449 and 451.

[26] The reaction product was dissolved in methylene chloride (2 ml)containing methanol (a few drops) and a 6M hydrogen chloride solution indiethyl ether (2 equivalents) was added. Diethyl ether (50 ml) was addedand the resultant precipitate was isolated, washed with diethyl etherand dried under vacuum to give the product as a dihydrochloride salt(0.135 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.9-2.1 (m, 2H), 2.1-2.2(m, 2H), 3.55 (m, 2H), 3.79 (s, 3H), 3.92 (m, 2H), 4.0 (s, 3H), 5.15 (m,1H), 6.9 (s, 1H), 6.95 (m, 1H), 7.15 (d, 1H), 7.45 (d, 1H), 7.7 (d, 1H),8.85 (s, 1H); Mass Spectrum: M+H⁺ 460 and 462.

[27] The reaction product was triturated under a mixture of a 5Msolution of hydrogen chloride in isopropanol was added. The resultantprecipitate was isolated, washed with diethyl ether and dried undervacuum to give the product as the dihydrochloride salt; NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 1.9 (m, 2H), 2.05 (m, 2H), 2.35 (m, 2H), 3.05 (m,2H), 3.3 (m, 2H), 3.6 (m, 2H), 4.05 (s, 3H), 4.65 (t, 2H), 6.15 (s, 2H),6.95 (d, 1H), 7.1 (m, 2H), 7.15 (d, 1H), 8.85 (s, 1H); Mass Spectrum:M+H⁺ 457 and 459.

The4-(6-chloro-2,3-methylenedioxyanilino)-5-hydroxy-7-methoxyquinazolineused as a starting material was prepared as follows:—

Phosphoryl chloride (2.7 ml) was added dropwise to a mixture of5,7-dimethoxy-3,4-dihydroquinazolin-4-one (1 g), diisopropylethylamine(2.27 ml) and 1,2-dichloroethane (20 ml) and the resultant mixture wasstirred and heated to 80° C. for 3 hours. The mixture was evaporated.There was thus obtained 4-chloro-5,7-dimethoxyquinazoline which was usedwithout further purification. The material so obtained was suspended inisopropanol (14 ml) and 6-chloro-2,3-methylenedioxyaniline (Example 17,Note [30]; 0.915 g) and a 5N solution of hydrogen chloride inisopropanol (0.97 ml) were added in turn. The reaction mixture wasstirred and heated to 90° C. for 1.5 hours. The mixture was cooled toambient temperature and the precipitate was isolated, washed withisopropanol and with diethyl ether and dried under vacuum. The materialso obtained was dissolved in a mixture of methylene chloride andmethanol and a saturated methanolic ammonia solution was added. Theresultant mixture was filtered and the filtrate was evaporated. Therewas thus obtained4-(6-chloro-2,3-methylenedioxyanilino)-5,7-dimethoxyquinazoline (1.36g); NMR Spectrum: (DMSOd₆) 3.95 (s, 3H), 4.1 (s, 3H), 6.1 (s, 2H), 6.85(d, 1H), 6.9 (d, 1H), 7.05 (d, 1H), 7.1 (d, 1H), 8.65 (s, 1H).

Pyridine (0.54 ml) was dissolved in methylene chloride (5 ml) and a 5Nsolution of hydrogen chloride in isopropanol (1.34 ml) was added. Aftera few minutes the mixture was evaporated. Pyridine (24 ml) was addedfollowed by4-(6-chloro-2,3-methylenedioxyanilino)-5,7-dimethoxyquinazoline (1.2 g)and the reaction mixture was heated to 125° C. for 6 hours. Theresultant mixture was evaporated and the residue was triturated underwater. The resultant solid was isolated, washed with water and driedunder vacuum. The material so obtained was purified by columnchromatography on silica using a 7:3 mixture of methylene chloride andacetonitrile as eluent. There was thus obtained4-(6-chloro-2,3-methylenedioxyanilino)-5-hydroxy-7-methoxyquinazoline(0.72 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 3.9 (s, 3U), 6.15 (s, 2H),6.75 (m, 2H), 7.05 (d, 1H), 7.1 (d, 1H), 8.75 (s, 1H).

[28] The reaction product was triturated under a mixture of a 5Msolution of hydrogen chloride in isopropanol was added. The resultantprecipitate was isolated, washed with diethyl ether and dried undervacuum to give the product as the dihydrochloride salt; NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 2.35 (m, 2H), 2.9 (s, 3H), 3.2-4.0 (m, 10H), 4.05(s, 3H), 4.65 (t, 2H), 6.15 (s, 2H), 6.95 (d, 1H), 7.1 (m, 3H), 8.85 (s,1H); Mass Spectrum: M+H⁺ 486 and 488.

EXAMPLE 34-(2-bromo-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline

A mixture of 4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.11 g), 2-bromo-5-methoxyaniline hydrochloride (0.099 g) andisopropanol (8 ml) was stirred and heated to 80° C. for 30 minutes. Themixture was evaporated and the residue was triturated under the minimumvolume of isopropanol. The resultant solid was isolated, washed withisopropanol and with diethyl ether and dried under vacuum. There wasthus obtained the title compound as a dihydrochloride salt (0.06 g). Asample of the material was treated with a saturated methanolic ammoniasolution. The mixture was filtered and the filtrate was evaporated togive the title compound in free base form; NMR Spectrum (CDCl₃):2.15-2.25 (m, 6H), 2.35 (s, 3H), 2.9 (m, 2H), 3.84 (s, 3H), 3.93 (s,3H), 4.6 (br s, 1H), 6.62 (s, 1H), 6.6 (m, 1H), 6.85 (s, 1H), 7.5 (d,1H), 7.9 (s, 1H), 8.55 (s, 1H), 9.64 (br s, 1H); Mass Spectrum: M+H⁺ 473and 475.

The 4-chloro-7-methoxy-5-(h-methylpiperidin-4-yloxy)quinazoline used asa starting material was prepared as follows:—

Pyridine (40 ml) was added dropwise to magnesium bromide (3.6 g) whichhad been cooled to 0° C. 5,7-Dimethoxy-3,4-dihydroquinazolin-4-one (4 g)was added and the mixture was heated to reflux for 15 minutes. Themixture was evaporated and the residue was stirred under a mixture ofglacial acetic acid (12 ml) and water (80 ml) for 10 minutes Theresultant solid was isolated, washed with water and dried under vacuumat 50° C. There was thus obtained5-hydroxy-7-methoxy-3,4-dihydroquinazolin one (3.75 g);NMR Spectrum:(DMSOd₆) 3.95 (s, 3H), 6.45 (s, 1H), 6.62 (s, 1H), 8.1 (s, 1H).

A portion (1.8 g) of the material so obtained was added to a stirredsuspension of sodium hydride (0.79 g of a 60% dispersion in mineral oilwhich was washed with THF) in DMF (18 ml). The mixture was stirred atambient temperature for 1 hour. The mixture was cooled to 0° C. andchloromethyl pivalate (1.62 ml) was added dropwise. The mixture wasstirred at ambient temperature for 1 hour, poured into a mixture ofglacial acetic acid (50 ml) and water (200 ml) and stirred at ambienttemperature for 5 minutes. The resultant precipitate was isolated,washed with water and dried overnight under vacuum. The solid wastriturated under pentane, isolated and dried under vacuum. There wasthus obtained5-hydroxy-7-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (2.5g); NMR Spectrum: (CDCl₃) 1.2 (s, 9H), 3.9 (s, 3H), 5.88 (s, 2H), 6.5(s, 1H), 6.68 (s, 1H), 8.15 (s, 1H), 11.36 (s, 1H).

A solution of di-tert-butyl azodicarboxylate (1.7 g) in methylenechloride (5 ml) was added to a stirred mixture of5-hydroxy-7-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (1.5g), triphenylphosphine (1.9 g), 4-hydroxy-1-methylpiperidine (0.675 g)and methylene chloride (20 ml) which had been cooled to 5° C. Themixture was stirred at ambient temperature for 1 hour. The mixture wasevaporated and the residue was purified by column chromatography onsilica using a 9:10:1 mixture of methylene chloride, ethyl acetate and asaturated methanolic ammonia solution as eluent. The material soobtained was triturated under diethyl ether. The resultant solid waswashed with diethyl ether and dried under vacuum to give7-methoxy-5-(N-methylpiperidin-4-yloxy)-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one(1.75 g); NMR Spectrum: (CDCl₃):1.2 (s, 9H), 2.05 (br s, 4H), 2.3 (s,3H), 2.3-2.42 (m, 2H), 2.7-2.8 (m, 2H), 3.9 (s, 3H), 4.48 (m, 1H), 5.9(s, 2H), 6.5 (d, 1H), 6.71 (d, 1H), 8.18 (s, 1H).

A mixture of the material so obtained and a saturated methanolic ammoniasolution (100 ml) was stirred at ambient temperature for 15 hours. Themixture was evaporated and the residue was triturated under diethylether. The resultant precipitate was isolated, washed with diethyl etherand dried under vacuum. There was thus obtained7-methoxy-5-(N-methylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(0.855 g); NMR Spectrum: (DMSOd₆) 1.7 (m, 2H), 1.9 (m, 2H), 2.15 (s,3H), 1.15-1.25 (m, 2H), 2.55-2.7 (m, 2H), 3.85 (s, 3H), 4.5 (m, 1H),6.55 (d, 1H), 6.65 (d, 1H), 7.89 (s, 1H), 11.62 (br s, 1H).

A mixture of7-methoxy-5-(N-methylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(0.65 g), triphenylphosphine (1.18 g), carbon tetrachloride (0.45 ml)and methylene chloride (25 ml) was stirred and heated to reflux for 2hours. The mixture was evaporated and the residue was purified by columnchromatography on silica using a 10:9:1 mixture of ethyl acetate,methylene chloride and a saturated methanolic ammonia solution aseluent. The material so obtained was triturated under pentane and theresultant solid was isolated and dried under vacuum. There was thusobtained 4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.5 g); NMR Spectrum: (CDCl₃) 1.95-2.15 (m, 4H), 2.3 (s, 3H),2.3-2.45(m, 2H), 2.6-2.8 (m, 2H), 3.92 (s, 3H), 4.55 (br s, 1H), 6.56 (s, 1H),6.9 (s, 1H), 8.77 (s, 1H).

EXAMPLE 4

Using an analogous procedure to that described in Example 3, theappropriate 4-chloroquinazoline was reacted with the appropriate anilineto give the compound described in Table II. TABLE II

No. and Note (R¹)_(m) Q¹ (R²)_(n) [1] 7-methoxy N-methylpiperidin-4-yl2,4-dichloro- 5-methoxy [2] 7-methoxy N-methylpiperidin-4-yl2-fluoro-4-chloro- 5-methoxy [3] 7-(2-pyrrolidin- 4-tetrahydropyranyl2,5-dimethoxy 1-ylethoxy) [4] 7-methoxy N-methylpiperidin-4-yl 6-chloro-2,3-methylenedioxy [5] 7-fluoro 4-tetrahydropyranyl 6-chloro-2,3-methylenedioxy [6] 7-(2-pyrrolidin- 4-tetrahydropyranyl2,3-ethylenedioxy 1-ylethoxy) [7] 7-methoxy N-methylpiperidin-4-yl2,3-ethylenedioxy [8] 7-methoxy piperidin-4-yl 2,3-ethylenedioxyNotes[1] The reaction product was obtained as the dihydrochloride salt fromwhich the free base was isolated using an analogous procedure to thatdescribed in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 2.0-2.15 (m, 2H), 2.15-2.3 (m, 4H), 2.32 (s, 3H), 2.85(m, 2H), 3.92 (s, 3H), 3.95 (s, 3H), 4.55 (m, 1H), 6.56 (d, 1H), 6.86(d, 1H), 7.42 (s, 1H), 8.31 (s, 1H), 8.56 (s, 1H), 9.87 (s, 1H); MassSpectrum: M+H⁺ 463 and 465.[2] The reaction product was obtained as the dihydrochloride salt; NMRSpectrum: (DMSOd₆ and NaOD) 1.9-2.1 (m, 2H), 2.2-2.35 (m, 2H), 2.6 (s,3H), 2.6 (m, 2H), 3.1-3.2 (m, 2H), 3.92 (s, 3H), 3.95 (s, 3H), 4.95 (m,1H), 6.92 (s, 1H), 6.95 (s, 1H), 7.6 (d, 1H), 8.6 (s, 1H), 8.7 (br s,1H); Mass Spectrum: M+H⁺ 447 and 449.

The 4-chloro-2-fluoro-5-methoxyaniline used as starting material wasprepared as follows:

A 6N aqueous sodium hydroxide solution (17 ml) was added dropwise to astirred solution of4-chloro-2-fluoro-5-methoxycarbonyloxy-1-nitrobenzene (J. Med. Chem.,1999, 42, 5369; 25 g) in methanol (200 ml) which was cooled to 5° C. Thereaction mixture was stirred at ambient temperature for 30 minutes. A12N aqueous hydrochloric acid solution (8.5 ml) was added and themixture was evaporated. The residue was partitioned between methylenechloride and water. The organic layer was washed with brine, dried overmagnesium sulphate and evaporated to give4-chloro-2-fluoro-5-hydroxy-1-nitrobenzene (18.5 g); NMR Spectrum:(CDCl₃) 5.8 (br s, 1H), 7.35 (d, 1H), 7.75 (d, 1H).

Dimethyl sulphate (10.5 ml) was added to a stirred mixture of4-chloro-2-fluoro-5-hydroxy-1-nitrobenzene (14 g), potassium carbonate(13 g) and DMF (70 ml) and the reaction mixture was stirred at ambienttemperature for 16 hours. The mixture was poured into water (500 ml) andthe resultant precipitate was isolated and dried under vacuum. The solidso obtained was partitioned between methylene chloride and water. Theorganic layer was washed with brine, dried over magnesium sulphate andevaporated to give 4-chloro-2-fluoro-5-methoxy-1-nitrobenzene (14.1 g);NMR Spectrum: (CDCl₃) 3.94 (s, 3H), 7.4 (d, 1H), 7.6 (d, 1H).

A mixture of the material so obtained, platinum oxide (0.5 g) andethanol (250 ml) was stirred under 1.2 atmosphere pressure of hydrogenfor 2 hours. The mixture was filtered and the filtrate was evaporated.The residue was purified by column chromatography on silica usingmethylene chloride as eluent. There was thus obtained4-chloro-2-fluoro-5-methoxyaniline (8.5 g); NMR Spectrum: (CDCl₃) 3.7(br s, 2H), 3.81 (s, 3H), 6.38 (d, 1H), 7.02 (d, 1H), 7.28 (s, 1H).

[3] The reaction product was obtained as the dihydrochloride salt; NMRSpectrum: (DMSOd₆ and CF₃CO₂D) 1.85-2.0 (m, 4H), 2.0-2.15 (m, 2H),2.2-2.3 (m, 2H), 3.15-3.25 (m, 2H), 3.58 (t, 2H), 3.65-3.75 (m, 4H),3.78 (s, 3H), 3.95 (s, 3H), 4.02 (m, 2H), 4.6 (m, 2H), 5.2 (m, 1H), 6.9(m, 1H), 7.02 (d, 1H), 7.16 (d, 1H), 7.23 (d, 1H), 8.16 (d, 1H), 8.98(s, 1H); Mass Spectrum: M+H⁺ 495.

The4-chloro-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material is described in Example 19, Note [6].

[4] The reaction product was obtained as the dihydrochloride salt fromwhich the free base was isolated using an analogous procedure to thatdescribed in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 2.0-2.15 (m, 2H), 2.15-2.3 (m, 2H), 2.3 (s, 3H),2.3-2.5 (m, 2H), 2.75 (m, 2H), 3.92 (s, 3H), 4.6 (m, 1H), 6.05 (s, 2H),6.50 (d, 1H), 6.72 (d, 1H), 6.84 (d, 1H), 6.97 (d, 1H), 8.52 (s, 1H),9.26 (s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

[5] The reaction product was obtained as the dihydrochloride salt fromwhich the free base was isolated using an analogous procedure to thatdescribed in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 1.92-2.1 (m, 2H), 2.2-2.3 (m, 2H), 3.6-3.7 (m, 2H),4.0-4.1 (m, 2H), 4.8 (m, 1H), 6.1 (s, 2H), 6.7 (m, 1H), 6.75 (d, 1H),6.98 (d, 1H), 7.15 (m, 1H), 8.6 (s, 1H), 9.32 (s, 1H); Mass Spectrum:M+H⁺ 418 and 420.

The 4-chloro-7-fluoro-5-tetrahydropyran4-yloxyquinazoline used as astarting material was prepared as follows:

A solution of 3,5-difluoroaniline (10.8 g) in a mixture of 12N aqueoushydrochloric acid solution (7.5 ml) and water (90 ml) was added to astirred mixture of chloral hydrate (9.2 ml), sodium sulphate decahydrate(240 g) and water (210 ml). A solution of hydroxylamine hydrochloride(18.6 g) in water (90 ml) was then added and the mixture was heated to120° C. for 45 minutes. The mixture was cooled to ambient temperatureand the precipitate was isolated and dried under vacuum. The material soobtained was added to concentrated sulphuric acid (60 ml) and themixture was stirred and heated to 80-90° C. for 10 minutes. The mixturewas cooled to ambient temperature and poured onto a 1:1 mixture of iceand water (600 ml). The precipitate was isolated, washed with water anddried under vacuum at 50° C. to give 4,6-difluoro-2,3-dioxoindoline (14g); NMR Spectrum: (DMSOd₆) 6.61 (m, 1H), 6.9 (m, 1H).

Hydrogen peroxide (35% solution in water, 23 ml) was added dropwise to astirred solution of 4,6-difluoro-2,3-dioxoindoline (14 g) in aconcentrated aqueous sodium hydroxide solution (33%, 115 ml) that washeated to 70° C. The mixture was heated to 70° C. for 15 minutes.. Theresultant mixture was cooled to 0° C. and the the mixture was acidifiedto pH4 by the addition of concentrated aqueous hydrochloric acid. Themixture was extracted with ethyl acetate. The organic layer wasseparated, washed with brine, dried over magnesium sulphate andevaporated to give 2-amino-4,6-difluorobenzoic acid (12 g); NMRSpectrum: (DMSOd₆) 6.25 (m, 1H), 6.38 (m, 1H).

Diethyl azodicarboxylate (26.7 ml) was added dropwise to a stirredmixture of 2-amino-4,6-difluorobenzoic acid (26.6 g), triphenylphosphine(45 g), methanol (9 ml) and methylene chloride (350 ml) that had beencooled to 5° C. The mixture was allowed to warm to ambient temperatureand was stirred for 2 hours. The reaction mixture was poured onto achromatography column loaded with silica and eluted with methylenechloride. There was thus obtained methyl 2-amino-4,6-difluorobenzoate(25.2 g); NMR Spectrum: (DMSOd₆) 3.8 (s, 3H), 6.3 (m, 1H), 6.4 (m, 1H),7.0 (br s, 2H); Mass Spectrum: M+H⁺ 188.

A mixture of methyl 2-amino-4,6-difluorobenzoate (47 g), formamidineacetate (79 g) and 2-methoxyethanol (750 ml) was stirred and heated toreflux for 10 hours. A second portion (26 g) of formamidine acetate wasadded and the mixture was heated to reflux for a further 2.5 hours. Themixture was cooled to ambient temperature and evaporated. The residuewas washed with diethyl ether and with water and dried under vacuum overphosphorus pentoxide. The filtrate was evaporated to dryness and theresidue was triturated under diethyl ether. The resultant solid wasisolated and dried under vacuum. The two batches of solid were combinedand purified by column chromatography on silica using a 19:1 mixture ofmethylene chloride and methanol as eluent. There was thus obtained5,7-difluoro-3,4-dihydroquinazolin-4-one (33.7 g); NMR Spectrum:(DMSOd₆) 7.3-7.4 (m, 2H), 8.12 (s, 1H); Mass Spectrum: M+H⁺ 183.

Sodium hydride (60% dispersion in mineral oil; 0.6 g) was addedportionwise to a solution of 4-hydroxytetrahydropyran (0.78 g) in DMF(10 ml) that had been cooled to 5° C. The mixture was allowed to warm toambient temperature and was stirred for 15 minutes.5,7-Difluoro-3,4-dihydroquinazolin-4-one (0.9 g) was added and themixture was stirred at ambient temperature for 30 minutes. The mixturewas poured into water (100 ml) and, with vigorous stinring, glacialacetic acid was added to acidify the mixture to pH5. The resultant solidwas isolated, washed with water and with diethyl ether and dried undervacuum. There was thus obtained7-fluoro-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (1.1 g);NMR Spectrum: (DMSOd₆) 1.6-1.75 (m, 2H), 1.9-2.0 (m, 2H), 3.5-3.6 (m,2H), 3.85-3.95 (m, 2H), 4.8 (m, 1H), 6.9 (m, 1H), 7.05 (m, 1H), 8.0 (s,1H); Mass Spectrum: M+H⁺ 265.

A mixture of7-fluoro-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (1 g),phosphoryl chloride (4 ml), diisopropylethylamine (1.5 ml) and1,2-dichloroethane (15 ml) was stirred and heated to 80° C. for 3 hours.The mixture was evaporated to give4-chloro-7-fluoro-5-tetrahydropyran-4-yloxyquinazoline which was usedwithout further purification.

[6] 2,3-Ethylenedioxyaniline (J. Med. Chem., 1995, 38 4044) was used asa starting material. The reaction product was obtained as thedihydrochloride salt; NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.8-2.0 (m,4H), 2.0-2.1 (m, 2H), 2.15-2.25 (m, 2H), 3.1-3.25 (m, 2H), 3.55 (m, 2H),3.6-3.75 (m, 4H), 4.0 (m, 2H), 4.32 (m, 2H), 4.42 (m, 2H), 4.58 (t, 2H),5.2 (m, 1H), 6.85 (d, 1H), 6.95 (m, 1H), 6.99 (d, 1H), 7.2 (d, 1H), 8.0(d, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 493.

[7] The reaction product was obtained as the dihydrochloride salt fromwhich the free base was isolated using an analogous procedure to thatdescribed in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 1.95-2.1 (m, 2H), 2.15-2.3 (m, 4H), 2.3 (s, 3H), 2.9(m, 2H), 3.9 (s, 3H), 4.32 (m, 2H), 4.4 (m, 2H), 4.52 (m, 1H), 6.5 (d,1H), 6.65 (m, 1H), 6.8 (d, 1H), 6.92 (m, 1H), 8.3 (d, 1H), 8.6 (s, 1H),10.05 (s, 1H); Mass Spectrum: M+H⁺ 423.

[8] The reactants were5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-chloro-7-methoxyquinazolineand 2,3-ethylenedioxyaniline. The precipitate from the reaction mixturewas isolated, washed in turn with isopropanol, ethyl acetate and diethylether and dried under vacuum. The material so obtained was dissolved ina 2M solution of hydrogen chloride in diethyl ether and the mixture wasstirred at ambient temperature for 2 hours. The resultant solid wasisolated, washed with diethyl ether and dried under vacuum. The reactionproduct so obtained was obtained a dihydrochloride salt; NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 2.0-2.15 (m, 2H), 2.35-2.55 (m, 2H), 3.2 (m, 2H),3.45 (m, 2H), 4.02 (s, 3H), 4.4 (m, 2H), 4.52 (m, 2H), 5.2 (m, 1H), 6.85(d, 1H), 6.98 (m, 2H), 7.2 (d, 1H), 8.05 (d, 1H), 8.98 (s, 1H); MassSpectrum: M+H⁺ 409.

The5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4chloro-7-methoxyquinazolineused as a starting material is described in Example 33.

EXAMPLE 54-(5-chloronaphth-1-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

A mixture of 4-chloro-7-methoxy-5-(L-methylpiperidinyloxy)quinazoline(0.08 g), 5-chloro-1-naphthylamine (0.055 g), 6.2M hydrogen chloride inisopropanol (0.044 ml) and isopropanol (3 ml) was stirred and heated toreflux for 2 hours. The mixture was cooled to ambient temperature andthe precipitate was isolated, washed with diethyl ether and dried undervacuum. There was thus obtained the title compound (0.129 g), a portionof which was treated with a saturated methanolic ammonia solution. Themixture was filtered and the filtrate was evaporated to give the freebase; NMR Spectrum: (CDCl₃) 1.9-2.1 (m, 4H), 2.22 (s, 3H), 2.25-2.4 (m,2H), 2.6-2.7 (m, 2H), 3.94 (s, 3H), 4.7 (br s, 1H), 6.6 (s, 1H), 6.9 (s,1H), 7.4 (m, 1H), 7.62 (d, 1H), 7.7 (m, 1H), 8.0 (m, 2H), 8.25 (d, 1H),8.46 (s, 1H), 9.9 (br s, 1H); Mass Spectrum: M+H⁺ 449 and 451.

EXAMPLE 64-(3-chlorobenzofuran-7-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

Using an analogous procedure to that described in Example 5,4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline was reactedwith 7-amino-3-chlorobenzofuran to give the title compound, a portion ofwhich was treated with a saturated methanolic ammonia solution. Themixture was filtered and the filtrate was evaporated to give the freebase; NMR Spectrum: (CDCl₃) 2.0-2.4 (m, 6H), 2.33 (s, 3), 2.9 (m, 2H),3.93 (s, 3H), 4.6 (m, 1H), 6.56 (s, 1H), 6.9 (s, 1H), 7.3-7.4 (m, 2H),7.7 (br s, 1H), 8.64 (s, 1H), 8.7 (d, 1H), 10.3 (br s, 1H); MassSpectrum: M+H⁺ 439 and 441.

The 7-amino-3-chlorobenzofuran used as a starting material was preparedas follows:—

For a 30 minute period, chlorine gas was bubbled through a solution of7-nitrobenzofuran (1.2 g) in glacial acetic acid (12 ml) which had beencooled at 18° C. The resultant mixture was evaporated and the residuewas partitioned between diethyl ether and water. The organic layer waswashed in turn with a saturated aqueous sodium bicarbonate solution,water and a saturated aqueous sodium chloride solution, dried (MgSO₄)and evaporated. The residue was purified by column chromatography onsilica to give a mixture of cis and trans2,3-dichloro-7-nitro-2,3-dihydrobenzofuran. The material so obtained wasdissolved in ethanol (2 ml) and a solution of 0.8M potassium hydroxidein ethanol (2.7 ml) was added. The mixture was stirred at ambienttemperature for 75 minutes. The mixture was evaporated to remove theethanol. The residue was diluted with water and the mixture wasacidified to pH2 by the addition of concentrated hydrochloric acid. Themixture was extracted with diethyl ether. The organic extract was washedwith water and with a saturated aqueous sodium chloride solution, dried(MgSO₄) and evaporated. There was thus obtained3-chloro-7-nitrobenzofuran (0.7 g); NMR Spectrum: DMSOd₆) 7.63 (m, 1H),8.12 (d, 1H), 8.3 (d, 1H), 8.65 (s, 1H); Mass Spectrum: M+H⁺ 197 and199.

A suspension of hydrazine hydrate (0.049 ml) and Raney nickel (0.01 g)in methanol (2 ml) was heated to 60° C. and added dropwise to a mixtureof 3-chloro-7-nitrobenzofuran (0.04 g) and methanol (4 ml). Theresultant mixture was heated to reflux for 10 minutes, filtered andevaporated. The residue was partitioned between methylene chloride andwater. The organic layer was washed with water, dried (MgSO₄) andevaporated. The residue was purified by column chromatography on silicausing a 1:1 mixture of methylene chloride and petroleum ether as eluent.There was thus obtained 3-chloro-7-aminobenzofuran (0.021 g); NMRSpectrum: (DMSOd₆ and CF₃COOD) 6.65 (d, 1H), 6.75 (d, 1H), 7.05 (m, 1H),8.2 (s, 1H); Mass Spectrum: M+H⁺ 167.

EXAMPLE 74-(2,3-methylenedioxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

Using an analogous procedure to that described in Example 5,4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline was reactedwith 2,3-methylenedioxyaniline (J. Med. Chem., 1979, 22, 1354) to givethe title compound, a portion of which was treated with a saturatedmethanolic ammonia solution. The mixture was filtered and the filtratewas evaporated to give the free base; NMR Spectrum: (CDCl₃) 2.0-2.1 (m,2H), 2.15-2.3 (m, 4H), 2.31 (s, 3H), 2.85 (m, 2H), 3.91 (s, 3H), 6.01(s, 2H), 6.5 (d, 1H), 6.68 (d, 1H), 6.82 (d, 1H), 6.91 (m, 1H), 8.0 (d,1H), 8.6 (s, 1H), 9.72 (s, 1H); Mass Spectrum: M+H⁺ 409.

EXAMPLE 84-(2-chloro-5-methoxyanilino)-5-(N-methylpiperidin-4-ylmethoxy)quinazoline

A mixture of5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-(2-chloro-5-methoxyanilino)quinazoline(0.2 g), a concentrated aqueous formaldehyde solution (37%, 0.4 ml) andformic acid (4 ml) was stirred and heated to 100° C. for 2.5 hours. Themixture was cooled to ambient temperature and evaporated. The residuewas triturated under diethyl ether and the resultant solid was isolatedand dried under vacuum. There was thus obtained4-(2-chloro-5-methoxyanilino)-5-(N-methylpiperidin-4-ylmethoxy)quinazoline,as a formic acid salt (0.09 g); NMR Spectrum: (CDCl₃) 1.8-2.0 (m, 2H),2.05-2.15 (m, 2H), 2.35 (in, 1H), 2.6 (t, 2H), 3.55 (d, 2H), 3.93 (s,3H), 4.21 (d, 2H), 6.68 (m, 1H), 6.95 (d, 1H), 7.31 (d, 1H), 7.54 (d,1H), 7.7 (m, 1H), 8.35 (br s, 1H), 8.39 (d, 1H), 8.7 (s, 1H); MassSpectrum: M+H⁺ 413.

EXAMPLE 94-(2-bromo-5-methoxyanilino)-5-(1-methylpiperidin-4-ylmethoxy)quinazoline

Using an analogous procedure to that described in Example 8,4-(2-bromo-5-methoxyanilino)-5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]quinazoline(0.22 g) was reacted with concentrated aqueous formaldehyde solution(0.4 ml) to give the title compound, as a formic acid salt (0.183 g);NMR Spectrum: (CDCl₃) 1.7-1.9 (m, 2H), 2.06 (d, 2H), 2.2 (m, 1H), 2.58(t, 2H), 2.68 (s, 3H), 3.51 (d, 2H), 3.8 (s, 3H), 4.24 (d, 2H), 6.64 (m,1H), 6.94 (d, 1H), 7.48 (d, 1H), 7.54 (d, 1H), 7.69 (m, 1H), 8.2 (d,1H), 8.3 (br s, 1H), 8.69 (s, 1H), 9.94 (s, 1H); Mass Spectrum: M+H⁺ 457and 459.

EXAMPLE 104-(2-bromo-5methoxyanilino)-5-piperidin-4-ylmethoxyquinazoline

A mixture of4-(2-bromo-5-methoxyanilino)-5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]quinazoline(0.108 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) wasstirred at ambient temperature for 1.5 hours. The mixture was evaporatedand the residue was triturated under diethyl ether. The resultant solidwas isolated and dried under vacuum. The solid was dissolved inmethylene chloride and few drops of a saturated methanolic ammoniasolution was added. The solution was poured onto a chromatography columnfilled with silica and eluted with a 97:3 mixture of methylene chlorideand a saturated methanolic ammonia solution. There was thus obtained thetitle compound (0.082 g); NMR Spectrum: (CDCl₃) 1.2-1.4 (m, 2H), 1.9 (d,2H), 2.3 (m, 1H), 2.65 (t, 2H), 3.12 (d, 2H), 3.84 (s, 3H), 4.2 (d, 2H),6.61 (m, 1H), 6.93 (d, 1H), 7.5 (d, 2H), 7.68 (m, 1H), 8.22 (d, 1H),8.68 (s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

EXAMPLE 114-(2-chloro-5-methoxyanilino)-7-hydroxy-5-(3-morpholinopropoxy)quinazoline

A mixture of7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-(3-morpholinopropoxy)quinazoline(0.185 g), 10% palladium on charcoal catalyst (0.018 g), ethanol (2.5ml), THF (2.5 ml) and DMF (1 ml) was stirred under an atmospherepressure of hydrogen for 16 hours. The mixture was filtered and thefiltrate was evaporated. The residue was purified by columnchromatography on silica using a 9:1 mixture of methylene chloride and asaturated methanolic ammonia solution as eluent. There was thus obtainedthe title compound (0.045 g); NMR Spectrum: (DMSOd₆) 2.05 (m, 2H), 2.35(br s, 4H), 2.45 (t, 2H), 3.55 (t, 4H), 3.8 (s, 3H), 4.42 (t, 2H), 6.7(d, 2H), 7.45 (d, 1I), 8.3 (s, 1H), 8.45 (s, 1H), 10.05 (s, 1H); MassSpectrum: M+H⁺ 445.

EXAMPLE 124-(2-chloro-5-methoxyanilino)-5,7-di-(3-morpholinopropoxy)quinazoline

Di-tert-butyl azodicarboxylate (0.035 g) was added dropwise to a stirredmixture of4-(2-chloro-5-methoxyanilino)-7-hydroxy-5-(3-morpholinopropoxy)quinazoline(0.045 g), 4-(3-hydroxypropyl)morpholine (0.016 g), triphenylphosphine(0.04 g) and methylene chloride (1 ml). The reaction mixture was stirredat ambient temperature for 10 minutes. The mixture was evaporated andthe residue was purified by column chromatography on silica using a9:10:1 mixture of methylene chloride, ethyl acetate and a saturatedmethanolic ammonia solution as eluent. The material so obtained wastriturated under diethyl ether. The resultant solid was isolated, washedwith diethyl ether and dried under vacuum to give the title compound(0.018 g); NMR Spectrum: DMSOd₆ and CF₃COOD) 2.2-2.4 (m, 4H), 3.15 (m,4H), 3.35 (m, 4H), 3.5 (m, 4H), 3.7 (m, 4H), 3.8 (s, 3H), 4.02 (t, 4H),4.35 (t, 2H), 4.6 (t, 2H), 6.95 (s, 1H), 7.03 (s, 1H), 7.05 (m, 1H), 7.5(s, 1H), 7.6 (d, 1H), 8.88 (s, 1H); Mass Spectrum: M+H⁺ 572 and 574.

EXAMPLE 134-(2-chloro-5-methoxyanilino)-7-hydroxy-5-(3-pyrrolidin-1-ylpropoxy)quinazoline

A mixture of7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-(3-pyrrolidin-1-ylpropoxy)quinazoline(0.68 g), 10% palladium on charcoal catalyst (0.16 g), ethanol (13 ml)and THF (13 ml) was stirred under 5 atmospheres pressure of hydrogen for16 hours. The mixture was filtered and the filtrate was evaporated. Theresidue was triturated under methanol. The resulatnt solid was isolated,washed with diethyl ether and dried under vacuum. There was thusobtained the title compound (0.405 g); NMR Spectrum: (DMSOd₆) 1.65 (brs, 4H), 2.1 (m, 2H), 2.4 (br s, 4H), 2.55 (t, 2H), 3.8 (s, 3H), 4.4 (t,2H), 6.7 (m, 2H), 6.75 (m, 1H), 7.48 (d, 1H), 8.3 (d, 1H), 8.4 (s, 1H),10.05 (s, 1H).

EXAMPLE 14

Using an analogous procedure to that described in Example 12, theappropriate 7-hydroxy-substituted quinazoline was reacted with theappropriate alcohol to give the compounds described in Table III. TABLEIII

No. & Note (R¹)_(m) Q¹ (R²)_(n)  [1] 7-(3-morpholinopropoxy)3-pyrrolidin-1-ylpropyl 2-chloro-5-methoxy  [2]7-[3-(4-methylpiperazin-1-yl)propoxy] 3-pyrrolidin-1-ylpropyl2-chloro-5-methoxy  [3] 7-(2-methoxyethoxy) 3-pyrrolidin-1-ylpropyl2-chloro-5-methoxy  [4] 7-[2-(2-methoxyethoxy)ethoxy]3-pyrrolidin-1-ylpropyl 2-chloro-5-methoxy  [5] 7-isopropoxy4-piperidinyl 2-bromo-5-methoxy  [6] 7-(3-methylsulphonyl)propoxy4-piperidinyl 2-bromo-5-methoxy  [7] 7-(2-pyridylmethoxy)N-(2-pyridylmethyl)-piperidin-4-yl 2-bromo-5-methoxy  [8]7-[3-(4-methylpiperazin-1-yl)propoxy] 4-tetrahydropyranyl2-chloro-5-methoxy  [9] 7-(3-morpholinopropoxy) 4-tetrahydropyranyl2-chloro-5-methoxy [10] 7-(N-methylpiperidin-4-yloxy)4-tetrahydropyranyl 2-bromo-5-methoxy [11] 7-(2-pyrrolidin-1-ylethoxy)4-tetrahydropyranyl 2-bromo-5-methoxy [12] 7-(3-pyrrolidin-1-ylpropoxy)4-tetrahydropyranyl 2-bromo-5-methoxy [13] 7-(2-piperidinoethoxy)4-tetrahydropyranyl 2-bromo-5-methoxy [14]7-[2-(4-methylpiperazin-1-yl)ethoxy] 4-tetrahydropyranyl2-bromo-5-methoxy [15] 7-[3-(4-methylpiperazin-1-yl)propoxy]4-tetrahydropyranyl 2-bromo-5-methoxy [16] 7-[2-(2-morpholinomethyl-4-tetrahydropyranyl 2-bromo-5-methoxy 5-methylimidazol-1-yl)ethoxy] [17]7-{2-[2-(N,N-dimethylcarbamoyl)- 4-tetrahydropyranyl 2-bromo-5-methoxypyrrolidin-1-yl]ethoxy} [18] 7-{3-[2-(N,N-dimethylcarbamoyl)-4-tetrahydropyranyl 2-bromo-5-methoxy pyrrolidin-1-yl]propoxy} [19]7-[2-(2,5-dimethoxymethyl- 4-tetrahydropyranyl 2-bromo-5-methoxypyrrolidin-1-yl)ethoxy] [20] 7-[2-(4-pyridyloxy)ethoxy]4-tetrahydropyranyl 2-bromo-5-methoxy [21] 7-(3-morpholinopropoxy)cyclohexyl 2-chloro-5-methoxy [22] 7-(2-pyrrolidin-1-ylethoxy)cyclopentyl 2,4-dichloro-5-methoxy [23] 7-(3-morpholinopropoxy)isopropyl 2-chloro-5-methoxy [24] 7-[3-(4-methylpiperazin-1-yl)propoxy]isopropyl 2-chloro-5-methoxy [25] 7-(2-pyrrolidin-1-ylethoxy)4-tetrahydropyranyl 2,3-methylenedioxy [26] 7-(3-pyrrolidin-1-ylpropoxy)4-tetrahydropyranyl 2,3-methylenedioxy [27] 7-(3-pyridylmethoxy)4-piperidinyl 2-bromo-5-methoxy [28] 7-(2-pyrrolidin-1-ylethoxy)4-tetrahydropyranyl 2,4-dichloro-5-methoxy [29]7-(3-pyrrolidin-1-ylpropoxy) 4-tetrahydropyranyl 2,4-dichloro-5-methoxy[30] 7-(2-piperidinoethoxy) 4-tetrahydropyranyl 2,4-dichloro-5-methoxy[31] 7-[2-(4-methylpiperazin-1-ylethoxy] 4-tetrahydropyranyl2,4-dichloro-5-methoxy [32] 7-(2-morpholinoethoxy) 4-tetrahydropyranyl2,4-dichloro-5-methoxy [33] 7-{2-[2-(N-methylcarbamoyl)-4-tetrahydropyranyl 2,4-dichloro- pyrrolidin-1-yl]ethoxy} 5-methoxy [34]7-[2-(2-carbamoylpyrrolidin-1- 4-tetrahydropyranyl 2,4-dichloro-yl)ethoxy] 5-methoxy [35] 7-[2-(2-morpholinocarbonyl-4-tetrahydropyranyl 2,4-dichloro- pyrrolidin-1-yl)ethoxy] 5-methoxy [36]7-{2-[2-(4-methylpiperazin-1- 4-tetrahydropyranyl 2,4-dichloro-ylcarbonyl)pyrrolidin-1-yl]ethoxy} 5-methoxy [37]7-{2-[2-(pyrrolidin-1-ylcarbonyl)- 4-tetrahydropyranyl 2,4-dichloro-pyrrolidin-1-yl]ethoxy} 5-methoxy [38] 7-[2-(2-piperidinocarbonyl-4-tetrahydropyranyl 2,4-dichloro- pyrrolidin-1-yl)ethoxy] 5-methoxy [39]7-[2-(2-methylpyrrolidin-1- 4-tetrahydropyranyl 2,4-dichloro- yl)ethoxy]5-methoxy [40] 7-[2-(2-methoxymethylpyrrolidin-1- 4-tetrahydropyranyl2,4-dichloro- yl)ethoxy] 5-methoxy [41] 7-[2-(4-pyridyloxy)ethoxy]4-tetrahydropyranyl 2,4-dichloro-5-methoxy [42] 7-(3-pyridylmethoxy)4-tetrahydropyranyl 2,4-dichloro-5-methoxy [43] 7-(4-pyridylmethoxy)4-tetrahydropyranyl 2,4-dichloro-5-methoxy [44]7-(N-methylpiperidin-4-yloxy) 4-tetrahydropyranyl 2,4-dichloro-5-methoxy[45] 7-{2-[2-(N-methylcarbamoyl)- 4-tetrahydropyranyl 2-bromo-5-methoxypyrrolidin-1-yl]ethoxy} [46] 7-[2-(2-morpholinocarbonyl-4-tetrahydropyranyl 2-bromo-5-methoxy pyrrolidin-1-yl)ethoxy] [47]7-{2-[2-(4-methylpiperazin-1- 4-tetrahydropyranyl 2-bromo-5-methoxyylcarbonyl)pyrrolidin-1-yl]ethoxy} [48]7-{2-[2-(pyrrolidin-1-ylcarbonyl)- 4-tetrahydropyranyl 2-bromo-5-methoxypyrrolidin-1-yl]ethoxy} [49] 7-[2-(2-piperidinocarbonyl-4-tetrahydropyranyl 2-bromo-5-methoxy pyrrolidin-1-yl)ethoxy] [50]7-[2-(2-carbamoylpyrrolidin-1-yl)ethoxy] 4-tetrahydropyranyl2-bromo-5-methoxy [51] 7-[2-(2-methylpyrrolidin-1-yl)ethoxy]4-tetrahydropyranyl 2-bromo-5-methoxy [52]7-[2-(2-methoxymethylpyrrolidin-1- 4-tetrahydropyranyl 2-bromo-5-methoxyyl)ethoxy] [53] 7-(3-pyridylmethoxy) 4-tetrahydropyranyl2-bromo-5-methoxy [54] 7-(4-pyridylmethoxy) 4-tetrahydropyranyl2-bromo-5-methoxy [55] 7-isopropoxy 4-piperidinyl 6-chloro-2,3-methylenedioxy [56] 7-ethoxy 4-piperidinyl 6-chloro-2,3-methylenedioxy [57] 7-isobutoxy 4-piperidinyl 6-chloro-2,3-methylenedioxy [58] 7-(2-fluoroethoxy) 4-piperidinyl 6-chloro-2,3-methylenedioxy [59] 7-[2-(2,5-dimethoxymethyl- 4-tetrahydropyranyl2,3-methylenedioxy pyrrolidin-1-yl)ethoxy] [60]7-[2-(4-pyridyloxy)ethoxy] 4-tetrahydropyranyl 2,3-methylenedioxy [61]7-(3-pyridylmethoxy) 4-tetrahydropyranyl 2,3-methylenedioxy [62]7-(4-pyridylmethoxy) 4-tetrahydropyranyl 2,3-methylenedioxy [63]7-{2-[2-(N-methylcarbamoyl)- 4-tetrahydropyranyl 2,3-methylenedioxypyrrolidin-1-yl]ethoxy} [64] 7-[2-(2-morpholinocarbonyl-4-tetrahydropyranyl 2,3-methylenedioxy pyrrolidin-1-yl)ethoxy] [65]7-{2-[2-(4-methylpiperazin-1- 4-tetrahydropyranyl 2,3-methylenedioxyylcarbonyl)pyrrolidin-1-yl]ethoxy} [66]7-{2-[2-(pyrrolidin-1-ylcarbonyl)- 4-tetrahydropyranyl2,3-methylenedioxy pyrrolidin-1-yl]ethoxy} [67]7-[2-(2-piperidinocarbonyl- 4-tetrahydropyranyl 2,3-methylenedioxypyrrolidin-1-yl)ethoxy] [68] 7-[2-(2-carbamoylpyrrolidin-1-yl)ethoxy]4-tetrahydropyranyl 2,3-methylenedioxy [69]7-[2-(2-methylpyrrolidin-1-yl)ethoxy] 4-tetrahydropyranyl2,3-methylenedioxy [70] 7-[2-(2-methoxymethylpyrrolidin-1-4-tetrahydropyranyl 2,3-methylenedioxy yl)ethoxy] [71]7-(3-piperazin-1-ylpropoxy) 4-tetrahydropyranyl 6-chloro-2,3-methylenedioxy [72] 7-[3-(4-methylpiperazin-1- 4-tetrahydropyranyl6-chloro- yl)propoxy] 2,3-methylenedioxy [73] 7-[2-(4-methylpiperazin-1-4-tetrahydropyranyl 6-chloro- yl)ethoxy] 2,3-methylenedioxy [74]7-(2-piperidinoethoxy) 4-tetrahydropyranyl 6-chloro- 2,3-methylenedioxy[75] 7-(2-piperidin-4-ylethoxy) 4-tetrahydropyranyl 6-chloro-2,3-methylenedioxy [76] 7-[2-(4-pyridyloxy)ethoxy] 4-tetrahydropyranyl6-chloro- 2,3-methylenedioxy [77] 7-[N-(tert-butoxycarbonyl)piperidin-4-tetrahydropyranyl 6-chloro- 4-ylmethoxy] 2,3-methylenedioxy [78]7-(3-pyrrolidin-1-ylpropoxy) cyclopentyl 2,3-methylenedioxy [79]7-[3-(4-methylpiperazin-1-yl)propoxy] cyclopentyl 2,3-methylenedioxy[80] 7-[2-(4-methylpiperazin-1-yl)ethoxy] cyclopentyl 2,3-methylenedioxy[81] 7-(2-piperidinoethoxy) cyclopentyl 2,3-methylenedioxy [82]7-{2-[2-(4-methylpiperazin-1- cyclopentyl 2,3-methylenedioxyylcarbonyl)pyrrolidin-1-yl]ethoxy} [83] 7-piperidin-4-ylmethoxy)cyclopentyl 2,3-methylenedioxy [84] 7-(3-piperazin-1-ylpropoxy)cyclopentyl 2,3-methylenedioxyNotes[1] The reaction product was treated with a 6M solution of hydrogenchloride in diethyl ether (5 ml) at ambient temperature for 30 minutes.The resultant solid was isolated, washed with isopropanol and withdiethyl ether and dried under vacuum to give the product as thetrihydrochloride salt; NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.8-2.1 (m,4H), 2.35 (m, 4H), 3.05 (m, 2H), 3.15 (t, 2H), 3.35 (m, 4H), 3.55 (m,4H), 3.8 (s, 3H), 3.85 (t, 2H), 4.05 (d, 2H), 4.4 (t, 2H), 4.7 (t, 2H),7.0-7.15 (m, 3H), 7.52 (d, 1H), 7.56 (d, 1H), 8.86 (s, 1H); MassSpectrum: M+H⁺ 556 and 558.[2] The reaction product was treated with a 6M solution of hydrogenchloride in diethyl ether (5 ml) at ambient temperature for 30 minutes.The resultant solid was isolated, washed with isopropanol and withdiethyl ether and dried under vacuum to give the product as thetrihydrochloride salt; NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.8-2.05 (m,4H), 2.4 (m, 4H), 2.95 (s, 3H), 3.02 (m, 2H), 3.2-3.65 (m, 12H), 3.8 (t,2H), 3.85 (s, 3H), 4.4 (t, 2H), 4.7 (t, 2H), 7.02 (s, 1H), 7.05 (m, 1H),7.1 (s, 1H), 7.5 (s, 1H), 7.6 (d, 1H), 7.95 (s, 1H).[3] The reaction product was treated with a 6M solution of hydrogenchloride in diethyl ether (5 ml) at ambient temperature for 30 minutes.The resultant solid was isolated, washed with isopropanol and withdiethyl ether and dried under vacuum to give the product as thedihydrochloride salt; NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.85-2.1 (m,4H), 2.38 (m, 2H), 3.05 (m, 2H), 3.35 (t, 2H), 3.4 (s, 3H), 3.6 (m, 2H),3.8 (s, 3H), 3.85 (m, 2H), 4.4 (t, 2H), 4.65 (t, 2H), 7.0 (s, 1H), 7.05(m, 1H), 7.12 (s, 1H), 7.52 (d, 1H), 7.6 (d, 1H), 8.87 (s, 1H); MassSpectrum: M+H⁺ 487 and 489.[4] The reaction product was treated with a 6M solution of hydrogenchloride in diethyl ether (5 ml) at ambient temperature for 30 minutes.The resultant solid was isolated, washed with isopropanol and withdiethyl ether and dried under vacuum to give the product as thedihydrochloride salt; NMR Spectrum: (DMSOd₆ and CF₃COOD) 1.8-2.05 (m,4H), 2.35 (m, 2H), 3.0 (m, 2H), 3.25 (s, 3H), 3.35 (t, 2H), 3.5 (t, 2H),3.55 (m, 2H), 3.65 (t, 2H), 3.8 (s, 3H), 3.85 (m, 2H), 4.35 (m, 2H),4.65 (t, 2H), 7.0 (s, 1H), 7.05 (m, 1H), 7.12 (s, 1H), 7.45 (s, 1H),7.57 (d, 1H), 8.85 (s, 1H); Mass Spectrum: M+H⁺ 531 and 533.[5] The reaction mixture was stirred at ambient temperature for 2 hours.The reaction product was treated with 6M hydrogen chloride inisopropanol to give4-(2-bromo-5-methoxyanilino)-7-isopropoxy-5-piperidin-4-yloxyquinazolinedihydrochloride, a portion of which was converted to the free base usingan analogous procedure to that described in Example 3. The free basegave the following data: NMR Spectrum: (CDCl₃) 1.45 (d, 6H), 1.8-2.0 (m,2H), 2.25 (d, 2H), 2.75 (m, 2H), 3.2 (m, 2H), 3.82 (s, 3H), 4.65 (m,1H), 4.75 (m, 1H), 6.52 (d, 1H), 6.65 (m, 1H), 6.85 (d, 1H), 7.5 (d,1H), 7.92 (d, 1H), 8.52 (s, 1H), 9.72 (s, 1H); Mass Spectrum: M+H⁺ 487and 489.

The4-(2-bromo-5-methoxyanilino)-7-hydroxy-5-piperidin-4-yloxyquinazolineused as a starting material is described in Example 20 hereinafter.

[6] The reaction mixture was stirred at ambient temperature for 1 hourwhereafter a second portion of each of di-tert-butyl azodicarboxylateand triphenylphosphine were added and the reaction mixture was stirredat ambient temperature for 30 minutes. The reaction product wasdissolved in methanol containing potassium carbonate and heated toreflux for 15 minutes. The mixture was filtered and the filtrate wasevaporated to give the required product; NMR Spectrum: (CDCl₃) 1.85-2.0(m, 2H), 2.25 (d, 2H), 2.42 (m, 2H), 2.8 (m, 2H), 3.0 (s, 3H), 3.21 (m,2H), 3.3 (m, 2H), 3.82 (s, 3H), 4.25 (m, 2H), 4.65 (m, 1H), 6.55 (d,1H), 6.62 (m, 1H), 6.82 (d, 1H), 7.5 (d, 1H), 7.9 (d, 1H), 8.52 (s, 1H),9.75 (s, 1H); Mass Spectrum: M+H⁺ 565 and 567.

[7] The reactants were4-(2-bromo-5-methoxyanilino)-7-hydroxy-5-piperidin-4-yloxyquinazolineand 2-pyridylmethanol. The reaction mixture was stirred at ambienttemperature for 1 hour whereafter a second portion of each ofdi-tert-butyl azodicarboxylate and triphenylphosphine were added and thereaction mixture was stirred at ambient temperature for 30 minutes. Thereaction product was dissolved in methanol containing potassiumcarbonate and heated to reflux for 15 minutes. The mixture was filteredand the filtrate was evaporated to give the required product; NMRSpectrum: (CDCl₃) 2.05-2.2 (m, 2H), 2.2-2.3 (m, 2H), 2.35 (m, 2H), 2.92(d, 2H), 3.68 (s, 3H), 3.82 (s, 3H), 4.6 (m, 1H), 5.32 (s, 2H), 6.62 (m,1H), 6.7 (d, 1H), 6.92 (d, 1H), 7.2 (m, 1H), 7.4 (d, 1H), 7.5 (m, 2H),7.65 (m, 1H), 7.75 (m, 1H), 7.88 (d, 1H), 8.52 (s, 1H), 8.55 (m, 2H),8.65 (d, 1H), 9.72 (s, 1H); Mass Spectrum: M+H⁺ 627 and 629.

[8] The reaction mixture was stirred at ambient temperature for 2 hours.The reaction product, obtained as the free base, gave the followingdata: NMR Spectrum: (CDCl₃) 2.0-2.15 (m, 6H), 2.3 (s, 3H), 2.35-2.7 (m,10H), 3.6 (t, 2H), 3.85 (s, 3H), 4.0-4.2 (m, 4H), 4.75 (m, 1H), 6.6 (s,1H), 6.7 (m, 1H), 6.9 (s, 1H), 7.32 (d, 1H), 8.2 (s, 1H), 8.58 (s, 1H),9.85 (s, 1H); Mass Spectrum: M+H⁺ 542 and 544.

The4-(2-chloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline,used as a startng material, is described in Example 21.

[9] The reaction mixture was stirred at ambient temperature for 2 hours.The reaction product, obtained as the free base, gave the followingdata: NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.85-2.0 (s, 2H), 2.18 (d, 2H),2.2-2.3 (m, 2H), 3.15 (m, 2H), 3.3-3.4 (m, 2H), 3.5 (d, 2H), 3.7 (t,2H), 3.8 (s, 3H), 3.95.(m, 2H), 4.05 (d, 2H), 4.3 (t, 2H), 5.15 (m, 1H),6.9 (s, 1H), 7.02 (m, 1H), 7.1 (s, 1H), 7.6 (m, 2H), 8.9 (s, 1H); MassSpectrum: M+H⁺ 529 and 531.

[10] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.8-2.0 (m, 2H), 2.0-2.2 (m,4H), 2.2-2.3 (m, 4H), 2.33 (s, 3H), 2.78 (m, 2H), 3.6 (m, 2H), 3.84 (s,3H),4.08 (m, 2H), 4.45 (m, 1H), 4.75 (m, 1H), 6.55 (s, 1H), 6.65 (m,1H), 6.85 (d, 1H), 7.5 (d, 1H), 7.92 (d, 1H), 8.52 (s, 1H), 9.7 (s, 1H);Mass Spectrum: M+H⁺ 543 and 545.

The4-(2-bromo-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline,used as a starting material, is described in Example 24.

[11] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.85 (m, 4H), 2.1 (m, 2H),2.22 (d, 2H), 2.65 (m, 4H), 2.98 (t, 2H), 3.58 (t, 2H), 3.85 (s, 3H),4.05 (m, 2H), 4.22 (t, 2H), 4.75 (m, 1H), 6.65 (m, 2H), 6.87 (s, 1H),7.5 (d, 1H), 7.95 (s, 1H), 8.55 (s, 1H), 9.7 (s, 1H); Mass Spectrum:M+H⁺ 543 and 545.

[12] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.8 (m, 4H), 2.0-2.2 (m, 4H),2.22 (d, 2H), 2.45-2.6 (m, 4H), 2.68 (m, 2H), 3.6 (m, 2H), 3.85 (s,3H),4.05 (m, 2H), 4.15 (m, 2H), 4.78 (m, 1H), 6.55 (d, 1H), 6.65 (m,1H), 6.85 (d, 1H), 7.5 (d, 1H), 7.95 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H);Mass Spectrum: M+H⁺ 557 and 559.

[13] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.63 (br s, 6H), 2.0-2.2 (m,2H), 2.25 (d, 2H), 2.55 (br s, 4H), 2.85 (t, 2H), 3.6 (m, 2H), 384 (s,3H), 4.05 (m, 2H), 4.25 (m, 2H), 4.75 (m, 1H), 6.62 (m, 2H), 6.85 (d,1H), 7.5 (d, 1H), 7.95 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H); MassSpectrum: M+H⁺ 557 and 559.

[14] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 2.0-2.18 (m, 2H), 2.25 (d,2H), 2.31 (s, 3H), 2.5 (br s, 4H), 2.65 (br s, 4H), 2.9 (t, 2H), 3.6 (m,2H), 3.84 (s, 3H), 4.05 (m, 2H), 4.25 (t, 2H), 4.75 (m, 1H), 6.62 (m,2H), 6.85 (d, 1H), 7.5 (d, 1H), 7.95 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H);Mass Spectrum: M+H⁺ 572 and 574.

[15] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 2.02-2.2 (m, 4H), 2.25 (d,2H), 2.29 (s, 3H), 2.35-2.7 (m, 10H), 3.6 (m, 2H), 3.84 (s, 3H), 4.1 (m,2H), 4.15 (t, 2H), 4.75 (m, 1H), 6.55 (s, 1H), 6.65 (m, 1H), 6.85 (d,1H), 7.5 (d, 1H), 7.95 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H); MassSpectrum: M+H⁺ 586 and 588.

[16] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 2.0-2.2 (m, 2H), 2.22 (d, 2H),2.3 (s, 3H), 2.45 (br s, 4H), 3.6 (t, 2H), 3.65 (br s, 6H), 3.85 (s,3H), 4.05 (m, 2H), 4.42 (m, 2H), 4.45 (m, 2H), 4.75 (m, 1H), 6.48 (s,1H), 6.65 (m, 1H), 6.7 (s, 1H), 6.82 (d, 1H), 7.5 (d, 1H), 7.92 (d, 1H),8.55 (s, 1H), 9.68 (s, 1H); Mass Spectrum: M+H⁺ 653 and 655.

The 1-(2-hydroxyethyl)-5-methyl-2-morpholinomethylimidazole used as astarting material was prepared as follows:

A mixture of 4-methyl-1-tritylimidazole (J. Heterocyclic Chem., 1982,19, 253; 32.5 g), methyl bromoacetate (11.4 ml) and acetone (500 ml) washeated to reflux for 2 hours. The solvent was removed by evaporation andthe residue was dissolved in methanol (100 ml) and heated to refiux for45 minutes. The mixture was evaporated and the residue was trituratedunder diethyl ether. The resultantprecipitate was isolated and stirredat ambient temperature for 1 hour in a mixture of diethyl ether (200 ml)and a saturated methanolic ammonia solution (20 ml). The mixture wasfiltered and the filtrate was evaporated. The residue was purified bycolumn chromatography on silica using a 49:1 mixture of methylenechloride and methanol as eluent. There was thus obtained methyl2-(5-methylimidazol-1-yl)acetate (6 g); NMR Spectrum: (CDCl₃) 2.16 (s,3H), 3.78 (s, 3H), 4.61 (s, 3H), 6.8 (s, 1H), 7.42 (s, 1H).

A solution of a portion (1.7 g) of the material so obtained in diethylether (20 ml) was added dropwise to a stirred suspension of lithiumaluminium hydride (0.76 g) in diethyl ether (70 ml) which was cooled to0° C. The resultant mixture was stirred at ambient temperature for 1hour. The mixture was cooled to 0° C. and a 6N aqueous sodium hydroxidesolution (0.8 ml) and water (2.4 ml) were added dropwise in turn. Themixture was stirred at ambient temperature for 30 minutes and thenevaporated. The residue was dissolved in methylene chloride, dried overmagnesium sulphate and evaporated to give1-(2-hydroxyethyl)-5-methylimidazole (1.1 g); NMR Spectrum: (CDCl₃) 2.17(s, 3H), 3.81 (t, 2H), 3.92 (t, 2H), 6.6 (s, 1H), 7.24 (s, 1H).

Tert-butyldimethylsilyl chloride (9.05 g) was added to a stirred mixtureof 1-(2-hydroxyethyl)-5-methylimidazole (6.4 g), imidazole (7.5 g) andmethylene chloride (30 ml) which was cooled to 0° C. The reactionmixture was stirred at ambient temperature for 4 hours. The mixture waspoured into water. The organic layer was washed with brine, dried overmagnesium sulphate and evaporated to give1-(2-tert-butyldimethylsilyloxyethyl)-5-methylimidazole (11.7 g); NMRSpectrum: (CDCl₃) −0.04 (s, 6H), 0.85 (s, 6H), 2.2 (s, 3H), 3.8 (m, 2H),3.94 (m, 2H), 6.75 (s, 1H), 7.43 (s, 1H).

The material so obtained was dissolved in TBF (400 ml) and the solutionwas cooled at −60° C. n-Butyllithium (2.5M in hexane, 40 ml) was addeddropwise and the mixture was stirred at −50° C. for 1 hour. The mixturewas cooled to −60° C. and DMF (12.5 ml) was added dropwise. Theresultant mixture was allowed to warm to ambient temperature and wasstirred for 2 hours. Diethyl ether (500 ml) was added and the reactionmixture was poured into a saturated aqueous ammonium chloride solution.The organic layer was separated, washed with brine, dried over magnesiumsulphate and evaporated. The material so obtained was purified by columnchromatography on silica using increasingly polar mixtures of methylenechloride and a saturated methanolic ammonia solution as eluent. Therewas thus obtained1-(2-tert-butyldimethylsilyloxyethyl)-2-formyl-5-methylinidazole (11 g);NMR Spectrum: (CDCl₃) −0.1 (s, 6H), 0.79 (s, 9H), 2.32 (s, 3H), 3.91 (t,2H), 4.4 (t, 2H), 7.07 (s, 1H), 9.71 (s, 1H).

A portion (0.79 g) of the material so obtained was dissolved inmethylene chloride (24 ml) and morpholine (0.263 ml) and acetic acid(0.175 ml) were added. Sodium borohydride triacetate (0.8 g) was addedportionwise and the mixture was stirred at ambient temperature for 16hours. The mixture was evaporated and the residue was purified by columnchromatography on silica using a 49:1 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. There was thusobtained1-(2-tert-butyldimethylsilyloxyethyl)-5-methyl-2-morpholinomethylimidazole(0.5 g); NMR Spectrum: (CDCl₃) 0 (s, 6H), 0.82 (s, 9H), 2.25 (s, 3H),2.45 (m, 4H), 3.6 (s, 2H), 3.68 (m, 4H), 3.85 (t, 2H), 4.1 (t, 2H), 6.7(s, 1H).

A mixture of the material so obtained, 12N aqueous hydrochloric acid(0.26 ml) and methanol (10 ml) was stirred at ambient temperature for 5hours. The mixture was evaporated and the residue was triturated underpentane. The resultant solid was isolated and dried under vacuum. Thesolid was stirred at ambient temperature for 1 hour in a mixture ofmethylene chloride and a saturated methanolic ammonia solution. Themixture was filtered and the filtrate was evaporated. The residue waspurified by column chromatography on silica using a 19:1 mixture ofmethylene chloride and a saturated methanolic ammonia solution aseluent. There was thus obtained1-(2-hydroxyethyl)-5-methyl-2-morpholinomethylimidazole (0.25 g); NMRSpectrum: (CDCl₃) 2.2 (s, 3H), 2.6 (br s, 4H), 3.58 (s, 2H), 3.7 (m,4H), 3.85 (t, 2H), 4.1 (t, 2H), 6.5-6.9 (br s, 1H), 6.65 (s, 1H).

[17] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.75-2.3 (m, 8H), 2.5 (m, 1H),2.8-2.9 (m, 1H), 2.9 (s, 3H), 3.1 (s, 3H), 3.18 (m, 1H), 3.35 (m, 1H),3.48 (m, 1H), 3.58 (m, 2H), 3.82 (s, 3H), 4.05 (m, 2H), 4.2 (m, 2H),4.72 (m, 1H), 6.6 (m, 2H), 6.8 (s, 1H), 7.5 (d, 1H), 7.92 (d, 1H), 8.5(s, 1H), 9.68 (s, 1H); Mass Spectrum: M+H⁺ 614 and 616.

The (2S)-1-(2-hydroxyethyl)-N,N-dimethylpyrrolidine-2-carboxamide usedas a starting material was prepared as follows:

A mixture of 1-(tert-butoxycarbonyl)-L-proline (10.75 g),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.6 g),dimethylamine hydrochloride (5.33 g), 4-dimethylaminopyridine (6.1 g)and methylene chloride (200 ml) was stirred at ambient temperature for 4hours. The mixture was poured into water. The organic layer wasseparated, washed in turn with a 1N aqueous potassium hydrogen sulphatesolution, with a 5% aqueous sodium bicarbonate solution and brine, driedover magnesium sulphate and evaporated to give1-(tert-butoxycarbonyl)-N,N-dimethyl-L-prolinamide (11.2 g); NMRSpectrum: (CDCl₃) 1.4 and 1.5 (2 s, 9H), 1.8-1.9 (m, 2H), 1.95-2.2 (m,2H), 3.0 and 3.1 (2 d, 6H), 3.35-3.6 (m, 2H), 4.55 and 4.7 (2 m, 1H).

A mixture of a portion (0.24 g) of the material so obtained andtrifluoroacetic acid (3 ml) was stirred at ambient temperature for 2hours. The mixture was evaporated and the residue was triturated underdiethyl ether. A slight excess of a 2M solution of hydrogen chloride indiethyl ether was added and the precipitate was isolated and dried undervacuum to give N,N-dimethyl-L-prolinamide hydrochloride salt (0.25 g);NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.7-2.0 (m, 3H), 2.3-2.5 (m, 1H),2.95 (s, 3H), 3.05 (s, 3H), 3.1-3.4 (m, 2H), 4.6 (m, 1H).

A mixture of N,N-dimethyl-L-prolinamide hydrochloride salt (6.3 g),2-bromoethanol (3.8 ml), potassium carbonate (14 g) and acetonitrile (70ml) was stirred and heated to reflux for 16 hours. The mixture wasfiltered and the filtrate was evaporated. The residue was purified bycolumn chromatography on silica using a 24:1 mixture of methylenechloride and a saturated methanolic ammonia solution as eluent. Therewas thus obtained(2S)1-(2-hydroxyethyl)-N,N-dimethylpyrrolidine-2-carboxamide (3.4 g);NMR Spectrum: (CDCl₃) 1.6 (m, 1H), 1.6-2.0 (m, 4H), 2.1-2.3 (m, 2H), 2.4(m, 1H), 2.9 (m, 1H), 3.0 (s, 3H), 3.05 (s, 3H), 3.25-3.4 (m, 2H), 3.75(m, 1H), 3.9 (m, 1H), 5.1 (br s, 1H); Mass Spectrum: M+H⁺ 187.

[18] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.7-2.5 (m, 12H), 2.95 (s,3H), 3.1 (s, 3H), 2.8-3.0 (m, 1H), 3.2-3.4 (m, 2H), 3.58 (t, 2H), 3.82(s, 3H), 4.05 (m, 2H), 4.1 (t, 2H), 4.75 (m, 1H), 6.55 (d, 1H), 6.6 (m,1H), 6.8 (d, 1H), 7.48 (d, 1H), 7.92 (d, 1H), 8.5 (s, 1H), 9.65 (s, 1H);Mass Spectrum: M+H⁺ 628 and 630. The(2S)-1-(3-hydroxypropyl)-N,N-dimethylpyrrolidine-2-carboxamide used as astarting material was prepared as follows using an analogous procedureto that described in International Patent Application WO 98/13354(Example 76 thereof):

Using an analogous procedure to that described in the last paragraph ofthe portion of Note [17] immediately above that is concerned with thepreparation of starting materials, 3-bromopropanol was reacted withN,N-dimethyl-L-prolinamide hydrochloride salt.

[19] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt. A portion thereof wastreated with a saturated methanolic ammonia solution, the mixture wasfiltered and the filtrate evaporated to give the free base which gavethe following data: NMR Spectrum: (CDCl₃) 1.6-1.8 (m, 2H), 1.9-2.0 (m,2H), 2.05-2.15 (m, 2H), 2.25 (d, 2H), 3.21 (m, 2H), 3.25-3.5 (m, 6H),3.33 (s, 3H), 3.34 (s, 3H), 3.58 (m, 2H), 3.84 (s, 3H), 4.05 (m, 2H),4.25 (m, 2H), 4.75 (m, 1H), 6.6 (d, 1H), 6.65 (m, 1H), 6.9 (d, 1H), 7.5(d, 1H), 7.95 (d, 1H), 8.55 (s, 1H), 9.7 (s, 1H); Mass Spectrum: M+H⁺631 and 633.

The (2R,5R)-1 -(2-hydroxyethyl)-2,5-dimethoxymethylpyrrolidine used as astarting material was prepared as follows:

A mixture of (2R,5R)-2,5-dimethoxymethylpyrrolidine (0.25 g),2-bromoethanol (1.1 ml), potassium carbonate (2.8 g) and acetonitrile(10 ml) was stirred and heated to reflux for 18 hours. The mixture wasfiltered and the filtrate was poured on a column of silica and eluted bya 49:1 mixture of methylene chloride and a saturated methanolic ammoniasolution. There was thus obtained(2R,5R)-1-(2-hydroxyethyl)-2,5-dimethoxymethylpyrrolidine (0.23 g); MassSpectrum: M+H⁺ 204.

[20] 4-(2-Hydroxyethoxy)pyridine (J. Chem. Soc. Perkin II 1987, 1867)was used as a starting material. The product gave the following data:NMR Spectrum: (DMSOd₆) 1.65-1.9 (m, 2H), 2.25 (d, 2H), 3.55 (m, 2H),3.78 (s, 3H), 3.9 (m, 2H), 4.4-4.55 (m, 4H), 5.1 (m, 1H), 6.78 (m, 1H),6.85 (d, 1H), 7.0 (d, 1H), 7.05 (d, 2H), 7.6 (d, 1H), 7.84 (d, 1H), 8.4(d, 2H), 8.45 (s, 1H), 9.69 (s, 1H); Mass Spectrum: M+H⁺ 567 and 569.

[21] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product, obtained as the free base, gave thefollowing data: NMR Spectru: (DMSOd₆ and CF₃CO₂D) 1.2-1.35 (m, 1H),1.4-1.5 (m, 2H), 1.6 (m, 1H), 1.7-1.8 (m, 4H), 2.1-2.15 (m, 2H), 2.2-2.3(m, 2H), 3.1-3.2 (t, 2H), 3.35 (t, 2H), 3.55 (d, 2H), 3.7 (t, 2H),3.8(s, 3H), 4.05 (d, 2H), 4.3 (t, 2H), 4.92 (m, 1H), 6.9 (s, 1H), 7.02 (d,1H), 7.05 (s, 1H), 7.58 (d, 1H), 7.58 (s, 1H), 7.9 (s, 1H); MassSpectrum: M+H⁺ 527 and 529.

The 4-(2-chloro-5-methoxyanlino)-5-cyclohexyloxy-7-hydroxyquinazolineused as a starting material was prepared as follows:

Using an analogous procedure to that described in Example 1,7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-hydroxyquinazoline (0.53 g)was reacted with cyclohexanol to give7-benzyloxy-4-(2-chloro-5-methoxyanilino)5-cyclohexyloxyquinazoline(0.25 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.3-1.4 (m, 1H), 1.4-1.55(m, 2H), 1.55-1.65 (m, 1H), 1.7-1.85 (m, 4H), 2.15 (m, 2H), 3.82 (s,3H), 4.95 (m, 1H), 5.4 (s, 2H), 7.0 (d, 1H), 7.05 (m, 1H), 7.2 (s, 1H),7.4-7.65 (m, 7H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 490 and 492.

Using an analogous procedure to that described in Example 20,7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-cyclohexyloxyquinazoline wasreacted with trifluoroacetic acid to give4-(2-chloro-5-methoxyanilino)-5-cyclohexyloxy-7-hydroxyquinazoline; NMRSpectrum: (DMSOd₆ and CF₃CO₂D) 1.2-1.35 (m, 1H), 1.4-1.55 (m, 2H),1.55-1.65 (m, 1H), 1.7-1.85 (m, 4H), 2.15 (m, 2H), 3.82 (s, 3H), 4.85(m, 1H), 6.8 (s, 1H), 7.0 (s, 1H), 7.05 (m, 1H), 7.55 (d, 1H), 7.6 (d,1H), 8.82 (s, 1H); Mass Spectrum: M+H⁺ 400 and 402.

[22] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product, obtained as the free base, gave thefollowing data: NMR Spectrum: (CDCl₃) 1.65-1.75 (m, 2H), 1.75-1.8 (m,2H), 1.8-1.9 (m, 4H), 2.05-2.18 (m, 4H), 2.65 (m, 4H), 2.98 (m, 2H),3.95 (s, 3H), 4.22 (m, 2H), 5.02 (m, 1H), 6.62 (d, 1H), 6.85 (d, 1H),7.4 (s, 1H), 8.38 (s, 1H), 8.55 (s, 1H), 9.8 (s, 1H); Mass Spectrum:M+H⁺ 517 and 519.

The5-cyclopentyloxy-4-(2,4dichloro-5-methoxyanilino)-7-hydroxyquinazolineused as a starting material was prepared as follows:

Di-tert-butyl azodicarboxylate (1.1 g) was added portionwise to astirred mixture 5-hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one (1 g),cyclopentanol (0.385 ml), triphenylphosphine (1.28 g) and methylenechloride (16 ml) which was maintained at ambient temperature using awater bath. The mixture was stirred at ambient temperature for 1 hour. A6M solution of hydrogen chloride in diethyl ether (4 ml) was added andthe mixture was stirred at ambient temperature for 10 ninutes. Theresultant precipitate was isolated, washed with methylene chloride andwith ethyl acetate and dried under vacuum. The product so obtained wasstirred in methanol (16 ml) containing sodium hydroxide (0.28 g) atambient temperature for 1 hour. The mixture was evaporated and the solidwas triturated under water (20 ml) containing acetic acid (1 ml). Theresultant precipitate was isolated, washed in turn with water, ethylacetate and diethyl ether. There was thus obtained5-cyclopentyloxy-7-methoxy-3,4-dihydroquinazoline4-one (0.52 g); NMRSpectrum (CDCl₃) 1.55 (br s, 2H), 1.75 (m, 4H), 1.9 (m, 2H), 3.85 (s,3H), 4.9 (br s, 1H), 6.5 (s, 1H), 6.62 (s, 1H), 7.9 (s, 1H), 11.62 (brs, 1H); Mass Spectrum: M+H⁺ 261.5.

The material so obtained was mixed with potassium carbonate (0.414 g)and N-methylpyrrolidin-2-one (10 ml) and thiophenol (0.306 ml) wasadded. The resultant mixture was stirred and heated to 175° C. for 30minutes. The mixture was evaporated and the residue was poured intowater (20 ml) containing acetic acid (1 ml). The resultant precipitatewas isolated, washed with ethyl acetate and dried under vacuum to give5-cyclopentyloxy-7-hydroxy-3,4-dihydroquinazolin4-one (0.4 g); NMRSpectrum: (DMSOd₆) 1.6 (m, 2H), 1.8 (m, 4H), 1.9 (m, 2H), 4.8 (br s,1H), 6.38 (s, 1H), 6.5 (s, 1H), 7.8 (s, 1H), 10.35 (s, 1H), 11.5 (br s,1H); Mass Spectrum: M+H⁺ 247.5.

A mixture of 5-cyclopentyloxy-7-hydroxy-3,4-dihydroquinazolin-4-one (13g), acetic anhydride (25 ml) and pyridine (21 ml) was stirred and heatedto 100° C. for 1 hour. The mixture was evaporated and the residue wasdissolved in a mixture of water (70 ml) and methanol (70 ml) and stirredat 15° C. for 30 minutes. The methanol was evaporated and the resultantprecipitate was isolated, washed with water and dried under vacuum togive 7-acetoxy-5-cyclopentyloxy-3,4-dihydroquinazolin-4-one (12.2 g);NMR Spectrum: DMSOd₆) 1.6 (br s, 2H), 1.8 (m, 4H), 1.92 (m, 2H), 2.3 (s,3H), 4.9 (m, 1H), 6.8 (s, 1H), 6.9 (s, 1H), 7.95 (s, 1H), 11.9 (br s,1H); Mass Spectrum: M+H⁺ 289.6.

Using an analogous procedure to that described in the last paragraph ofNote [9] in Example 15,7-acetoxy-5-cyclopentyloxy-3,4-dihydroquinazolin-4-one (5 g) was reactedwith carbon tetrachloride and triphenylphosphine to give7-acetoxy-4-chloro-5-cyclopentyloxyquinazoline (5.3 g); NMR Spectrum:(CDCl₃) 1.65-1.8 (m, 2H), 1.8-2.05 (m, 4H), 2.1 (m, 2H), 2.4 (s, 3H),4.95 (m, 1H), 6.78 (d, 1H), 7.35 (d, 1H), 8.9 (s, 1H); Mass Spectrum:M+H⁺307 and 309.

A mixture of a portion (1 g) of the material so obtained,2,4-dichloro-5-methoxyaniline hydrochloride (0.82 g), triethylamine(0.408 ml) and isopropanol (6 ml) was stirred and heated to 80° C. for1.5 hours. The precipitate was isolated, washed in turn withisopropanol, ethyl acetate and diethyl ether and dried under vacuum togive7-acetoxy-5-cyclopentyloxy-4-(2,4-dichloro-5-methoxyanilino)quinazoline(1.2 g); NMR Spectrum: (DMSOd₆) 1.6-1.8 (m, 4H), 1.95-2.2 (m, 4H), 2.4(s, 3H), 3.9 (s, 3H), 5.25 (br s, 1H), 7.3 (s, 2H), 7.82 (s, 1H), 7.9(s, 1H), 8.82 (s, 1H), 10.32 (s, 1H); Mass Spectrum: M+H⁺ 462 and 464.

A mixture of the material so obtained and a saturated methanolic ammoniasolution (20 ml) was stirred at ambient temperature for 4 hours. Themixture was evaporated and the residue was triturated under water. Theresultant solid was isolated and dried under vacuum to give5-cyclopentyloxy-4-(2,4-dichloro-5-methoxyanilino)-7-hydroxyquinrazoline(1 g); NMR Spectrum: (DMSOd₆) 1.6-1.8 (m, 4H), 1.95 (m, 2H), 2.0-2.15(m, 2H), 3.9 (s, 3H), 5.15 (m, 1H), 6.7 (s, 2H), 7.7 (s, 1H), 8.3 (s,1H), 8.4 (s, 1H), 9.7 (s, 1H), 10.5-10.7 (br s, 1H); Mass Spectrum: M+H⁺420 and 422.

[23] The free base product gave the following data: NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 1.5 (d, 6H), 2.2-2.3 (m, 2H), 3.15 (t, 2H), 3.3-3.4(m, 2H), 3.52 (d, 2H), 3.7 (m, 2H), 3.8 (s, 3H), 4.02 (d, 2H), 4.3 (t,2H), 5.1-5.2 (m, 1H), 6.9 (s, 1H), 7.0 (m, 2H), 7.55 (d, 1H), 7.65 (s,1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 487 and 489.

[24] The free base product gave the following data: NMR Spectrum:(DMSOd₆) 1.5 (d, 6H), 1.95 (m, 2H), 2.18 (s, 3H), 2.2-2.6 (m, 10H), 3.8(s, 3H), 4.2 (t, 2H), 5.1 (m, 1H), 6.75-6.85 (m, 3H), 7.48 (d, 1H), 8.2(s, 1H), 8.5 (s, 1H), 10.0 (s, 1H); Mass Spectrum: M+H⁺ 500 and 502.

[25] The reaction mixture was stirred at ambient temperature for 2hours. The free base product gave the following data: NMR Spectrum:(DMSOd₆) 1.7 (br s, 4H), 1.8-1.95 (m, 2H), 2.15 (d, 2H), 2.55 (br s,4H), 2.85 (m, 2H), 3.55 (m, 2H), 3.95 (m, 2H), 4.22 (m, 2H), 5.05 (m,1H), 6.15 (s, 2H), 6.75 (d, 1H), 6.85 (d, 1H), 6.9-7.0 (m, 2H), 8.1 (d,1H), 8.5 (s, 1H), 9.85 (s, 1H); Mass Spectrum: M+H⁺ 479.

The4-(2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

A mixture of7-acetoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (3.04g), diisopropylethylamine (4.34 ml), phosphoryl chloride (1.02 ml) and1,2-dichloroethane (60 ml) was stirred and heated to 80° C. for 2 hours.The mixture was evaporated to give7-acetoxy-4-chloro-5-tetrahydropyran-4-yloxyquinazoline which was usedwithout further purification.

A mixture of the material so obtained, 2,3-methylenedioxyaniline (1.5 g)and isopropanol (20ml) was stirred and heated to 80° C. for 1 hour. Themixture was cooled to ambient temperature and the resultant solid wasisolated, washed in turn with isopropanol and diethyl ether and driedunder vacuum. There was thus obtained7-acetoxy-4-(2,3-methylenedioxyanilino)-5-tetrahydropyran4yloxyquinazolinehydrochloride (3.6 g); NMR Spectrum: (DMSOd₆) 1.9-2.05 (m, 2H), 2.1-2.25(m, 2H), 2.4 (s, 3H), 3.55 (m, 2H), 3.98 (m, 2H), 5.1 (m, 1H), 6.2 (s,2H), 6.95-7.05 (m, 2H), 7.32 (s, 1H), 7.5 (s, 1H), 7.62. (m, 1H), 9.0(s, 1H); Mass Spectrum: M+H⁺ 424.

Using an analogous procedure to that described in the last paragraph ofNote [22] immediately above,7-acetoxy-4-(2,3-methylenedioxyanilino)-5-tetrahydropyran-4-yloxyquinazolinewas reacted with a saturated methanolic ammonia solution to give4-(2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline;NMR Spectrum: (DMSOd₆) 1.8-1.95 (m, 2H), 2.1-2.2 (m, 2H), 3.52 (m, 2H),3.8 (s, 3H), 3.9 (m, 2H), 4.95 (m, 1H), 6.7 (s, 1H), 6.75 (d, 1H), 6.85(s, 1H), 7.6 (d, 1H), 7.88 (s, 1H), 8.4 (s, 1H), 9.65 (s, 1H), 10.6 (brs, 1H); Mass Spectrum: M+H⁺ 382.

[26] The reaction mixture was stirred at ambient temperature for 2hours. The free base product gave the following data: NMR Spectrum:(DMSOd₆) 1.7 (br s, 4H), 1.75-1.9 (m, 2H), 1.9-2.0 (m, 2H), 2.15 (d,2H), 2.5 (br s, 4H), 2.6 (m, 2H), 3.55 (m, 2H), 3.9 (m, 2H), 4.18 (m,2H), 5.0 (m, 1H), 6.1 (s, 2H), 6.72 (d, 1H), 6.8 (s, 1H), 6.9 (m, 2H),8.08 (d, 1H), 8.5 (s, 1H), 8.82 (s, 1H); Mass Spectrum: M+H⁺ 493.

[27] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride inisopropanol to give4-(2-bromo-5-methoxyanilino)-5-piperidin-4-yloxy-7-(3-pyridylmethoxy)quinazolinedihydrochloride, a portion of which was converted to the free base usingan analogous procedure to that described in Example 3. The free basegave the following data: NMR Spectrum: (CDCl₃) 1.85-2.0 (m, 2H), 2.25(d, 2H), 2.78 (m, 2H), 3.2 (m, 2H), 3.85 (s, 3H), 4.65 (m, 1H), 5.2 (s,2H), 6.62 (s, 1H), 6.65 (m, 1H), 6.92 (d, 1H), 7.38 (m, 1H), 7.5 (d,1H), 7.82 (d, 1H), 7.92 (d, 1H), 8.55 (s, 1H), 8.65 (d, 1H), 8.75 (s,1H), 9.72 (s, 1H); Mass Spectrum: M+H⁺ 536 and 538.

[28] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product gave the following data: NMR Spectrun:(CDCl₃) 1.8-1.9 (m, 4H), 1.95-2.1 (m, 2H), 2.12 (d, 2H), 2.68 (br s,4H), 3.0 (t, 2H), 3.58 (t, 2H), 3.98 (s, 3H), 4.08 (m, 2H), 4.25 (t,2H), 4.72 (m, 1H), 6.8 (d, 1H), 6.9 (d, 1H), 7.42 (s, 1H), 8.4 (s, 1H),8.6 (s, 1H), 9.9 (s, 1H); Mass Spectrun: M+H⁺ 533 and 535.

The4-(2,4-dichloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

A mixture of 7-acetoxy-4-chloro-5-tetrahydropyran-4-yloxyquinazolineprepared from7-acetoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (3.04 g)and phosphoryl chloride), 2,4-dichloro-5-methoxyaniline (2.1 g) andisopropanol (20ml) was stirred and heated to 80° C. for 1 hour. Themixture was cooled to ambient temperature and the resultant solid wasisolated, washed in turn with isopropanol and diethyl ether and driedunder vacuum. There was thus obtained7-acetoxy-4-(2,4-dichloro-5-methoxyanilino)-5-tetrahydropyran-4-yloxyquinazolinehydrochloride (3.5 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.9-2.1(m,2H), 2.15 (d, 2H), 2.4 (s, 3H), 3.52 (t, 2H), 3.9 (s, 3H), 3.95 (m,2H), 5.1 (m, 1H), 7.4 (d, 1H), 7.55 (d, 1H), 7.78 (s, 1H), 7.95 (s, 1H),8.95 (s, 1H); Mass Spectrum: M+H⁺ 478 and 480.

Using an analogous procedure to that described in the last paragraph ofNote [22] immediately above,7-acetoxy-4(2,4-dichloro-5-methoxyanilino)-5-tetrahydropyran-4-yloxyquinazolinewas reacted with a saturated methanolic ammonia solution to give4-(2,4-dichloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline;NMR Spectrum: (DMSOd₆) 1.75-1.9 (m, 2H), 2.18 (d, 2H), 3.52 (t, 2H), 3.9(s, 3H), 3.95 (m, 2H), 4.95 (m, 1H), 6.7 (d, 1H), 6.82 (d, 1H), 7.7 (s,1H), 8.35 (s, 1H), 8.42 (s, 1H), 9.85 (s, 1H), 10.5-10.7 (br s, 1H);Mass Spectrum: M+H⁺ 436 and 438.

[29] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product gave the following data: NMR Spectrum:(CDCl₃) 1.85 (br s, 4H), 2.0-2.15 (m, 4H), 2.25 (d, 2H), 2.6 (br s, 4H),2.68 (t, 2H), 3.6 (t, 2H), 3.96 (s, 3H), 4.08 (m, 2H), 4.18 (t, 2H),4.75 (m, 1H), 6.6 (d, 1H), 6.88 (d, 1H), 7.45 (s, 1H), 8.4 (s, 1H), 8.6(s, 1H); Mass Spectrum: M+H⁺ 547 and 549.

[30] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product gave the following data: NMR Spectrum:(CDCl₃) 1.4-1.5 (m, 2H), 1.5-1.75 (m, 6H), 2.0-2.1 (m, 2H), 2.25 (d,2H), 2.52 (br s, 4H), 2.85 (t, 2H), 3.58 (m, 2H), 3.96 (s, 3H), 4.08 (m,2H), 4.25 (t, 2H), 4.75 (m, 1H), 6.65 (d, 1H), 6.68 (d, 1H), 7.25 (s,1H), 8.4 (s, 1H), 8.58 (s, 1H), 9.85 (s, 1H); Mass Spectrum: M+H⁺ 547and 549.

[31] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product gave the following data: NMR Spectrum:(CDCl₃) 1.98-2.12 (m, 4H), 2.22 (d, 2H), 2.32 (s, 3H), 2.5 (br s, 2H),2.65 (br s, 2H), 2.9 (t, 2H), 3.6 (m, 2H), 3.96 (s, 3H), 4.08 (m, 2H),4.25 (t, 2H), 4.75 (m, 1H), 6.61 (d, 1H), 6.86 (d, 1H), 7.42 (s, 1H),8.4 (s, 1H), 8.6 (s, 1H), 9.85 (d, 1H); Mass Spectrum: M+H⁺ 562 and 564.

[32] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product gave the following data: NMR Spectrum:(CDCl₃) 2.0-2.1 (m, 2H), 2.22 (d, 2H), 2.6 (m, 4H), 2.9 (t, 2H), 3.6 (m,2H), 3.8 (m, 4H), 3.98 (s, 3H), 4.08. (m, 2H), 4.25 (t, 2H), 4.75 (m,1H), 6.62 (d, 1H), 6.88 (d, 1H), 7.42 (s, 1H), 8.4 (s, 1H), 8.6 (s, 1H),9.9 (s, 1H); Mass Spectrum: M+H⁺ 549 and 551.

[33] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺590 and 592.

The (2S)-1-(2-hydroxyethyl)-N-methylprolinamide used as a startingmaterial was obtained as follows:

A mixture of 1-tert-butoxycarbonyl)-L-proline (5.4 g),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (5.3 g), methylaminehydrochloride (2.2 g), 4-dimethylaminopyridine (3 g) and methylenechloride (50 ml) was stirred at ambient temperature for 16 hours. Theresultant mixture was poured in water and the organic layer wasseparated, washed in turn with a 1M aqueous potassium hydrogen sulphatesolution, a saturated aqueous sodium bicarbonate solution and brine,dried over magnesium sulphate and evaporated. There was thus obtained1-(tert-butoxycarbonyl)-N-methyl-L-prolinamide (5.6 g); Mass Spectrum:M+H⁺ 229.

A mixture of a portion (4.4 g) of the material so obtained andtrifluoroacetic acid (10 ml) was stirred at ambient temperature for 2hours. The mixture was evaporated and the residue was triturated underdiethyl ether. The resultant solid was isolated, washed with diethylether and dried under vacuum. There was thus obtained to giveN-methyl-L-prolinamide trifluoroacetic acid salt (3.7 g); NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 1.85-2.05 (m, 3H), 2.2-2.3 (m, 1H), 2.73 (s, 3H),3.2-3.4 (m, 2H), 4.2 (m, 1H).

A mixture of a portion (2.5 g) of the material so obtained,2-bromoethanol (2.15 ml), potassium carbonate (5.5 g) and acetonitrile(20 ml) was stirred and heated to reflux for 18 hours. The mixture wascooled to ambient temperature, filtered and evaporated and the residuewas purified by column chromatography on silica using a 49:1 mixture ofmethylene chloride and a saturated methanolic ammonia solution aseluent. There was thus obtained(2S)-1-(2-hydroxyethyl)-N-methylprolinamide (0.5 g); NMR Spectrum:(CDCl₃) 1.6-2.0 (m, 4H), 2.1-2.3 (m, 1H), 2.3-2.45 (m, 1H), 2.6-2.7 (m,1H), 2.85 (d, 3H), 2.8-2.9 (m, 1H), 3.1-3.2 (m, 1H), 3.2-3.3 (m, 1H),3.6-3.8 (m, 2H); Mass Spectrum: M+H⁺ 173.

[34] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺576 and 578.

The (2S)-1-(2-hydroxyethyl)prolinamide used as a starting material wasprepared by the reaction of L-prolinamide and 2-bromoethanol using ananalogous procedure to that described in Note [33] immediately above.There was thus obtained the required starting material; NMR Spectrum:(CDCl₃) 1.6-2.0 (m, 4H), 2.1-2.25 (m, 1H), 2.35-2.45 (m, 1H), 2.6-2.7(m, 1H), 2.8-3.0 (m, 1H); 3.1 (m, 1H), 3.2-3.3 (m, 1H), 3.6-3.8 (m, 2H),5.6 (br s, 1H), 7.4 (br s, 1H); Mass Spectrum: M+H⁺ 159.

35] The reaction mixture was stirred at ambient temperature for 3 hours.The reaction product gave the following data: Mass Spectrum: M+H⁺ 646and 648.

The (2S)-1-(2-hydroxyethyl)-2-morpholinocarbonylpyrrolidine used as astarting material was prepared as follows:

Using analogous procedures to those described in Note [33] immediatelyabove, 1-tert-butoxycarbonyl)-L-proline was reacted with morpholine togive (2S)-1-(tert-butoxycarbonyl)-2-morpholinocarbonylpyrrolidine whichwas deprotected and reacted with 2-bromoethanol. There was thus obtainedthe required starting material; NMR Spectrum: (CDCl₃) 1.7-2.0 (m, 4H),2.1-2.2 (m, 1H), 2.4-2.5 (m, 1H), 2.6-2.7 (m, 1H), 2.8-2.9 (m, 1H),3.3-3.4 (m, 2H), 3.4-3.8 (m, 10H); Mass Spectrum: M+H⁺ 229.

[36] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺659 and 661.

The(2S)-1-(2-hydroxyethyl)-2-(4-methylpiperazin-1-ylcarbonyl)pyrrolidineused as a starting material was prepared as follows:

Using analogous procedures to those described in Note [33] immediatelyabove, 1-tert-butoxycarbonyl)-L-proline was reacted with1-methylpiperazine to give(2S)-1-tert-butoxycarbonyl)-2-(4-methylpiperazin-1-ylcarbonyl)pyrrolidinewhich was deprotected and reacted with 2-bromoethanol. There was thusobtained the required starting material; NMR Spectrum: (CDCl₃) 1.7-2.05(m, 4H), 2.1-2.25 (m, 1H), 2.32 (s, 3H), 2.35-2.5 (m, 4H), 2.6-2.7 (m,1H), 2.8-2.9 (m, 1H), 3.3-3.7 (m, 8H), 4.15 (br s, 1H); Mass Spectrum:M+H⁺ 242.

[37] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺630 and 632.

The (2S)-1-(2-hydroxyethyl)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidine usedas a starting material was prepared as follows:

Using analogous procedures to those described in Note [33] immediatelyabove, 1-tert-butoxycarbonyl)-L-proline was reacted with pyrrolidine togive (2S)-1-(tert-butoxycarbonyl)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidinewhich was deprotected and reacted with 2-bromoethanol. There was thusobtained the required starting material; NMR Spectrun: (CDCl₃) 1.7-2.05(m, 8H), 2.1-2.3 (m, 1H), 2.4-2.5 (m, 1H), 2.55-2.7 (m, 1H), 2.8-2.9 (m,1H), 3.2-3.3 (m, 2H), 3.4-3.7 (m, 5H), 4.1 (br s, 1H); Mass Spectrun:M+H⁺ 213.

[38] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺644 and 646.

The (2S)-1-(2-hydroxyethyl)-2-piperidinocarbonylpyrrolidine used as astarting material was prepared as follows:

Using analogous procedures to those described in Note [33] immediatelyabove, 1-tert-butoxycarbonyl)-L-proline was reacted with piperidine togive (2S)-1-tert-butoxycarbonyl)-2-piperidinocarbonylpyrrolidine whichwas deprotected and reacted with 2-bromoethanol. There was thus obtainedthe required starting material; NMR Spectrum: (CDCl₃) 1.5-1.9 (m, 10H),1.9-2.0 (m, 1H), 2.1-2.2 (m, 1H), 2.4-2.5 (m, 1H), 2.55-2.65 (m, 1H),2.8-2.9 (m, 1H), 3.3-3.7 (m, 6H), 4.3 (br s, 1H); Mass Spectrum: M+H⁺227.

[39] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺547 and 549.

The (2R)-1-(2-hydroxyethyl)-2-methylpyrrolidine used as a startingmaterial was obtained as follows:

A mixture of (2R)-2-methylpyrrolidine (0.853 g), 2-bromoethanol (1.1ml), potassium carbonate (2.8 g) and acetonitrile (10 ml) was stirredand heated to reflux for 18 hours. The mixture was filtered and thefiltrate was evaporated. The resultant residue was purified by columnchromatography on silica using a 49:1 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. There was thusobtained (2R)-1-(2-hydroxyethyl)-2-methylpyrrolidine (0.35 g); NMRSpectrum: (CDCl₃) 1.1 (d, 3H), 1.3-1.5 (m, 1H), 1.6-1.8 (m, 3H), 1.95(m, 1H), 2.15 (m, 1H), 2.28 (m, 1H), 2.4-2.5 (m, 1H), 2.95-3.05 (m, 1H),3.2 (m, 1H), 3.5-3.8 (m, 2H); Mass Spectrum: M+H⁺ 130.

[40] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺577 and 579.

The (2S)-1-(2-hydroxyethyl)-2-methoxymethylpyrrolidine used as astarting material was obtained as follows:

Using an analogous procedure to those described in Note [39] immediatelyabove, (2S)-2-methoxymethylpyrrolidine was reacted with 2-bromoethanolto give (2S)-1-(2-hydroxyethyl)-2-methoxymethylpyrrolidine; NMRSpectrum: (CDCl₃) 1.5-1.65 (m, 1H), 1.65-1.8 (m,2H), 1.8-2.0 (m, 2H),2.3 (m, 1H), 2.6 (m, 1H), 2.8 (m, 1H), 2.95-3.05 (m, 1H), 3.17 (m, 1H),3.3 (t, 1H), 3.35 (t, 1H), 3.37 (s, 3H), 3.5-3.7 (m, 2H).

[41] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum:M+H⁺557 and 559.

[42] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺527 and 529.

[43] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺527 and 529.

[44] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺533 and 535.

[45] (2S)-1-(2-Hydroxyethyl)-N-methylprolinamide was used as a startingmaterial and the reaction mixture was stirred at ambient temperature for3 hours. The reaction product gave the following data: Mass Spectrum:M+H⁺ 600 and 602.

[46] (2S)-1-(2-Hydroxyethyl)-2-morpholinocarbonylpyrrolidine was used asa starting material and the reaction mixture was stirred at ambienttemperature for 3 hours. The reaction product gave the following data:Mass Spectrum: M+H⁺ 658 and 660.

[47](2S)-1-(2-Hydroxyethyl)-2-(4-methylpiperazin-1-ylcarbonyl)pyrrolidinewas used as a starting material and the reaction mixture was stirred atambient temperature for 3 hours. The reaction product gave the followingdata: Mass Spectrum: M+H⁺ 671 and 673.

[48] (2S)-1-(2-Hydroxyethyl)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidine wasused as a starting material and the reaction mixture was stirred atambient temperature for 3 hours. The reaction, product gave thefollowing data: Mass Spectrum: M+H⁺ 642 and 644.

[49] (2S)-1-(2-Hydroxyethyl)-2-piperidinocarbonylpyrrolidine was used asa starting material and the reaction mixture was stirred at ambienttemperature for 3 hours. The reaction product gave the following data:Mass Spectrum: M+H⁺ 656 and 658.

[50] (2S)-1-(2-Hydroxyethyl)prolinamide was used as a starting materialand the reaction mixture was stirred at ambient temperature for 3 hours.The reaction product gave the following data: Mass Spectrum: M+H⁺ 588and 590.

[51] (2R)-1-(2-Hydroxyethyl)-2-methylpyrrolidine was used as a startingmaterial and the reaction mixture was stirred at ambient temperature for3 hours. The reaction product gave the following data: Mass Spectrum:M+H⁺ 557 and 559.

[52] (2S)-1-(2-Hydroxyethyl)-2-methoxymethylpyrrolidine was used as astarting material and the reaction mixture was stirred at ambienttemperature for 3 hours; The reaction product gave the following data:Mass Spectrum: M+H⁺ 587 and 589.

[53] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺537 and 539.

[54] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product gave the following data: Mass Spectrum: M+H⁺537 and 539.

[55] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazolineand isopropanol. The reaction mixture was stirred at ambient temperaturefor 1 hour. Thereafter, a 6M solution of hydrogen chloride in diethylether was added and the reaction mixture was stirred at ambienttemperature for 1 hour. The resultant precipitate was isolated, washedwith ethyl acetate and diethyl ether and dried. There was thus obtainedthe required product,4-(6-chloro-2,3-methylenedioxyanilino)-7-isopropoxy-5-piperidin-4-yloxyquinazoline;NMR Spectrum: (CDCl₃) 1.4 (d, 6H), 1.8-1.9 (m, 2H), 2.25 (m, 2H),1.75-1.85 (m, 2H), 3.1-3.2 (m, 2H), 4.7 (m, 1H), 4.72 (m, 1H), 6.05 (s,2H), 6.5 (d, 1H), 6.7 (d, 1H), 6.82 (d, 1H), 6.98 (d, 1H), 8.5 (s, 1H),9.32 (s, 1H); Mass Spectrum: M+H⁺ 457 and 459.

The5-[N-tert-butoxycarbonyl)piperidin-4-yloxy]4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazolineused as a starting material is described in Example 35 hereinafter.

[56] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazolineand ethanol. The reaction mixture was stirred at ambient temperature for1 hour. Thereafter, a 6M solution of hydrogen chloride in diethyl etherwas added and the reaction mixture was stirred at ambient temperaturefor 1 hour. The resultant precipitate was isolated, washed with ethylacetate and diethyl ether and dried. There was thus obtained therequired product,4-(6-chloro-2,3-methylenedioxyanilino)-7-ethoxy-5-piperidin4-yloxyquinazoline;NMR Spectrum: (CDCl₃) 1.45 (t, 3H), 1.7-1.9 (m, 2H), 2.1-2.25 (m, 2H),2.7-2.8 (m, 2H), 3.05-3.2 (m, 2H), 4.12 (q, 2H), 4.6 (m, 1H), 6.02 (s,2H), 6.48 (d, 1H), 6.7 (d, 1H), 6.8 (d, 1H), 6.92 (d, 1H), 8.5 (s, 1H),9.3 (s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

[57] The reactants were5-[N-tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazolineand isobutanol. The reaction mixture was stirred at ambient temperaturefor 1 hour. Thereafter, a 6M solution of hydrogen chloride in diethylether was added and the reaction mixture was stirred at ambienttemperature for 1 hour. The resultant precipitate was isolated, washedwith ethyl acetate and diethyl ether and dried. There was thus obtainedthe required product,4-(6-chloro-2,3-methylenedioxyanilino)-7-isobutoxy-5-piperidin-4-yloxyquinazoline;NMR Spectrum: (CDCI₃) 1.05 (d, 6H), 1.8-1.9 (m, 2H), 2.12 (m, 1H),2.2-2.3 (m, 2H), 2.75-2.9 (m, 2H), 3.1-3.2 (m, 2H), 4.85 (d, 2H), 4.65(m, 1H), 6.05 (s, 2H), 6.5 (d, 1H), 6.7 (d, 1H), 6.8 (d, 1H), 6.95 (d,1H), 8.5 (s, 1H), 9.32 (s, 1H); Mass Spectrum: M+H⁺ 471 and 473.

[58] The reactants were5-N-tert-butoxycarbonyl)piperidin-4yloxy]4(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazolineand 2-fluoroethanol. The reaction mixture was stirred at ambienttemperature for 1 hour. Thereafter, a 6M solution of hydrogen chloridein diethyl ether was added and the reaction mixture was stirred atambient temperature for 1 hour. The resultant precipitate was isolated,washed with ethyl acetate and diethyl ether and dried. There was thusobtained the required product,4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-fluoroethoxy)-5-piperidin-4-yloxyquinazoline;NMR Spectrum: (CDCl₃) 1.8-2.0 (m, 2H), 2.2-2.3 (m, 2H), 2.8-2.9 (m, 2H),3.1-3.3 (m, 2H), 4.3 (m, 1H), 4.4 (m, 1H), 4.7 (m, 1H), 4.8 (m, 1H), 4.9(m, 1H), 6.08 (s, 2H), 6.6 (d, 1H), 6.75 (d, 1H), 6.82 (d, 1H), 7.0 (d,1H), 8.55 (s, 1H), 9.35 (s, 1H); Mass Spectrum: M+H⁺ 461 and 463.

[59] (2R,5R)-1-(2-Hydroxyethyl)-2,5-dimethoxymethylpyrrolidine was usedas a starting material and the reaction mixture was stirred at ambienttemperature for 2 hours. The reaction product was treated with 6Mhydrogen chloride in diethyl ether to give the dihydrochloride salt. Aportion thereof was treated with a saturated methanolic ammoniasolution, the mixture was filtered and the filtrate evaporated to givethe free base which gave the following data: NMR Spectrum: (CDCl₃)1.6-1.7 (m, 4H), 1.9-2.1 (m, 2H), 2.22 (m, 2H), 3.15-3.5 (m, 8H), 3.33(s, 6H), 3.6 (m, 2H), 4.08 (m, 2H), 4.12 (m, 2H), 4.75 (m, 1H), 6.05 (s,2H), 6.58 (d, 1H), 6.7 (d, 1H), 6.9 (d, 1H), 6.95 (m, 1H), 8.1 (d, 1H),8.6 (s, 1H), 9.75 (s, 1H); Mass Spectrun: M+H⁺ 567.

[60] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product was purified by column chromatography onsilica using a 24:1 mixture of methylene chloride and a saturatedmethanolic ammonia solution as eluent. The resultant product gave thefollowing data: Mass Spectrum: M+H⁺ 503.

[61] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product was purified by column chromatography onsilica using increasingly polar mixtures of methylene chloride and asaturated methanolic ammonia solution as eluent. The resultant productgave the following data: Mass Spectrum: M+H⁺ 473.

[62] The reaction mixture was stirred at ambient temperature for 3hours. The reaction product was purified by column chromatography onsilica using increasingly polar mixtures of methylene chloride and asaturated methanolic ammonia solution as eluent. The resultant productgave the following data: Mass Spectrum: M+H⁺ 473.

[63] (2S)-1-(2-Hydroxyethyl)-N-methylprolinamide was used as a startingmaterial and the reaction mixture was stirred at ambient temperature for3 hours. The reaction product gave the following data: Mass Spectrum:M+H⁺ 536.

[64] (2S)-1-(2-Hydroxyethyl)-2-morpholinocarbonylpyrrolidine was used asa starting material and the reaction mixture was stirred at ambienttemperature for 3 hours. The reaction product gave the following data:Mass Spectrum: M+H⁺ 592.

[65](2S)-1-(2-Hydroxyethyl)-2-(4-methylpiperazin-1-ylcarbonyl)pyrrolidinewas used as a starting material and the reaction mixture was stirred atambient temperature for 3 hours. The reaction product gave the followingdata: Mass Spectrum: M+H⁺ 605.

[66] (2S)-1-(2-Hydroxyethyl)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidine wasused as a starting material and the reaction mixture was stirred atambient temperature for 3 hours. The reaction product gave the followingdata: Mass Spectrum: M+H⁺ 576.

[67] (2S)-1-(2-Hydroxyethyl)-2-piperidinocarbonylpyrrolidine was used asa starting material and the reaction mixture was stirred at ambienttemperature for 3 hours. The reaction product gave the following data:Mass Spectrum: M+H⁺ 590.

[68] (2S)-1-(2-Hydroxyethyl)prolinamide was used as a starting materialand the reaction mixture was stirred at ambient temperature for 3 hours.The reaction product gave the following data: Mass Spectrum: M+H⁺ 522.

[69] (2R)-1-(2-Hydroxyethyl)-2-methylpyrrolidine was used as a startingmaterial and the reaction mixture was stirred at ambient temperature for3 hours. The reaction product gave the following data: Mass Spectrun:M+H⁺ 493.

[70] (2S)-1-(2-Hydroxyethyl)-2-methoxymethylpyrrolidine was used as astarting material and the reaction mixture was stirred at ambienttemperature for 3 hours. The reaction product gave the following data:Mass Spectrurn: M+H⁺ 523.

[71] The reactants were4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazolineand 1-(tert-butoxycarbonyl)-4(3-hydroxypropyl)piperazine and thereaction mixture was stirred at ambient temperature for 2 hours.Thereafter, trifluoroacetic acid (1 ml) was added and the mixture wasstirred at ambient temperature for 16 hours. The mixture was evaporatedand the residue was triturated under a saturated methanolic ammoniasolution (1 ml). Methylene chloride was added and the mixture wasfiltered. The ifitrate was evaporated and the residue was purified bycolumn chromatography on silica using a 97:3 mixture of methylenechloride and a saturated methanolic ammonia solution as eluent. Thematerial so obtained was treated with a 6M solution of hydrogen chloridein diethyl ether. The precipitate was isolated, washed with diethylether and dried under vacuum to give the dihydrochloride salt (0.11 g)of the required product, a portion of which was converted to the freebase using an analogous procedure to that described in Example 3. Thefree base gave the following data: NMR Spectrum: (CDCl₃) 1.9-2.1 (m,4H), 2.2-2.3 (m, 2H), 2.3-2.5 (m, 4H), 2.55 (m, 2H), 2.91 (m, 4H), 3.65(m, 2H), 4.05 (m, 2H), 4.15 (m, 2H), 4.8 (m, 1H), 6.06 (s, 2H), 6.5 (d,1H), 6.72 (d, 1H), 6.84 (d, 1H), 6.97 (d, 1H), 8.5 (s, 1H), 9.26 (s,1H); Mass Spectrum: M+H⁺ 542 and 544.

The4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

A mixture of7-benzyloxy4-(6-chloro-2,3-methylenedioxyanilino)-5-tetrahydropyran-4-yloxyquinazoline(Example 17[34], 0.2 g) and trifluoroacetic acid (2 ml) was stirred andheated to 80° C. for 6 hours. The mixture was evaporated and the residuewas triturated under a 6M solution of hydrogen chloride in diethylether. The resultant solid was isolated, washed with diethyl ether anddried under vacuum. The solid was treated with a saturated methanolicammonia solution. The mixture was filtered, the filtrate was evaporatedand the residue was triturated under methylene chloride. The solid soobtained was washed with methylene chloride and dried under vacuum.There was thus obtained4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline(0.17 g); NMR Spectrum: (DMSOd₆) 1.8-1.9 (m, 2H), 2.05-2.2 (m, 2H),3.5-3.6 (m, 2H), 3.8-3.9 (m, 2H), 4.95 (m, 1H), 6.08 (s, 2H), 6.7 (d,1H), 6.8 (d, 1H), 6.95 (d, 1H), 7.05 (d, 1H), 8.35 (s, 2H), 9.32 (s,1H), 10.8 (br s, 1H); Mass Spectrun: M−H⁻ 414 and 416.

The 1-tert-butoxycarbonyl)-4-(3-hydroxypropyl)piperazine used as astarting material was prepared using an analogous procedure to thatdescribed in European Patent Application No.0388309:

A mixture of 3-bromopropanol (25 ml), 1-tert-butoxycarbonyl)piperazine(29 ml), potassium carbonate (83 g) and ethanol (200 ml) was stirred andheated to refiux for 20 hours. The mixture was cooled to ambienttemperature and filtered. The filtrate was evaporated and the residuewas triturated under diethyl ether. The resultant mixture was filteredand the filtrate was evaporated. The residue was purified bydistillation to give the required starting material as an oil.

[72] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt of the product, a portionof which was converted to the free base using an analogous procedure tothat described in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 1.9-2.1 (m, 4H), 2.15-2.3 (m, 2H), 2.28 (s, 3H),2.4-2.7 (m, 10H), 3.6-3.7 (m, 2H), 4.0-4.1 (m, 2H), 4.15 (m, 2H), 4.75(m, 1H), 6.05 (s, 2H), 6.5 (d, 1H), 6.72 (d, 1H), 6.83 (d, 1H), 6.97 (d,1H), 8.52 (s, 1H), 9.26 (s, 1H); Mass Spectrum: M+H⁺ 556 and 558.

[73] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt of the product, a portionof which was converted to the free base using an analogous procedure tothat described in Example 3. The free base gave the following data: NMRSpectrum: (CDCl₃) 1.9-2.05 (m, 2H), 2.2-2.3 (m, 2H), 2.31 (s, 3H),2.4-2.7 (m, 8H), 2.87 (m, 2H), 2.55-2.7 (m, 2H), 3.95-4.05 (m, 2H), 4.25(m, 2H), 4.75 (m, 1H), 6.05 (s, 2H), 6.55 (d, 1H), 6.72 (d, 1H), 6.83(d, 1H), 6.97 (d, 1H), 8.52 (s, 1H), 9.26 (s, 1H); Mass Spectrum: M+H⁺542 and 544.

[74] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt of the product, a portionof which was converted to the free base using an analogous procedure tothat described in Example 3. The free base gave the following data : NMRSoectrum: (CDCl₃) 1.4-1.5 (m, 2H), 1.6-1.7 (m, 4H), 1.9-2.05 (m, 2H),2.2-2.3 (m, 2H), 2.5 (br s, 4H), 2.82 (m, 2H), 3.62 (m, 2H), 4.05 (m,2H), 4.22 (m, 2H), 4.75 (m, 1H), 6.05 (s, 2H), 6.55 (d, 1H), 6.71 (d,1H), 6.83 (d, 1H), 6.97 (d, 1H), 8.52 (s, 1H), 9.27 (s, 1H); MassSpectrum: M+H⁺ 527 and 529.

[75] The reactants were4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazolineand N-(tert-butoxycarbonyl)-4-(2-hydroxyethyl)piperidine (J. Med. Chem.,1994, 3, 2721) and the reaction mixture was stirred at ambienttemperature for 2 hours. Thereafter, triiluoroacetic acid (1 ml) wasadded and the mixture was stirred at ambient temperature for 16 hours.The mixture was evaporated and the residue was triturated under asaturated methanolic ammonia solution (1 ml). Methylene chloride wasadded and the mixture was filtered. The filtrate was evaporated and theresidue was purified by column chromatography on silica using a 97:3mixture of methylene chloride and a saturated methanolic ammoniasolution as eluent. The material so obtained was treated with a 6Msolution of hydrogen chloride in diethyl ether. The precipitate wasisolated, washed with diethyl ether and dried under vacuum to give therequired product; NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.35-1.5 (m, 2H),1.75-1.95 (m, 5H), 2.0-2.15 (m, 4H), 2.8-2.95 (m, 2H), 3.3 (d, 2H), 3.55(m, 2H), 3.92 (m, 2H), 4.25 (m, 2H), 5.15 (m, 1H), 6.14 (s, 2H), 6.94(d, 1H), 7.04 (d, 1H), 7.13 (d, 1H), 7.15 (s, 1H), 8.84 (s, 1H); MassSpectrum: M+H⁺ 527 and 529.

[76] The reaction mixture was stirred at ambient temperature for 2hours. The reaction product was treated with 6M hydrogen chloride indiethyl ether to give the dihydrochloride salt of the product, a portionof which was converted to the free base using an analogous procedure tothat described in Example 3. The free base gave the following data : NMRSpectrum: (CDCl₃) 1.9-2.1 (m, 2H), 2.2-2.3 (m, 2H), 3.6-3.7 (m, 2H),4.0-4.1 (m, 2H), 4.42 (m, 2H), 4.5 (m, 2H), 4.8 (m, 1H), 6.06 (s, 2H),6.56 (d, 1H), 6.73 (d, 1H), 6.9 (m, 3H), 7.0 (d, 1H), 8.47 (d, 2H), 8.54(s, 1H), 9.28 (s, 1H); Mass Spectrum: M+H⁺ 537 and 539.

[77] The reaction mixture was stirred at ambient temperature for 2hours. The product gave the following data: NMR Spectrum: (CDCl₃)1.25-1.4 (m, 2H), 1.5 (s, 9H), 1.75-1.9 (m, 2H), 1.9-2.1 (m, 3H),2.2-2.3 (m, 2H), 2.7-2.8 (m, 2H), 3.6-3.7 (m, 2H), 3.95 (d, 2H), 4.0-4.1(m, 2H), 4.1-4.3 (m, 2H), 4.78 (m, 1H), 6.08 (s, 2H), 6.5 (d, 1H), 6.75(d, 1H), 6.82 (d, 1H), 6.97 (d, 1H), 8.52 (s, 1H), 9.28 (s, 1H); MassSpectrum: M+H⁺ 613 and 615.

[78] The reaction mixture was stirred at ambient temperature for 1 hour.The reaction product gave the following data: NMR Spectrum: (CDCl₃)1.6-1.75 (m, 4H), 1.75-1.9 (m, 6H), 2.0-2.2 (m, 4H), 2.55 (m, 4H), 2.65(m, 2H), 4.15 (m, 2H), 5.0 (m, 1H), 6.02 (s, 2H), 6.5 (d, 1H), 6.65 (d,1H), 6.8 (d, 1H), 6.9 (m, 1H), 8.12 (d, 1H), 8.58 (s, 1H), 8.8 (s, 1H);Mass Spectrum: M+H⁺ 477.

[79] The reaction mixture was stirred at ambient temperature for 1 hour.The reaction product gave the following data: NMR Spectrum: (CDCl₃)1.65-1.8 (m, 4H), 1.9 (m, 2H), 2.0-2.2 (m, 8H), 2.3 (s, 3H), 2.3-2.7 (m,6H), 4.15 (t, 2H), 5.0 (m, 1H), 6.02 (s, 2H), 6.5 (s, 1H), 6.65 (d, 1H),6.8 (d, 1H), 6.92 (m, 1H), 8.15 (d, 1H), 8.6 (s, 1H), 9.8 (s, 1H); MassSpectrum: M+H⁺ 506.

[80] The reaction mixture was stirred at ambient temperature for 1 hour.The reaction product gave the following data: NMR Spectrum: (CDCl₃)1.65-1.8 (m, 2H), 1.8-1.95 (m, 2H), 1.95-2.2 (m, 4H), 2.3 (s, 3H),2.4-2.6 (m, 4H), 2.6-2.8 (m, 4H), 2.9 (m, 2H), 4.2 (m, 2H), 5.0 (m, 1H),6.0 (s, 2H), 6.52 (d, 1H), 6.65 (d, 1H), 6.8 (d, 1H), 6.9 (m, 1H), 8.15(d, 1H), 8.6 (s, 1H), 9.8 (s, 1H); Mass Spectrum: M+H⁺ 492.

[81] The reaction mixture was stirred at ambient temperature for 1 hour.The reaction product gave the following data: NMR Spectrum: (CDCl₃)1.6-1.7 (m, 6H), 1.7-1.8 (m, 2H), 1.8-1.95 (m, 2H), 2.0-2.2 (m, 4H),2.55 (br s, 4H), 2.82 (m, 2H), 4.22 (m, 2H), 5.0 (m, 1H), 6.02 (s, 2H),6.52 (s, 1H), 6.65 (d, 1H), 6.8 (d, 1H), 6.9 (m, 1H), 8.15 (d, 1H), 8.6(s, 1H), 9.8 (s, 1H); Mass Spectrum: M+H⁺ 477.

[82](2S)-1-(2-Hydroxyethyl)-2-(4-methylpiperazin-1-ylcarbonyl)pyrrolidinewas used as a starting material and the reaction mixture was stirred atambient temperature for 1 hour. The reaction product gave the followingdata: Mass Spectrum: M+H⁺ 589.

[83] N-tert-Butoxycarbonyl)piperidin-4-ylmethanol was used as areactant. The reaction mixture was stirred at ambient temperature for 1hour. Thereafter, a 6M solution of hydrogen chloride in diethyl ether (2ml) was added and the reaction mixture was stirred at ambienttemperature for 16 hours. The mixture was diluted with methylenechloride (10 ml) and a saturated methanolic ammonia solution (3 ml) wasadded. The mixture was filtered and the filtrate was evaporated todryness. The residue was purified by column chromatography on silicausing a 50:47:3 mixture of methylene chloride, ethyl acetate and asaturated methanolic ammonia solution as eluent. The reaction productgave the following data : NMR Spectrum: (CDCl₃) 1.25-1.42 (m, 2H),1.6-1.7 (m, 4H), 1.8-2.0 (m, 3H), 2.0-2.2 (m, 4H), 2.7 (m, 2H), 3.15 (d,2H), 3.95 (d, 2H), 5.05 (m, 1H), 6.02 (s, 2H), 6.5 (d, 1H), 6.65 (d,1H), 6.8 (d, 1H), 6.9 (m, 1H), 8.15 (d, 1H), 8.6 (s, 1H), 8.8 (s, 1H);Mass Spectrum: M+H⁺ 463.

[84] 1-(tert-Butoxycarbonyl)-4-(3-hydroxypropyl)piperazine was used as areactant. The reaction mixture was stirred at ambient temperature for 1hour. Thereafter, a 6M solution of hydrogen chloride in diethyl ether (2ml) was added and the reaction mixture was stirred at ambienttemperature for 16 hours. The mixture was diluted with methylenechloride (10 ml) and a saturated methanolic ammonia solution (3 ml) wasadded. The mixture was filtered and the filtrate was evaporated todryness. The residue was purified by column chromatography on silicausing a 50:47:3 mixture of methylene chloride, ethyl acetate and asaturated methanolic ammnonia solution as eluent. The reaction productgave the following data : NMR Spectrum: (CDCl₃) 1.9-2.1 (m, 2H),1.8-1.95 (m, 2H), 1.95-2.2 (m, 6H), 1.9 (br s, 4H), 1.95 (m, 2H), 2.9(m, 4H), 4.15 (m, 2H), 5.0 (m, 1H), 6.02 (s, 2H), 6.5 (d, 1H), 6.65 (d,1H), 6.8 (d, 1H), 6.9 (m, 1H), 8.12 (d, 1H), 8.6 (s, 1H), 8.8 (s, 1H);Mass Spectrum: M+H⁺ 492.

EXAMPLE 15

Using an analogous procedure to that described in Example 5, theappropriate 4-chloroquinazoline was reacted with the appropriate anilinein the presence of hydrogen chloride to give the dihydrochloride saltsof the compounds described in Table IV, a portion of each of which wasconverted to the free base. TABLE IV

No. and Note (R¹)_(m) Q¹ (R²)_(n)  [1] 7-methoxy piperidin-4-ylmethyl2-bromo-5-methoxy  [2] 7-methoxy piperidin-4-ylmethyl 2-chloro-5-methoxy [3] 7-methoxy piperidin-4-ylmethyl 2,5-dimethoxy  [4] 7-methoxypiperidin-4-ylmethyl 2,5-dichloro  [5] 7-methoxy piperidin-4-ylmethyl2,3-methylenedioxy  [6] 7-methoxy N-methylpiperidin-4-yl 2,5-dichloro [7] 7-methoxy N-methylpiperidin-4-yl 2-bromo-5-chloro  [8] 7-benzyloxypiperidin-4-yl 2-bromo-5-methoxy  [9] 6-methoxy N-methylpiperidin-2-chloro-5-methoxy 4-yl [10] 7-[3-(4-methyl- 4-tetrahydropyranyl2,4-dichloro-5- piperazin-1- methoxy yl)propoxy] [11] 6-[3-(4-methyl-4-tetrahydropyranyl 2-chloro-5-methoxy piperazin-1- yl)propoxy] [12]6-[3-(4-methyl- 4-tetrahydropyranyl 2,5-dichloro piperazin-1-yl)propoxy] [13] 6-[3-(4-methyl- 4-tetrahydropyranyl 2-bromo-5-methoxypiperazin-1- yl)propoxy] [14] 7-[3-(4-methyl- 4-tetrahydropyranyl4-chloro-2-fluoro- piperazin-1- 5-methoxy yl)propoxy] [15]7-[3-(4-methyl- 4-tetrahydropyranyl 4-bromo-2-fluoro piperazin-1-yl)propoxy] [16] 7-[3-(4-methyl- 4-tetrahydropyranyl 2-pyrrolidin-1-yl-piperazin-1- 5-methoxy yl)propoxy] [17] 7-[3-(4-methyl-4-tetrahydropyranyl 2,3-methylenedioxy piperazin-1- yl)propoxy] [18]7-benzyloxy N-tert-butoxycarbonyl- 6-chloro- piperidin-4-yl2,3-methylenedioxy [19] 7-hydroxy cyclopentyl 2,3-methylenedioxyNotes[1] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-chloro-7-methoxyquinazolineand 2-bromo-5-methoxyaniline hydrochloride and the reaction mixture washeated to 80° C. for 2 hours. A second portion of 6M hydrogen chloridein isopropanol (0.06 ml) was added and the reaction mixture was heatedto 80° C. for a further 4 hours. The reaction product was obtained asthe dihydrochloride salt, a portion of which was converted to the freebase which gave the following data: NMR Spectrum: (CDCl₃) 1.3 (m, 2H),1.9 (d, 2H), 2.3 (m, 1H), 2.68 (m, 2H), 3.12 (d, 2H), 3.85 (s, 3H), 3.95(s, 3H), 4.15 (d, 2H), 6.52 (d, 1H), 6.62 (m, 1H), 6.88 (s, 1H), 7.5 (d,1H), 8.22 (d, 1H), 8.6 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 473 and475.

The5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-chloro-7-methoxyquinazolineused as a starting material was prepared as follows:

Diethyl azodicarboxylate (3.85 ml) was added dropwise to a stirredmixture of5-hydroxy-7-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (5g), N-(tert-butoxycarbonyl)piperidin-4-ylmethanol (4.2 g),triphenylphosphine (6.4 g) and methylene chloride (50 ml) which had beencooled to 10° C. The mixture was stirred at ambient temperature for 1hour. The resultant mixture was poured onto a column of silica andeluted with increasingly polar mixtures of methylene chloride and ethylacetate. The product so obtained was dissolved in a saturated methanolicammonia solution (250 ml) and solid sodium hydrbxide (0.65 g) was added.The resultant mixture was stirred at ambient temperature for 30 minutes.The mixture was evaporated and the residue was purified by columnchromatography on silica using increasingly polar mixtures of methylenechloride and ethyl acetate and then methylene chloride, ethyl acetateand methanol as eluent. The product so obtained was triturated underdiethyl ether. The resultant solid was isolated, washed with diethylether and dried under vacuum. There was thus obtained5-N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-7-methoxy-3,4-dihydroquinazolin-4-one(3.4 g); NMR Spectrum: (CDCl₃) 1.3-1.4 (m, 2H), 1.46 (s, 9H), 1.95 (d,2H), 2.15 (m, 1H), 2.35 (t, 2H), 3.9 (s, 3H), 3.9 (m, 2H), 4.15 (br s,2H), 6.45 (d, 1H), 6.75 (d, 1H), 7.93 (s, 1H), 11.0 (br s, 1H); MassSpectrum: M+H⁺ 390.

A mixture of a portion (2.9 g) of the material so obtained, triphenylphosphine (5.3 g), carbon tetrachloride (3 ml) and 1,2-dichloroethane(50 ml) was stirred and heated to 70° C. for 2.5 hours. The mixture waspoured onto silica and eluted with increasingly polar mixtures ofmethylene chloride and ethyl acetate. The material so obtained wastriturated under diethyl ether. The resultant precipitate was isolated,washed with diethyl ether and dried. There was thus obtained5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-chloro-7-methoxyquinazoline(1.9 g); NMR Spectrum: (CDCl₃) 1.35-1.5 (m, 2H), 1.45 (s, 9H), 1.92 (d,2H), 2.15 (m, 1H), 2.8 (t, 2H), 3.95 (d, 2H), 3.97 (s, 3H), 4.2 (br s,2H), 6.6 (d, 1H), 6.98 (d, 1H), 8.82 (s, 1H).

[2] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-chloro-7-methoxyquinazolineand 2-chloro-5-methoxyaniline and the reaction mixture was heated to 80°C. for 2 hours. A second portion of 6M hydrogen chloride in isopropanol(0.06 ml) was added and the reaction mixture was heated to 80° C. for afurther 4 hours. The reaction product was obtained as thedihydrochloride salt, a portion of which was converted to the free basewhich gave the following data: NMR Spectrum: (CDCl₃) 1.3-1.4 (m, 2H),1.92 (d, 2H), 2.3 (m, 1H), 2.7 (t, 2H), 3.2 (d, 2H), 3.85 (s, 3H), 3.95(s, 3H), 4.15 (d, 2H), 6.52 (s, 1H), 6.65 (m, 1H), 6.9 (s, 1H), 7.32 (d,1H), 8.4 (s, 1H), 8.62 (s, 1H), 10.2 (s, 1H); Mass Spectrum: M+H⁺ 429and 431.

[3] The reactants were5-N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]4-chloro-7-methoxyquinazolineand 2,5-diinethoxyaniline and the reaction mixture was heated to 80° C.for 2 hours. The reaction mixture was evaporated and the residue wasdissolved in methylene chloride (1 ml). Trifluoroacetic acid (1 ml) wasadded and the mixture was stirred at ambient temperature for 15 minutes.The resultant mixture was evaporated and the residue was partitionedbetween ethyl acetate and IN aqueous sodium hydroxide solution Theorganic layer was washed with brine, dried over magnesium sulphate andevaporated. The residue was dissolved in isopropanol (1 ml) and 6Mhydrogen chloride in isopropanol (0.1 ml) was added. The resultantprecipitate was isolated, washed with isopropanol and with diethyl etherand dried under vacuum. There was thus obtained the required product asthe dihydrochloride salt, a portion of which was converted to the freebase which gave the following data: NMR Spectrum: (CDCl₃) 1.3-1.5 (m,2H), 1.95 (d, 2H), 2.25 (m, 1H), 2.7 (m, 2H), 3.2 (d, 2H), 3.84 (s, 3H),3.92 (s, 3H), 3.93 (s, 3H), 4.1 (d, 2H), 6.5 (s, 1H), 6.6 (m, 1H), 6.9(m, 2H), 8.52 (d, 1H), 8.6 (s, 1H), 10.15 (s, 1H); Mass Spectrum: M+H⁺425.

[4] The reactants were5-[N-(tert-butoxycarbonyl)piperidin4-ylmethoxy]-4-chloro-7-methoxyquinazolineand 2,5-dichloroaniline and the reaction mixture was heated to 80° C.for 2 hours. The reaction mixture was evaporated and the residue wasdissolved in methylene chloride (1 ml). Trifluoroacetic acid (1 ml) wasadded and the mixture was stirred at ambient temperature for 15 minutes.The resultant mixture was evaporated and the residue was partitionedbetween ethyl acetate and 1N aqueous sodium hydroxide solution. Theorganic layer was washed with brine, dried over magnesium sulphate andevaporated. The residue was purified by column chromatography on silicausing a 9:10:1 mixture of methylene chloride, ethyl acetate and methanolas eluent. The material so obtained was dissolved in isopropanol (1 ml)and 6M hydrogen chloride in isopropanol (0.1 ml) was added. Theresultant precipitate was isolated, washed with isopropanol and withdiethyl ether and dried under vacuum. There was thus obtained therequired product as the dihydrochloride salt, a portion of which wasconverted to the free base which gave the following data: NMR Spectrum:(CDCl₃) 1.25-1.4 (m, 2H), 1.9 (d, 2H), 2.25 (m, 1H), 2.65 (m, 2H), 3.15(d, 2H), 3.95 (s, 3H), 4.12 (d, 2H), 6.55 (d, 1H), 6.9 (d, 1H), 7.05 (m,1H), 7.35 (d, 1H), 8.6 (s, 1H), 8.87 (d, 1H), 10.09 (br s, 1H); MassSpectrum: M+H⁺ 433 and 435.

[5] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-chloro-7-methoxyquinazolineand 2,3-methylenedioxyaniline and the reaction mixture was heated to 80°C. for 2 hours. The reaction mixture was evaporated and the residue wasdissolved in methylene chloride (1 ml). Trifluoroacetic acid (1 ml) wasadded and the mixture was stirred at ambient temperature for 15 minutes.The resultant mixture was evaporated and the residue was partitionedbetween ethyl acetate and 1N aqueous sodium hydroxide solution. Theorganic layer was washed with brine, dried over magnesium sulphate andevaporated. The residue was dissolved in isopropanol (1 ml) and 6Mhydrogen chloride in isopropanol (0.1 ml) was added. The resultantprecipitate was isolated, washed with isopropanol and with diethyl etherand dried under vacuum. There was thus obtained the required product asthe dihydrochloride salt, a portion of which was converted to the freebase which gave the following data: NMR Spectrum: (CDCl₃) 1.25-1.4 (m,2H), 1.85 (d, 2H), 2.2 (m, 1H), 2.65 m, 2H), 3.2 (d, 2H), 3.9 (s, 3H),4.02 (d, 2H), 6.0 (s, 2H), 6.48 (d, 1H), 6.62 (d, 1H), 6.85 (d, 1H), 6.9(m, 1H), 8.07 (d, 1H), 8.58 (s, 1H), 9.6 (s, 1H); Mass Spectrum: M+H⁺409.

[6] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.35 (m, 4H), 2.3 (s, 3H), 2.85 (m, 2H), 3.92 (s,3H), 4.5 (m, 1H), 6.55 (d, 1H), 6.85 (d, 1H), 7.03 (m, 1H), 7.3 (d, 1H),8.6 (s, 1H), 8.85 (s, 1H); Mass Spectrum: M+H⁺ 433 and 435.

[7] The free base gave the following data: NMR Spectrum: (CDCl₃)2.0-2.15 (m, 2H), 2.15-2.3 (m, 4H), 2.28 (s, 3H), 2.85 (m, 2H), 3.92 (s,3H), 4.5 (m, 1H), 6.5 (s, 1H), 6.85 (s, 1H), 7.0 (m, 1H), 7.5 (d, 1H),8.35 (s, 1H), 8.55 (s, 1H), 9.7 (s, 1H); Mass Spectrum: M+H⁺ 477, 479and 481.

[8] The reactants were7-benzyloxy-5-N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-chloroquinazolineand 2-bromo-5-methoxyaniline hydrochloride and the reaction mixture asheated to 80° C. for 2 hours. A second portion of 6M hydrogen chloridein isopropanol (0.06 ml) was added and the reaction mixture was heatedto 80° C. for a further 4 hours. The reaction product was obtained asthe dihydrochloride salt, a portion of which was converted to the freebase which gave the following data: NMR Spectrum: (CDCl₃) 1.95-2.1 (m,2H), 2.25 (d, 2H), 2.8 (m, 2H), 3.22 (m, 2H), 3.78 (s, 3H), 4.6 (m, 1H),5.12 (s, 3H), 6.58 (m, 2H), 6.9 (d, 1H), 7.25-7.5 (m, 5H), 7.89 (d, 1H),8.5 (s, 1H), 9.6 (s, 1H); Mass Spectrum: M+H⁺ 535 and 537.

The7-benzyloxy-5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-chloroquinazolineused as a starting material was prepared as follows:

A mixture of 5,7-dibenzyloxy-3,4-dihydroquinazolin-4-one (2 g),magnesium bromide (1 g) and pyridine (10 ml) was stirred and heated to120° C. for 20 minutes. The mixture was evaporated and the residue wasdissolved in a mixture of water (20 ml) and glacial acetic acid (4 ml)and stirred for 10 minutes. The resultant precipitate was isolated,washed with water and dried under vacuum over phosphorus pentoxide at50° C. There was thus obtained7-benzyloxy-5-hydroxy-3,4dihydroquinazolin-4-one (1.5 g); NMR Spectrum:(DMSOd₆) 5.22 (s, 2H), 6.5 (d, 1H), 6.7 (d, 1H), 7.3-7.5 (m, 5H), 8.05(s, 1H); Mass Spectrum: M+H⁺ 269.5.

The material so obtained was added portionwise to a stirred suspensionof sodium hydride (60% dispersion in mineral oil, 0.46 g; washed withpentane) in DMF (15 ml) which was cooled to 0° C. The mixture wasstirred at ambient temperature for 30 minutes. The resultant mixture wascooled at 0° C., chloromethyl pivalate (1.2 ml) was added and themixture was stirred at ambient temperature for 1 hour. The mixture waspoured into water (70 ml) containing acetic acid (4 ml) and theresultant precipitate was isolated and dried under vacuum. The materialso obtained was dissolved in methylene chloride and the organic solutionwas dried over magnesium sulphate and evaporated. The residue wastriturated under pentane and the resultant solid was isolated and driedunder vacuum. There was thus obtained7-benzyloxy-5-hydroxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one(1.95 g); NMR Spectrum: (CDCl₃) 1.2 (s, 9H), 5.12 (s, 2H), 5.88 (s, 2H),6.58 (d, 1H), 6.72 (d, 1H), 7.3-7.5 (m, 5H), 8.15 (s, 1H), 11.32 (s,1H); Mass Spectrum: M+H⁺ 383.

The material so obtained was reacted withN-(tert-butoxycarbonyl)-4-hydroxypiperidine using an analogous procedureto that described in the first paragraph of the portion of Note [1]immediately above that is concerned with the preparation of startingmaterials. There was thus obtained7-benzyloxy-5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-3,4-dihydroquinazolin-4-one(1.4 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.82 (m, 4H), 3.52 (m, 2H),3.7 (m, 2H), 4.65 (m, 1H), 5.2 (s, 2H), 6.6 (d, 1H), 6.9 (d, 1H),7.3-7.5 (m, 5H), 7.92 (s, 1H), 10.56 (br s, 1H); Mass Spectrum: M+H⁺452.6.

A mixture of the material so obtained, triphenylphosphine (1.66 g),carbon tetrachloride (0.92 ml) and 1,2-dichloroethane (40 ml) wasstirred and heated to 70° C. for 1.5 hours. The mixture was evaporatedand the residue was purified by column chromatography on silica using a9:1 mixture of methylene chloride and ethyl acetate as eluent. There wasthus obtained7-benzyloxy-5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-chloroquinazoline(1.1 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.98 (m, 4H), 3.5-3.7 (m,4H), 4.75 (m, 1H), 5.2 (s, 2H), 6.7 (d, 1H), 7.08 (d, 1H), 7.32-7.52 (m,5H), 8.82 (s, 1H); Mass Spectrum: M+H⁺ 470.

[9] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.15 (m, 6H), 2.25 (s, 3H), 2.85 (br s, 2H), 3.87 (s, 3H), 4.02 (s,3H), 4.45 (m, 1H), 6.65 (m, 1H), 7.35 (d, 1H), 7.55 (d, 1H), 7.7 (d,1H), 8.5 (d, 1H), 8.6 (s, 1H), 10.45 (br s, 1H); Mass Spectrum: M+H⁺ 429and 431.

The 4-chloro-6-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline used asa starting material was prepared as follows:

A solution of ferrous sulphate heptahydrate (99 g) in water (410 ml)that had been heated to 70° C. was added to a mixture of2-benzyloxy-3-methoxy-6-nitrobenzoic acid (Bull. Soc. Chim. France,1965, 1417; 15.5 g) and concentrated aqueous ammonium hydroxide (370 ml)which was heated to 70° C. The resultant mixture was heated to refluxfor 30 minutes. The mixture was filtered and the basicity of thefiltrate was adjusted to pH8 by the addition of 2N aqueous hydrochloricacid and then the filtrate was acidified to pH4 by the addition of 1Maqueous citric acid solution. The mixture was partitioned between ethylacetate and water. The organic layer was washed with water and withbrine, dried over magnesium sulphate and evaporated to give6-amino-2-benzyloxy-3-methoxybenzoic acid (12.15 g); NMR Spectrum:(CDCl₃) 3.9 (s, 3H), 5.22 (s, 2H), 6.5 (d, 1H), 7.05 (d, 1H), 7.35-7.55(m, 5H): Mass Spectrum: M+H⁺ 274.

A mixture of the material so obtained, triazine (3.6 g), piperidine (3ml) and ethanol (275 ml) was stirred and heated to reflux for 16 hours.The mixture was cooled to ambient temperature. The precipitate wasisolated, washed with ethanol and with diethyl ether and dried undervacuum to give 5-benzyloxy-6-methoxy-3,4-dihydroquinazolinone (10.3 g);NMR Spectrum: (CDCl₃) 3.9 (s, 3H), 5.15 (s, 2H), 7.2-7.45 (m, 4H), 7.5(d, 1H), 7.62 (d, 2H), 7.8 (s, 1H), 11.1 (br s, 1H); Mass Spectrum: M+H⁺283.

A solution of a portion (5 g) of the material so obtained intrifluoroacetic acid (50 ml) was stirred at ambient temperature for 30minutes. The mixture was evaporated and the residue was dissolved inwater. The solution was basified to pH8.5 by the portionwise addition ofsodium bicarbonate. The resultant precipitate was isolated, washed withwater and dried under vacuum at 50° C. over phosphorus pentoxide. Therewas thus obtained 5-hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one (3.4g); NMR Spectrum: (DMSOd₆) 3.85 (s, 3H), 7.12 (d, 1H), 7.52 (d, 1H),7.98 (s, 1H), 11.89 (s, 1H); Mass Spectrum: M+H⁺ 193.

The material so obtained was added to a stirred suspension of sodiumhydride (1.59 g of a 60% dispersion in mineral oil which was washed withpentane) in DMF (18 ml) which was cooled to 0° C. The mixture wasstirred at ambient temperature for 30 minutes. The mixture was cooled to0° C. and chloromethyl pivalate (4.1 ml) was added dropwise. The mixturewas stirred at ambient temperature for 1.5 hours. The resultantprecipitate was isolated, washed with water and dried overnight undervacuum. The solid was dissolved in methylene chloride and the solutionwas dried over magnesium sulphate. The solution was evaporated and theresidue was triturated under pentane. The resultant solid was isolatedand dried under vacuum. There was thus obtained5-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (4.6g); NMR Spectrum: (CDCl₃) 1.25 (s, 9H), 4.0 (s, 3H), 5.9 (s, 2H), 7.2(d, 1H), 7.38 (d, 1H), 8.08 (s, 1H), 11.5 (s,1H); Mass Spectrum: M+H⁺307.

A solution of di-tert-butyl azodicarboxylate (1.75 g ) in methylenechloride (3 ml) was added to a stirred mixture of5-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one(1.55 g), triphenylphosphine (1.99 g), 4-hydroxy-1-methylpiperidine(0.75 g) and methylene chloride (12 ml) which had been cooled to 5° C.The mixture was stirred at ambient temperature for 1 hour. The mixturewas evaporated and the residue was purified by column chromatography onsilica using a 9:10:1 mixture of methylene chloride, ethyl acetate and asaturated methanolic ammonia solution as eluent. The material soobtained was stirred in a saturated methanolic ammonia solution for 48hours. The mixture was evaporated and the residue was triturated underdiethyl ether. The resultant solid was washed with diethyl ether anddried under vacuum to give6-methoxy-5-(N-methylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(0.92 g); NMR Spectrum: (DMSOd₆) 1.7-1.9 (m, 4H), 1.95 (t, 2H), 2.15 (s,3H), 2.7 (m, 2H), 3.85 (s, 3H), 4.08 (m, 1H), 7.4 (d, 1H), 7.6 (d, 1H),7.85 (s, 1H), 11.8 (br s, 1H); Mass Spectrum: M+H⁺ 290.

A mixture of a portion (0.3 g) of the material so obtained,triphenylphosphine (0.54 g), carbon tetrachloride (0.3 ml) and1,2-dichloroethane (13 ml) was stirred and heated to 70° C. for 2.5hours. The mixture was evaporated and the residue was purified by columnchromatography on silica using a 10:9:1 mixture of ethyl acetate,methylene chloride and a saturated methanolic ammonia solution aseluent. There was thus obtained4-chloro-6-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline (0.22 g);NMR Spectrum: (CDCl₃) 1.82-2.1 (m, 6H), 2.25 (s, 3H), 2.85 (m, 2H), 4.0(s, 3H), 4.4 (m, 1H), 7.7 (d, 1H), 7.8 (d, 1H), 8.82 (s, 1H).

[10] The free base gave the following data: NMR Spectrum: (CDCl₃) 2.02(m, 4H), 2.2 (d, 2H), 2.4 (s, 3H), 2.5-2.8 (m, 10H), 3.55 (t, 2H), 3.95(s, 3H), 4.05 (m, 2H), 4.1 (t, 2H), 4.7 (m, 1H), 6.55 (d, 1H), 6.82 (d,1H), 7.4 (s, 1H), 8.35 (s, 1H), 8.55 (s, 1H), 9.82 (s, 1H); MassSpectrum: M+H⁺ 576 and 578.

The4-chloro-7-[3-(4methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

5-Hydroxy-7-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one(0.61 g) was reacted with 4-hydroxytetrahydropyran (0.23 ml) using ananalogous procedure to that described in the first paragraph of theportion of Note [1] immediately above that is concerned with thepreparation of starting materials. There was thus obtained7-methoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (0.3 g);NMR Spectrum: (DMSOd₆) 1.6-1.75 (m, 2H), 1.9-2.0 (m, 2H), 3.52 (m, 2H),3.85 (s, 3H), 3.95 (m, 2H), 4.75 (m, 1H), 6.65 (d, 1H), 6.7 (m, 1H),7.92 (s, 1H).

A mixture of7-methoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (4 g),thiophenol (2.2 ml), potassium carbonate (3 g) andN-methylpyrrolidin-2-one (40 ml) was stirred and heated to 200° C. for25 minutes. The mixture was evaporated and the residue was acidified bythe addition of 12N aqueous hydrochloric acid (2 ml). Methylene chloride(5 ml) was added. The resultant precipitate was isolated, washed in turnwith water and diethyl ether and dried under vacuum to give7-hydroxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (3.4 g);NMR Spectrum: (DMSOd₆) 1.6-1.75 (m, 2H), 1.9-2.0 (m, 2H), 3.45-3.6 (m,2H), 3.8 (m, 3H), 4.65 (m, 1H), 6.5 (d, 1H), 6.65 (m, 1H), 7.92 (s, 1H),10.4 (s, 1H), 11.5 (s, 1H); Mass Spectrum: M+H⁺ 263.

A mixture of7-hydroxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquiazolin-4-one (3.2 g),pyridine (3.2 ml) and acetic anhydride (20 ml) was stirred and heated to100° C. for 2 hours. The mixture was evaporated. The residue wasdissolved in a mixture of methanol and water and stirred at ambienttemperature for 2 hours. The mixture was evaporated to remove themethanol and the residual aqueous layer was freeze-dried. The residuewas purified by column chromatography on silica using a 19:1 mixture ofmethylene chloride and methanol as eluent. There was thus obtained7-acetoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (3.1 g);NMR Spectrum: (DMSOd₆) 1.7 (m, 2H), 1.92 (m, 2H), 2.3 (s, 3H), 3.5 (m,2H), 3.9 (m, 2H), 4.72 (m, 1H), 6.95 (d, 2H), 7.98 (s, 1H), 10.9 (br s,1H); Mass Spectrum: M+H⁺ 305.

A mixture of a portion (1.2 g) of the material so obtained, phosphorylchloride (0.41 ml), di-isopropylethylamine (1.74 ml) and1,2-dichloroethane (30 ml) was stirred and heated to 80° C. for 2.5hours. The mixture was evaporated. The material so obtained wasdissolved in a saturated methanolic ammonia solution and stirred for 2.5hours. The mixture was evaporated and the residue was purified bycolumrn chromatography on silica using a 97:3 mixture of methylenechloride and methanol as eluent. There was thus obtained4-chloro-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline (0.5 g); NMRSpectrum: (DMSOd₆) 1.8 (m, 2H), 2.08 (m, 2H), 3.6 (m, 2H), 3.9 (m, 2H),4.9 (m, 1H), 6.9 (d, 2H), 8.76 (s, 1H); Mass Spectrum: M+H⁺ 281 and 283.

Di-tert-butyl azodicarboxylate (0.65 g) was added to a stirred mixtureof 4chloro-7-hydroxy-5-tetrahydropyran4-yloxyquinazoline (0.5 g),triphenylphosphine (0.75 g), 1-(3-hydroxypropyl)4methylpiperazine (0.34g) and methylene chloride (20 ml) and the mixture was stirred at ambienttemperature for 1.5 hours. The mixture was poured onto a column ofsilica and eluted initially with a 49:1 mixture of methylene chlorideand methanol followed by a 97:3 mixture of methylene chloride and asaturated methanolic ammonia solution. There was thus obtained4chloro-7-[3-(4-methylpiperazin-4-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.54 g); NMR Spectrum: (CDCl₃) 1.9-2.2 (m, 6H), 2.25 (s, 3H), 2.32-2.68(m, 10H), 3.68 (m, 2H), 4.05 (m, 2H), 4.15 (t, 2H), 4.72 (m, 1H), 6.58(d, 1H), 6.92 (d, 1H), 8.8 (s, 1H); Mass Spectrum: M+H⁺ 421 and 423.

[11] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.2 (m, 6H), 2.5 (s, 3H), 2.6-2.9 (m, 10H), 3.35 (m, 2H), 3.9 (s,3H), 4.02 (m, 2H), 4.25 (t, 2H), 4.6 (m, 1H), 6.65 (m, 1H), 7.35 (d,1H), 7.55 (d, 1H), 7.68 (d, 1H), 8.55 (s, 1H), 8.65 (s, 1H), 10.45 (s,1H); Mass Spectrum: M+H⁺ 542 and 544.

The4-chloro-6-[3-(4-methylpiperazin-1-yl)propoxyl-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

Di-tert-butyl azodicarboxylate (3.6 g ) was added portionwise to astirred mixture of5-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (3g), triphenylphosphine (4.1 g), 4-hydroxytetrahydropyran (1.2 ml) andmethylene chloride (50 ml) and the mixture was stirred at ambienttemperature for 30 minutes. The mixture was evaporated and the residuewas stirred in a saturated methanolic ammonia solution for 7 hours. Themixture was evaporated and the residue was purified by columnchromatography on silica using a 9:10:1 mixture of methylene chloride,ethyl acetate and a saturated methanolic ammonia solution as eluent.There was thus obtained6-methoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin4-one (2.3 g);NMR Spectrum: DMSOd₆) 1.65-1.8 (m, 2H), 1.8-1.9 (m, 2H), 3.35 (m, 2H),3.9 (s, 3H), 3.92 (m, 2H), 4.3 (m, 1H), 7.42 (d, 1H), 7.6 (d, 1H), 7.9(s, 1H), 11.8 (br s, 1H); Mass Spectrum: M+H⁺ 277.

A mixture of a portion (1.9 g) of the material so obtained, thiophenol(1 ml), potassium carbonate (1.4 g) and N-methylpyrrolid-2-one (20 ml)was stirred and heated to 200° C. for 30 minutes. The mixture wasevaporated. The residue was dissolved in a mixture of methylene chloride(25 ml), methanol (1 ml) and acetic acid (2 ml) and the solution waspoured onto a column of silica and was eluted with a 9:10:1 mixture ofmethylene chloride, ethyl acetate and methanol. The material so obtainedwas triturated under diethyl ether and the resultant solid was washedwith diethyl ether and dried under vacuum. There was thus obtained6-hydroxy-5-tetrahydropyranyloxy-3,4-dihydroquinazolin-4one (1.65 g);NMR Spectrum: (DMSOd₆) 1.7-1.9 (m, 4H), 3.2-3.4 (m, 2H), 3.92 (m, 2H),4.3 (m, 1H), 7.3 (d, 1H), 7.35 (d, 1H), 7.85 (s, 1H), 9.55 (br s, 1H),11.75 (br s, 1H); Mass Spectrum : M+H⁺ 263.

A mixture of a portion (0.7 g) of the material so obtained, piperidine(0.7 ml) and acetic anhydride (10 ml) was heated to reflux for 1 hour.The mixture was evaporated. The residue was dissolved in a 1:1 mixtureof methanol and water (18 ml) and stirred at ambient temperature for 1hour. The resultant precipitate was isolated, washed with water anddried under vacuum to give6-acetoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (0.54g); NMR Spectrum: (CDCl₃) 1.8-2.0 (m, 2H), 2.0-2.1 (m, 2H), 2.4 (s, 3H),3.45 (m, 2H), 4.02 (m, 2H), 4.4 (m, 1H), 7.5-7.6 (m, 2H), 8.0 (s, 1H),10.5 (br s, 1H); Mass Spectrum: M+H⁺ 305.

A mixture of the material so obtained, triphenylphosphine (0.93 g),carbon tetrachloride (0.515 ml) and 1,2-dichloroethane (24 ml) wasstirred and heated to 70° C. for 2.5 hours. The mixture was evaporatedand the residue was dissolved in a saturated methanolic ammonia solution(20 ml) and stirred at ambient ternperature for 1 hour. The mixture wasfiltered and the filtrate was poured onto a column of silica and elutedin turn with methylene chloride, a 1:1 mixture of methylene chloride andethyl acetate and a 24:25:1 mixture of methylene chloride, ethyl acetateand methanol. There was thus obtained4-chloro-6-hydroxy-5-tetrahydropyran4-yloxyquinazoline.

Using an analogous procedure to that described in the last paragraph ofthe portion of Note [10] immediately above that is concerned with thepreparation of starting materials,4-chloro-6-hydroxy-5-tetrahydropyran4-yloxyquinazoline (1.12 g) wasreacted with 1-(3-hydroxypropyl)-4-methylpiperazine to give4-chloro-6-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.56 g); NMR Spectrum: (CDCl₃) 1.85-2.2 (m, 6H), 2.32 (s, 3H), 2.35-2.7(m, 10H), 3.42 (m, 2H), 4.05 (m, 2H), 4.25 (m, 2H), 4.65 (m, 1H), 7.75(d, 1H), 7.85 (d, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 421 and 423.

[12] The free base gave the following data: NMR Spectrum: (CDCl₃)1.82-2.18 (m, 6H), 2.35 (s, 3H), 2.4-2.7 (m, 10H), 3.35 (m, 2H), 4.02(d, 2H), 4.25 (t, 2H), 4.65 (m, 1H), 7.08 (m, 1H), 7.4 (d, 1H), 7.6 (d,1H), 7.7 (d, 1H), 8.68 (s, 1H), 9.0 (s, 1H), 10.5 (s, 1H); MassSpectrum: M+H⁺ 546 and 548.

[13] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.15 (m, 6H), 2.35 (s, 3H), 2.4-2.75 (m, 10H),3.35 (m, 2H),3.89 (s,3H), 4.02 (m,2H), 4.25 (t, 2H), 4.65 (m, 1H), 6.65 (m, 1H), 7.5 (d, 1H),7.55 (d, 1H), 7.65 (d, 1H), 8.35 (d, 1H), 8.6 (s, 1H), 10.28 (s, 1H);Mass Spectrum: M+H⁺ 586 and 588.

[14] 4-Chloro-2-fluoro-5-methoxyaniline is disclosed in InternationalPatent Application WO 86/02642. The free base of the product gave thefollowing data: NMR Spectrum: (CDCl₃) 1.9-2.1 (m, 4H), 2.22 (d, 2H),2.27 (s, 3H), 2.32-2.62 (m, 10H), 3.55 (m, 2H), 3.94 (s, 3H), 4.08 (m,2H), 4.15 (t, 2H), 4.7 (m, 1H), 6.52 (s, 1H), 6.82 (s, 1H), 7.15 (d,1H), 8.6 (s, 1H), 8.8 (d, 1H), 10.1 (s, 1H); Mass Spectrum: M+H⁺ 560 and562.

[15] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.1 (m, 4H),2.22 (d, 2H), 2.28 (s, 3H), 2.35-2.7 (m, 10H), 3.6 (m,2H), 4.08 (m, 2H), 4.12 (t, 2H), 4.7 (m, 1H), 6.5 (d, 1H), 6.82 (d, 1H),7.25-7.35 (m, 2H), 8.57 (s, 1H), 8.77 (m, 1H), 10.02 (s, 1H); MassSpectrum: M+H⁺ 574 and 576.

[16] 2-Pyrrolidin-1-yl-5-methoxyaniline is disclosed in InternationalPatent Application WO 85/01939. The free base of the product gave thefollowing data: NMR Spectrum: (CDCl₃) 1.8-2.0 (m, 8H), 2.2 (d, 2H), 2.29(s, 3H), 2.4-2.7 (m, 12H), 3.1 (t, 2H), 3.6 (m, 2H), 3.82 (s, 3H), 4.02(m, 2H), 4.15 (t, 2H), 4.7 (m, 1H), 6.5 (d, 1H), 6.65 (m, 1H), 6.85 (d,1H), 7.05 (d, 1H), 7.9 (d, 1H), 8.55 (s, 1H), 9.82 (s, 1H); MassSpectrum: M+H⁺ 577.

[17] The free base gave the following data: NMR Spectrum: (CDCl₃) 1.95(m, 4H), 2.18 (d, 2H), 2.25 (s, 3H), 2.3-2.6 (m, 10H), 3.55 (t, 2H),4.02 (m, 2H), 4.1 (t, 2H), 4.68 (m, 1H), 5.95 (s, 2H), 6.45 (s, 1H), 6.6(d, 1H), 6.78 (s, 1H),.6.85 (m, 1H), 8.02 (d, 1H), 8.5 (s, 1H), 9.68 (s,1H); Mass Spectrum: M+H⁺ 522.

[18] The reactants were7-benzyloxy-5-[-N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-chloroquinazoline(1.92 g) and 6-chloro-2,3-methylenedioxyaniline (0.771 g) and thereaction mnixture was heated to reflux for 1.5 hours. The reactionmixture was cooled to ambient temperature and the precipitate wasisolated, washed in turn with isopropanol, ethyl acetate and diethylether and dried under vacuum. The material so obtained was dissolved ina 2M solution of hydrogen chloride in diethyl ether and stirred atambient temperature for 2 hours. The resultant solid was isolated,washed with diethyl ether and dried under vacuum. There was thusobtained the required compound as a dihydrochloride salt (2.4 g) whichgave the following data: NMR Spectrum: (DMSOd₆) 1.4 (s, 9H), 1.8-1.95(m, 2H), 2.0-2.1 (m, 2H), 2.9-3.1 (m, 2H), 3.4 (m, 2H), 5.08 (m, 1H),5.35 (s, 2H), 6.12 (s, 2H), 7.0-7.05 (m, 2H), 7.12 (d, 1H), 7.22 (d,1H), 7.3-7.6 (m, 5H), 8.75 (s, 1H), 10.1 (s, 1H); Mass Spectrum: M+H⁺605 and 607.

[19] The reactants were 7-acetoxy 4chloro-5-cyclopentyloxyquinazolineand 2,3-methylenedioxyaniline. The precipitate from the reaction mixturewas isolated, dissolved in a saturated methanolic ammonia solution (20ml) and stirred at ambient temperature for 2 hours. The mixture wasevaporated and the residue was triturated under water. The solid soobtained was washed with water and dried overnight under vacuum. Theproduct gave the following data: NMR Spectrum: (DMSOd₆) 1.6-1.7 (m, 2H),1.7-1.9 (m, 2H), 1.9-2.15 (m, 4H), 5.1 (br s, 1H), 6.12 (s, 2H), 6.63(s, 1H), 6.65 (s, 1H), 6.72 (d, 1H), 6.9 (m, 1H), 8.15 (d, 1H), 8.42 (s,1H), 9.8 (s, 1H), 10.58 (s, 1H); Mass Spectrum: M+H⁺ 366.

EXAMPLE 164-(2-iodoanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

A mixture of 4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.08 g), 2-iodoaniline (0.068 g), 6M hydrogen chloride in isopropanol(0.05 ml) and isopropanol (3 ml) was stirred and heated to 80° C. for 2hours. The mixture was cooled to 0° C. and diethyl ether was added. Theresultant precipitate was isolated, washed with diethyl ether and driedunder vacuum. The solid so obtained was dissolved in methylene chlorideand the solution was washed with a saturated aqueous sodium bicarbonatesolution. The organic solution was poured onto a column of silica andeluted with a 9:10:1 mixture of methylene chloride, ethyl acetate andmethanol followed by a 9:10:1 mixture of methylene chloride, ethylacetate and a saturated methanolic ammonia solution. The material soobtained was dissolved in diethyl ether and 6M hydrogen chloride indiethyl ether (0.1 ml) was added. The resultant precipitate wasisolated, washed with diethyl ether and dried under vacuum. There wasthus obtained the title compound (0.081 g), as the dihydrochloride salt,a portion of which was converted to the free base using an analogousprocedure to that described in Example 3. The free base gave thefollowing data: NMR Spectrum: (CDCl₃) 2.1-2.4 (m, 6H), 2.3 (s, 3H), 2.8(m, 2H), 3.92 (s, 3H), 4.6 (m, 1H), 6.55 (s, 1H), 6.85 (s, 1H), 6.95 (t,1H), 7.42 (t, 1H), 7.9 (d, 2H), 8.5 (s, 1H), 9.5 (s, 1H); Mass Spectrum:M+H⁺ 491.

EXAMPLE 17

Using an analogous procedure to that described in Example 16, theappropriate 4-chloroquinazoline was reacted with the appropriate anilinein the presence of hydrogen chloride to give the dihydrochloride salt ofeach of the compounds described in Table V, a portion of each of whichwas converted to the free base using an analogous procedure to thatdescribed in Example 3. TABLE V

No. and Note (R¹)_(m) Q¹ (R²)_(n)  [1] 7-methoxy N-methylpiperidin-4-yl2,4-dichloro  [2] 7-methoxy N-methylpiperidin-4-yl 4-bromo-2-chloro  [3]7-methoxy N-methylpiperidin-4-yl 2-chloro-4-cyano  [4] 7-methoxyN-methylpiperidin-4-yl 2-bromo-4-fluoro  [5] 7-methoxyN-methylpiperidin-4-yl 2-bromo-4-chloro  [6] 7-methoxyN-methylpiperidin-4-yl 2,4-dibromo  [7] 7-methoxy N-methylpiperidin-4-yl2-bromo  [8] 7-methoxy N-methylpiperidin-4-yl 2-bromo-4-methyl  [9]7-methoxy N-methylpiperidin-4-yl 2-fluoro-4-chloro [10] 7-methoxyN-methylpiperidin-4-yl 2-fluoro-4-bromo [11] 7-methoxyN-methylpiperidin-4-yl 2-fluoro-3-chloro [12] 7-methoxyN-methylpiperidin-4-yl 2,4-dimethoxy [13] 7-methoxyN-methylpiperidin-4-yl 2,3-dimethoxy [14] 7-methoxyN-methylpiperidin-4-yl 2-methoxy-5-methyl [15] 7-methoxyN-methylpiperidin-4-yl 2-methoxy-5-chloro [16] 7-methoxyN-methylpiperidin-4-yl 2-methoxy [17] 7-methoxy N-methylpiperidin-4-yl2-ethoxy [18] 7-methoxy N-methylpiperidin-4-yl 2-methylthio [19]7-methoxy N-methylpiperidin-4-yl 2-acetyl-4-chloro [20] 7-methoxyN-methylpiperidin-4-yl 2-methyl-5-chloro [21] 7-methoxyN-methylpiperidin-4-yl 2-methyl-3-chloro [22] 7-methoxyN-methylpiperidin-4-yl 2-methyl-4-chloro [23] 7-methoxyN-methylpiperidin-4-yl 2-methyl-5-methoxy [24] 7-methoxyN-methylpiperidin-4-yl 2-isopropenyl [25] 7-methoxyN-methylpiperidin-4-yl 2-(1-pyrrolyl) [26] 7-methoxyN-methylpiperidin-4-yl 2-piperidino [27] 7-(2-pyrrolidin- cyclopentyl2-bromo-5-methoxy 1-ylethoxy) [28] 7-(2-pyrrolidin- cyclopentyl5-methoxy- 1-ylethoxy) 2-pyrrolidin-1-yl [29] 7-(2-pyrrolidin-cyclopentyl 5-methoxy- 1-ylethoxy) 2-morpholinomethyl [30]7-(2-pyrrolidin- cyclopentyl 6-chloro- 1-ylethoxy) 2,3-methylenedioxy[31] 7-methoxy piperidin-4-ylmethyl 6-chloro- 2,3-methylenedioxy [32]7-(2-pyrrolidin- 4-tetrahydropyranyl 6-chloro- 1-ylethoxy)2,3-methylenedioxy [33] 7-(3-pyrrolidin- 4-tetrahydropyranyl 6-chloro-1-ylethoxy) 2,3-methylenedioxy [34] 7-benzyloxy 4-tetrahydropyranyl6-chloro- 2,3-methylenedioxyNotes[1] The free base gave the following data: NMR Spectrum: (CDCl₃) 2.0-2.1(m, 2H), 2.15-2.4 (m, 4H), 2.3 (s, 3H), 2.75-2.9 (m, 2H), 3.89 (s, 3H),4.55 (m, 1H), 6.5 (s, 1H), 6.82 (s, 1H), 7.28 (m, 1H), 7.42 (d, 1H),8.35 (d, 1H), 8.5 (s, 1H), 9.8 (s, 1H); Mass Spectrum: M+H⁺ 433 and 435.[2] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.35 (m, 4H), 2.3 (s, 3H), 2.7-2.9 (m, 2H), 3.9(s, 3H), 4.42-4.6 (m, 1H), 6.55 (d, 1H), 6.82 (d, 1H), 7.4 (m, 1H), 7.55(d, 1H), 8.3 (d, 1H), 8.51 (s, 1H), 9.8 (s, 1H); Mass Spectrum: M+H⁺ 477and 479.[3] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.1-2.25 (m, 4H), 2.28 (s, 3H), 2.85 (br d, 2H), 3.9(s, 3H), 4.5 (m, 1H), 6.55 (d, 1H), 6.85 (d, 1H), 7.58 (m, 1H), 7.7 (s,1H), 8.6 (s, 1H), 8.82 (d, 1H); Mass Spectim: M+H⁺ 424 and 426.[4] The free base gave the following data: NMR Spectrum: (CDCl₃) 2.0-2.1(m, 2H), 2.15-2.4 (m, 4H), 2.28 (s, 3H), 2.8 (m, 2H), 3.9 (s, 3H), 4.55(m, 1H), 6.5 (s, 1H), 6.8 (s, 1H), 7.1 (m, 1H), 7.35 (m, 1H), 8.05 (m,1H), 8.48 (s, 1H), 9.55 (br s, 1H); Mass Spectrum: M+H⁺ 461 and 463.[5] The free base gave the following data: NMR Spectrum: (CDCl₃)2.0-2.15 (m, 2H), 2.2-2.4 (m, 4H), 2.3 (s, 3H), 2.8 (m, 2H), 3.9 (s,3H), 4.5-4.6 (m, 1H), 6.5. (d, 1H), 6.8 (d, 1H), 7.3 (m, 1H), 7.6 (d,1H), 8.15 (d, 1H), 8.5 (s, 1H), 9.6 (br s, 1H); Mass Spectrum: M+H⁺ 477and 479.[6] The free base gave the following data: NMR Spectrum: (CDCl₃) 2.0-2.2(m, 2H), 2.2-2.35 (m, 4H), 2.25 (s, 3H), 2.7-2.9 (m, 2H), 3.9 (s, 3H),4.5-4.6 (m, 2H), 6.55 (s, 1H), 6.85 (s, 1H), 7.15 (m, 1H), 7.45 (d, 1H),8.45 (s, 1H), 8.55 (s, 1H), 9.68 (br s, 1H); Mass Spectrum: +H⁺ 521, 523and 525.[7] The free base gave the following data: NMR Spectrum: (CDCl₃)2.0-2.15 (m, 2H1), 2.15-2.38 (m, 4H), 2.3 (s, 3H), 2.8 (m, 2H), 3.9 (s,3H), 4.55 (m, 1H), 6.5 (d, 1H), 6.82 (d, 1H), 7.02 (m, 1H), 7.35 (m,1H), 7.36 (d, 1H), 8.15 (d, 1H), 8.5 (s, 1H), 9.65 (s, 1H); MassSpectrum: M+H⁺ 443 and 445.[8] The free base gave the following data: NMR Spectrum: (CDCl₃)2.0-2.15 (m, 2H), 2.2-2.4 (m, 4H), 2.28 (s, 3H), 2.31 (s, 3H), 2.8 (m,2H), 3.89 (s, 3H), 4.55 (m, 1H), 6.5 (s, 1H), 6.8 (s, 1H), 7.15 (m, 1H),7.42 (s, 1H), 7.95 (d, 1H), 8.48 (s, 1H), 9.55 (s, 1H); Mass Spectrum:M+H⁺ 457 and 449.[9] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.3 (m, 4H), 2.3 (s, 3H), 2.85 (d, 1H), 3.9 (s,3H), 4.5 (m, 1H), 6.5 (d, 1H), 6.82 (d, 1H), 7.1-7.2 (m, 2H), 8.58 (s,1H), 8.75 (m, 1H); Mass Spectrum: M+H⁺ 417 and 419.[10] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.35 (m, 4H), 2.32 (s, 3H), 2.9 (m, 2H), 3.89 (s,3H), 4.55 (m, 1H), 6.5 (d, 1H), 6.85 (d, 1H), 7.25-7.35 (m, 2H), 8.58(s, 1H), 8.75 (m, 1H); Mass Spectrum: M+H⁺ 461 and 463.[11] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.12-2.28 (m, 4H), 2.28 (s, 3H), 2.85 (m, 2H), 3.86(s, 3H), 4.5 (m, 1H), 6.5 (s, 1H), 6.8 (s, 1H), 7.0-7.1 (m, 2H), 8.55(s, 1H), 8.68 (m, 1H); Mass Spectrum: M+H⁺ 417 and 419.[12] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.1-2.22 (m, 4H), 2.25 (s, 3H), 2.82 (m, 2H), 3.77 (s,3H), 3.83 (s, 3H), 3.85 (s, 3H), 4.48 (m, 1H), 6.45 (d, 1H), 6.52 (m,1H), 6.8 (m, 2H), 8.45 (d, 1H), 8.52 (s, 1H); Mass Spectrum: M+H⁺ 425.[13] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.1 (m, 2H), 2.1-2.25 (m, 4H), 2.28 (s, 3H), 2.7-2.9 (m, 2H), 3.8(s, 3H), 3.85 (s, 3H), 3.9 (s, 3H), 4.5 (m, 1H), 6.45 (d, 1H), 6.5-6.6(m, 2H), 6.8 (d, 1H), 8.4 (d, 1H), 8.5 (s, 1H), 9.85 (s, 1H); MassSpectrum: M+H⁺ 425.[14] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.3 (m, 4H), 2.27 (s, 3H), 2.3 (s, 3H), 2.85 (m,2H), 3.87 (s, 3H), 3.89 (s, 3H), 4.5 (m, 1H), 6.5 (s, 1H), 6.8-6.9 (m,3H), 8.45 (s, 1H), 8.55 (s, 1H); Mass Spectrum: M+H⁺ 409.[15] The free base gave the following data: NMR Spectrum: (CDCl₃)1.95-2.1 (m, 2H), 2.15-2.3 (m, 4H), 2.3 (s, 3H), 2.85 (d, 2H), 3.89 (s,3H), 3.9 (s, 3H), 4.5 (m, 1H), 6.5 (d, 1H), 6.8 (m, 2H), 7.0 (m, 1H),8.6 (s, 1H), 8.85 (d, 1H); Mass Spectrum: M+H⁺ 429 and 431.[16] The free base gave the following data: NMR Spectrum: (CDCl₃)2.0-2.1 (m, 2H), 2.15-2.3 (m, 4H), 2.29 (s, 3H), 2.85 (m, 2H), 3.88 (s,3H), 3.9 (s, 3H), 4.52 (m, 1H), 6.5 (s, 1H), 6.8 (s, 1H), 6.95 (m, 1H),7.02 (m, 2H), 8.55 (s, 1H), 8.65 (m, 1H); Mass Spectrum: M+H⁺ 395.[17] The free base gave the following data: NMR Spectrum: (CDCl₃) 1.4(t, 3H), 1.9-2.1 (m, 2H), 2.1-2.3 (m, 4H), 2.24 (s, 3H), 2.7-2.9 (m,2H), 3.9 (s, 3H), 4.2 (q, 2H), 4.4-4.55 (m, 1H), 6.5 (d, 1H), 6.8 (d,1H), 6.9 (m, 1H), 6.95-7.1 (m, 2H), 8.38 (m, 1H), 8.5 (s, 1H), 9.85 (brs, 1H); Mass Spectrum: M+H⁺ 409.[18] The free base gave the following data: NMR Spectrum: (CDCl₃)2.05-2.35 (m, 6H), 2.27 (s, 3H), 2.38 (s, 3H), 2.7-2.9.(m, 2H), 3.9 (s,3H), 4.5-4.6 (m, 1H), 6.5 (d, 1H), 6.8 (d, 1H), 7.15 (m, 1H), 7.26 (m,1H), 7.38 (m, 1H), 7.98 (d, 1H), 8.5 (s, 1H), 9.7 (br s, 1H); MassSpectrum: M+H⁺ 411.[19] The free base gave the following data: NMR Spectrum: (CDCl₃)2.15-2.35 (m, 6H), 2.27 (s, 3H), 2.57 (s, 3H), 2.82 (m, 2H), 3.89 (s,3H), 4.55 (m, 1H), 6.52 (s, 1H), 6.8 (s, 1H), 7.48 (m, 1H), 7.75 (d,1H), 8.3 (d, 1H), 8.5 (s, 1H); Mass Spectrum: M+H⁺ 441 and 443.[20] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.0 (m, 2H), 2.15-2.4 (m, 4H), 2.26 (s, 3H), 2.28 (s, 3H), 2.75 (brs, 2H), 3.9 (s, 3H), 4.55 (br s, 1H), 6.5 (d, 1H), 6.82 (s, 1H), 7.1 (m,1H), 7.18 (d, 1H), 7.8 (s, 1H), 8.48 (s, 1H), 9.1 (s, 1H); MassSpectrum: M+H⁺ 413 and 415.[21] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.0 (m, 2H), 2.15-2.25 (m, 2H), 2.28 (s, 3H), 2.25-2.38 (m, 2H),2.35 (s, 3H), 2.7 (br s, 2H), 3.9 (s, 3H), 4.6 (m, 1H), 6.5 (d, 1H), 6.8(d, 1H), 7.18 (m, 1H), 7.28 (m, 1H), 7.5 (d, 1H), 8.45 (s, 1H), 9.35 (s,1H); Mass Spectrum: M+H⁺ 413 and 415.[22] The free base gave the following data: NMR Spectrum: (CDCl₃)1.9-2.0 (m, 2H), 2.2-2.4 (m, 4H), 2.27 (s, 3H), 2.65-2.8 (m, 2H), 3.89(s, 3H), 4.55 (m, 1H), 6.5 (d, 1H), 6.8 (d, 1H), 7.15-7.25 (m, 2H), 7.6(d, 1H), 8.45 (s, 1H), 9.25 (s, 1H); Mass Spectrum: M+H⁺ 413 and 415.[23] The free base gave the following data: NMR Spectrum: (CDCI₃)1.9-2.0 (m, 2H), 2.15-2.22 (m, 4H), 2.17 (s, 3H), 2.22 (s, 3H), 2.72 (m,2H), 3.78 (s, 3H), 3.89 (s, 3H), 4.55 (m, 1H), 6.5 (d, 1H), 6.7 (m, 1H),6.8 (d, 1H), 7.15 (d, 1H), 7.3 (d, 1H), 8.45 (s, 1H), 9.3 (s, 1H); MassSpectrum: M+H⁺ 409.[24] The free base gave the following data: NMR Spectrum: (CDCI₃)1.85-2.0 (m, 2H), 2.05 (s, 3H), 2.1-2.3 (m, 4H), 2.28 (s, 3H), 2.72 (m,2H), 3.92 (s, 3H), 4.5 (m, 1H), 5.1 (s, 1H), 5.25 (s, 1H), 6.5 (s, 1H),6.82 (s, 1H), 7.2 (t, 1H), 7.3 (d, 1H), 7.35 (t, 1H), 7.85 (d, 1H), 8.5(s, 1H), 9.35 (s, 1H).[25] The free base gave the following data: NMR Spectrum: (CDCl₃)1.45-1.6 (m, 2H), 1.8-1.95 (m, 2H), 2.05-2.2 (m, 2H), 2.2 (s, 3H),2.4-2.55 (br s, 2H), 3.95 (s, 3H), 4.25-4.35 (m, 2H), 6.25 (d, 2H), 6.4(s, 1H), 6.8 (s, 1H), 6.85 (d, 2H), 7.2 (m, 1H), 7.3 (m, 1H), 7.35 (m,1H), 8.05 (d, 1H), 8.5 (s, 1H), 9.25 (br s, 1H); Mass Spectrum: M+H⁺430.[26] The free base gave the following data: NMR Spectrum: (CDCl₃) 1.6(m, 2H), 1.7 (m, 4H), 2.1 (m, 2H), 2.2 (s, 3H), 2.2 (m, 2H), 2.3 (m,2H), 2.7 (m, 2H), 2.9 (m, 4H), 3.95 (s, 3H), 4.6 (m, 1H), 6.1 (d, 1H),6.9 (d, 1H), 7.1-7.2 (m, 3H), 8.02 (m, 1H), 8.52 (s, 1H), 9.72 (s, 1H);Mass Spectrum: M+H⁺ 448.[27] The free base gave the following data: NMR Spectrum: (CDCl₃)1.6-1.78 (m, 4H), 1.85 (m, 4H), 2.1 (m, 4H), 2.65 (m, 4H), 2.98 (m, 2H),3.82 (s, 3H), 4.25 (m, 2H), 5.02 (m, 1H), 6.4 (d, 1H), 6.45 (m, 1H),6.82 (d, 1H), 7.5 (d, 1H), 7.85 (d, 1H), 8.52 (s, 1H), 9.62 (s, 1H);Mass Spectrum: M+H⁺ 527 and 529.

The 4-chloro-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazolineused as a starting material was prepared as follows:

A mixture of 7-acetoxy-4-chloro-5-cyclopentyloxyquinazoline (1 g), asaturated methanolic amnmonia solution (10 ml) and methanol (10 ml) wasstirred at ambient temperature for 30 minutes. The mixture wasevaporated and the residue was triturated under water. The resultantsolid was isolated, washed with water and dried uwder vacuum to give4-chloro-5-cyclopentyloxy-7-hydroxyquinazoline (0.67 g); NMR Spectrum:(DMSOd₆) 1.6-1.75 (m, 2H), 1.75-1.85 (m, 2H), 1.85-2.05 (m, 4H), 5.0 (m,1H), 6.72 (d, 1H), 6.8.(d, 1H), 8.7 (s, 1H); Mass Spectrum: M+H⁺ 265.

Using an analogous procedure to that described in Example 1,4-chloro-5-cyclopentyloxy-7-hydroquinazoline (0.84 g) was reacted with2-pyrrolidin-1-ylethanol (0.448 ml). There was thus obtained4-chloro-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline (0.82g); NMR Spectrum: (CDCl₃) 1.65-2.12 (m, 12H), 2.65 (m, 4H), 2.97 (m,2H), 4.25 (m, 2H), 4.9 (m, 1H), 6.65 (d, 1H), 6.92 (d, 1H), 8.8 (s, 1H);Mass Spectrum: M+H⁺ 362 and 364.

[28] The reaction product was purified by column chromatography onreversed phase silica using decreasingly polar mixtures of water,acetonitrile and a saturated methanolic ammonia solution as eluent. Thefree base gave the following data: NMR Spectrum: (CDCl₃) 1.6-1.75 (m,2H), 1.8 (m, 2H), 1.8-1.95 (m, 8H), 2.05 (m, 4H), 2.65 (br s, 1H), 2.95(m, 2H), 3.05 (br s, 4H), 3.8 (s, 3H), 4.25 (m, 2H), 4.95 (m, 1H), 6.55(s, 1H), 6.65 (m, 1H), 6.8 (s, 1H), 7.1 (d, 1H), 7.75 (d, 1H), 8.5 (s,1H), 9.7 (s, 1H); Mass Spectrum: M+H⁺ 518.

[29] The free base gave the following data: NMR Spectrum: (CDCl₃)1.65-1.9 (m, 8H), 1.9-2.15 (m, 4H), 2.35 (m, 4H), 2.65 (m, 4H), 2.98(in, 2H), 3.42 (s, 2H), 3.55 (m, 4H), 3.82 (s, 3H), 4.25 (m, 2H), 5.0(m, 1H), 6.6 (s, 1H), 6.8 (m, 2H), 7.1 (s, 1H), 7.38 (d, 1H), 8.42 (s,1H), 9.3 (s, 1H); Mass Spectrum: M+H⁺ 548.

The 2-morpholinomethyl-5-methoxyaniline used as a starting material wasprepared as follows:

A mixture of 4-methoxy-2-nitrotoluene (20 g), N-bromosuccinliide (23 g),a catalytic amount of benzoyl peroxide and carbon tetrachloride (100 ml)was heated to reflux for 8 hours. The mixture was diluted with methylenechloride (200 ml) and washed in turn with a 2N aqueous sodium hydroxidesolution and brine. The organic layer was dried over magnesium sulphateand evaporated. There was thus obtained 4-methoxy-2-nitrobenzyl bromide(29 g) which was used without further purification.

Morpholine (2.8 ml) was added to a stirred solution of4-methoxy-2-nitrobenzyl bromide (4 g) in diethyl ether (150 ml) whichwas cooled to 0° C. The resultant mixture was stirred at ambienttemperature for 16 hours. The mixture was filtered and the filtrate wasevaporated. There was thus obtained2-morpholinomethyl-5-methoxy-1-nitrobenzene (4 g); NMR Spectrum: (CDCl₃)2.4 (m, 4H), 3.68 (m, 4H), 3.7 (s, 2H), 3.88 (s, 3H), 7.1 (m, 1H), 7.35(d, 1H), 7.45 (d, 1H).

A mixture of the material so obtained, 10% palladium on charcoalcatalyst (0.2 g) and methanol (100 ml) was stirred under an atmospherepressure of hydrogen for 1 hour. The mixture was filtered and thefiltrate was evaporated. The residue was purified by columnchromatography on silica using a 49:1 mixture of methylene chloride andmethanol as eluent. There was thus obtained2-morpholinomethyl-5-methoxyaniline (1.9 g); NMR Spectrum: (CDCl₃) 2.4(br s, 4H), 3.48 (s, 2H), 3.7 (m, 4H), 3.78 (s, 3H), 4.75 (br s, 2H),6.2 (s, 1H), 6.25 (d, 1H), 6.9 (d, 1H).

[30] The free base gave the following data: NMR Spectrum: (CDCl₃)1.7-1.8 (m, 2H), 1.9 (br s, 4H), 2.1 (m, 2H), 2.65 (br s, 4H), 3.0 (brs, 2H), 4.25 (m, 2H), 5.0 (m, 1H), 6.05 (s, 1H), 6.55 (d, 1H), 6.7 (d,1H), 6.8 (d, 1H), 6.98 (d, 1H), 8.5 (s, 1H), 9.3 (s, 1H); Mass Spectrum:M+H⁺ 497 and 499.

The 6-chloro-2,3-methylenedioxyaniline used as a starting material wasprepared as follows:

Sulphuryl chloride (72.5 ml) was added dropwise during 1.7 hours to astirred mixture of benzodioxole (100 g), aluminium trichloride (0.43 g)and diphenyl sulphide (0.55 ml). Once the reaction started with theevolution of sulphur dioxide, the reaction mixture was cooled in a waterbath to a temperature of approximately 22° C. After completion of theaddition. the reaction mixture was stirred at ambient temperature for 45minutes. The reaction mixture was degassed under vacuum and filtered andthe filtrate was distilled at atmospheric pressure using a Vigreuxdistillation column. There was thus obtained 5-chloro-1,3-benzodioxole;b.p. 185-187° C.; NMR Spectrum: (CDCl₃) 6.0 (s, 2H); 6.7 (d, 1H);6.75-6.9 (m, 2H).

A mixture of diisopropylamine (4.92 ml) and TBF (100 ml) was cooled to−78° C. and n-butyllithium (2.5 M in hexane, 14 ml) was added dropwise.The mixture was stirred at −78° C. for 15 minutes.5-Chloro-1,3-benzodioxole (3.73 ml) was added dropwise and the reactionmixture was stirred at −78° C. for 30 minutes. Dry carbon dioxide gaswas bubbled into the reaction mixture for 30 minutes. The resultantreaction mixture was allowed to warm to ambient temperature and wasstirred for a further hour. Water was added and the organic solvent wasevaporated. The residue was acidified to pH2 by the addition of 2Naqueous hydrochloric acid solution. The resultant solid was isolated andwashed in turn with water and diethyl ether. There was thus obtained5-chloro-1,3-benzodioxole-4-carboxylic acid (5.4 g); NMR Spectrum:(DMSOd₆) 6.15 (s, 2H), 7.0 (m, 2H), 13.7 (br s, 1H).

A portion (1 g) of the material so obtained was dissolved in 1,4-dioxane(15 ml) and anhydrous tert-butanol (4 ml), diphenylphosphoryl azide(1.12 ml) and triethylamine (0.73 ml) were added in turn. The resultantmixture was stirred and heated to 100° C. for 4 hours. The mixture wasevaporated and the residue was partitioned between ethyl acetate and a5% aqueous citric acid solution. The organic phase was washed in turnwith water, a saturated aqueous sodium bicarbonate solution and brine,dried over magnesium sulphate and evaporated. The residue was purifiedby column chromatography on silica using a 9:1 mixture of petroleumether (b.p. 40-60° C.) and ethyl acetate as eluent. There was thusobtained tert-butyl 5-chloro-1,3-benzodioxol-4-ylcarbamate (1.1 g); NMRSpectrum: (DMSOd₆) 1.45 (s, 9H), 6.1 (s, 2H), 6.85 (d, 1H), 6.95 (d,1H), 8.75 (s, 1H).

A mixture of the material so obtained (1.1 g), trifluoroacetic acid (6ml) and methylene chloride (20 ml) was stirred at ambient temperaturefor 3 hours. The solvent was evaporated and the residue was partitionedbetween ethyl acetate and a saturated aqueous sodium bicarbonatesolution. The organic phase was washed with brine, dried over magnesiumsulphate and evaporated. There was thus obtained6-chloro-2,3-methylenedioxyaniline (0.642 g); NMR Spectrum: (DMSOd₆)5.15 (s, 2H), 6.0 (s, 2H), 6.25 (d, 1H), 6.75 (d, 1H).

[31] The reactants were5-[N-(tert-butoxycarbonyl)piperidin-1-ylmethoxy]-4-chloro-7-methoxyquinazoline(0.4 g) and 6-chloro-(2,3-methylenedioxy)aniline (0.089 g). Afterbasification and purification by column chromatography, the reactionproduct was suspended in a 2M solution of hydrogen chloride in diethylether (15 ml) and stirred at ambient temperature for 3 hours. Theresultant solid was isolated, washed with diethyl ether and dried undervacuum. The dihydrochloride salt so obtained gave the following data:NMR Spectrum: (DMSOd₆) 1.4-1.6 (m, 2H), 1.95 (d, 2H), 2.3-2.4 (m, 1H),2.8-2.9 (m, 2H), 3.3 (m, 2H), 3.97 (s, 3H), 4.4 (d, 2H), 6.12 (s, 2H),6.95 (d, 1H), 7.03 (d, 1H), 7.07 (d, 1H), 7.11 (d, 1H), 8.74 (s, 1H),8.8-9.0 (m, 2H), 10.25 (br s, 1H); Mass Spectrum: M+H⁺ 443 and 445.

[32] The free base gave the following data: NMR Spectrum: (CDCl₃)1.8-1.9 (m, 4H), 1.9-2.05 (m, 2H), 2.2-2.3 (m, 2H), 2.6-2.7 (m, 4H),2.95 (m, 2H), 3.6-3.7 (m, 2H), 4.05 (m, 2H), 4.25 (m, 2H), 4.75 (m, 1H),6.05 (s, 2H), 6.6 (d, 1H), 6.71 (d, 1H), 6.84 (d, 1H), 6.97 (d, 1H), 8.5(s, 1H), 9.3 (s, 1H); Mass Spectrum: M+H⁺ 513 and 515.

The4-chloro-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material is described in Note [6] in Example 19.

[33] The free base gave the following data: NMR Spectrum: (CDCl₃)1.75-1.9 (m, 4H), 1.9-2.15 (m, 4H), 2.2-2.3 (m, 2H), 2.55 (br s, 4H),2.65 (m, 2H), 3.65 (m, 2H), 4.02 (m, 2H), 4.15 (m, 2H), 4.8 (m, 1H),6.05 (s, 2H), 6.52 (d, 1H), 6.72 (d, 1H), 6.82 (d, 1H), 6.97 (d, 1H),8.5 (s, 1H), 9.26 (s, 1H); Mass Spectrum: M+H⁺ 527 and 529.

The4-chloro-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

Using an analogous procedure to that described in Note [6] below Example19, 4-chloro-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline (0.112 g)was reacted with 1-(3-hydroxypropyl)pyrrolidine (0.062 g) to give4-chloro-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline(0.125 g); NMR Spectrum: (CDCl₃) 1.7-1.9 (m, 4H), 1.95-2.2 (m, 6H), 2.55(br s, 4H), 2.65 (m, 2H), 3.65-3.75 (m, 2H), 4.0-4.1 (m, 2H), 4.2 (m,2H), 4.75 (m, 1H), 6.6 (d, 1H), 6.95 (d, 1H), 8.8 (s, 1H); MassSpectrum: M+H⁺ 392 and 394.

[34] The free base gave the following data: NMR Spectrum: (CDCl₃)2.1-2.2 (m, 2H), 2.15-2.3 (m, 2H), 3.52-3.65 (m, 2H), 3.95-4.08 (m, 2H),4.75 (m, 1H), 5.18 (s, 2H), 6.05 (s, 2H), 6.6 (d, 1H), 6.75 (d, 1H),6.9-7.0 (m, 2H), 7.3-7.5 (m, 5H), 8.55 (s, 1H), 9.34 (s, 1H); MassSpectrum: M+H⁺ 506 and 508.

The 7-benzyloxy-4-chloro-5-tetrahydropyran-4-yloxyquinazoline used as astarting material was prepared as follows:—

Di-tert-butyl azodicarboxylate (16.3 g) was added portionwise to astirred mixture of7-benzyloxy-5-hydroxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one(17 g), 4-hydroxytetrahydropyran (5.4 g) and methylene chloride (200 ml)that had been cooled to 5° C. The mixture was allowed to warm to ambienttemperature and was stirred for 2 hours. The mixture was evaporated andthe residue was dissolved in a saturated methanolic ammonia solution.The resultant mixture was stirred at ambient temperature for 16 hours.The mixture was evaporated and the residue was triturated under diethylether. The solid so obtained was dried under vaccuum to give7-benzyloxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (12.5g); NMR Spectrum: (DMSOd₆) 1.6-1.7 (m, 2H), 1.85-1.95 (m, 2H), 3.5 (m,2H), 3.9 (m, 2H), 4.75 (m, 1H), 5.22 (s, 2H), 6.7 (d, 1H), 6.8 (d, 1H),7.3-7.5 (m, 5H), 7.9 (s, 1H); Mass Spectrum: M+H⁺ 353.

A mixture of7-benzyloxy-5-tetrahydropyran-4-yloxy-3,4dihydroquinazolin-4-one (9 g),phosphoryl chloride (2.8 ml), di-isopropylethylamine (11.4 ml) and1,2-dichloroethane (130 ml) was stirred and heated to 80° C. for 3hours. The mixture was evaporated to give7-benzyloxy-4-chloro-5-tetrahydropyran-4-yloxyquinazoline which was usedwithout further purification.

EXAMPLE 184-(2,6-dichloroanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

Sodium hexamethyldisilazane (1M solution in THF; 0.65 ml) was added to asolution of 2,6-dichloroaniline (0.105 g) in DMF (3 ml) and the mixturewas stirred at ambient temperature for 5 minutes. A solution of4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline (0.1 g) inDMF (8 ml) was added and the mixture was stirred at ambient temperaturefor 1 hour. A saturated aqueous ammonium chloride solution was added andthe mixture was extracted with ethyl acetate. The organic layer wasevaporated and the residue was purified by column chromatography onsilica using as eluent a 9:10:1 mixture of methylene chloride, ethylacetate and methanol followed by a 9:10:1 mixture of methylene chloride,ethyl acetate and a saturated methanolic ammonia solution. The materialso obtained was triturated under diethyl ether. The solid was isolatedand dried under vacuum. The material so obtained was dissolved in amixture of isopropanol (2 ml) and diethyl ether (2 ml) and 6M hydrogenchloride in isopropanol (0.11 ml) was added. The mixture was evaporatedand the residual solid was dried under vacuum. There was thus obtainedthe title compound as a dihydrochloride salt (0.06 g), a portion ofwhich was converted into the free base using an analogous procedure tothat described in Example 3. The free base gave the followingcharacterising data: NMR Spectrum: (CDCl₃) 2.0-2.1 (m, 2H), 2.15-2.25(m, 2H), 2.3 (s, 3H), 2.4 (m, 2H), 2.68 (m, 2H), 3.95 (s, 3H), 4.65 (m,1H), 6.55 (d, 1H), 6.85 (d, 1H), 7.22 (m, 1H), 7.45 (d, 2H), 8.5 (s, 1,9.3 (s, 1H); Mass Spectrum: M+H⁺ 433 and 435.

EXAMPLE 19

Using an analogous procedure to that described in Example 18, theappropriate 4-chloroquinazoline was reacted with the appropriate anilinein the presence of sodium hexamethyldisilazane to give the compoundsdescribed in Table VI. Each product was purified by way of itsdihydrochloride salt and, unless otherwise stated, a portion of eachcompound was converted to the free base using an analogous procedure tothat described in Example 3. TABLE VI

No. & Note (R¹)_(m) Q¹ (R²)_(m) [1] 7-methoxy N-methyl-2-bromo-4-chloro- piperidin-4-yl 6-fluoro [2] 7-methoxy N-methyl-4-chloro-2- piperidin-4-yl trifluoromethyl [3] 7-methoxy N-methyl-4-cyano-2- piperidin-4-yl trifluoromethyl [4] 7-(2-pyrrolidin-1-cyclopentyl 2-bromo-4-chloro- ylethoxy) 6-fluoro [5] 7-(2-pyrrolidin-1-cyclopentyl 4-chloro-2- ylethoxy) trifluoromethyl [6] 7-(2-pyrrolidin-1-4-tetrahydropyranyl 4-chloro-2- ylethoxy) trifluoromethyl [7]7-(2-pyrrolidin-1- 4-tetrahydropyranyl 2-bromo-4-chloro- ylethoxy)6-fluoroNotes[1] The free base gave the following data: NMR Spectrum: (CDCl₃)1.98-2.1 (m, 2H), 2.22 (m, 2H), 2.31 (s, 3H), 2.4 (m, 2H), 2.7 (br s,2H), 3.95 (s, 3H), 4.65 (m, 1H), 6.55 (d, 1H), 6.85 (d, 1H), 7.25 (m,1H), 7.52 (d, 1H), 8.48 (s, 1H), 9.15 (s, 1H); Mass Spectrum: M+H⁺ 495,497 and 499.[2] The free base gave the following data: NMR Spectrum: (CDCl₃)1.82-2.05 (m, 2H), 2.1-2.3 (m, 4H), 2.25 (s, 3H), 2.75 (m, 2H), 3.9 (s,3H), 4.5 (m, 1H), 6.5 (d, 1H), 6.8 (d, 1H), 7.55 (m, 1H), 7.65 (d, 1H),7.82 (d, 1H), 8.4 (s, 1H), 9.5 (s, 1H); Mass Spectrum: M+H⁺ 467 and 469.[3] The free base gave the following data: NMR Spectrum: (CDCl₃) 1.9-2.0(m, 2H), 2.15-2.25 (m, 4H), 2.3 (s, 3H), 2.85 (br s, 2H), 3.85 (s, 3H),4.55 (m, 1H), 6.6 (d, 1H), 6.9 (d, 1H), 7.88 (m, 1H), 8.0 (s, 1H), 8.3(d, 1H), 8.52 (s, 1H), 9.78 (s, 1H); Mass Spectrum: M+H⁺ 458.[4] The free base gave the following data: NMR Spectrum: (CDCl₃)1.7-1.95 (m, 8H), 2.05 (br s, 4H), 2.65 (br s, 4H), 2.95 (m, 2H), 4.25(m, 2H), 5.02 (m, 1H), 6.6 (s, 1H), 6.85 (s, 1H), 7.2 (m, 1H), 7.5 (s,1H), 8.45 (s, 1H), 9.1 (s, 1H); Mass Spectrum: M+H⁺ 549 and 551.[5] The free base gave the following data: NMR Spectrum: (CDCl₃)1.5-1.75 (m, 2H), 1.75-1.9 (m, 6H), 1.9-2.05 (m, 2H), 2.05-2.15 (m, 2H),2.62 (br s, 4H), 2.98 (m, 2H), 4.25 (m, 2H), 4.98 (m, 1H), 6.6 (s, 1H),6.85 (s, 1H), 7.55 (m, 1H), 7.65 (d, 1H), 7.85 (d, 1H), 8.45 (s, 1H),9.45 (s, 1H); Mass Spectrun: M+H⁺ 521 and 523.[6] The dihydrochloride salt gave the following data: NMR Spectum:(DMSOd₆ and CF₃CO₂D) 1.8-2.2 (m, 8H), 3.1-3.3 (m, 2H), 3.5 (t, 2H),3.6-3.75 (m, 4H), 3.95 (d, 2H), 4.6 (t, 2H), 5.1 (m, 1H), 7.0 (d, 1H),7.2 (d, 1H), 7.75 (d, 1H), 7.95 (m, 1H), 8.0 (d, 1H), 8.8 (s, 1H); MassSpectrum: M+H⁺ 537 and 539.

The4-chloro-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

Di-tert-butyl azodicarboxylate (0.99 g) was added to a stirred mixtureof 4-chloro-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline (0.75 g),triphenylphosphine (1.14 g), 1-(2-hydroxyethyl)pyrrolidine (0.372 g) andmethylene chloride (20 ml) and the mixture was stirred at ambienttemperature for 0.5 hours. The mixture was poured onto a column ofsilica and eluted initially with a 49:1 mixture of methylene chlorideand methanol followed by a 97:3 mixture of methylene chloride and asaturated methanolic ammonia solution. There was thus obtained4-chloro-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline(0.9 g); NMR Spectrum: (CDCl₃) 1.8-1.9 (m, 4H), 1.9-2.05 (m, 2H),2.1-2.2 (m, 2H), 2.6-2.7 (m, 4H), 2.97 (m, 2H), 3.65-3.75 (m, 2H),4.0-4.1 (m, 2H), 4.25 (m, 2H), 4.75 (m, 1H), 6.7 (d, 1H), 6.96 (d, 1H),9.81 (s, 1H); Mass Spectrum: M+H⁺ 378 and 380.

[7] The dihydrochloride salt gave the following data: NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 1.85-2.2 (m, 8H), 3.15-3.25 (m, 2H), 3.5-3.65 (m,2H), 3.65-3.75 (m, 4H), 4.0 (m, 2H), 4.6 (t, 2H), 5.15 (m, 1H), 7.0 (d,1H), 7.22 (d, 1H), 7.73 (m, 1H), 7.87 (d, 1H), 8.88 (s, 1H); MassSpectrum: M+H⁺ 565 and 567.

EXAMPLE 204-(2-bromo-5-methoxyanilino)-7-hydroxy-5-piperidin-4-yloxyquinazoline

A mixture of7-benzyloxy-4-(2-bromo-5-methoxyanilino)-5-piperidin-4-yloxyquinazoline(0.35 g) and trifluoroacetic acid (6 ml) was stirred and heated to 80°C. for hours. The mixture was evaporated and the residue was dissolvedin water (12 ml). The solution was basified to pH8 by the addition ofsodium bicarbonate. The resultant precipitate was isolated, washed withwater and with ethyl acetate and dried under vacuum. There was thusobtained the title compound (0.26 g); NMR Spectrum: (DMSOd₆) 1.95-2.15(m, 2H), 2.32 (d, 2H), 3.05 (t, 2H), 3.3-3.4 (m, 2H), 3.8 (s, 3H), 5.0(r, 1H), 6.75 (m, 2H), 6.85 (s, 1H), 7.6 (d, 1H), 7.98 (s, 1H), 8.4 (s,H), 9.58 (s, 1H); Mass Spectrum: M+H⁺ 445 and 447.

EXAMPLE 214-(2-chloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline

Using an analogous procedure to that described in Example 20,7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-tetrahydropyran-4-yloxyquinazoline(0.78 g) was, reacted with trifluoroacetic acid (5 ml). The reactionmixture was evaporated and the residue was triturated under diethylether. The precipitate was isolated and the solid was dissolved in amixture of methylene chloride and a saturated methanolic ammoniasolution. The mixture was evaporated and the residue was purified bycolumn chromatography on silica using a 97:3 mixture of methylenechloride and methanol as eluent. There was thus obtained the titlecompound (0.47 g); NMR Spectrum: (DMSOd₆) 1.8-1.9 (m, 2H), 2.2 (d, 2H),3.52 (t, 2H), 3.8 (s, 3H), 3.92 (m, 2H), 4.95 (m, 1H), 6.7 (s, 1H),6.75-6.85 (m, 2H), 7.5 (d, 1H), 8.12 (d, 1H), 8.4 (s, 1H), 9.85 (s, 1H);Mass Spectrum: M+H⁺ 402 and 404.

EXAMPLE 224-(2-chloro-5-methoxyanilino)-7-[(2R)-2-hydroxy-3-morpholinopropoxy]-5-tetrahydropyran-4-yloxyquinazoline

A mixture of4-(2-chloro-5-methoxyanilino)-7-[(2R)-2,3-epoxypropoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.08 g), morpholine (0.044 ml), ethanol (1 ml) and chloroform (1 ml)was stirred and heated to 45° C. for 16 hours. The mixture was cooled toambient temperature and evaporated. The residue was triturated underpentane. The resultant solid was isolated, washed with diethyl ether anddried under vacuum to give the title compound (0.08 g); NMR Spectrum:(DMSOd₆ and CF₃CO₂D) 1.9-2.05 (m, 2H), 2.15 (d, 2H), 3.1-3.45 (m, 5H),3.45-3.6 (m, 3H), 3.7-3.9 (m, 2H), 3.8 (s, 3H), 3.9-4.1 (m, 2H), 4.22 m,1H), 4.45 (m, 11), 5.15 (m, 1H), 6.95 (s, 1H), 7.02 (in, 1H), 7.15 (s,1H), 7.5-7.6 (m, 2H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 545 and 547.

The4-(2-chloro-5-methoxyanilino)-7-[(2R)-2,3-epoxypropoxy]-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:

Caesium fluoride (0.213 g) and (2R)-(−)-glycidyl tosylate (0.119 g) wereadded in turn to a solution of4-(2-chloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline(0.19 g) in DMA (2 ml) and the reaction mixture was stirred and heatedto 50° C. for 4.5 hours. The mixture was evaporated and the residue waspartitioned between ethyl acetate and a saturated aqueous sodiumbicarbonate solution. The organic layer was washed with water and withbrine, dried over magnesium sulphate and evaporated. The residue waspurified by column chromatography on silica using a 49:1 mixture ofmethylene chloride and methanol as eluent. There was thus obtained4-(2-chloro-5-methoxyanilino)-7-[(2R)-2,3-epoxypropoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.155 g); NM Spectrum: (CDCl₃) 2.0-2.1 (m, 2H), 2.25 (d, 2H), 2.8 (m,1H), 2.98 (m, 1H), 3.45 (br s, 1H), 3.6 (t, 2H), 3.85 (s, 3H), 3.95-4.1(m, 3H), 4.45 (m, 1H), 4.75 (m, 1H), 6.6-6.7 (m, 2H), 6.85 (s, 1H), 7.32(d, 1H), 8.2 (d, 1H), 8.6 (s, 1H), 9.85 (s, 1H); Mass Spectrum: M+H⁺ 458and 460.

EXAMPLE 234-(2-chloro-5-methoxyanilino)-7-[(2R)-2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline

Using an analogous procedure to that described in Example 22,4-(2-chloro-5-methoxyanilino)-7-[(2R)-2,3-epoxypropoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.07 g) was reacted with 1-methylpiperazine (0.05 ml) to give the titlecompound (0.04 g); NMR Spectrum: (DMSOd₆) 1.8-1.9 (m, 2H), 2.2 (s, 3H),2.2 (d, 2H), 2.25-2.6 (m, 10H), 3.55 (t, 2H), 3.8 (s, 3H), 3.92 (m, 2H),4.05 (m, 2H), 4.2 (m, 1H), 4.9 (d, 1H), 5.1 (m, 1H), 6.8 (m, 1H), 6.85(d, 1H), 6.95 (d, 1H), 7.5 (d, 1H), 8.12 (d, 1H), 8.5 (s, 1H), 9.9 (s,1H); Mass Spectrum: M+H⁺ 558 and 560.

EXAMPLE 244-(2-bromo-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline

A mixture of 7-acetoxy-4-chloro-5-tetrahydropyran-4yloxyquinazoline (1.7g), 2-bromo-5-methoxy aniline-(1.1 g) and isopropanol (10 ml).wasstirred and heated to 80° C. for 1 hour. The resultant precipitate wasisolated, washed with isopropanol and dried under vacuum to give7-acetoxy-4-(2-bromo-5-methoxyanilino)₅-tetrahydropyran-4-yloxyquinazolinehydrochloride (2 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.9-2.1 (m, 2H),2.17 (d, 2H), 2.38 (s, 3H), 3.5 (t, 2H), 3.8 (s, 3H), 3.95 (m, 2H), 5.1(m, 1H), 7.0 (m, 1H), 7.32 (s, 1H), 7.42 (d, 1H), 7.5 (s, 1H), 7.7 (d,1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 488 and 490.

A mixture of a portion (0.15 g) of the material so obtained and asaturated methanolic ammonia solution (5 ml) was stirred at ambienttemperature for 16 hours. The mixture was evaporated and the residue wastriturated under water. The resultant solid was isolated and dried undervacuum to give the title compound (0.091 g); NMR Spectrum: (DMSOd₆)1.8-2.0. (m, 2H), 2.15 (d, 2H), 3.52 (t, 21), 3.8 (s, 3H), 3.9 (m, 2H),4.95 (m, 1H), 6.7 (s, 1H), 6.75 (m, 1H), 6.8 (d, 1H), 7.6 (d, 1H), 7.85(d, 1H), 8.35 (s, 1H), 9.65 (s, 1H), 10.58 (s, 1H); Mass Spectrum: M+H⁺446 and 448.

The 7-acetoxy-4-chloro-5-tetrahydropyran-4-yloxyquinazoline used as astarting material was prepared as follows:—

A solution of7-acetoxy-5-tetrahydropyran-4-yloxy-3,4-dihydroquinazolin-4-one (1.52 g)in 1,2-dichloroethane (30 ml) containing phosphorus oxychloride (0.51ml) and di-isopropylethylamine (2.17 ml) was stirred and heated to 80°C. for 2 hours. The mixture was evaporated to give the required materialwhich was used without further purification.

EXAMPLE 254-(2-chloro-5-methoxyanilino)-7-hydroxy-5-tetrahydrofuran-3-yloxyquinazoline

Using an analogous procedure to that described in Example 20,7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-tetrahydrofuran-3-yloxyquinazoline(0.39 g) was reacted with trifluoroacetic acid (2.5 ml). The reactionmixture was evaporated and the residue was triturated under diethylether. The precipitate was isolated and the solid was dissolved in amixture of methylene chloride and a saturated methanolic ammoniasolution. The mixture was evaporated and the residue was purified bycolumn chromatography on silica using a 97:3 mixture of methylenechloride and methanol as eluent. There was thus obtained the titlecompound (0.47 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 2.2-2.3 (m, 1H),2.3-2.5 (m, 1H), 3.8 (s, 3H), 3.75-3.9 (m, 1H), 3.9-4.0 (m, 2H), 4.2 (d,1H), 5.5 (m, 1H), 6.8 (s, 1H), 6.92 (s, 1H), 7.02 (m, 1H), 7.55 (d, 1H),7.6 (d, 1H), 8.85 (s, 1H); Mass Spectrum: M+H⁺ 388 and 390.

EXAMPLE 264-(2-chloro-5-methoxyanilino)-7-hydroxy-5-isopropoxyquinazoline

Using an analogous procedure to that described in Example 20,7-benzyloxy-4-(2-chloro-5-methoxyanilino)-5-isopropoxyquinazoline (0.33g) was reacted with trifluoroacetic acid. There was thus obtained thetitle compound (0.17 g); NMR Spectrum: (DMSOd₆ and CF₃CO₂D) 1.55 (d,6H), 3.85 (s, 3H), 5.1 (m, 1H), 6.8 (s, 1H), 6.92 (s, 1H), 7.0 (m, 1H),7.58 (d, 1H), 7.65 (d, 1H), 8.85 (s, 1H); Mass Spectrum: M+H⁺ 360 and362.

EXAMPLE 274-(benzofuran-7-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazolinedihydrochloride

Using an analogous procedure to that described in Example 5,4-chloro-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline was reactedwith 7-aminobenzofuran to give the title compound, a portion of whichwas treated with a saturated methanolic ammonia solution. The mixturewas filtered and the filtrate was evaporated to give the free base; NMRSpectrum: (CDCl₃) 2.15-2.35 (m, 6H), 2.32 (s, 3H), 2.92 (m, 2H), 3.9 (s,3H), 4.6 (m, 1H), 6.5 (d, 1H), 6.8 (d, 1H), 6.85 (d, 1H), 7.25-7.4 (m,2H), 7.68 (d, 1H), 8.58 (d, 1H), 8.6 (s, 1H), 10.25 (br s, 1H); MassSpectrum: M+H⁺ 405.

The 7-aminobenzofuran used as a starting material was prepared asfollows

Hydrazine hydrate (0.45 ml) was added dropwise to a stirred mixture of7-nitrobenzofuran (J. Med. Chem., 1988, 31, 1934; 0.5 g), Raney nickel(0.02 g) and methanol (9 ml) that had been warmed to 55° C. Theresultant mixture was heated to reflux for 30 minutes. The catalyst wasremoved by filtration and the filtrate was evaporated. The residue waspartitioned between methylene chloride and water. The organic phase wasdried over magnesium sulphate and evaporated to give 7-aminobenzofuran(0.4 g) as an oil; NMR Spectrum: (DMSOd₆) 5.25 (br s, 2H), 6.55 (d, 1H),6.8 (m, 2H), 6.9 (t, 1H), 7.85 (d, 1H).

EXAMPLE 284-(3-chlorobenzofuran-7-ylamino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazolinedihydrochloride

Using an analogous procedure to that described in Example 5,4-chloro-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazolinewas reacted with 7-amino-3-chlorobenzofuran to give the title compound,a portion of which was treated with a saturated methanolic ammoniasolution. The mixture was filtered and the filtrate was evaporated togive the free base; NMR Spectrum: (CDCl₃) 2.07 (m, 2H), 2.1 (m, 2H),2.25 (m, 2H), 2.27 (s, 3H), 2.35-2.68 (m, 10H), 3.6 (t, 2H), 4.0-4.2 (m,4H), 4.75 (m, 1H), 6.52 (s, 1H), 6.85 (s, 1H), 7.35 (m, 2H), 7.65 (s,1H), 8.6 (s, 1H), 8.7 (d, 1H), 10.3 (s, 1H); Mass Spectrum: M+H⁺ 522 and524.

EXAMPLE 294-(2,4-dichloro-5-methoxyanilino)-7-(3-piperazin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazolinedihydrochloride

A mixture of4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-tert-butoxycarbonylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.12 g) and trifluoroacetic acid (2 ml) was stirred at ambienttemperature for 2 hours. The mixture was evaporated and the residue wastriturated under diethyl ether. The resultant solid was isolated anddried under vacuum. The solid was dissolved in diethyl ether and 6Mhydrogen chloride gas in diethyl ether (0.5 ml) was added. The resultantsolid was isolated, washed with diethyl ether and dried under vacuum.There was thus obtained the title compound (0.112 g); NMR Spectrum:(DMSOd₆ and CF₃CO₂H) 1.9-2.1 (m, 2H), 2.15 (d, 2H), 2.28-2.4 (m, 2H),3.4 (m, 2H), 3.4-3.9 (m, 10H), 3.92 (s, 3H), 3.95 (m, 2H), 4.39 (t, 2H),5.2 (m, 1H), 7.0 (d, 1H), 7.2 (d, 1H), 7.78 (s, 1H), 7.82 (s, 1H), 8.9(s, 1H); Mass Spectrum: M+H⁺ 562 and 564.

The4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-tert-butoxycarbonylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:—

Using an analogous procedure to that described in Example 12,4-(2,4-dichloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline(0.109 g) was reacted with1-tert-butoxycarbonyl-4-(3-hydroxypropyl)piperazine (0.074 g) to give4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-tert-butoxycarbonylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline(0.12 g).

EXAMPLE 304-(2,4-dichloro-5-methoxyanilino)-7-piperidin-4-ylmethoxy-5-tetrahydropyran-4yloxyquinazoline

A mixture of4-(2,4-dichloro-5-methoxyanilino)-7-(1-tert-butoxycarbonylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline(0.11 g) and trifluoroacetic acid (2 ml) was stirred at ambienttemperature for 2 hours. The mixture was evaporated and the residue wastriturated under diethyl ether. The resultant solid was isolated anddried under vacuum. The solid was dissolved in diethyl ether and 6Mhydrogen chloride gas in diethyl ether (0.5 ml) was added. The resultantsolid was isolated, washed with diethyl ether and dried under vacuum.There was thus obtained the dihydrochloride salt of the title compound.The solid was dissolved in methylene chloride and few drops of asaturated methanolic ammonia solution was added. The solution was pouredonto a chromatography column filled with silica and eluted with a 24:1mixture of methylene chloride and a saturated methanolic ammoniasolution. There was thus obtained the title compound (0.08 g); NMRSpectrum: (CDCl₃) 1.9-2.1 (m, 2H), 1.95 (d, 2H), 1.9-2.15 (m, 3H), 2.52(d, 2H), 2.7 (m, 2H), 3.2 (d, 2H), 3.6 (m, 2H), 3.9-4.0 (m, 2H), 4.05(s, 3H), 4.1 (td, 2H), 4.75 (m, 1H), 6.6 (d, 1H), 6.85 (m, 1H), 7.45 (s,1H), 8.4 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H⁺ 533 and 535.

The4-(2,4-dichloro-5-methoxyanilino)-7-(1-tert-butoxycarbonylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:—

Using an analogous procedure to that described in Example 12,4-(2,4-dichloro-5-methoxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline(0.109 g) was reacted with 1-tert-butoxycarbonylpiperidin-4-ylmethanol(0.065 g) to give4-(2,4-dichloro-5-methoxyanilino)-7-(1-tert-butoxycarbonylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline(0.11 g).

EXAMPLE 314-(6-chloro-2,3-methylenedioxyanilino)-7-fluoro-5-piperidin-4-yloxyquinazolinedihydrochloride

A mixture of5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-fluoroquinazolinedihydrochloride (0.12 g) and a 2M solution of hydrogen chloride indiethyl ether (5 ml) was stirred at ambient temperature for 1 hour. Theresultant precipitate was isolated, washed with diethyl ether and driedunder vacuum. There was thus obtained the title compound (0.086 g); NMRSpectrum: (DMSOd₆) 2.1-2.3 (m, 4H), 3.0-3.15 (m, 2H), 3.3 (m, 2H), 5.1(m, 1H), 6.12 (s, 2H), 7.01 (d, 1H), 7.1 (d, 1H), 7.3 (d, 1H), 7.53 (d,1H), 8.75 (s, 1H), 9.05 (br s, 1H), 9.3 (br s, 1H), 9.95 (br s, 1H);Mass Spectrum: M+H⁺ 417 and 419.

The5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-fluoroquinazolinedihydrochloride used as a starting material was prepared as follows:—

Sodium hydride (60% dispersion in mineral oil; 0.55 g) was addedportionwise to a solution of tert-butyl 4hydroxypiperidine-1-carboxylate(1.65 g) in DMF (10 ml) and the resultant mixture was stirred at ambienttemperature for 15 minutes. 5,7-Difluoro-3,4-dihydroquinazolin-4-one (1g) was added and the mixture was stirred at ambient temperature for 30minutes. The mixture was poured into water (100 ml) and, with vigorousstirring, glacial acetic acid was added to acidify the mixture to pH5.The resultant solid was isolated, washed with water and with diethylether and dried under vacuum. There was thus obtained5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-7-fluoro-3,4-dihydroquinazolin-4-one(1.4 g); NMR Spectrum: (CDCl₃) 1.47 (s, 9H), 1.94 (m, 4H), 3.5-3.8 (m,4H), 4.7 (m, 1H), 6.68 (m, 1H), 7.0 (m, 1H), 7.9 (s, 1H), 10.55 (br s,1H); Mass Spectrum: M+H⁺ 364.

A mixture of5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-7-fluoro-3,4-dihydroquinazolin-4-one(0.15 g), triphenylphosphine (0.216 g), carbon tetrachloride (0.12 ml)and 1,2-dichloroethane (5 ml) was stirred and heated to 70° C. for 1hour. The mixture was evaporated and the residue was purified by columnchromatography on silica using a 9:1 mixture of methylene chloride andethyl acetate as eluent. There was thus obtained5-(1-tert-butoxycarbonylpiperidin-4-yloxy) chloro-7-fluoroquinazoline(0.1 g); NMR Spectrum: (CDCl₃) 1.48 (s, 9H), 2.0 (m, 4H), 3.5-3.7 (m,4H), 4.8 (m, 1H), 6.8 (m, 1H), 7.3 (m, 1H), 8.9 (s, 1H); Mass Spectrum:M+H⁺ 382 and 384.

A mixture of the material so obtained,6-chloro-2,3-methylenedioxyaniline (0.049 g), 5M hydrogen chloride inisopropanol (1 drop) and isopropanol (1 ml) was stirred and heated to50° C. for 15 minutes and then to 80° C. for 45 minutes. The precipitatewas isolated, washed in turn with isopropanol, ethyl acetate and diethylether and dried under vacuum. There was thus obtained5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-fluoroquinazolinedihydrochloride (0.065 g); NMR Spectrum: (DMSOd₆) 1.4 (s, 9H), 1.8-2.0(m, 2H), 2.0-2.15 (m, 2H), 3.05 (br s, 2H), 3.9 (d, 2H), 5.05 (m, 1H),6.11 (s, 2H), 7.1 (d, 1H), 7.16 (d, 1H), 7.2 (m, 1H), 7.52 (d, 1H), 8.7(s, 1H), 9.92 (br s, 1H); Mass Spectrum: M+H⁺ 517 and 519.

EXAMPLE 324-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-yloxyquinazolinedihydrochloride

Using an analogous procedure to that described in Example 31,5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)quinazolinedihydrochloride (0.14 g) was reacted with hydrogen chloride to give thetitle compound (0.113 g); NMR Spectrum: (DMSOd₆) 2.15-2.34 (m, 4H), 3.15(m, 2H), 3.3 (m, 2H), 5.17 (m, 1H), 6.17 (s, 2H), 7.07 (d, 1H),7.16 (d,1H), 7.58 (m, 1H), 8.06 (m, 1H), 8.88 (s, 1H), 9.14 (br s, 1H), 9.32 (brs, 1H), 10.28 (s, 1H); Mass Spectrum: M+H⁺ 399 and 401.

The5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6chloro-2,3-methylenedioxyanilino)quinazolinedihydrochloride used as a starting material was prepared as followsusing analogous procedures to those described in the portion of Example31 that is concerned with the preparation of starting materials:—

Thus, tert-butyl 4-hydroxypiperidine-1-carboxylate (0.33 g) was reactedwith 5-fluoro-3,4-dihydroquinazolin-4-one (0.18 g) to give5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(0.39 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.9-2.0 (m, 4H), 3.52 (m,2H), 3.7 (m, 2H), 4.72 (m, 1H), 6.95 (d, 1H), 7.32 (d, 1H), 7.65 (m,1H), 7.95 (s, 1H), 10.22 (br s, 1H); Mass Spectrum: M+H⁺ 346;

5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(0.31 g) was reacted with triphenylphosphine and carbon tetrachloride togive 5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-chloroquinazoline(0.156 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.9-2.1 (m, 4H), 3.5-3.8(m, 4H), 4.8 (m, 1H), 7.05 (d, 1H), 7.65 (d, 1H), 7.82 (m, 1H), 8.95 (s,1H); Mass Spectrum: M+H⁺ 364 and 366; and

-   -   a portion (0.124 g) of the material so obtained and        6-chloro-2,3-methylenedioxyaniline (0.064 g) were reacted to        give        5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)quinazoline        dihydrochloride (0.14 g); NMR Spectrum: (DMSOd₆) 1.4 (s, 9H),        1.85-2.0 (m, 2H), 2.1 (m, 2H), 2.95-3.2 (m, 2H), 3.92 (d, 2H),        5.1 (m, 1H), 6.15 (s, 2H), 7.08 (d, 1H), 7.15 (d, 1H), 7.55 (d,        1H), 7.6 (d, 1H), 8.05 (m, 1H), 8.86 (s, 1H), 10.35 (s, 1H);        Mass Spectrum: M+H⁺ 499 and 501.

EXAMPLE 334-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-yloxyquinazoline

A mixture of5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxyquinazolinedihydrochloride (2.39 g), trifluoroacetic acid (10 ml) and methylenechloride (35 ml) was stirred at ambient temperature for 1.5 hours. Themixture was evaporated and the residue was partitioned between ethylacetate and a 1N aqueous sodium hydroxide solution. The organic layerwas washed with water and brine, dried over magnesium sulphate andevaporated. The residue was purified by column chromatography on silicausing a 19:1 mixture of methylene chloride and methanol as eluent. Therewas thus obtained the title compound (1.44 g); NMR Spectrum: (CDCl₃)1.8-2.0 (m, 2H), 2.15-2.3 (m, 2H), 2.75-2.9 (m, 2H), 3.1-3.2 (m, 2H),3.9 (s, 3H), 4.65 (m, 1H), 6.0 (s, 2H), 6.46 (d, 1H), 6.72 (d, 1H), 6.8(d, 1H), 6.91 (d, 1H), 8.5 (s, 1H), 9.21 (s, 1H); Mass Spectrum: M+H⁺429 and 431.

The5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxyquinazolinedihydrochloride used as a starting material was prepared as follows:—

Di-tert-butyl azodicarboxylate (1.13 g) was added portionwise to astirred mixture of5-hydroxy-7-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (1g), tert-butyl 4-hydroxypiperidine-1-carboxylate (0.788 g),triphenylphosphine (1.28 g) and methylene chloride (155 ml) which hadbeen cooled to 10° C. The mixture was allowed to warm to ambienttemperature and was stirred for 1 hour. The mixture was evaporated andthe residue was dissolved in methanol (25 ml). Sodium hydroxide (0.2 g)was added and the mixture was stirred at ambient temperature for 1 hour.The resultant mixture was evaporated and the residue was purified bycolumn chromatography on silica using a 47:50:3 mixture of methylenechloride, ethyl acetate and methanol as eluent. There was thus obtained5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-7-methoxy-3,4-dihydroquinazolin-4-one(1.09 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.87-2.0 (m, 4H), 3.48-3.6(m, 2H), 3.6-3.75 (m, 2H), 3.9 (s, 3H), 4.65 (m, 1H), 6.5 (d, 1H), 6.77(d, 1H), 7.91 (s, 1), 10.7 (br s, 1H); Mass Spectrum: M+H⁺ 376.

Using an analogous procedure to that described in the portion of Example31 that is concerned with the preparation of starting materials,5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-7-methoxy-3,4-dihydroquinazolin-4-one(1 g) was reacted with triphenylphosphine and carbon tetrachloride togive5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-chloro-7-methoxyquinazoline(0.8 g); NMR Spectrum: (CDCl₃) 1.5 (s, 9H), 1.9-2.1 (m, 4H), 3.5-3.7 (m,4H), 3.96 (s, 3H), 4.72 (m, 2H), 6.6 (d, 1H), 6.98 (d, 1H), 8.82 (s,1H); Mass Spectrum: M+H⁺ 394 and 396.

Using an analogous procedure to that also described in the portion ofExample 31 that is concerned with the preparation of starting materials,5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4chloro-7-methoxyquinazoline(0.14 g) and 6-chloro-2,3-methylenedioxyaniline (0.064 g) were reactedto give5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxyquinazolinedihydrochloride (0.17 g); NMR Spectrum: (DMSOd₆) 1.42 (s, 9H), 1.8-2.0(m, 2H), 2.0-2.15 (m, 2H), 3.0-3.2 (m, 2H), 3.85-3.95 (m, 2H), 3.99 (s,3H), 5.1 (m, 1H), 6.96 (d, 1H), 7.05 (d, 1H), 7.12 (s, 1H), 7.15 (d,1H), 8.78 (s, 1H), 10.1 (s, 1H); Mass Spectrum: M+H⁺ 529 and 531.

EXAMPLE 344-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-piperidin-4-yloxyquinazoline

A mixture of7-benzyloxy-5-[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)quinazolinedihydrochloride (2.3 g) and trifluoroacetic acid (28 ml) was stirred andheated to 80° C. for 6 hours. The mixture was evaporated and the residuewas dissolved in water and the solution was basified to pH10 by theaddition of 1N aqueous sodium hydroxide solution. The mixture wasstirred at ambient temperature for 1 hour. The solid was isolated,washed with water and dried under vacuum. There was thus obtained thetitle compound (1.1 g); NMR Spectrum: (DMSOd₆) 1.6-1.8 (m, 2H), 2.0-2.15(m, 2H), 2.65-2.75 (m, 2H), 2.9-3.05 (m, 2H), 4.8 (m, 1H), 6.1 (s, 2H),6.62 (s, 1H), 6.7 (s, 1H), 6.92 (d, 1H), 7.05 (d, 1H), 8.25 (s, 11), 9.2(s, 1H); Mass Spectrum: M+H⁺ 415 and 417.

EXAMPLE 355[N-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazoline

A mixture of4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-piperidin-4-yloxyquinazoline(1.4 g), di-tert-butyl dicarbonate (0.737 g) and DMF (14 ml) was stirredat ambient temperature for 2 hours. The mixture was evaporated and theresidue was partitioned between ethyl acetate and water. The organicphase was washed with brine, dried over magnesium sulphate andevaporated. The residue was purified by column chromatography on silicausing a 24:1 mixture of methylene chloride and methanol as eluent. Therewas thus obtained the title compound (1.2 g); NMR Spectrum: (CDCl₃) 1.5(s, 9H), 1.7-1.9 (m, 2H), 2.0-2.15 (m, 2H), 3.0-3.15 (m, 2H), 3.8-3.95(m, 2H), 4.6 (m, 1H), 6.02 (s, 2H), 6.55 (s, 1H), 6.72 (d, 1H), 6.98 (m,2H), 8.4 (s, 1H), 9.4 (s, 1H); Mass Spectrum: M+H⁺ 515 and 517.

EXAMPLE 364-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-yloxy-7-(2,2,2-trifluoroethoxy)quinazoline

A mixture of5-[N-tert-butoxycarbonyl)piperidin-4-yloxy]-4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxyquinazoline(0.15 g), 2,2,2-trifluoroethyl 4-toluenesulphonate-(0.089 g), potassiumcarbonate (0.1 g) and DMF (3 ml) was stirred and heated to 95° C. for 24hours. The mixture was cooled to ambient temperature and partitionedbetween ethyl acetate and water. The organic solution was washed with 1Naqueous sodium hydroxide solution and with brine and dried overmagnesium sulphate. The organic solution was filtered and a 6N solutionof hydrogen chloride in diethyl ether (2 ml) was added. The mixture wasstirred at ambient temperature for 16 hours. The mixture was evaporated.The residue was dissolved in methylene chloride (3 ml) and a saturatedmethanolic ammonia solution (1 ml) was added. The mixture was filteredand the filtrate was evaporated. The residue was purified by columnchromatography on silica using a 19:1 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. There was thusobtained the title compound (0.061 g); NMR Spectrum: (CDCl₃) 1.85-2.0(m, 2H), 2.3 (m, 2H), 2.8-2.95 (m, 2H), 3.1-3.3 (m, 2H), 4.5 (m, 2H),4.72 (m, 1H), 6.08 (s, 2H), 6.6 (d, 1H), 6.75 (d, 1H), 6.82 (d, 1H), 7.0(d, 1H), 8.58 (s, 1H), 9.32 (s, 1H); Mass Spectrum: M+H⁺ 497 and 499.

EXAMPLE 374-(6-chloro-2,3-methylenedioxyanilino)-5-(N-methylpiperidin-4yloxy)quinazoline

4-Hydroxy-1-methylpiperidine (0.049 g) was added to a stirred suspensionof sodium hydride (60% dispersion in mineral oil, 0.043 g) in DMF (2 ml)and the mixture was stirred at ambient temperature for 5 minutes. Thedihydrochloride salt of4-(6-chloro-2,3-methylenedioxyanilino)-5-fluoroquinazoline was treatedwith a saturated methanolic ammonia solution to give the free base (0.1g) which was added to the above-mentioned solution of the sodium salt of4-hydroxy-1-methylpiperidine. The resultant mixture was stirred andheated to 50° C. for 30 minutes. The mixture was cooled to ambienttemperature and partitioned between ethyl acetate and water. The organiclayer was washed with water and with brine, dried over magnesiumsulphate and evaporated. The residue was purified by columnchromatography on silica using a 25:24:1 mixture of ethyl acetate,methylene chloride and a saturated methanolic ammonia solution aseluent. There was thus obtained4-(6-chloro-2,3-methylenedioxyanilino)-5-(h-methylpiperidin-4-yloxy)quinazoline(0.054 g); NMR Spectrum: (CDCl₃) 1.95-2.1 (m, 2H), 2.1-2.25 (m, 2H), 2.3(s, 3H), 2.3-2.4 (m, 2H), 2.7 (br s, 2H), 4.65 (m, 1H), 6.01 (s, 2H),6.7 (d, 1H), 6.8 (d, 1H), 6.85 (d, 1H), 7.45 (d, 1H), 7.6 (m, 1H), 8.56(s, 1H), 9.5 (br s, 1i); Mass Spectrum: M+H⁺ 413 and 415.

The 4-(6-chloro-2,3-methylenedioxyanilino)-5-fluoroquinazolinedihydrochloride used as a starting material was prepared was prepared asfollows using analogous procedures to those described in the portion ofExample 31 that is concerned with the preparation of startingmaterials:—

Thus, 5-fluoro-3,4 dihydroquinazolin-4-one (2 g) was reacted withtriphenylphosphine and carbon tetrachloride to give5-fluoro-4-chloroquinazoline (1.34 g); NMR Spectrum: (CDCl₃) 7.4-7.5 (m,1H), 7.9-8.0 (m, 2H), 9.1 (s, 1H); and

-   -   a portion (0.4 g) of the material so obtained and        6-chloro-2,3-methylenedioxyaniline (0.413 g) were reacted to        give 4-(6-chloro-2,3-methylenedioxyanilino)-5-fluoroquinazoline        dihydrochloride (0.73 g); NMR Spectrum: (DMSOd₆) 6.18 (s, 2H),        7.05 (d, 1H), 7.12 (d, 1H), 7.7 (m, 1i), 7.85 (d, 1H), 8.12 (m,        1), 8.87 (s, 1H); Mass Spectrum: M+H⁺ 318 and 320.

EXAMPLE 384-(6-chloro-2,3-methylenedioxyanilino)-7-isopropoxy-5-(N-methylpiperidin-4-yloxy)quinazoline

Sodium triacetoxyborohydride (0.087 g) was added portionwise to astirred mixture of4-(6-chloro-2,3-methylenedioxyanilino)-7-isopropoxy-5-piperidin-4-yloxyquinazoline(0.125 g), aqueous formaldehyde (13N, 0.042 ml), acetic acid (0.019 ml),methylene chloride (5 ml) and methanol (2 ml) and the resultant mixturewas heated to reflux for 3 minutes. The mixture was evaporated and theresidue was partitioned between ethyl acetate and 1N aqueous, sodiumhydroxide solution. The organic layer was washed with brine, dried overmagnesium sulphate and evaporated to give the title compound (0.11 g);NMR Spectrum: (CDCl₃) 1.42 (d, 6H), 1.95-2.1 (m, 2H), 2.15-2.25 (m, 2H),2.3 (s, 3H), 2.3-2.4 (m, 2H), 2.7-2.8 (m, 2H), 4.6 (m, 1H), 4.72 (m,1H), 6.05 (s, 2H), 6.5 (d, 1H), 6.75 (d, 1H), 6.82 (d, 1H), 6.99 (d,1H), 8.52 (s, 1H), 9.3 (s, 1H); Mass Spectrum: M+H⁺ 471 and 473.

EXAMPLE 394-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-ylmethoxyquinazolinedihydrochloride

Using an analogous procedure to that described in Example 37,N-(tert-butoxycarbonyl)piperidin-4-ylmethanol was reacted with4-(6-chloro-2,3-methylenedioxyanilino)-5-fluoroquinazoline (0.1 g). Theproduct so obtained was dissolved in a 2M solution of hydrogen chloridein diethyl ether (20 ml) and stirred at ambient temperature for 3 hours.The mixture was evaporated and the residue was triturated under diethylether. The solid so obtained was washed with diethyl ether and driedunder vacuum. There was thus obtained the tilte compound (0.121 g); NMRSpectrum: (DMSOd₆) 1.5-1.6 (m, 2H), 1.9-2.0 (m, 2H), 2.3-2.4 (m, 1H),2.8-2.9 (m, 2H), 3.3 (d, 2H), 4.42 (d, 2H), 6.15 (s, 2H), 7.07 (d, 1H),7.15 (d, 1H), 7.53 (m, 2H), 8.06 (m, 1H), 8.87 (s, 1H), 10.57 (br s,1H); Mass Spectrum: M+H⁺ 413 and 415.

EXAMPLE 404-(6-chloro-2,3-methylenedioxyanilino)₅-(N-methylpiperidin-4-ylmethoxy)quinazolinedihydrochloride

Using an analogous procedure to that described in Example 38,4-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-ylmethoxyquinazoline(obtained from the dihydrochloride salt by trituration under a saturatedmethanolic ammonia solution) was reacted with aqueous formaldehyde andsodium triacetoxyborohydride. The reaction product, obtained as the freebase, was triturated under a 2M solution of hydrogen chloride in diethylether. The resultant precipitate was isolated, washed with diethyl etherand dried under vacuum. There was thus obtained the title compound, aportion of which was converted to the free base by trituration under asaturated methanolic ammonia solution. The free base gave the followingdata: NMR Spectrum: (CDCl₃) 1.35-1.55 (m, 2H), 1.9-2.1 (m, 5H), 2.3 (s,3H), 2.9 (d, 2H), 4.12 (d, 2H), 6.04 (s, 2H), 6.75 (d, 1H), 6.9 (d, 1H),6.98 (d, 1H), 7.48 (d, 1H), 7.64 (m, 1H), 8.62 (s, 1H), 9.38 (s, 1H);Mass Spectrum: M+H⁺ 427 and 429.

EXAMPLE 414-(6-chloro-2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline

A mixture of7-(3-bromopropoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-tetrahydropyran-4-yloxyquinazoline(0.536 g), piperidine (0.12 ml), potassium carbonate (0.4 g) and DMF (2ml) was stirred at ambient temperature for 16 hours. The mixture wasevaporated and the residue was triturated under methylene chloride. Themixture was filtered and the filtrate was purified by columnchromatography on silica using initially a 1:1 mixture of ethyl acetateand methylene chloride and then a 10:9:1 mixture of ethyl acetate,methylene chloride and a saturated methanolic ammonia solution aseluent. There was thus obtained the title compound (0.53 g); NMRSpectrum: (CDCl₃) 1.4-1.5 (m, 2H), 1.55-1.7 (m, 4H), 1.9-2.1 (m, 4H),2.2-2.3 (m, 2H), 2.4 (m, 4H), 2.5 (m, 2H), 3.6-3.7 (m, 2H), 4.0-4.1 (m,2H), 4.15 (m, 2H), 4.8 (m, 1H), 6.08 (s, 2H), 6.52 (d, 1H), 6.75 (d,1H), 6.85 (d, 1H), 7.0 (d, 1H), 8.55 (s, 1H), 9.35 (s, 1H); MassSpectrum: M+H⁺ 541 and 543.

The7-(3-bromopropoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-tetrahydropyran-4-yloxyquinazolineused as a starting material was prepared as follows:—

Di-tert-butyl azodicarboxylate (1.66 g) was added to a stirred mixtureof 4-(6chloro2,3-methylenedioxyanilino)-7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline(1.5 g), 3-bromopropan-1-ol (0.49 ml), triphenylphosphine (1.9 g) andmethylene chloride (20 ml) and the mixture was stirred at ambienttemperature for 1 hour. A second portion (1.66 g) of di-tert-butylazodicarboxylate was added and the mixture was stirred at ambienttemperature for 16 hours. The mixture was filtered and the filtrate waspurified by column chromatography on silica using initially a 1:1mixture of ethyl acetate and methylene chloride and then a 25:24:1mixture of ethyl acetate, methylene chloride and methanol as eluent. Thematerial so obtained was triturated under diethyl ether. The resultantsolid was isolated, washed with diethyl ether and dried under vacuum togive the required starting material (0.536 g).

EXAMPLE 42

Using an analogous procedure to that described in Example 41, theappropriate haloalkoxy substituted quinazoline was reacted with theappropriate amine to give the compound described in Table VII. TABLE VII

No. & Note (R¹)_(m) Q¹ (R²)_(n) [1] 7-[3-(4-hydroxy-piperidin-4-tetrahydro- 6-chloro-2,3- 1-yl)propoxy] pyranyl methylenedioxyNote[1] 4-Hydroxypiperidine was used as the amine. The product gave thefollowing data: NMR Spectrum: (CDCl₃) 1.5-1.7 (m, 2H), 1.85-2.05 (m,6H), 2.05-2.25 (m, 4H), 2.5 (m, 2H), 2.8 (m, 2H), 3.55-3.65 (m, 2H), 3.6(m, 1H), 3.95-4.05 (m, 2H), 4.12 (m, 2H), 4.75 (m, 1H), 6.05 (s, 2H),6.5 (s, 1H), 6.7 (d, 1H), 6.8 (d, 1H), 6.95 (d, 1H), 8.5 (s, 1H), 9.25(s, 1H); Mass Spectrum: M+H⁺ 557 and 559.

EXAMPLE 434-(6-chloro-2,3-methylenedioxyanilino)-7-piperidin-4-ylmethoxy-5-tetrahydropyran-4-yloxyquinazoline

A mixture of7-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-tetrahydropyranyloxyquinazoline(0.25 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) wasstirred at ambient temperature for 1.5 hours. The mixture was evaporatedand the residue was purified by column chromatography on silica using a93:7 mixture of methylene chloride and a saturated methanolic ammoniasolution as eluent. The material so obtained was partitioned betweenethyl acetate and an aqueous ammonium hydroxide solution. The organiclayer was dried over magnesium sulphate and evaporated. There was thusobtained the title compound (0.07 g); NMR Spectrum: (CDCl₃ and D₂O)1.5-1.7 (m, 2H), 1.9-2.1 (m, 4H), 2.2-2.3 (m, 2H), 2.8 (m, 2H), 3.32 (d,2H), 3.65 (m, 2H), 3.9-4.1 (m, 3H), 4.8 (m, 1H), 6.08 (s, 2H), 6.52 (brs, 1H), 6.72 (d, 1H), 6.8 (s, 1H), 6.98 (d, 1H), 8.5 (s, 1H); MassSpectrum: M+H⁺ 513 and 515.

EXAMPLE 444-(6-chloro-2,3-methylenedioxyanilino)-7-(N-methylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline

A mixture of7-[N-(tert-butoxycarbonyl)piperidin-4-ylmethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-tetrahydropyran-4-yloxyquinazoline(0.25 g), a concentrated aqueous formaldehyde solution (37%, 0.5 ml) andformic acid (5 ml) was stirred and heated to 100° C. for 2 hours. Themixture was cooled to ambient temperature and evaporated. The residuewas purified by column chromatography on silica using a 24:1 mixture ofmethylene chloride and a saturated methanolic ammonia solution aseluent. The material so obtained was partitioned between methylenechloride and an aqueous ammonium hydroxide solution. The organic layerwas dried over magnesium sulphate and evaporated. There was thusobtained the title compound (0.1 g); NMR Spectrum: (CDCl₃) 1.4-1.6 (m,2H), 1.75-1.9 (m, 3H), 1.9-2.1 (m, 4H), 2.2-2.3 (m, 2H), 2.29 (s, 3H),2.9 (d, 2H), 3.6-3.7 (m, 2H), 3.95 (d, 2H), 4.0-4.1 (m, 2H), 4.75 (m,1H), 6.05 (s, 2H), 6.5 (d, 1H), 6.72 (d, 1H), 6.81 (d, 1H), 6.97 (d,1H), 8.5 (s, 11, 9.26 (s, 1H); Mass Spectrum: M+H⁺ 527 and 529.

EXAMPLE 454-(6-chloro-2,3-methylenedioxyanilino)-7-[(2R)-2,3-epoxypropoxy]-5-tetrahydropyran-4-yloxyquinazoline

Caesium fluoride (0.46 g) and (2R)-(−)-glycidyl tosylate (0.275 g) wereadded in turn to a solution of4-(6-chloro-2,3-methylenedioxyanilino)-7-fluoro-5-tetrahydropyran-4-yloxyquinazoline(0.416 g) in DMF (5 ml) and the reaction mixture was stirred and heatedto 60° C. for 2 hours and to 70° C. for a further 1.5 hours. The mixturewas evaporated and the residue was partitioned between ethyl acetate anda saturated aqueous sodium bicarbonate solution. The organic layer waswashed with water and with brine, dried over magnesium sulphate andevaporated. The residue was purified by column chromatography on silicausing a 49:1 mixture of methylene chloride and methanol as eluent. Therewas thus obtained the title compound (0.36 g); NMR Spectrum: (CDCl₃)1.9-2.1 (m, 2H), 2.2-2.3 (m, 2H), 2.8 (m, 1H), 2.98 (m, 1H), 3.42 (m,1H), 3.6-3.7 (m, 2H), 3.95-4.1 (m, 3H), 4.45 (m, 1H), 4.8 (m, 1H), 6.02(s, 2H), 6.59 (m, 12H), 6.72 (d, 1H), 6.81 (d, 1H), 6.97 (d, 1H), 8.5(s, 1H), 9.27 (s, 1H); Mass Spectrum: M+H⁺ 472 and 474.

EXAMPLE 464-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-cyanomethylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline

A mixture of4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-piperazin-1-ylpropoxy)-5-tetrahydropyran-4yloxyquinazoline(1.3 g), 2-chloroacetonitrile (0.167 ml), sodium iodide (0.036 g),potassium carbonate (0.331 g) and DMF (15 ml) was stirred at ambienttemperature for 5 hours. The mixture was evaporated and the residue waspartitioned between ethyl acetate and water. The organic phase waswashed with brine, dried over magnesium sulphate and evaporated. Theresidue was purified by column chromatography on silica using a 10:9:1mixture of ethyl acetate, methylene chloride and methanol as eluent.There was thus obtained the title compound (0.69 g); NMR Spectrum:(CDCl₃) 1.85-2.0 (m, 4H), 2.1 (m, 2H), 2.4-2.5 (m, 6H), 2.5-2.6 (m, 4H),3.42 (s, 2H), 3.5-3.6 (m, 2H), 3.9-4.0 (m, 2H), 4.0-4.1 (m, 2H), 4.7 (m,1H), 6.0 (s, 2H), 6.42 (s, 1H), 6.65 (d, 1H), 6.78 (d, 1H), 6.9 (d, 1H),8.42 (s, 1H), 9.2 (s, 1H); Mass Spectrum: M+H⁺ 581 and 583.

EXAMPLE 474-(6-chlorobenzofuran-7-ylamino)-7-(2-pyrrolidin-1-ylethoxy)-5-cyclopentyloxyquinazolinedihydrochloride

Sodium hexamethyldisilazane (1M solution in THF; 0.55 ml) was added to asolution of 7-amino-6-chlorobenzofuran (0.093 g) in DMF (3 ml) which wascooled to 10° C. and the mixture was stirred at 10° C. for 5 minutes. Asolution of4chloro-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline (0.1 g)in DMF-(8 ml)-was added and the mixture was stirred at ambienttemperature for 1 hour. The mixture was partitioned between ethylacetate and water. The organic layer was evaporated and the residue waspurified by column chromatography on silica using a 49:1 mixture ofmethylene chloride and methanol as eluent. The material so obtained wasdissolved in diethyl ether and 6M hydrogen chloride in isopropanol (0.1ml) was added. The mixture was stirred for 5 minutes and thenevaporated. There was thus obtained the title compound as adihydrochloride salt (0.095 g), a portion of which was converted intothe free base using an analogous procedure to that described in Example3. The free base gave the following characterising data: NMR Spectrum:(CDCl₃) 1.55-1.75 (m, 4H), 1.75-1.95 (m, 4H), 2.08 (m, 2H), 2.6-2.75 (m,4H), 3.0 (m, 2H), 4.25 (m, 2H), 5.05 (m, 1H), 6.6 (d, 1H), 6.8 (d, 1H),6.85 (d, 1H), 7.38 (d, 1H), 7.45 (d, 1H), 7.6 (d, 1H), 8.42 (s, 1H), 9.5(s, 1H); Mass Spectrum: M+H⁺ 493 and 495.

The 7-amino-6-chlorobenzofuran used as a starting material was preparedas follows

Sodium hydride (60% dispersion in mineral oil; 4.6 g) was added to astirred solution of 6-chloroanthranilic acid (18 g) in DMF (100 ml) andthe mixture was stirred at ambient temperature for 30 minutes. Ethyliodide (10 ml) was added and the reaction mixture was stirred at ambienttemperature for 2 days. The solvent was evaporated and the residue waspartitioned between ethyl acetate and water. The organic phase waswashed in turn with water and brine, dried over magnesium sulphate andevaporated. The residue was purified by column chromatography on silicausing a 4:1 mixture of petroleum ether (b.p. 60-80° C.) and ethylacetate as eluent. There was thus obtained ethyl 6-chloroanthranilate(15.8 g) as an oil; NMR Spectrum: (DMSOd₆) 1.3 (t, 3H), 4.3 (q, 2H), 5.7(br s, 2H), 6.6 (d, 1H), 6.7 (d, 1H), 7.1 (t, 1H).

A solution of sodium nitrite (4.5 g) in water (100 ml) was addeddropwise during 5 minutes to a stirred suspension of ethyl6-chloroanthranilate (12.7 g) in a mixture of concentrated sulphuricacid (27.9 ml), water (38 ml) and ice (76 g). The reaction mixture wasstirred at 0° C. for an additional 20 minutes and then heated to 120° C.for 1 hour. The resultant mixture was poured into a mixture of ice andwater and the product was extracted with diethyl ether. The organicphase was washed in turn with water and brine, dried over magnesiumsulphate and evaporated. The residue was purified by columnchromatography on silica using a 4:1 mixture of petroleum ether (b.p.60-80° C.) and methylene chloride as eluent. There was thus obtainedethyl 6-chloro-2-hydroxybenzoate (9.8 g); NMR Spectrum: (DMSOd₆) 1.3 (t,3H), 4.3 (q, 2H), 6.9 (d, 1H), 6.95 (d, 1H), 7.25 (d, 1H), 10.45 (br s,1H).

Allyl bromide (5.5 ml)-was added to a stirred mixture of ethyl6-chloro-2-hydroxybenzoate (9.8 g), 1,5,7-triazabicyclo[4,4,0]dec-5-ene(10.4 g) and acetonitrile (250 ml) and the reaction mixture was stirredat ambient temperature for 20 hours. The mixture was evaporated and theresidue was purified by column chromatography on silica using a 17:3mixture of petroleum ether (b.p. 60-80° C.) and diethyl ether as eluent.There was thus obtained ethyl 2-allyloxy-6-chlorobenzoate (10.3 g); NMRSpectrum: (DMSOd₆) 1.3 (t, 3H), 4.35 (q, 2H), 4.65 (d, 2H), 5.25 (d,1H), 5.4 (d, 1H), 6.0 (m, 1H), 7.15 (m, 2H), 7.45 (t, 1H).

The material so obtained was heated to 230° C. for 1 hour. The reactionproduct was cooled to ambient temperature and purified by columnchromatography on silica using a 4:1 mixture of petroleum ether (b.p.60-80° C.) and methylene chloride as eluent. There was thus obtainedethyl 3-allyl-6-chloro-2-hydroxybenzoate (7.3 g); NMR Spectrum: (DMSOd₆)1.3 (t, 3H), 3.3 (m, 2H), 4.35 (q, 2H), 5.05 (m, 2H), 5.95 (m, 1H), 6.95(d, 1H), 7.15 (d, 1H), 9.7 (br S, 1H).

The material so obtained was dissolved in methanol and cooled to −78° C.Ozone was bubbled through the solution for 30 min. Dimethyl sulfide (5.4ml) was added and the reaction mixture was allowed to warm to ambienttemperature. The mixture was evaporated and the residue was partitionedbetween diethyl ether and water. The organic phase was washed in turnwith water and brine, dried over magnesium sulphate and evaporated. Theresidue was purified by column chromatography on silica using a 1:1mixture of petroleum ether (b.p. 60-80° C.) and methylene chloride andthen a 9:1 mixture of methylene chloride and diethyl ether as eluent.There was thus obtained2-(4-chloro-3-ethoxycarbonyl-2-hydroxyphenyl)acetaldehyde which wasimmediately suspended in 85% phosphoric acid (18 ml) and the mixture washeated to 100° C. for 1 hour. The mixture was cooled to ambienttemperature and partitioned between diethyl ether and water. The organicphase was washed in turn with water and brine, dried over magnesiumsulphate and evaporated. The residue was purified by columnchromatography on silica using a 1:1 mixture of petroleum ether (b.p.60-80° C.) and methylene chloride as eluent. There was thus obtainedethyl 6-chlorobenzofuran-7-carboxylate (5.9 g); NMR Spectrum: (DMSOd₆)1.35 (t, 3H), 4.45 (q, 2H), 7.10 (d, 1H), 7.45 (d, 1H), 7.85 (d, 1H),8.15 (d, 1H).

A mixture of the material so obtained, 35% aqueous potassium hydroxidesolution (12.7 ml) and methanol (20 ml) was stirred and heated to refluxfor 1 hour. The methanol was evaporated and the residue was diluted withwater and acidified to pH1 by the addition of 6N aqueous hydrochloricacid. The resultant precipitate was isolated, washed with water anddried under vacuum over phosphorus pentoxide to give6-chlorobenzofuran-7-carboxylic acid (4.6 g); NMR Spectrum: (DMSOd₆)7.05 (d, 1H), 7.4 (d, 1H), 7.75 (d, 1H), 8.1 (d, 1H).

A mixture of a portion (1 g) of the material so obtained,diphenylphosphoryl azide (2.2 ml), triethylamine (1.4 ml) andtert-butanol (2.7 ml) was stirred and heated to reflux for 18 hours. Themixture was allowed to cool to ambient temperature, poured into waterand extracted with ethyl acetate. The organic phase was washed in turnwith water and brine, dried over magnesium sulphate and evaporated. Theresidue was purified by column chromatography on alumina usingincreasingly polar solvent mixtures starting with mixtures of petroleumether and methylene chloride and ending with a 4:1 mixture of methylenechloride and ethyl acetate. There was thus obtained a mixture of7-amino-6-chlorobenzofuran and tert-butyl6-chlorobenzofuran-7-carbamate. A solution of the mixture so obtained inmethylene chloride (15 ml) was cooled to 0° C. and trifluoroacetic acid(1.2 ml) was added. The resultant mixture was stirred for 1 hour. Themixture was evaporated and the residue was partitioned between ethylacetate and a saturated aqueous sodium bicarbonate solution. The organicphase was dried over magnesium sulphate and evaporated. The residue waspurified by column chromatography on silica using a 3:1 mixture ofpetroleum ether (b.p. 60-80° C.) and methylene chloride as eluent. Therewas thus obtained 7-amino-6-chlorobenzofuran (0.376 g); NMR Spectrum:(DMSOd₆) 5.5 (br s, 2H), 6.85 (m, 2H), 7.1 (d, 1H), 7.95 (d, 1H); MassSpectrum: M+H⁺ 167.

EXAMPLE 484-(3-chlorobenzofuran-7-ylamino)-7-(2-pyrrolidin-1-ylethoxy)-5-cyclopentyloxyquinazolinedihydrochloride

Using an analogous procedure to that described in Example 47,4-chloro-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline (0.1 g)was reacted with 7-amino-3-chlorobenzofuran (0.051 g) to give the titlecompound, as a dihydrochloride salt (0.074 g), a portion of which wasconverted into the free base using an analogous procedure to thatdescribed in Example 3. The free base gave the following characterisingdata: NMR Spectrum: (CDCl₃) 1.7-1.8 (m, 2H), 1.8-2.0 (m, 6H), 2.1-2.3(m, 41), 2.7 (br s, 4H), 3.02 (m, 2H), 4.3 (t, 2H), 5.08 (m, 1H), 6.61(d, 1H), 6.84 (d, 1H), 7.3-7.45 (m, 2H), 7.65 (s, 1H), 8.64 (s, 1H),8.76 (d, 1H), 10.3 (s, 1H); Mass Spectrum: M+H⁺ 493 and 495.

EXAMPLE 494-(2-chloro-5methoxyanilino)-5-(4methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazolinetrihydrochloride

Using an analogous procedure to that described in Example 5,4chloro-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazoline(0.11 g) was reacted with 2-chloro-5-methoxyaniline hydrochloride (0.064g) in the presence of a 6M solution of hydrogen chloride in isopropanol(0.05 ml) to give the title compound, as a trihydrochloride salt (0.092g), a portion of which was converted into the free base using ananalogous procedure to that described in Example 3. The free base gavethe following characterising data: NMR Spectrum: (CDCl₃) 1.8-1.9 (m,4H), 2.32 (s, 3H), 2.48 (m, 2H), 2.65 (br s, 4H), 2.82 (d, 2H), 2.98 (m,4H), 3.2 (d, 2H), 3.82 (s, 3H), 4.25 (m, 2H), 6.65 (m, 1H), 6.95 (m,1H), 7.3 (d, 1H), 8.02 (d, 1H), 8.52 (s, 1H); Mass Spectrum: M+H⁺ 497and 499.

The4-chloro-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazolineused as a starting material was prepared as follows

A mixture of 5,7-difluoro-3,4-dihydroquinazolin-4-one (0.091 g),1-methylpiperazine (0.1 g) and DMF (2 ml) was stirred and heated to 100°C. for 1 hour. The mixture was evaporated and the residue was purifiedby column chromatography using a 97:3 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. There was thusobtained 7-fluoro-5-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one(0.09 g); NMR Spectrum: (CDCl₃) 2.42 (s, 3H), 2.72 (br s, 4H), 3.2 (brs, 4H), 6.72 (m, 1H), 7.0 (m, 1H), 8.0 (s, 1H); Mass Spectrum: M+H⁺ 263.

Sodium hydride (60% dispersion in mineral oil; 0.96 g) was added to astirred solution of 1-(2-hydroxyethyl)pyrrolidine (1.4 ml) in DMF (20ml) and the mixture was stirred at ambient temperature for 10 minutes.7-Fluoro-5-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one (0.09 g)was added and the mixture was stirred and heated to 100° C. for 3 hours.The resultant mixture was evaporated and acetic acid (1.4 ml) andmethylene chloride were added in turn to the residue. The mixture wasfiltered and the filtrate was poured onto a column of silica and elutedwith a 19:1 mixture of methylene chloride and a saturated methanolicammonia solution. The material so obtained as triturated under pentane,isolated, washed with pentane and dried under vacuum. There was thusobtained5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)-3,4-dihydroquinazolin-4-one(0.74 g); NMR Spectrum: (CDCl₃) 1.7-1.9 (m, 4H), 2.4 (s, 3H), 2.6-2.8(m, 8H), 2.92 (t, 2H), 3.15 (br s, 4H), 4.2 (t, 2H), 6.6 (d, 1H), 6.8(d, 1H), 7.92 (s, 1H); Mass Spectrum: M+H⁺ 358.

A mixture of a portion (0.65 g) of the material so obtained, phosphorylchloride (0.252 ml), diisopropylethylamine (0.94 ml) and1,2-dichloroethane (30 ml) was stirred and heated to 80° C. for 2 hours.The mixture was evaporated and the residue was purified by columnchromatography on silica using a 24:1 mixture of methylene chloride anda saturated methanolic ammonia solution as eluent. There was thusobtained4-chloro-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazoline(0.23 g); NMR Spectrum: (CDCl₃) 1.9-2.1 (br s, 4H), 2.5 (s, 3H), 2.65(m, 2H), 2.85-3.1 (m, 10H), 3.32 (d, 2H), 4.4 (br s, 2H), 6.85 (d, 1H),7.05 (d, 1H), 8.8 (s, 11); Mass Spectrum: M+H⁺ 376.

EXAMPLE 504-(6-chloro-2,3-methylenedioxyanilino)-5-(N-methylpiperidin-4-yloxy)7-(2,2,2-trifluoroethoxy)quinazoline

A mixture of4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.1 g), 2,2,2-trifluoroethyl 4-toluenesulphonate (0.071 g), potassiumcarbonate (0.08 g) and DMF (2 ml) was stirred and heated to 95° C. for24 hours. The mixture was cooled to ambient temperature and partitionedbetween ethyl acetate and water. The organic solution was washed withwater and with brine, dried over magnesium sulphate and evaporated Theresidue was purified by column chromatography on silica using a 45:46:4mixture of methylene chloride, ethyl acetate and methanol as eluent.There was thus obtained the title compound (0.058 g); NMR Spectrum:(CDCl₃) 1.95-2.1 (m, 2H), 2.1-2.3 (m, 2H), 2.32 (s, 3H), 2.3-2.45 (m,2H), 2.75 (m, 2H), 4.48 (m, 2H), 4.64 (m, 1H), 6.05 (s, 2H), 6.6 (d,1H), 6.74 (d, 1H), 6.78 (d, 1H), 6.97 (d, 1H), 8.5 (s, 1H), 9.28 (s,1H); Mass Spectrum: M+H⁺ 511 and 513.

The4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazolineused as a starting material was prepared as follows:—

A solution of di-tert-butyl azodicarboxylate (5.44 g) in methylenechloride (20 ml) was added dropwise to a stirred mixture of7-benzyloxy-5-hydroxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (6g) 4-hydroxy-N-methylpiperidine (2.17 g), triphenylphosphine (6.17 g)and methylene chloride (100 ml) that had been cooled to 0° C. Theresultant mixture was stirred at ambient temperature for 1 hour. Themixture was evaporated and the residue was purified by columnchromatography on silica using a 10:9:1 mixture of methylene chloride,ethyl acetate and a saturated methanolic ammonia solution as eluent. Thematerial so obtained was dissolved in a saturated methanolic ammoniasolution (240 ml) and stirred at ambient temperature for 16 hours. Themixture was evaporated and the residue was triturated under diethylether. The resultant solid was isolated, washed with diethyl ether anddried under vacuum. There was thus obtained7-benzyloxy-5-(t-methylpiperidin-4-yloxy)-3,4-dihydroquinazolin-4-one(3.68 g); NMR Spectrum: (CDCl₃) 2.0 (m, 4H), 2.3 (s, 3H), 2.35 (m, 2H),2.75 (m, 2H), 4.5 (m, 1H), 5.15 (s, 2H), 6.6 (d, 1H), 6.82 (d, 1H),7.3-7.5 (m, 5H), 7.92 (s, 1H); Mass Spectrum: M+H⁺ 366.

A mixture of the material so obtained, triphenylphosphine (8.65 g),carbon tetrachloride (10 ml) and 1,2-dichloroethane (100 ml) was stirredand heated to 70° C. for 2 hours. The mixture was evaporated and the7-benzyloxy-4chloro-5-(N-methylpiperidin-4-yloxy)quinazoline so obtainedwas dissolved in isopropanol (2 ml) and6-chloro-2,3-methylenedioxyaniline (1.9 g) and a 5M hydrogen chloridesolution in isopropanol (2.1 ml) were added in turn. The resultantmixture was stirred at 50° C. for 20 minutes and at 80° C. for 30minutes. The mixture was evaporated and the residue was suspended inethyl acetate and stirred for 1 hour at ambient temperature. Theresultant solid was isolated, washed with ethyl acetate and with diethylether. The solid was dissolved in a 19:1 mixture of methylene chlorideand a saturated methanolic ammonia solution and stirred at ambienttemperature for 15 minutes. The mixture was filtered, the filtrate wasevaporated and the residue was purified by column chromatography onsilica using a 50:47:3 mixture of ethyl acetate, methylene chloride andmethanol as eluent. There was thus obtained7-benzyloxy-4-(6-chloro-2,3-methylenedioxyanilino)-5-(N-methylpiperidin-4-yloxy)quinazoline(4.2 g); NMR Spectrum: (CDCl₃) 2.0-2.1 (m, 2H), 2.2 (m, 2H), 2.3 (s,3H), 2.25-2.35 (m, 2H), 2.75 (m, 2H), 4.6 (m, 1H), 5.2 (s, 2H), 6.1 (s,2H), 6.6 (s, 1H), 6.75 (d, 1H), 6.95 (s, 1H), 7.0 (d, 1H), 7.32-7.52 (m,5H), 8.52 (s, 1H), 9.3 (s, 1H); Mass Spectrum: M+H⁺ 519 and 521.

A mixture of a portion (1.5 g) of the material so obtained andtrifluoroacetic acid (15 ml) was stirred and heated to reflux for 6hours. The mixture was evaporated and the residue was dissolved in waterand basified to pH9 by the addition of solid sodium bicarbonate. Themixture was extracted with ethyl acetate and the organic layer waswashed with brine, dried over magnesium sulphate and evaporated. Theresidue was purified by column chromatography on silica using a 10:9:2mixture of ethyl acetate, methylene chloride and methanol as eluent.There was thus obtained4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.8 g); NMR Spectrum: (CDCl₃) 1.9-2.05 (m, 2H), 2.05-2.15 (m, 2H),2.2-2.3 (m, 2H), 2.28 (s, 3H), 2.7 (m, 2H), 4.5 (br s, 1H), 6.05 (s,2H), 6.5 (d, 1H), 6.7 (d, 1H), 6.85 (d, 1H), 6.95 (d, 1H), 8.4 (s, 1H),9.35 (s, 1H); Mass Spectrum M+H⁺ 429 and 431.

EXAMPLE 514-(6-chloro-2,3-methylenedioxyanilino)-7-ethoxy-5-(1-methylpiperidin-4-yloxy)quinazoline

A solution of di-tert-butyl azodicarboxylate (0.26 g) in methylenechloride (1 ml) was added dropwise to a stirred mixture of4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazoline(0.12 g), ethanol (0.019 g), triphenylphosphine (0.15 g) and methylenechloride (2 ml) and the resultant mixture was stirred at ambienttemperature for 1 hour. A 2M solution of hydrogen chloride in diethylether (3 ml) was added and the mixture was stirred at ambienttemperature for 1.5 hours. Diethyl ether (1 ml) was added and theprecipitate was isolated and dried under vacuum. The solid so obtainedwas dissolved in a 9:1 mixture of methylene chloride and a saturatedmethanolic ammonia solution. The mixture was filtered and the filtratewas evaporated. The residue was triturated under pentane and theresultant solid was isolated and dried under vacuum. There was thusobtained the title compound (0.092 g); NMR Spectrum: (CDCl₃) 1.5 (t,3H), 1.95-2.1 (m, 2H), 2.15-2.5 (m, 2H), 2.3 (s, 3H), 2.3-2.4 (m, 2H),2.7 (br s, 2m), 4.15 (m, 2H), 4.6 (m, 1H), 6.05 (s, 2H), 6.5 (d, 1H),6.7 (d, 1H), 6.8 (d, 1H), 6.95 (d, 1H), 8.5 (s, 1H), 9.25 (br s, 1H);Mass Spectrum: M+H⁺ 457 and 459.

EXAMPLE 524-(6-chloro-2,3-methylenedioxyanilino)-7-(2-fluoroethoxy)-5-(N-methylpiperidin-4-yloxy)quinazoline

Using an analogous procedure to that described in Example 51,4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazolinewas reacted with 2-fluoroethanol to give the title compound; NMRSpectrum: (CDCl₃) 2.0-2.1 (m, 2H), 2.15-2.3 (m, 2H), 2.35 (s, 3H),2.3-2.4 (m, 2H), 2.8 (br s, 2H), 4.32 (m, 1H), 4.4 (m, 1H), 4.65 (m,1H), 4.8 (m, 1H), 4.9 (m, 1H), 6.05 (s, 2H), 6.6 (s, 1H), 6.75 (d, 1H),6.85 (s, 1H), 7.0 (d, 1H), 8.55 (s, 1H), 9.3 (s, 1H); Mass Spectrum:M+H⁺ 475 and 477.

EXAMPLE 534-(6chloro-2,3-methylenedioxyanilino)-7-isobutoxy-5-(N-methylpiperidin-4-yloxy)quinazoline

Using an analogous procedure to that described in Example 51,4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-(N-methylpiperidin-4-yloxy)quinazolinewas reacted with isobutanol to give the title compound; NMR Spectrum:(CDCl₃) 1.05 (d, 6H), 1.95-2.05 (m, 2H), 2.08-2.28 (m, 3H), 2.3 (s, 3H),2.3-2.4 (m, 2H), 2.7 (br s, 2H), 3.82 (d, 2H), 4.6 (m, 1H), 6.03 (s,2H), 6.5 (s, 1H), 6.7 (d, 1H), 6.8 (s, 1H), 6.95 (d, 1H), 8.5 (s, 1H),9.25 (s, 1H); Mass Spectrum: M+H⁺ 485 and 487.

EXAMPLE 544-(2,3-methylenedioxyanilino)-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazolinetrihydrochloride

Using an analogous procedure to that described in Example 5,4-chloro-5-(4-methylpiperazin-1-yl)-7-(2-pyrrolidin-1-ylethoxy)quinazoline(0.11 g) was reacted with 2,3-methylenedioxyaniline (0.045 g) in thepresence of a 6M solution of hydrogen chloride in isopropanol to givethe title compound, as a trihydrochloride salt (0.105 g), a portion ofwhich was converted into the free base using an analogous procedure tothat described in Example 3. The free base gave the followingcharacterising data: NMR Spectrum: (CDCl₃) 1.78 (br s, 4H), 2.3 (s, 3H),2.5 (m, 2H), 2.6 (br s, 4H), 2.8 (d, 2H), 2.95 (m, 4H), 3.08 (d, 2H),4.18 (m, 2H), 5.98 (s, 2H), 6.6 (d, 1H), 6.86 (m, 1H), 6.94 (s, 1H),8.06 (d, 1H), 8.5 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H⁺ 477.

EXAMPLE 554-(6chloro-2,3-methylenedioxyanilino)-5-morpholino-7-(2-pyrrolidin-1-ylethoxy)quinazoline

A mixture of4-chloro-5-morpholino-7-(2-pyrrolidin-1-ylethoxy)quinazoline (0.27 g),6-chloro-2,3-methylenedioxyaniline (0.14 g) and isopropanol (4 ml) wasstirred and heated to 80° C. for 1 hour. The mixture was evaporated andthe residue was dissolved in a 49:1 mixture of methylene chloride and asaturated methanolic ammonia solution. The mixture was filtered and thefiltrate was poured onto a column of silica and eluted with a 97:3mixture of methylene chloride and a saturated methanolic ammoniasolution. The material so obtained was triturated under diethyl ether.The resultant solid was isolated, washed with diethyl ether and driedunder vacuum. There was thus obtained the title compound (0.035 g); NMRSpectrum: (CDCl₃) 1.85 (br s, 4H), 2.65 (br s, 4H), 3.0 (m, 2H), 3.08(m, 2H), 3.18 (d, 2H), 3.82 (m, 2H), 4.05 (m, 2H), 4.25 (m, 2H), 6.05(s, 2), 6.75 (d, 1H), 6.95-7.1 (m, 3H), 8.52 (s, 1H); Mass Spectrum:M+H⁺ 498 and 500.

The 4-chloro-5-morpholino-7-(2-pyrrolidin-1-ylethoxy)quinazoline used asa starting material was prepared as follows:—

A mixture of 5,7-difluoro-3,4-dihydroquinazolin-4-one (0.91 g),morpholine (0.9 ml) and DMF (20 ml) was stirred and heated to 100° C.for 1 hour. The mixture was evaporated. A saturated methanolic ammoniasolution (1 ml) was added to the residue and the mixture was stirred atambient temperature for 5 minutes. The mixture was evaporated and theresidue was triturated under water. The resultant solid was isolated,washed with water and with diethyl ether and dried under vacuum. Therewas thus obtained 7-fluoro-5-morpholino-3,4-dihydroquinazolin-4-one(0.85 g); NMR Spectrum: (DMSOd₆) 3.05 (br s, 4H), 3.8 (t, 4H), 6.8 (m,1H), 6.92 (m, 1H), 8.02 (s, 1H); Mass Spectrum: M+H⁺ 250.

Sodium hydride (60% dispersion in mineral oil, 0.5 g) was added to astirred solution of 1-(2-hydroxyethyl)pyrrolidine (0.7 ml) in DMF (15ml) which had been cooled to 5° C. The mixture was stirred for 10minutes. 7-Fluoro-5-morpholino-3,4-dihydroquinazolinone (0.75 g) wasadded and the mixture was heated to 80° C. for 1 hour and then to 90° C.for 3 hours. The mixture was evaporated and the residue was dissolved inacetic acid (0.9 ml) and diluted with a mixture of methylene chlorideand methanol. The resultant solution was poured onto a column of silicaand eluted with a 47:3 mixture of methylene chloride and methanol aseluent. The material so obtained was triturated under diethyl ether andthe resultant solid was isolated, washed with diethyl ether and driedunder vacuum. There was thus obtained5-morpholino-7-(2-pyrrolidin-1-ylethoxy)-3,4-dihydroquinazolin-4-one(0.5 g); NMR Spectrum: (DMSOd₆) 1.7 (br s, 4H), 2.8 (m, 2H), 3.02 (br s,4H), 3.8 (m, 4H), 4.2 (m, 2H), 6.45 (d, 1H), 6.7 (d, 1H), 7.92 (s, 1H),11.7 (br s, 1H); Mass Spectrum: M+H⁺ 345.

A mixture of a portion (0.26 g) of the material so obtained, phosphorylchloride (0.084 ml), diisopropylethylamine (0.34 ml) and1,2-dichloroethane (5 ml) was stirred and heated to 80° C. for 3 hours.The mixture was evaporated to give4-chloro-5-morpholino-7-(2-pyrrolidin-1-ylethoxy)quinazoline which wasused without further purification.

EXAMPLE 56 4-(6chloro-2,3-methylenedioxyanilino)-5-phenoxyquinazolinemonohydrochloride

A mixture of 4-(6-chloro-2,3-methylenedioxyanilino)-5-fluoroquinazoline(0.213 g), phenol (0.45 g), potassium carbonate (0.828 g) and DMF (3 ml)was stirred and heated to 90° C. for 30 hours. The mixture wasevaporated and the residue was partitioned between ethyl acetate and a2N aqueous sodium hydroxide solution. The organic layer was washed withbrine, dried over magnesium sulphate and evaporated. The residue waspurified by column chromatography on silica using a 99:1 mixture ofmethylene chloride and methanol as eluent. The material so obtained wasdissolved in diethyl ether and a 6M solution of hydrogen chloride indiethyl ether (1 equivalent) was added. The resultant solid wasisolated, washed with diethyl ether and dried under vacuum. There wasthus obtained the title compound (0.05 g); NMR Spectrum: (DMSOd₆ andCF₃CO₂D) 6.18 (s, 2H), 6.95 (d, 1H), 7.05 (d, 1H), 7.1 (d, 1H), 7.35 (d,1H), 7.42 (m, 1H), 7.52-7.62 (m, 3H), 8.0 (m, 1H), 9.0 (s, 1H); MassSpectrum: M+H⁺ 392 and 394.

EXAMPLE 57

Pharmaceutical Compositions

The following illustrate representative pharmaceutical dosage forms ofthe invention as defined herein (the active ingredient being termed“Compound X”), for therapeutic or prophylactic use in humans: (a) TabletI mg/tablet Compound X 100 Lactose Ph.Eur 182.75 Croscarmellose sodium12.0 Maize starch paste (5% w/v paste) 2.25 Magnesium stearate 3.0

(b) Tablet II mg/tablet Compound X 50 Lactose Ph.Eur 223.75Croscarmellose sodium 6.0 Maize starch 15.0 Polyvinylpyrrolidone (5% w/vpaste) 2.25 Magnesium stearate 3.0

(c) Tablet III mg/tablet Compound X 1.0 Lactose Ph.Eur 93.25Croscarmellose sodium 4.0 Maize starch paste (5% w/v paste) 0.75Magnesium stearate 1.0

(d) Capsule mg/capsule Compound X 10 Lactose Ph.Eur 488.5 Magnesium 1.5(e) Injection I (50 mg/ml) Compound X 5.0% w/v 1M Sodium hydroxidesolution 15.0% v/v  0.1M Hydrochloric acid (to adjust pH to 7.6)Polyethylene glycol 400 4.5% w/v Water for injection to 100%

(f) Injection II (10 mg/ml) Compound X 1.0% w/v Sodium phosphate BP 3.6%w/v 0.1M Sodium hydroxide solution 15.0% v/v  Water for injection to100%

(g) Injection III (1 mg/ml, buffered to pH6) Compound X  0.1% w/v Sodiumphosphate BP 2.26% w/v Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection to 100%

(h) Aerosol I mg/ml Compound X 10.0 Sorbitan trioleate 13.5Trichlorofluoromethane 910.0 Dichlorodifluoromethane 490.0

(i) Aerosol II mg/ml Compound X 0.2 Sorbitan trioleate 0.27Trichlorofluoromethane 70.0 Dichlorodifluoromethane 280.0Dichlorotetrafluoroethane 1094.0

(j) Aerosol III mg/ml Compound X 2.5 Sorbitan trioleate 3.38Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0Dichlorotetrafluoroethane 191.6

(k) Aerosol IV mg/ml Compound X 2.5 Soya lecithin 2.7Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0Dichlorotetrafluoroethane 191.6

(l) Ointment ml Compound X 40 mg Ethanol 300 μl Water 300 μl1-Dodecylazacycloheptan-2-one 50 μl Propylene glycol to 1 mlNote

The above formulations may be obtained by conventional procedures wellknown in the pharmaceutical art. The tablets (a)-(c) may be entericcoated by conventional means, for example to provide a coating ofcellulose acetate phthalate. The aerosol formulations (h)-(k) may beused in conjunction with standard, metered dose aerosol dispensers, andthe suspending agents sorbitan trioleate and soya lecithin may bereplaced by an alternative suspending agent such as sorbitan monooleate,sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleicacid.

1. The use of a quinazoline derivative of the Formula I

wherein m is 0, 1, 2 or 3; each R¹ group, which may be the same ordifferent, is selected from halogeno, trifluoromethyl, cyano, isocyano,nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl,(1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy,(2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio,(1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, n-(1-6C)alkylcarbamoyl,N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy,(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,(3-6C)alkenoylamino, n-(1-6C)alkyl-(3-6C)alkenoylamino,(3-6C)alkynoylamino, n-(1-6C)alkyl-(3-6C)alkynoylamino,N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,or from a group of the formula:Q³-X¹— wherein X¹ is a direct bond or is selected from O, S, SO, SO₂,N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂, OC(R⁴)₂,SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is hydrogen or (1-6C)alkyl, and Q³is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,(3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R¹)_(m) is(1-3C)alkylenedioxy, and wherein adjacent carbon atoms in any(2-6C)alkylene chain within a R¹ substituent are optionally separated bythe insertion into the chain of a group selected from O, S, SO, SO₂,N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH═CH and C≡Cwherein R⁵ is hydrogen or (1-6C)alkyl, and wherein any CH₂═CH— or HC≡C—group within a R¹ substituent optionally bears at the terminal CH₂═ orHC≡ position a substituent selected from halogeno, carboxy, carbamoyl,(1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,(1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl orfrom a group of the formula:Q⁴-X²— wherein X² is a direct bond or is selected from CO and N(R⁶)CO,wherein R⁶ is hydrogen or (1-6C)alkyl, and Q⁴ is aryl, aryl-(1-6C)alkyl,heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl orheterocyclyl-(1-6C)alkyl, and wherein any CH₂ or CH₃ group within a R¹substituent optionally bears on each said CH₂ or CH₃ group one or morehalogeno or (1-6C)alkyl substituents or a substituent selected fromhydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,(2-6C)alkanoyloxy, (2-6C)alkanoylamino,N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, NN-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino andN-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of theformula:—X³-Q⁵ wherein X³ is a direct bond or is selected from O, S, SO, SO₂,N(R⁷), CO, CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, C(R⁷)₂O,C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q⁵is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,(3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,heterocyclyl or heterocyclyl-(1-6C)alkyl, and wherein any aryl,heteroaryl or heterocyclyl group within a substituent on R¹ optionallybears 1, 2 or 3 substituents, which may be the same or different,selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino,carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,(1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio,(1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy,(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,or from a group of the formula:—X⁴—R⁸ wherein X⁴ is a direct bond or is selected from O and N(R⁹),wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is halogeno-(1-6C)alkyl,hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl,amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or(1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula:—X⁵-Q⁶ wherein X⁵ is a direct bond or is selected from O, CO and N(R¹⁰),wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁶ is aryl,aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl orheterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents,which may be the same or different, selected from halogeno, (1-6C)alkyland (1-6C)alkoxy, and wherein any heterocyclyl group within asubstituent on R¹ optionally bears 1 or 2 oxo or thioxo substituents; R²is hydrogen or (1-6C)alkyl; R³ is hydrogen or (1-6C)alkyl; Z is a directbond or is selected from O, S, SO, SO₂, N(R¹¹), CO, CH(OR¹¹), CON(R¹¹),N(R¹¹)CO, SO₂N(R¹¹), N(R¹¹)SO₂, OC(R¹¹)₂, SC(R¹¹)₂ and N(R¹¹)C(R¹¹)₂,wherein R¹¹ is hydrogen or (1-6C)alkyl; Q¹ is aryl, aryl-(1-6C)alkyl,(3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,heterocyclyl or heterocyclyl-(1-6C)alkyl, or, when Z is a direct bond orO, Q¹ may be (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio-(1-6C)alkyl,(1-6C)alkylsulphinyl-(1-6C)alkyl or (1-6C)alkylsulphonyl-(1-6C)alkyl,and wherein adjacent carbon atoms in any (2-6C)alkylene chain within theQ¹-Z- group are optionally separated by the insertion into the chain ofa group selected from O, S, SO, SO₂, N(R¹²), CO, CH(OR¹²), CON(R¹²),N(R¹²)CO, SO₂N(R¹²), N(R¹²)SO₂, CH═CH and C≡C wherein R¹² is hydrogen or(1-6C)alkyl, and wherein any CH₂═CH— or HC≡C— group within the Q¹-Z-group optionally bears at the terminal CH₂═or HC≡ position a substituentselected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl;N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl anddi-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula:Q⁷-X⁶— wherein X⁶ is a direct bond or is selected from CO and N(R¹³)CO,wherein R¹³ is hydrogen or (1-6C)alkyl, and Q⁷ is aryl,aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl orheterocyclyl-(1-6C)alkyl, and wherein any CH₂ or CH₃ group within theQ¹-Z- group optionally bears on each said CH₂ or CH₃ group one or morehalogeno or (1-6C)alkyl substituents or a substituent selected fromhydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy,(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,(2-6C)alkanoyloxy, (2-6C)alkanoylamino,N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino andN-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of theformula:—X⁷-Q⁸ wherein X⁷ is a direct bond or is selected from O, S, SO, SO₂,N(R¹⁴), CO, CH(OR¹⁴), CON(R¹⁴), N(R¹⁴)CO, SO₂N(R¹⁴), N(R¹⁴)SO₂,C(R¹⁴)₂O, C(R¹⁴)₂S and N(R¹⁴)C(R¹⁴)₂, wherein R¹⁴ is hydrogen or(1-6C)alkyl, and Q⁸ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,(3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl,(3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,heterocyclyl or heterocyclyl-(1-6C)alkyl, and wherein any aryl,heteroaryl or heterocyclyl group within the Q¹-Z- group optionally bears1, 2 or 3 substituents, which may be the same or different, selectedfrom halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy,carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy,(2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio,(1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy,(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,or from a group of the formula:—X⁸—R¹⁵ wherein X⁸ is a direct bond or is selected from O and N(R¹⁶),wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is halogeno-(1-6C)alkyl,hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl,amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl ordi-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula:—X⁹-Q⁹ wherein X⁹ is a direct bond or is selected from O, CO and N(R¹⁷),wherein R¹⁷ is hydrogen or (1-6C)alkyl, and Q⁹ is aryl,aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl orheterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents,which may be the same or different, selected from halogeno, (1-6C)alkyland (1-6C)alkoxy, and wherein any heterocyclyl group within the Q¹-Z-group optionally bears 1 or 2 oxo or thioxo substituents; and Q² is anaryl group of formula Ia

wherein G¹ is selected from halogeno, trifluoromethyl, cyano, nitro,hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl,(2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,(2-6C)alkanoyloxy, (2-6C)alkanoylamino,N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino andN-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of theformula:—X¹⁰—R¹⁸ wherein X¹⁰ is a direct bond or is selected from O and N(R¹⁹),wherein R¹⁹ is hydrogen or (1-6C)alkyl, and R¹⁸ is halogeno-(1-6C)alkyl,hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl,amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl ordi-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula:—X¹¹-Q¹⁰ wherein X¹¹ is a direct bond or is selected from O, S, SO, SO₂,N(R²⁰), CO, CH(OR²), CON(R²⁰), N(R²⁰)CO, SO₂N(R²⁰), N(R²⁰)SO₂, C(R²⁰)₂O,C(R²⁰)₂S and N(R²⁰)C(R²⁰)₂, wherein R²⁰ is hydrogen or (1-6C)alkyl, andQ¹⁰ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2substituents, which may be the same or different, selected fromhalogeno, (1-6C)alkyl and (1-6C)alkoxy, and any heterocyclyl groupwithin Q¹⁰ optionally bears 1 or 2 oxo or thioxo substituents, and eachof G², G³, G⁴ and G⁵, which may be the same or different, is selectedfrom hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino,(1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy,(1-6C)alkylamino and di-[(1-6C)alkyl]amino, or G¹ and G² together form agroup of formula:— —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—,—CH═CH—N═CH—, —CH═CH—CH═N—, —N═CH—N═CH—, —CH═N—CH═N, —N═CH—CH═N—,—N═N—CH═CH—, —CH═CH—N═N—, —CH═CH—O—, —O—CH═CH—, —CH═CH—S—, —S—CH═CH—,—CH₂—CH₂—O—, —O—CH₂—CH₂—, —CH₂—CH₂—S—, —S—CH₂—CH₂—, —O—CH₂—O—,—CH₂—CH₂—O—, —S—CH₂—S—, —S—CH₂—CH₂—S—, —CH═CH—NH—, —NH—CH═CH—,—CH₂—CH₂—NH—, —NH—CH₂—CH₂—, —N═CH—NH—, —NH—CH═N—, —NH—CH₂—NH—, —O—CH═N—,—N═CH—O—, —S—CH═N—, —N═CH—S—, —O—CH₂—NH—, —NH—CH₂—O—, —S—CH₂—NH—,—NH—CH₂—S—, —O—N═CH—, —CH═N—O—, —S—N═CH—, —CH═N—S—, —O—NH—CH₂—,—CH₂—NH—O—, —S—NH—CH₂—, —CH₂—NH—S—, —NH—N═CH—, —CH═N—NH—, —NH—NH—CH₂—,—CH₂—NH—NH—, —N═N—NH— or —NH—N═N—, or G¹ has any of the meanings definedhereinbefore and G² and G³ together or G³ and G⁴ together form a groupof formula:— —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—,—CH═CH—CH═N—, —N═CH—N═CH—, —CH═N—CH═N—, —N═CH—CH═N—, —N═N—CH═CH—,—CH═CH—N═N—, —CH═CH—O—, —O—CH═CH—, —CH═CH—S—, —S—CH═CH—, —CH₂—CH₂—O—,—O—CH₂—CH₂—, —CH₂—CH₂—S—, —S—CH₂—CH₂—, —O—CH₂—O—, —O—CH₂—CH₂—O—,—S—CH₂—S—, —S—CH₂—CH₂—S—, —CH═CH—NH—, —NH—CH═CH—, —CH₂—CH₂—NH—,—NH—CH₂—CH₂—, —N═CH—NH—, —NH—CH═N—, —NH—CH₂—NH—, —O—CH═N—, —N═CH—O—,—S—CH═N—, —N═CH—S—, —O—CH₂—NH—, —NH—CH₂—O—, —S—CH₂—NH—, —NH—CH₂—S—,—O—N—CH—, —CH═N—O—, —S—N═CH—, —CH═N—S—, —O—NH—CH₂—, —CH₂—NH—O—,—S—NH—CH₂—, —CH₂—NH—S—, —NH—N═CH—, —CH═N—NH—, —NH—NH—CH₂—, —CH₂—NH—NH—,—N═N—NH— or —NH—N═N—, and the 9- or 10-membered bicyclic heteroaryl orheterocyclic ring formed when G¹ and G² together, G² and G³ together orG³ and G⁴ together are linked optionally bears on the heteroaryl orheterocyclic portion of the bicyclic ring 1, 2 or 3 substituents, whichmay be the same or different, selected from halogeno, trifluoromethyl,cyano, nitro, hydroxy, amino, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,(1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino, and anybicyclic heterocyclic ring so formed optionally bears 1 or 2 oxo orthioxo groups; or a pharmaceutically-acceptable salt thereof; in themanufacture of a medicament for use in the prevention or treatment of Tcell mediated diseases or medical conditions in a warm-blooded animal.2. The use as claimed in claim 1 of a quinazoline derivative of theFormula I wherein: m is 0 or m is 1 and the R¹ group is located at the6- or 7-position and is selected from hydroxy, amino, methyl, ethyl,propyl, methoxy, ethoxy, propoxy, methylamino, ethylamino,dimethylamino, diethylamino, acetamido, propionamido, benzyloxy,2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy,piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy and3-homopiperazin-1-ylpropoxy, and wherein adjacent carbon atoms in any(2-6C)alkylene chain within a 10 substituent are optionally separated bythe insertion into the chain of a group selected from O, NH, CH═CH andC≡C, and wherein any CH₂ or CH₃ group within a R¹ substituent optionallybears on each said CH₂ or CH₃ group a substituent selected from hydroxy,amino, methoxy, methylsulphonyl, methylamino and dimethylamino, andwherein any phenyl or heterocyclyl group within a substituent on R¹optionally bears 1 or 2 substituents, which may be the same ordifferent, selected from fluoro, chloro, trifluoromethyl, hydroxy,amino, methyl, ethyl and methoxy, and wherein any heterocyclyl groupwithin a substituent on R¹ optionally bears 1 or 2 oxo substituents; theQ¹-Z- group is selected from propoxy, isopropoxy, 2-hydroxyethoxy,3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy, cyclopentyloxy,cyclohexyloxy, phenoxy, benzyloxy, tetrahydrofuran-3-yloxy,tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy,piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,2-piperidin-4ylethoxy, 2-homopiperidin-1-ylethoxy,3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy, and whereinany CH₂ or CH₃ group within the Q¹-Z- group optionally bears on eachsaid CH₂ or CH₃ group a substituent selected from hydroxy, amino,methoxy, methylsulphonyl, methylamino and dimethylamino, and wherein anyphenyl or heterocyclyl group within the Q¹-Z- group optionally bears 1or 2 substituents, which may be the same or different, selected fromfluoro, chloro, trifluoromethyl, hydroxy, amino, methyl, ethyl andmethoxy, and wherein any heterocyclyl group within the Q¹-Z- groupoptionally bears 1 or 2 oxo substituents; each of R² and R³ is hydrogen;and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo, iodo,trifluoromethyl, cyano, methyl, ethyl, vinyl, allyl, isopropenyl,ethynyl, methoxy and ethoxy, and each of G², G³, G⁴ and G⁵, which may bethe same-or different, is selected from hydrogen, fluoro, chloro, bromo,trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,isopropenyl, ethynyl, methoxy and ethoxy, or G¹ and G² together form agroup of formula:— —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or10-membered bicyclic heteroaryl or heterocyclic ring so formedoptionally bears on the heteroaryl or heterocyclic portion of thebicyclic ring 1 or 2 substituents, which may be the same or different,selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,methyl, ethyl, methoxy and ethoxy, and any bicyclic heterocyclic ring soformed optionally bears 1 or 2 oxo or thioxo groups, and each of G³, G⁴and G⁵, which may be the same or different, is selected from hydrogen,fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl,methoxy and ethoxy; or a pharmaceutically-acceptable acid-addition saltthereof.
 3. The use as claimed in claim 1 of a quinazoline derivative ofthe Formula I wherein: m is 1 and the R¹ group is located at the7-position and is selected from hydroxy, methoxy, benzyloxy,3-morpholinopropoxy, 2-hydroxy-3-morpholinopropoxy,3-(4-methylpiperazin-1-yl)propoxy,2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and2-(2-methoxyethoxy)ethoxy; the Q¹-Z- group is selected from isopropoxy,2-methoxyethoxy, cyclohexyloxy, tetrahydrofuran-3-yloxy,tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,2-(1,2,4-triazol-1-yl)ethoxy, 3-pyrrolidin-1-ylpropoxy,N-methylpyrrolidin-3-yloxy, 3-morpholinopropoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,N-methylpiperidin-4-yloxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy and 3-(4-methylpiperazin-1-yl)propoxy,each of R² and R³ is hydrogen; and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo and iodo, each of G³and G⁴, which may be the same or different, is selected from hydrogen,chloro and methoxy, and each of G² and G⁵ is hydrogen, or G¹ and G²together form a group of formula:— —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or—O—CH₂—O—, and each of G³, G⁴ and G⁵ is hydrogen; or apharmaceutically-acceptable acid-addition salt thereof.
 4. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 0 or m is 1 and the R¹ group is located at the 6- or 7-position andis selected from hydroxy, amino, methyl, ethyl, propyl, methoxy, ethoxy,propoxy, methylamino, ethylamino, dimethylamino, diethylamino,acetamido, propionamido, benzyloxy, 2-imidazol-1-ylethoxy,2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy,piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy and3-homopiperazin-1-ylpropoxy, and wherein adjacent carbon atoms in any(2-6C)alkylene chain within a R¹ substituent are optionally separated bythe insertion into the chain of a group selected from O, NH, CH═CH andC≡C, and wherein any CH₂ or CH₃ group within a R¹ substituent optionallybears on each said CH₂ or CH₃ group a substituent selected from hydroxy,amino, methoxy, methylsulphonyl, methylamino and dimethylamino, andwherein any phenyl or heterocyclyl group within a substituent on R¹optionally bears 1 or 2 substituents, which may be the same ordifferent, selected from fluoro, chloro, trifluoromethyl, hydroxy,amino, methyl, ethyl and methoxy, and wherein any heterocyclyl groupwithin a substituent on R¹ optionally bears 1 or 2oxo substituents; theQ¹-Z- group is selected from phenoxy, benzyloxy,tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy,piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy,2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,3-homopiperidin-1-ylpropoxy, homopiperidin-3-yloxy,homopiperidin-4-yloxy, homopiperidin-3-ylmethoxy,2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy, and whereinany CH₂ or CH₃ group within the Q¹-Z- group optionally bears on eachsaid CH₂ or CH₃ group a substituent selected from hydroxy, amino,methoxy, methylsulphonyl, methylamino and dimethylamino, and wherein anyphenyl or heterocyclyl group within the Q¹-Z- group optionally bears 1or 2 substituents, which may be the same or different, selected fromfluoro, chloro, trifluoromethyl, hydroxy, amino, methyl, ethyl andmethoxy, and wherein any heterocyclyl group within the Q¹-Z- groupoptionally bears 1 or 2 oxo substituents; each of R² and R³ is hydrogen;and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo, iodo,trifluoromethyl, cyano, methyl, ethyl, vinyl, allyl, isopropenyl,ethynyl, methoxy and ethoxy, and each of G², G³, G⁴ and G⁵, which may bethe same or different, is selected from hydrogen, fluoro, chloro, bromo,trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,isopropenyl, ethynyl, methoxy and ethoxy, or G¹ and G² together form agroup of formula:— —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or10-membered bicyclic heteroaryl or heterocyclic ring so formedoptionally bears on the heteroaryl or heterocyclic portion of thebicyclic ring 1 or 2 substituents, which may be the same or different,selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,methyl, ethyl, methoxy and ethoxy, and any bicyclic heterocyclic ring soformed optionally bears 1 or 2 oxo or thioxo groups, and each of G³, G⁴and G⁵, which may be the same or different, is selected from hydrogen,fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl,methoxy and ethoxy, or a pharmaceutically-acceptable acid-addition saltthereof.
 5. The use as claimed in claim 1 of a quinazoline derivative ofthe Formula I wherein: m is 1 and the R¹ group is located at the7-position and is selected from hydroxy, methoxy, ethoxy, propoxy,benzyloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,2-morpholinoethoxy, 3-morpholinopropoxy,2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,3-(4-methylpiperazin-1-yl)propoxy, 2-hydroxyethoxy, 3-hydroxypropoxy,2-methoxyethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy,3-methylsulphonylpropoxy and 2-(2-methoxyethoxy)ethoxy; and wherein anyCH₂ group within a R¹ substituent that is attached to two carbon atomsoptionally bears a hydroxy group on said CH₂ group; the Q¹-Z- group isselected from tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy,2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, piperidin-3-yloxy, N-methylpiperidin-3-yloxy,piperidinyloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy and3-(4-methylpiperazin-1-yl)propoxy, and wherein any CH₂ group within theQ¹-Z- group that is attached to two carbon atoms optionally bears ahydroxy group on said CH₂ group; and wherein any heterocyclyl groupwithin the Q¹-Z- group optionally bears 1 or 2 oxo substituents; each ofR² and R³ is hydrogen; and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo, iodo,trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl and ethynyl,each of G³ and G⁴, which may be the same or different, is selected fromhydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl, methoxy and ethoxy,and each of G² and G⁵ is hydrogen, or G¹ and G² together form a group offormula:— —CH═CH—CH═CH—, —O—CH═CH— or —O—CH₂—O—, and the 9- or10-membered bicyclic heteroaryl or heterocyclic ring so formedoptionally bears on the heteroaryl or heterocyclic portion of thebicyclic ring 1 or 2 substituents, which may be the same or different,selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy,methyl and methoxy, and each of G³, G⁴ and G⁵, which may be the same ordifferent, is selected from hydrogen, fluoro, chloro, bromo,trifluoromethyl, cyano, hydroxy, methyl and methoxy; or apharmaceutically-acceptable acid-addition salt thereof.
 6. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 1 and the R¹ group is located at the 7-position and is selectedfrom hydroxy, methoxy, benzyloxy, 3-morpholinopropoxy,2-hydroxy-3-morpholinopropoxy, 3-(4-methylpiperazin-1-yl)propoxy,2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and2-(2-methoxyethoxy)ethoxy, the Q¹-Z- group is selected fromtetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, 2-imidazol-1-ylethoxy,2-(1,2,4-triazol-1-yl)ethoxy, 3-pyrrolidin-1-ylpropoxy,N-methylpyrrolidin-3-yloxy, 3-morpholinopropoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,N-methylpiperidin-4-yloxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy and 3-(4-methylpiperazin-1-yl)propoxy,each of R² and R³ is hydrogen; and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo and iodo, each of G³and G⁴, which may be the same or different, is selected from hydrogen,chloro and methoxy, and each of G² and G⁵ is hydrogen, or G¹ and G²together form a group of formula:— —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or—O—CH₂—O—, and each of G³, G⁴ and G⁵ is hydrogen; or apharmaceutically-acceptable acid-addition salt thereof.
 7. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 1 and the R¹ group is located at the 7-position and is selectedfrom hydroxy, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy,2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy,2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, 2-piperidin-4-ylethoxy,2-(N-methylpiperidin-4-yl)ethoxy, 2-homopiperidin-1-ylethoxy,3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,3-(4-methylpiperazin-1-yl)propoxy,3-(4-cyanomethylpiperazin-1-yl)propoxy,2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-tetrahydropyran-4-ylethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy,2-methoxyethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy,3-methylsulphonylpropoxy, 2-(2-methoxyethoxy)ethoxy,piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy, 3-pyridylmethoxy,4-pyridylmethoxy and 3-cyanopyrid-4-ylmethoxy; and wherein any CH₂ groupwithin a R¹ substituent that is attached to two carbon atoms optionallybears a hydroxy group on said CH₂ group; the Q¹-Z- group is selectedfrom tetrahydrofuran-3-yloxy, tetrahydropyranyloxy,2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy,2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,3-piperidinopropoxy, 3-piperidinyloxy, N-methylpiperidin-3-yloxy,4-piperidinyloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy,N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy,3-(4-methylpiperazin-1-yl)propoxy, cyclobutyloxy, cyclopentyloxy andcyclohexyloxy, and wherein any CH₂ group within the Q¹-Z- group that isattached to two carbon atoms optionally bears a hydroxy group on saidCH₂ group; and wherein any heterocyclyl group within the Q¹-Z- groupoptionally bears 1 or 2 oxo substituents; each of R² and R³ is hydrogen;and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo, iodo,trifluoromethyl, cyano, methyl, ethyl, vinyl, isopropenyl, ethynyl,methoxy and pyrrolidin-lyl, G² is hydrogen, each of G³ and G⁴, which maybe the same or different, is selected from hydrogen, fluoro, chloro,bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl,isopropenyl, ethynyl, methoxy and ethoxy, and G⁵ is hydrogen or methoxy,or G¹ and G² together form a group of formula:— —CH—CH—CH═CH—, —O—CH═CH—or —O—CH₂—O—, and the 9- or 10-membered bicyclic heteroaryl orheterocyclic ring so formed optionally bears on the heteroaryl orheterocyclic portion of the bicyclic ring 1 or 2 substituents, which maybe the same or different, selected from fluoro, chloro, bromo,trifluoromethyl, cyano, hydroxy, methyl and methoxy, and each of G³, G⁴and G⁵, which may be the same or different, is selected from hydrogen,fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl andmethoxy, or a pharmaceutically-acceptable acid-addition salt thereof. 8.The use as claimed in claim 1 of a quinazoline derivative of the FormulaI wherein: m is 1 and the R¹ group is located at the 7-position and isselected from hydroxy, methoxy, benzyloxy, 3-morpholinopropoxy,2-hydroxy-3-morpholinopropoxy, 3-(4-methylpiperazin-1-yl)propoxy,2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy, 2-methoxyethoxy and2-(2-methoxyethoxy)ethoxy; the Q¹-Z- group is selected fromtetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,3-pyrrolidin-1-ylpropoxy, N-methylpyrrolidin-3-yloxy,3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,2-piperidinoethoxy, N-methylpiperidin-4-yloxy, piperidin-4ylmethoxy,N-methylpiperidin-4-ylmethoxy and 3-(4methylpiperazin-1-yl)propoxy, eachof R² and R³ is hydrogen; and Q² is an aryl group of formula Ia

wherein G¹ is selected from fluoro, chloro, bromo and iodo, each of G³and G⁴, which may be the same or different, is selected from hydrogen,chloro and methoxy, and each of G² and G⁵ is hydrogen, or G¹ and G²together form a group of formula:— —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or—O—CH₂—O—, and each of G³, G⁴ and G⁵ is hydrogen; or apharmaceutically-acceptable acid-addition salt thereof.
 9. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 1 and the R¹ group is located at the 7-position and is selectedfrom methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy,2-morpholinoethoxy, 3-morpholinopropoxy,2-(4-methylpiperazin-1-yl)ethoxy, 3-(4methylpiperazin-1-yl)propoxy,2-[(2S)-2-M-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-[(2S)-2-(,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy,3-pyridylmethoxy and 4-pyridylmethoxy, the Q¹-Z- group is selected fromtetrahydropyran-4-yloxy, 3-pyrrolidin-1-ylpropoxy,N-methylpyrrolidin-3-yloxy, 3-morpholinopropoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,4-piperidinyloxy, N-methylpiperidin-4-yloxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy, 3-(4-methylpiperazin-1-yl)propoxy,cyclopentyloxy and cyclohexyloxy; each of R² and R³ is hydrogen; and Q²is an aryl group of formula Ia

wherein G¹ is selected from chloro, bromo, trifluoromethyl, methyl,methoxy and pyrrolidin-1-yl, G² is hydrogen, G³ is selected fromhydrogen and chloro, G⁴ is methoxy, and G⁵ is hydrogen, or G¹ and G²together form a group of formula:— —CH═CH—CH═C(Cl)—, —O—CH═C(Cl)— or—O—CH₂—O—, each of G³ and G⁴ is hydrogen, and G⁵ is hydrogen or chloro;or a pharmaceutically-acceptable acid-addition salt thereof.
 10. The useas claimed in claim 1 of a quinazoline derivative of the Formula Iwherein: m is 1 and the R¹ group is located at the 7-position and isselected from methoxy, ethoxy, propoxy, isopropoxy, isobutoxy,2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy,2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy,3-piperidinopropoxy, 2-piperidin-4-ylethoxy,2-(N-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,3-(4-cyanomethylpiperazin-1-yl)propoxy,2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,3-methylsulphonylpropoxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy,3-pyridylmethoxy, 4-pyridylmethoxy and 2-cyanopyrid-4-ylmethoxy, andwherein any CH₂ group within a R¹ substituent that is attached to twocarbon atoms optionally bears a hydroxy group on said CH₂ group; theQ¹-Z- group is selected from tetrahydropyran-4-yloxy,3-pyrrolidin-1-ylpropoxy, N-methylpyrrolidin-3-yloxy,3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,2-piperidinoethoxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy,piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,3-(4-methylpiperazin-1-yl)propoxy, cyclopentyloxy and cyclohexyloxy;each of R¹ and R³ is hydrogen; and Q² is an aryl group of formula Ia

wherein G¹ is selected from chloro, bromo, trifluoromethyl, methyl,methoxy and pyrrolidin-1-yl, G² is hydrogen, G³ is selected fromhydrogen and chloro, G⁴ is methoxy, and G⁵ is hydrogen, or G¹ and G²together form a group of formula:— —O—CH═CH—, —O—CH═C(Cl)— or —O—CH₂—O—,each of G³ and G⁴ is hydrogen, and G⁵ is hydrogen or chloro; or apharmaceutically-acceptable acid-addition salt thereof.
 11. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 1 and the R¹ group is located at the 7-position and is selectedfrom methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy,2-morpholinoethoxy, 3-morpholinopropoxy,2-(4methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy,3-pyridylmethoxy and 4-pyridylmethoxy; the Q¹-Z- group is selected fromtetrahydropyran-4-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy,cyclopentyloxy and cyclohexyloxy, each of R² and R³ is hydrogen; and Q²is an aryl group of formula Ia

wherein G¹ and G² together form a group of formula:— —O—CH₂—O—, each ofG³ and G⁴ is hydrogen, and G⁵ is chloro; or apharmaceutically-acceptable acid-addition salt thereof.
 12. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I wherein:m is 1 and the R¹ group is located at the 7-position and is selectedfrom methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 2-fluoroethoxy,2,2,2-trifluoroethoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy,3-(4-hydroxypiperidin-1-yl)propoxy, 2-piperidin-4-ylethoxy,2-(N-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy,3-morpholinopropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,3-(4cyanomethylpiperazin-1-yl)propoxy,2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,2-[(2S)-2-(h-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,2-[(2S)-2-(N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,3-methylsulphonylpropoxy, piperidin-4-ylmethoxy,N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy,3-pyridylmethoxy and 4-pyridylmethoxy; the Q¹-Z- group is selected fromtetrahydropyran-4-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy,piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, cyclopentyloxy andcyclohexyloxy; each of R² and R³ is hydrogen; and Q² is an aryl group offormula Ia

wherein G¹ and G² together form a group of formula:— —O—CH₂—O—, each ofG³ and G⁴ is hydrogen, and G⁵ is chloro; or apharmaceutically-acceptable acid-addition salt thereof.
 13. The use asclaimed in claim 1 of a quinazoline derivative of the Formula I selectedfrom:—4-(2-chloro-5-methoxyanilino)-5,7-di-(3-morpholinopropoxy)quinazoline,4-(2-bromo-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,4-(2-chloro-5-methoxyanilino)-7-methoxy-5-1-methylpiperidin-4-yloxy)quinazoline,4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-(2-hydroxy-3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydrofuran-3-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydrofuran-3-yloxyquinazoline,4-(5-chloronaphth-1-ylamino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,4-(3-chlorobenzofuran-7-ylamino)-7-methoxy-5-(N-methylpiperidinyloxy)quinazoline,7-benzyloxy-4-(2-bromo-5-methoxyanilino)-5-piperidin-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-(3-methylsulphonylpropoxy)-5-piperidin-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,4-(2,5-dimethoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-(4-pyridyloxyethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-7-(4-pyridylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(5-methoxy-2-pyrrolidin-1-ylanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(2-bromo-5-methoxyanilino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,4-(2-chloro-5-methoxyanilino)-5-isopropoxy-7-(3-morpholinopropoxy)quinazoline,4-(2-chloro-5-methoxyanilino)-5-isopropoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-pyridyloxy)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(6-chloro-2,3-methylenedioxyanilino)-7-piperidin-4-ylmethoxy-5-tetrahydropyran-4-yloxyquinazolineand4-(6-chloro-2,3-methylenedioxyanilino)-7-(N-methylpiperidin-4-ylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline;or a pharmaceutically-acceptable acid-addition salt thereof.
 14. The useas claimed in claim 1 of a quinazoline derivative of the Formula Iselected from:—4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2,4-dichloro-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,4-(2-chloro-5-methoxyanilino)-5-isopropoxy-7-(3-morpholinopropoxy)quinazolineand4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,or a pharmaceutically-acceptable acid-addition salt thereof.